id	sid	tid	token	lemma	pos
ajlsi-3268	1	1	pa	pa	PROPN
ajlsi-3268	1	2	ge	ge	PROPN
ajlsi-3268	1	3	1	1	NUM
ajlsi-3268	1	4	pa	pa	PROPN
ajlsi-3268	1	5	ge	ge	PROPN
ajlsi-3268	1	6	27	27	NUM
ajlsi-3268	1	7	american	american	ADJ
ajlsi-3268	1	8	journal	journal	NOUN
ajlsi-3268	1	9	of	of	ADP
ajlsi-3268	1	10	life	life	NOUN
ajlsi-3268	1	11	science	science	NOUN
ajlsi-3268	1	12	and	and	CCONJ
ajlsi-3268	1	13	innovation	innovation	NOUN
ajlsi-3268	1	14	(	(	PUNCT
ajlsi-3268	1	15	ajlsi	ajlsi	ADJ
ajlsi-3268	1	16	)	)	PUNCT
ajlsi-3268	1	17	impact	impact	NOUN
ajlsi-3268	1	18	of	of	ADP
ajlsi-3268	1	19	bulky	bulky	ADJ
ajlsi-3268	1	20	&	&	CCONJ
ajlsi-3268	1	21	liposomal	liposomal	PROPN
ajlsi-3268	1	22	secukinumab	secukinumab	NOUN
ajlsi-3268	1	23	on	on	ADP
ajlsi-3268	1	24	lymphocytes	lymphocyte	NOUN
ajlsi-3268	1	25	of	of	ADP
ajlsi-3268	1	26	psoriatic	psoriatic	ADJ
ajlsi-3268	1	27	patients	patient	NOUN
ajlsi-3268	1	28	,	,	PUNCT
ajlsi-3268	1	29	to	to	PART
ajlsi-3268	1	30	determine	determine	VERB
ajlsi-3268	1	31	the	the	DET
ajlsi-3268	1	32	improvement	improvement	NOUN
ajlsi-3268	1	33	in	in	ADP
ajlsi-3268	1	34	bioavailability	bioavailability	NOUN
ajlsi-3268	1	35	of	of	ADP
ajlsi-3268	1	36	secukinumab	secukinumab	NOUN
ajlsi-3268	1	37	nanolipo	nanolipo	PROPN
ajlsi-3268	1	38	gazala	gazala	PROPN
ajlsi-3268	1	39	layas1	layas1	PROPN
ajlsi-3268	1	40	*	*	PROPN
ajlsi-3268	1	41	,	,	PUNCT
ajlsi-3268	1	42	mohammad	mohammad	PROPN
ajlsi-3268	1	43	isreb2	isreb2	PROPN
ajlsi-3268	1	44	,	,	PUNCT
ajlsi-3268	1	45	nader	nader	PROPN
ajlsi-3268	1	46	ghaderi3	ghaderi3	PROPN
ajlsi-3268	1	47	,	,	PUNCT
ajlsi-3268	1	48	fanila	fanila	PROPN
ajlsi-3268	1	49	shahzad1	shahzad1	PROPN
ajlsi-3268	1	50	,	,	PUNCT
ajlsi-3268	1	51	pouria	pouria	PROPN
ajlsi-3268	1	52	akhbari4	akhbari4	PROPN
ajlsi-3268	1	53	,	,	PUNCT
ajlsi-3268	1	54	diana	diana	PROPN
ajlsi-3268	1	55	anderson1	anderson1	PROPN
ajlsi-3268	1	56	,	,	PUNCT
ajlsi-3268	1	57	andrew	andrew	PROPN
ajlsi-3268	1	58	wright3	wright3	PROPN
ajlsi-3268	1	59	,	,	PUNCT
ajlsi-3268	1	60	mojgan	mojgan	NOUN
ajlsi-3268	1	61	najafzadeh1	najafzadeh1	PROPN
ajlsi-3268	2	1	volume	volume	NOUN
ajlsi-3268	2	2	4	4	NUM
ajlsi-3268	2	3	issue	issue	NOUN
ajlsi-3268	2	4	1	1	NUM
ajlsi-3268	2	5	,	,	PUNCT
ajlsi-3268	2	6	year	year	NOUN
ajlsi-3268	2	7	2024	2024	NUM
ajlsi-3268	2	8	issn	issn	X
ajlsi-3268	2	9	:	:	PUNCT
ajlsi-3268	2	10	2833	2833	NUM
ajlsi-3268	2	11	-	-	SYM
ajlsi-3268	2	12	1397	1397	NUM
ajlsi-3268	2	13	(	(	PUNCT
ajlsi-3268	2	14	online	online	ADJ
ajlsi-3268	2	15	)	)	PUNCT
ajlsi-3268	2	16	doi	doi	NOUN
ajlsi-3268	2	17	:	:	PUNCT
ajlsi-3268	3	1	https://doi.org/10.54536/ajlsi.v4i1.3268	https://doi.org/10.54536/ajlsi.v4i1.3268	PROPN
ajlsi-3268	3	2	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-3268	3	3	article	article	NOUN
ajlsi-3268	3	4	information	information	NOUN
ajlsi-3268	3	5	abstract	abstract	ADV
ajlsi-3268	3	6	received	receive	VERB
ajlsi-3268	3	7	:	:	PUNCT
ajlsi-3268	3	8	june	june	PROPN
ajlsi-3268	3	9	24	24	NUM
ajlsi-3268	3	10	,	,	PUNCT
ajlsi-3268	3	11	2024	2024	NUM
ajlsi-3268	3	12	accepted	accept	VERB
ajlsi-3268	3	13	:	:	PUNCT
ajlsi-3268	3	14	july	july	PROPN
ajlsi-3268	3	15	30	30	NUM
ajlsi-3268	3	16	,	,	PUNCT
ajlsi-3268	3	17	2024	2024	NUM
ajlsi-3268	3	18	published	publish	VERB
ajlsi-3268	3	19	:	:	PUNCT
ajlsi-3268	3	20	june	june	PROPN
ajlsi-3268	3	21	15	15	NUM
ajlsi-3268	3	22	,	,	PUNCT
ajlsi-3268	3	23	2025	2025	NUM
ajlsi-3268	3	24	psoriasis	psoriasis	NOUN
ajlsi-3268	3	25	is	be	AUX
ajlsi-3268	3	26	an	an	DET
ajlsi-3268	3	27	immune	immune	NOUN
ajlsi-3268	3	28	-	-	PUNCT
ajlsi-3268	3	29	mediated	mediate	VERB
ajlsi-3268	3	30	disease	disease	NOUN
ajlsi-3268	3	31	affecting	affect	VERB
ajlsi-3268	3	32	the	the	DET
ajlsi-3268	3	33	skin	skin	NOUN
ajlsi-3268	3	34	and	and	CCONJ
ajlsi-3268	3	35	joints	joint	NOUN
ajlsi-3268	3	36	.	.	PUNCT
ajlsi-3268	4	1	biologic	biologic	NOUN
ajlsi-3268	4	2	treatments	treatment	NOUN
ajlsi-3268	4	3	are	be	AUX
ajlsi-3268	4	4	often	often	ADV
ajlsi-3268	4	5	used	use	VERB
ajlsi-3268	4	6	in	in	ADP
ajlsi-3268	4	7	moderate	moderate	ADJ
ajlsi-3268	4	8	to	to	ADP
ajlsi-3268	4	9	severe	severe	ADJ
ajlsi-3268	4	10	cases	case	NOUN
ajlsi-3268	4	11	,	,	PUNCT
ajlsi-3268	4	12	administered	administer	VERB
ajlsi-3268	4	13	as	as	ADP
ajlsi-3268	4	14	a	a	DET
ajlsi-3268	4	15	monotherapy	monotherapy	NOUN
ajlsi-3268	4	16	or	or	CCONJ
ajlsi-3268	4	17	in	in	ADP
ajlsi-3268	4	18	combination	combination	NOUN
ajlsi-3268	4	19	with	with	ADP
ajlsi-3268	4	20	other	other	ADJ
ajlsi-3268	4	21	treatments	treatment	NOUN
ajlsi-3268	4	22	.	.	PUNCT
ajlsi-3268	5	1	liposomes	liposome	NOUN
ajlsi-3268	5	2	are	be	AUX
ajlsi-3268	5	3	versatile	versatile	ADJ
ajlsi-3268	5	4	and	and	CCONJ
ajlsi-3268	5	5	can	can	AUX
ajlsi-3268	5	6	enhance	enhance	VERB
ajlsi-3268	5	7	drug	drug	NOUN
ajlsi-3268	5	8	retention	retention	NOUN
ajlsi-3268	5	9	,	,	PUNCT
ajlsi-3268	5	10	reducing	reduce	VERB
ajlsi-3268	5	11	systemic	systemic	ADJ
ajlsi-3268	5	12	side	side	NOUN
ajlsi-3268	5	13	effects	effect	NOUN
ajlsi-3268	5	14	,	,	PUNCT
ajlsi-3268	5	15	and	and	CCONJ
ajlsi-3268	5	16	are	be	AUX
ajlsi-3268	5	17	used	use	VERB
ajlsi-3268	5	18	for	for	ADP
ajlsi-3268	5	19	therapy	therapy	NOUN
ajlsi-3268	5	20	and	and	CCONJ
ajlsi-3268	5	21	research	research	NOUN
ajlsi-3268	5	22	.	.	PUNCT
ajlsi-3268	6	1	this	this	DET
ajlsi-3268	6	2	research	research	NOUN
ajlsi-3268	6	3	study	study	NOUN
ajlsi-3268	6	4	aimed	aim	VERB
ajlsi-3268	6	5	to	to	PART
ajlsi-3268	6	6	investigate	investigate	VERB
ajlsi-3268	6	7	the	the	DET
ajlsi-3268	6	8	geno	geno	NOUN
ajlsi-3268	6	9	toxicity	toxicity	NOUN
ajlsi-3268	6	10	of	of	ADP
ajlsi-3268	6	11	secukinumab	secukinumab	NOUN
ajlsi-3268	6	12	,	,	PUNCT
ajlsi-3268	6	13	an	an	DET
ajlsi-3268	6	14	ideal	ideal	ADJ
ajlsi-3268	6	15	biologic	biologic	NOUN
ajlsi-3268	6	16	treatment	treatment	NOUN
ajlsi-3268	6	17	for	for	ADP
ajlsi-3268	6	18	psoriasis	psoriasis	NOUN
ajlsi-3268	6	19	(	(	PUNCT
ajlsi-3268	6	20	a	a	DET
ajlsi-3268	6	21	human	human	PROPN
ajlsi-3268	6	22	igg1k	igg1k	PROPN
ajlsi-3268	6	23	antibody	antibody	NOUN
ajlsi-3268	6	24	,	,	PUNCT
ajlsi-3268	6	25	anti	anti	ADJ
ajlsi-3268	6	26	-	-	ADJ
ajlsi-3268	6	27	il17a	il17a	ADJ
ajlsi-3268	6	28	)	)	PUNCT
ajlsi-3268	6	29	,	,	PUNCT
ajlsi-3268	6	30	in	in	ADP
ajlsi-3268	6	31	bulk	bulk	NOUN
ajlsi-3268	6	32	and	and	CCONJ
ajlsi-3268	6	33	liposome	liposome	VERB
ajlsi-3268	6	34	nanoparticles	nanoparticle	NOUN
ajlsi-3268	6	35	on	on	ADP
ajlsi-3268	6	36	the	the	DET
ajlsi-3268	6	37	lymphocytes	lymphocyte	NOUN
ajlsi-3268	6	38	of	of	ADP
ajlsi-3268	6	39	psoriatic	psoriatic	ADJ
ajlsi-3268	6	40	patients	patient	NOUN
ajlsi-3268	6	41	in	in	ADP
ajlsi-3268	6	42	comparison	comparison	NOUN
ajlsi-3268	6	43	with	with	ADP
ajlsi-3268	6	44	healthy	healthy	ADJ
ajlsi-3268	6	45	persons	person	NOUN
ajlsi-3268	6	46	.	.	PUNCT
ajlsi-3268	7	1	geno	geno	NOUN
ajlsi-3268	7	2	toxicity	toxicity	NOUN
ajlsi-3268	7	3	of	of	ADP
ajlsi-3268	7	4	secukinumab	secukinumab	NOUN
ajlsi-3268	7	5	in	in	ADP
ajlsi-3268	7	6	bulk	bulk	NOUN
ajlsi-3268	7	7	and	and	CCONJ
ajlsi-3268	7	8	liposomal	liposomal	ADJ
ajlsi-3268	7	9	form	form	NOUN
ajlsi-3268	7	10	was	be	AUX
ajlsi-3268	7	11	evaluated	evaluate	VERB
ajlsi-3268	7	12	and	and	CCONJ
ajlsi-3268	7	13	compared	compare	VERB
ajlsi-3268	7	14	by	by	ADP
ajlsi-3268	7	15	using	use	VERB
ajlsi-3268	7	16	the	the	DET
ajlsi-3268	7	17	comet	comet	NOUN
ajlsi-3268	7	18	and	and	CCONJ
ajlsi-3268	7	19	micronucleus	micronucleus	ADJ
ajlsi-3268	7	20	assays	assay	NOUN
ajlsi-3268	7	21	.	.	PUNCT
ajlsi-3268	8	1	from	from	ADP
ajlsi-3268	8	2	assays	assay	NOUN
ajlsi-3268	8	3	,	,	PUNCT
ajlsi-3268	8	4	it	it	PRON
ajlsi-3268	8	5	was	be	AUX
ajlsi-3268	8	6	demonstrated	demonstrate	VERB
ajlsi-3268	8	7	that	that	DET
ajlsi-3268	8	8	secukinumab	secukinumab	NOUN
ajlsi-3268	8	9	in	in	ADP
ajlsi-3268	8	10	both	both	DET
ajlsi-3268	8	11	forms	form	NOUN
ajlsi-3268	8	12	did	do	AUX
ajlsi-3268	8	13	not	not	PART
ajlsi-3268	8	14	exhibit	exhibit	VERB
ajlsi-3268	8	15	geno	geno	NOUN
ajlsi-3268	8	16	toxicity	toxicity	NOUN
ajlsi-3268	8	17	and	and	CCONJ
ajlsi-3268	8	18	reduced	reduce	VERB
ajlsi-3268	8	19	dna	dna	PROPN
ajlsi-3268	8	20	damage	damage	NOUN
ajlsi-3268	8	21	following	follow	VERB
ajlsi-3268	8	22	the	the	DET
ajlsi-3268	8	23	treatment	treatment	NOUN
ajlsi-3268	8	24	of	of	ADP
ajlsi-3268	8	25	psoriatic	psoriatic	ADJ
ajlsi-3268	8	26	patient	patient	NOUN
ajlsi-3268	8	27	lymphocytes	lymphocyte	NOUN
ajlsi-3268	8	28	and	and	CCONJ
ajlsi-3268	8	29	healthy	healthy	ADJ
ajlsi-3268	8	30	individual	individual	NOUN
ajlsi-3268	8	31	’s	’s	PART
ajlsi-3268	8	32	lymphocytes	lymphocyte	NOUN
ajlsi-3268	8	33	with	with	ADP
ajlsi-3268	8	34	secukinumab	secukinumab	NOUN
ajlsi-3268	8	35	bulk	bulk	NOUN
ajlsi-3268	8	36	and	and	CCONJ
ajlsi-3268	8	37	liposomes	liposome	NOUN
ajlsi-3268	8	38	format	format	NOUN
ajlsi-3268	8	39	.	.	PUNCT
ajlsi-3268	9	1	secukinumab	secukinumab	NOUN
ajlsi-3268	9	2	used	use	VERB
ajlsi-3268	9	3	(	(	PUNCT
ajlsi-3268	9	4	2.1	2.1	NUM
ajlsi-3268	9	5	and	and	CCONJ
ajlsi-3268	9	6	2.8	2.8	NUM
ajlsi-3268	9	7	µg	µg	NOUN
ajlsi-3268	9	8	/	/	SYM
ajlsi-3268	9	9	ml	ml	NOUN
ajlsi-3268	9	10	)	)	PUNCT
ajlsi-3268	9	11	with	with	ADP
ajlsi-3268	9	12	two	two	NUM
ajlsi-3268	9	13	different	different	ADJ
ajlsi-3268	9	14	concentrations	concentration	NOUN
ajlsi-3268	9	15	,	,	PUNCT
ajlsi-3268	9	16	and	and	CCONJ
ajlsi-3268	9	17	effectively	effectively	ADV
ajlsi-3268	9	18	decreased	decrease	VERB
ajlsi-3268	9	19	dna	dna	PROPN
ajlsi-3268	9	20	damage	damage	NOUN
ajlsi-3268	9	21	induced	induce	VERB
ajlsi-3268	9	22	by	by	ADP
ajlsi-3268	9	23	h2o2	h2o2	NOUN
ajlsi-3268	9	24	in	in	ADP
ajlsi-3268	9	25	both	both	DET
ajlsi-3268	9	26	groups	group	NOUN
ajlsi-3268	9	27	to	to	ADP
ajlsi-3268	9	28	almost	almost	ADV
ajlsi-3268	9	29	the	the	DET
ajlsi-3268	9	30	negative	negative	ADJ
ajlsi-3268	9	31	control	control	NOUN
ajlsi-3268	9	32	level	level	NOUN
ajlsi-3268	9	33	.	.	PUNCT
ajlsi-3268	10	1	secukinumab	secukinumab	NOUN
ajlsi-3268	10	2	bulk	bulk	NOUN
ajlsi-3268	10	3	and	and	CCONJ
ajlsi-3268	10	4	liposome	liposome	NOUN
ajlsi-3268	10	5	form	form	NOUN
ajlsi-3268	10	6	markedly	markedly	ADV
ajlsi-3268	10	7	reduced	reduce	VERB
ajlsi-3268	10	8	the	the	DET
ajlsi-3268	10	9	h2o2	h2o2	ADV
ajlsi-3268	10	10	-	-	ADJ
ajlsi-3268	10	11	induced	induced	ADJ
ajlsi-3268	10	12	damage	damage	NOUN
ajlsi-3268	10	13	and	and	CCONJ
ajlsi-3268	10	14	proficiently	proficiently	ADV
ajlsi-3268	10	15	diminished	diminish	VERB
ajlsi-3268	10	16	its	its	PRON
ajlsi-3268	10	17	adverse	adverse	ADJ
ajlsi-3268	10	18	effects	effect	NOUN
ajlsi-3268	10	19	both	both	CCONJ
ajlsi-3268	10	20	in	in	ADP
ajlsi-3268	10	21	the	the	DET
ajlsi-3268	10	22	comet	comet	NOUN
ajlsi-3268	10	23	(	(	PUNCT
ajlsi-3268	10	24	p<0.0001	p<0.0001	NOUN
ajlsi-3268	10	25	)	)	PUNCT
ajlsi-3268	10	26	and	and	CCONJ
ajlsi-3268	10	27	micronucleus	micronucleus	NOUN
ajlsi-3268	10	28	as	as	ADP
ajlsi-3268	10	29	-	-	PUNCT
ajlsi-3268	10	30	says	say	NOUN
ajlsi-3268	10	31	(	(	PUNCT
ajlsi-3268	10	32	p<0.01	p<0.01	PROPN
ajlsi-3268	10	33	)	)	PUNCT
ajlsi-3268	10	34	.	.	PUNCT
ajlsi-3268	11	1	overall	overall	ADJ
ajlsi-3268	11	2	,	,	PUNCT
ajlsi-3268	11	3	secukinumab	secukinumab	NOUN
ajlsi-3268	11	4	in	in	ADP
ajlsi-3268	11	5	both	both	DET
ajlsi-3268	11	6	forms	form	NOUN
ajlsi-3268	11	7	showed	show	VERB
ajlsi-3268	11	8	anti	anti	ADJ
ajlsi-3268	11	9	-	-	ADJ
ajlsi-3268	11	10	genotoxic	genotoxic	ADJ
ajlsi-3268	11	11	and	and	CCONJ
ajlsi-3268	11	12	protective	protective	ADJ
ajlsi-3268	11	13	effects	effect	NOUN
ajlsi-3268	11	14	by	by	ADP
ajlsi-3268	11	15	expressing	express	VERB
ajlsi-3268	11	16	its	its	PRON
ajlsi-3268	11	17	potential	potential	NOUN
ajlsi-3268	11	18	to	to	PART
ajlsi-3268	11	19	reduce	reduce	VERB
ajlsi-3268	11	20	dna	dna	PROPN
ajlsi-3268	11	21	damage	damage	NOUN
ajlsi-3268	11	22	produced	produce	VERB
ajlsi-3268	11	23	by	by	ADP
ajlsi-3268	11	24	oxidative	oxidative	ADJ
ajlsi-3268	11	25	stress	stress	NOUN
ajlsi-3268	11	26	and	and	CCONJ
ajlsi-3268	11	27	it	it	PRON
ajlsi-3268	11	28	was	be	AUX
ajlsi-3268	11	29	observed	observe	VERB
ajlsi-3268	11	30	that	that	SCONJ
ajlsi-3268	11	31	it	it	PRON
ajlsi-3268	11	32	would	would	AUX
ajlsi-3268	11	33	not	not	PART
ajlsi-3268	11	34	induce	induce	VERB
ajlsi-3268	11	35	any	any	DET
ajlsi-3268	11	36	further	further	ADJ
ajlsi-3268	11	37	damage	damage	NOUN
ajlsi-3268	11	38	in	in	ADP
ajlsi-3268	11	39	the	the	DET
ajlsi-3268	11	40	lymphocytes	lymphocyte	NOUN
ajlsi-3268	11	41	of	of	ADP
ajlsi-3268	11	42	healthy	healthy	ADJ
ajlsi-3268	11	43	individuals	individual	NOUN
ajlsi-3268	11	44	and	and	CCONJ
ajlsi-3268	11	45	patients	patient	NOUN
ajlsi-3268	11	46	.	.	PUNCT
ajlsi-3268	12	1	keywords	keyword	VERB
ajlsi-3268	12	2	geno	geno	NOUN
ajlsi-3268	12	3	toxicity	toxicity	NOUN
ajlsi-3268	12	4	,	,	PUNCT
ajlsi-3268	12	5	micronucleus	micronucleus	NOUN
ajlsi-3268	12	6	assay	assay	VERB
ajlsi-3268	12	7	,	,	PUNCT
ajlsi-3268	12	8	oxidative	oxidative	ADJ
ajlsi-3268	12	9	stress	stress	NOUN
ajlsi-3268	12	10	,	,	PUNCT
ajlsi-3268	12	11	psoriasis	psoriasis	NOUN
ajlsi-3268	12	12	,	,	PUNCT
ajlsi-3268	12	13	secukinumab	secukinumab	NOUN
ajlsi-3268	12	14	introduction	introduction	NOUN
ajlsi-3268	12	15	psoriasis	psoriasis	NOUN
ajlsi-3268	12	16	was	be	AUX
ajlsi-3268	12	17	initially	initially	ADV
ajlsi-3268	12	18	characterized	characterize	VERB
ajlsi-3268	12	19	as	as	ADP
ajlsi-3268	12	20	a	a	DET
ajlsi-3268	12	21	dermatologic	dermatologic	ADJ
ajlsi-3268	12	22	disorder	disorder	NOUN
ajlsi-3268	12	23	primarily	primarily	ADV
ajlsi-3268	12	24	affecting	affect	VERB
ajlsi-3268	12	25	epidermal	epidermal	ADJ
ajlsi-3268	12	26	keratinocytes	keratinocyte	NOUN
ajlsi-3268	12	27	.	.	PUNCT
ajlsi-3268	13	1	however	however	ADV
ajlsi-3268	13	2	,	,	PUNCT
ajlsi-3268	13	3	recent	recent	ADJ
ajlsi-3268	13	4	studies	study	NOUN
ajlsi-3268	13	5	have	have	AUX
ajlsi-3268	13	6	shed	shed	VERB
ajlsi-3268	13	7	light	light	NOUN
ajlsi-3268	13	8	on	on	ADP
ajlsi-3268	13	9	its	its	PRON
ajlsi-3268	13	10	immunemediated	immunemediate	VERB
ajlsi-3268	13	11	pathogenesis	pathogenesis	NOUN
ajlsi-3268	13	12	,	,	PUNCT
ajlsi-3268	13	13	making	make	VERB
ajlsi-3268	13	14	it	it	PRON
ajlsi-3268	13	15	one	one	NUM
ajlsi-3268	13	16	of	of	ADP
ajlsi-3268	13	17	the	the	DET
ajlsi-3268	13	18	most	most	ADV
ajlsi-3268	13	19	prevalent	prevalent	ADJ
ajlsi-3268	13	20	immune	immune	NOUN
ajlsi-3268	13	21	-	-	PUNCT
ajlsi-3268	13	22	mediated	mediate	VERB
ajlsi-3268	13	23	conditions	condition	NOUN
ajlsi-3268	13	24	(	(	PUNCT
ajlsi-3268	13	25	kadam	kadam	PROPN
ajlsi-3268	13	26	et	et	PROPN
ajlsi-3268	13	27	al	al	PROPN
ajlsi-3268	13	28	.	.	PROPN
ajlsi-3268	13	29	,	,	PUNCT
ajlsi-3268	13	30	2010	2010	NUM
ajlsi-3268	13	31	)	)	PUNCT
ajlsi-3268	13	32	.	.	PUNCT
ajlsi-3268	14	1	psoriasis	psoriasis	NOUN
ajlsi-3268	14	2	is	be	AUX
ajlsi-3268	14	3	a	a	DET
ajlsi-3268	14	4	chronic	chronic	ADJ
ajlsi-3268	14	5	autoimmune	autoimmune	ADJ
ajlsi-3268	14	6	disease	disease	NOUN
ajlsi-3268	14	7	characterized	characterize	VERB
ajlsi-3268	14	8	by	by	ADP
ajlsi-3268	14	9	systemic	systemic	ADJ
ajlsi-3268	14	10	manifestations	manifestation	NOUN
ajlsi-3268	14	11	and	and	CCONJ
ajlsi-3268	14	12	inflammatory	inflammatory	ADJ
ajlsi-3268	14	13	changes	change	NOUN
ajlsi-3268	14	14	that	that	PRON
ajlsi-3268	14	15	predominantly	predominantly	ADV
ajlsi-3268	14	16	affect	affect	VERB
ajlsi-3268	14	17	the	the	DET
ajlsi-3268	14	18	skin	skin	NOUN
ajlsi-3268	14	19	and	and	CCONJ
ajlsi-3268	14	20	joints	joint	NOUN
ajlsi-3268	14	21	.	.	PUNCT
ajlsi-3268	15	1	the	the	DET
ajlsi-3268	15	2	disease	disease	NOUN
ajlsi-3268	15	3	can	can	AUX
ajlsi-3268	15	4	significantly	significantly	ADV
ajlsi-3268	15	5	compromise	compromise	VERB
ajlsi-3268	15	6	the	the	DET
ajlsi-3268	15	7	overall	overall	ADJ
ajlsi-3268	15	8	quality	quality	NOUN
ajlsi-3268	15	9	of	of	ADP
ajlsi-3268	15	10	life	life	NOUN
ajlsi-3268	15	11	of	of	ADP
ajlsi-3268	15	12	those	those	PRON
ajlsi-3268	15	13	affected	affect	VERB
ajlsi-3268	15	14	.	.	PUNCT
ajlsi-3268	16	1	hyper	hyper	ADJ
ajlsi-3268	16	2	proliferating	proliferate	VERB
ajlsi-3268	16	3	body	body	NOUN
ajlsi-3268	16	4	patches	patch	NOUN
ajlsi-3268	16	5	are	be	AUX
ajlsi-3268	16	6	primarily	primarily	ADV
ajlsi-3268	16	7	caused	cause	VERB
ajlsi-3268	16	8	by	by	ADP
ajlsi-3268	16	9	autoimmune	autoimmune	ADJ
ajlsi-3268	16	10	illness	illness	NOUN
ajlsi-3268	16	11	,	,	PUNCT
ajlsi-3268	16	12	a	a	DET
ajlsi-3268	16	13	disorder	disorder	NOUN
ajlsi-3268	16	14	marked	mark	VERB
ajlsi-3268	16	15	by	by	ADP
ajlsi-3268	16	16	an	an	DET
ajlsi-3268	16	17	overactive	overactive	ADJ
ajlsi-3268	16	18	immune	immune	ADJ
ajlsi-3268	16	19	system	system	NOUN
ajlsi-3268	16	20	.	.	PUNCT
ajlsi-3268	17	1	psoriasis	psoriasis	NOUN
ajlsi-3268	17	2	is	be	AUX
ajlsi-3268	17	3	a	a	DET
ajlsi-3268	17	4	multifaceted	multifaceted	ADJ
ajlsi-3268	17	5	disease	disease	NOUN
ajlsi-3268	17	6	,	,	PUNCT
ajlsi-3268	17	7	and	and	CCONJ
ajlsi-3268	17	8	its	its	PRON
ajlsi-3268	17	9	pathogenesis	pathogenesis	NOUN
ajlsi-3268	17	10	is	be	AUX
ajlsi-3268	17	11	not	not	PART
ajlsi-3268	17	12	yet	yet	ADV
ajlsi-3268	17	13	fully	fully	ADV
ajlsi-3268	17	14	understood	understand	VERB
ajlsi-3268	17	15	.	.	PUNCT
ajlsi-3268	18	1	despite	despite	SCONJ
ajlsi-3268	18	2	the	the	DET
ajlsi-3268	18	3	availability	availability	NOUN
ajlsi-3268	18	4	of	of	ADP
ajlsi-3268	18	5	several	several	ADJ
ajlsi-3268	18	6	treatment	treatment	NOUN
ajlsi-3268	18	7	options	option	NOUN
ajlsi-3268	18	8	,	,	PUNCT
ajlsi-3268	18	9	psoriasis	psoriasis	NOUN
ajlsi-3268	18	10	remains	remain	VERB
ajlsi-3268	18	11	a	a	DET
ajlsi-3268	18	12	challenging	challenging	ADJ
ajlsi-3268	18	13	disease	disease	NOUN
ajlsi-3268	18	14	to	to	PART
ajlsi-3268	18	15	manage	manage	VERB
ajlsi-3268	18	16	.	.	PUNCT
ajlsi-3268	19	1	therefore	therefore	ADV
ajlsi-3268	19	2	,	,	PUNCT
ajlsi-3268	19	3	further	further	ADJ
ajlsi-3268	19	4	research	research	NOUN
ajlsi-3268	19	5	is	be	AUX
ajlsi-3268	19	6	necessary	necessary	ADJ
ajlsi-3268	19	7	to	to	PART
ajlsi-3268	19	8	understand	understand	VERB
ajlsi-3268	19	9	the	the	DET
ajlsi-3268	19	10	disease	disease	NOUN
ajlsi-3268	19	11	’s	’s	PART
ajlsi-3268	19	12	pathogenesis	pathogenesis	NOUN
ajlsi-3268	19	13	and	and	CCONJ
ajlsi-3268	19	14	develop	develop	VERB
ajlsi-3268	19	15	more	more	ADV
ajlsi-3268	19	16	effective	effective	ADJ
ajlsi-3268	19	17	treatments	treatment	NOUN
ajlsi-3268	19	18	to	to	PART
ajlsi-3268	19	19	improve	improve	VERB
ajlsi-3268	19	20	patients	patient	NOUN
ajlsi-3268	19	21	’	'	PUNCT
ajlsi-3268	19	22	quality	quality	NOUN
ajlsi-3268	19	23	of	of	ADP
ajlsi-3268	19	24	life	life	NOUN
ajlsi-3268	19	25	(	(	PUNCT
ajlsi-3268	19	26	rendon	rendon	PROPN
ajlsi-3268	19	27	&	&	CCONJ
ajlsi-3268	19	28	schäkel	schäkel	PROPN
ajlsi-3268	19	29	,	,	PUNCT
ajlsi-3268	19	30	2018	2018	NUM
ajlsi-3268	19	31	)	)	PUNCT
ajlsi-3268	19	32	.	.	PUNCT
ajlsi-3268	20	1	throughout	throughout	ADP
ajlsi-3268	20	2	the	the	DET
ajlsi-3268	20	3	world	world	NOUN
ajlsi-3268	20	4	population	population	NOUN
ajlsi-3268	20	5	,	,	PUNCT
ajlsi-3268	20	6	up	up	ADP
ajlsi-3268	20	7	to	to	PART
ajlsi-3268	20	8	2.5	2.5	NUM
ajlsi-3268	20	9	%	%	NOUN
ajlsi-3268	20	10	of	of	ADP
ajlsi-3268	20	11	psoriasis	psoriasis	NOUN
ajlsi-3268	20	12	vulgaris	vulgaris	NOUN
ajlsi-3268	20	13	(	(	PUNCT
ajlsi-3268	20	14	chronic	chronic	ADJ
ajlsi-3268	20	15	skin	skin	NOUN
ajlsi-3268	20	16	disorder	disorder	NOUN
ajlsi-3268	20	17	)	)	PUNCT
ajlsi-3268	20	18	prevalence	prevalence	NOUN
ajlsi-3268	20	19	rate	rate	NOUN
ajlsi-3268	20	20	was	be	AUX
ajlsi-3268	20	21	reported	report	VERB
ajlsi-3268	20	22	(	(	PUNCT
ajlsi-3268	20	23	elder	elder	ADJ
ajlsi-3268	20	24	,	,	PUNCT
ajlsi-3268	20	25	2018	2018	NUM
ajlsi-3268	20	26	)	)	PUNCT
ajlsi-3268	20	27	.	.	PUNCT
ajlsi-3268	21	1	various	various	ADJ
ajlsi-3268	21	2	psoriatic	psoriatic	ADJ
ajlsi-3268	21	3	clinical	clinical	ADJ
ajlsi-3268	21	4	phenotypes	phenotype	NOUN
ajlsi-3268	21	5	are	be	AUX
ajlsi-3268	21	6	highly	highly	ADV
ajlsi-3268	21	7	regarded	regard	VERB
ajlsi-3268	21	8	as	as	ADP
ajlsi-3268	21	9	chronic	chronic	ADJ
ajlsi-3268	21	10	plaque	plaque	NOUN
ajlsi-3268	21	11	(	(	PUNCT
ajlsi-3268	21	12	psoriasis	psoriasis	NOUN
ajlsi-3268	21	13	vulgaris	vulgaris	NOUN
ajlsi-3268	21	14	)	)	PUNCT
ajlsi-3268	21	15	with	with	ADP
ajlsi-3268	21	16	an	an	DET
ajlsi-3268	21	17	accountancy	accountancy	NOUN
ajlsi-3268	21	18	of	of	ADP
ajlsi-3268	21	19	90	90	NUM
ajlsi-3268	21	20	%	%	NOUN
ajlsi-3268	21	21	cases	case	NOUN
ajlsi-3268	21	22	(	(	PUNCT
ajlsi-3268	21	23	griffiths	griffiths	PROPN
ajlsi-3268	21	24	&	&	CCONJ
ajlsi-3268	21	25	barker	barker	PROPN
ajlsi-3268	21	26	,	,	PUNCT
ajlsi-3268	21	27	2007	2007	NUM
ajlsi-3268	21	28	)	)	PUNCT
ajlsi-3268	21	29	.	.	PUNCT
ajlsi-3268	22	1	genetically	genetically	ADV
ajlsi-3268	22	2	mutated	mutate	VERB
ajlsi-3268	22	3	individuals	individual	NOUN
ajlsi-3268	22	4	are	be	AUX
ajlsi-3268	22	5	believed	believe	VERB
ajlsi-3268	22	6	to	to	PART
ajlsi-3268	22	7	have	have	VERB
ajlsi-3268	22	8	high	high	ADJ
ajlsi-3268	22	9	rate	rate	NOUN
ajlsi-3268	22	10	of	of	ADP
ajlsi-3268	22	11	susceptibility	susceptibility	NOUN
ajlsi-3268	22	12	of	of	ADP
ajlsi-3268	22	13	psoriasis	psoriasis	NOUN
ajlsi-3268	22	14	vulgaris	vulgaris	NOUN
ajlsi-3268	22	15	through	through	ADP
ajlsi-3268	22	16	environmental	environmental	ADJ
ajlsi-3268	22	17	factors	factor	NOUN
ajlsi-3268	22	18	,	,	PUNCT
ajlsi-3268	22	19	as	as	ADP
ajlsi-3268	22	20	a	a	DET
ajlsi-3268	22	21	result	result	NOUN
ajlsi-3268	22	22	of	of	ADP
ajlsi-3268	22	23	which	which	PRON
ajlsi-3268	22	24	adaptive	adaptive	ADJ
ajlsi-3268	22	25	and	and	CCONJ
ajlsi-3268	22	26	innate	innate	ADJ
ajlsi-3268	22	27	immune	immune	ADJ
ajlsi-3268	22	28	pathways	pathway	NOUN
ajlsi-3268	22	29	activates	activate	VERB
ajlsi-3268	22	30	inflammatory	inflammatory	ADJ
ajlsi-3268	22	31	responses	response	NOUN
ajlsi-3268	22	32	.	.	PUNCT
ajlsi-3268	23	1	lesions	lesion	NOUN
ajlsi-3268	23	2	are	be	AUX
ajlsi-3268	23	3	highly	highly	ADV
ajlsi-3268	23	4	visible	visible	ADJ
ajlsi-3268	23	5	,	,	PUNCT
ajlsi-3268	23	6	directing	direct	VERB
ajlsi-3268	23	7	to	to	ADP
ajlsi-3268	23	8	a	a	DET
ajlsi-3268	23	9	substantial	substantial	ADJ
ajlsi-3268	23	10	proportion	proportion	NOUN
ajlsi-3268	23	11	of	of	ADP
ajlsi-3268	23	12	physical	physical	ADJ
ajlsi-3268	23	13	,	,	PUNCT
ajlsi-3268	23	14	emotional	emotional	ADJ
ajlsi-3268	23	15	,	,	PUNCT
ajlsi-3268	23	16	social	social	ADJ
ajlsi-3268	23	17	and	and	CCONJ
ajlsi-3268	23	18	psychological	psychological	ADJ
ajlsi-3268	23	19	disability	disability	NOUN
ajlsi-3268	23	20	in	in	ADP
ajlsi-3268	23	21	the	the	DET
ajlsi-3268	23	22	patients	patient	NOUN
ajlsi-3268	23	23	(	(	PUNCT
ajlsi-3268	23	24	nestle	nestle	PROPN
ajlsi-3268	23	25	et	et	PROPN
ajlsi-3268	23	26	al	al	PROPN
ajlsi-3268	23	27	.	.	PROPN
ajlsi-3268	23	28	,	,	PUNCT
ajlsi-3268	23	29	1994	1994	NUM
ajlsi-3268	23	30	;	;	PUNCT
ajlsi-3268	23	31	chen	chen	PROPN
ajlsi-3268	23	32	et	et	PROPN
ajlsi-3268	23	33	al	al	PROPN
ajlsi-3268	23	34	.	.	PROPN
ajlsi-3268	23	35	,	,	PUNCT
ajlsi-3268	23	36	2018	2018	NUM
ajlsi-3268	23	37	)	)	PUNCT
ajlsi-3268	23	38	.	.	PUNCT
ajlsi-3268	24	1	the	the	DET
ajlsi-3268	24	2	cause	cause	NOUN
ajlsi-3268	24	3	of	of	ADP
ajlsi-3268	24	4	psoriasis	psoriasis	NOUN
ajlsi-3268	24	5	is	be	AUX
ajlsi-3268	24	6	still	still	ADV
ajlsi-3268	24	7	unknown	unknown	ADJ
ajlsi-3268	24	8	.	.	PUNCT
ajlsi-3268	25	1	according	accord	VERB
ajlsi-3268	25	2	to	to	ADP
ajlsi-3268	25	3	a	a	DET
ajlsi-3268	25	4	study	study	NOUN
ajlsi-3268	25	5	,	,	PUNCT
ajlsi-3268	25	6	erythrocyte	erythrocyte	NOUN
ajlsi-3268	25	7	-	-	PUNCT
ajlsi-3268	25	8	superoxide	superoxide	NOUN
ajlsi-3268	25	9	dismutase	dismutase	NOUN
ajlsi-3268	25	10	activity	activity	NOUN
ajlsi-3268	25	11	was	be	AUX
ajlsi-3268	25	12	lower	low	ADJ
ajlsi-3268	25	13	in	in	ADP
ajlsi-3268	25	14	psoriasis	psoriasis	NOUN
ajlsi-3268	25	15	patients	patient	NOUN
ajlsi-3268	25	16	and	and	CCONJ
ajlsi-3268	25	17	blood	blood	NOUN
ajlsi-3268	25	18	levels	level	NOUN
ajlsi-3268	25	19	of	of	ADP
ajlsi-3268	25	20	malondialdehyde	malondialdehyde	NOUN
ajlsi-3268	25	21	and	and	CCONJ
ajlsi-3268	25	22	nitric	nitric	ADJ
ajlsi-3268	25	23	oxide	oxide	NOUN
ajlsi-3268	25	24	end	end	NOUN
ajlsi-3268	25	25	products	product	NOUN
ajlsi-3268	25	26	were	be	AUX
ajlsi-3268	25	27	greater	great	ADJ
ajlsi-3268	25	28	.	.	PUNCT
ajlsi-3268	26	1	the	the	DET
ajlsi-3268	26	2	pathogenesis	pathogenesis	NOUN
ajlsi-3268	26	3	of	of	ADP
ajlsi-3268	26	4	psoriasis	psoriasis	NOUN
ajlsi-3268	26	5	is	be	AUX
ajlsi-3268	26	6	not	not	PART
ajlsi-3268	26	7	fully	fully	ADV
ajlsi-3268	26	8	elucidated	elucidate	VERB
ajlsi-3268	26	9	;	;	PUNCT
ajlsi-3268	26	10	three	three	NUM
ajlsi-3268	26	11	factors	factor	NOUN
ajlsi-3268	26	12	are	be	AUX
ajlsi-3268	26	13	responsible	responsible	ADJ
ajlsi-3268	26	14	for	for	ADP
ajlsi-3268	26	15	the	the	DET
ajlsi-3268	26	16	disease	disease	NOUN
ajlsi-3268	26	17	pathogenicity	pathogenicity	NOUN
ajlsi-3268	26	18	including	include	VERB
ajlsi-3268	26	19	;	;	PUNCT
ajlsi-3268	26	20	t	t	PROPN
ajlsi-3268	26	21	-	-	PUNCT
ajlsi-3268	26	22	cells	cell	NOUN
ajlsi-3268	26	23	,	,	PUNCT
ajlsi-3268	26	24	tumor	tumor	NOUN
ajlsi-3268	26	25	necrosis	necrosis	NOUN
ajlsi-3268	26	26	factor	factor	NOUN
ajlsi-3268	26	27	-	-	PUNCT
ajlsi-3268	26	28	alpha	alpha	NOUN
ajlsi-3268	26	29	(	(	PUNCT
ajlsi-3268	26	30	tnfα	tnfα	NOUN
ajlsi-3268	26	31	)	)	PUNCT
ajlsi-3268	26	32	,	,	PUNCT
ajlsi-3268	26	33	and	and	CCONJ
ajlsi-3268	26	34	dendritic	dendritic	ADJ
ajlsi-3268	26	35	cells	cell	NOUN
ajlsi-3268	26	36	(	(	PUNCT
ajlsi-3268	26	37	matsuzaki	matsuzaki	PROPN
ajlsi-3268	26	38	&	&	CCONJ
ajlsi-3268	26	39	umemura	umemura	PROPN
ajlsi-3268	26	40	,	,	PUNCT
ajlsi-3268	26	41	2018	2018	NUM
ajlsi-3268	26	42	)	)	PUNCT
ajlsi-3268	26	43	.	.	PUNCT
ajlsi-3268	27	1	while	while	SCONJ
ajlsi-3268	27	2	its	its	PRON
ajlsi-3268	27	3	major	major	ADJ
ajlsi-3268	27	4	clinical	clinical	ADJ
ajlsi-3268	27	5	findings	finding	NOUN
ajlsi-3268	27	6	are	be	AUX
ajlsi-3268	27	7	the	the	DET
ajlsi-3268	27	8	presence	presence	NOUN
ajlsi-3268	27	9	of	of	ADP
ajlsi-3268	27	10	psoriatic	psoriatic	ADJ
ajlsi-3268	27	11	patches	patch	NOUN
ajlsi-3268	27	12	on	on	ADP
ajlsi-3268	27	13	epidermal	epidermal	ADJ
ajlsi-3268	27	14	layer	layer	NOUN
ajlsi-3268	27	15	and	and	CCONJ
ajlsi-3268	27	16	deep	deep	ADJ
ajlsi-3268	27	17	down	down	ADV
ajlsi-3268	27	18	histologically	histologically	ADV
ajlsi-3268	27	19	to	to	ADP
ajlsi-3268	27	20	the	the	DET
ajlsi-3268	27	21	dermis	dermis	NOUN
ajlsi-3268	27	22	,	,	PUNCT
ajlsi-3268	27	23	which	which	PRON
ajlsi-3268	27	24	revealed	reveal	VERB
ajlsi-3268	27	25	that	that	SCONJ
ajlsi-3268	27	26	it	it	PRON
ajlsi-3268	27	27	is	be	AUX
ajlsi-3268	27	28	not	not	PART
ajlsi-3268	27	29	restricted	restrict	VERB
ajlsi-3268	27	30	to	to	ADP
ajlsi-3268	27	31	the	the	DET
ajlsi-3268	27	32	epidermal	epidermal	ADJ
ajlsi-3268	27	33	layer	layer	NOUN
ajlsi-3268	27	34	.	.	PUNCT
ajlsi-3268	28	1	the	the	DET
ajlsi-3268	28	2	main	main	ADJ
ajlsi-3268	28	3	member	member	NOUN
ajlsi-3268	28	4	of	of	ADP
ajlsi-3268	28	5	the	the	DET
ajlsi-3268	28	6	il-17	il-17	NUM
ajlsi-3268	28	7	group	group	NOUN
ajlsi-3268	28	8	,	,	PUNCT
ajlsi-3268	28	9	il-17	il-17	X
ajlsi-3268	28	10	,	,	PUNCT
ajlsi-3268	28	11	interacts	interact	VERB
ajlsi-3268	28	12	with	with	ADP
ajlsi-3268	28	13	several	several	ADJ
ajlsi-3268	28	14	immune	immune	ADJ
ajlsi-3268	28	15	cell	cell	NOUN
ajlsi-3268	28	16	types	type	NOUN
ajlsi-3268	28	17	and	and	CCONJ
ajlsi-3268	28	18	keratinocytes	keratinocyte	NOUN
ajlsi-3268	28	19	in	in	ADP
ajlsi-3268	28	20	the	the	DET
ajlsi-3268	28	21	dermal	dermal	ADJ
ajlsi-3268	28	22	layer	layer	NOUN
ajlsi-3268	28	23	of	of	ADP
ajlsi-3268	28	24	the	the	DET
ajlsi-3268	28	25	skin	skin	NOUN
ajlsi-3268	28	26	,	,	PUNCT
ajlsi-3268	28	27	making	make	VERB
ajlsi-3268	28	28	psoriasis	psoriasis	NOUN
ajlsi-3268	28	29	more	more	ADV
ajlsi-3268	28	30	pathogenic	pathogenic	ADJ
ajlsi-3268	28	31	.	.	PUNCT
ajlsi-3268	29	1	there	there	PRON
ajlsi-3268	29	2	are	be	VERB
ajlsi-3268	29	3	six	six	NUM
ajlsi-3268	29	4	components	component	NOUN
ajlsi-3268	29	5	of	of	ADP
ajlsi-3268	29	6	il	il	PROPN
ajlsi-3268	29	7	17	17	NUM
ajlsi-3268	29	8	(	(	PUNCT
ajlsi-3268	29	9	a	a	NOUN
ajlsi-3268	29	10	-	-	PUNCT
ajlsi-3268	29	11	f	f	NOUN
ajlsi-3268	29	12	)	)	PUNCT
ajlsi-3268	29	13	.	.	PUNCT
ajlsi-3268	30	1	consequently	consequently	ADV
ajlsi-3268	30	2	,	,	PUNCT
ajlsi-3268	30	3	the	the	DET
ajlsi-3268	30	4	human	human	PROPN
ajlsi-3268	30	5	t	t	PROPN
ajlsi-3268	30	6	cell	cell	NOUN
ajlsi-3268	30	7	has	have	VERB
ajlsi-3268	30	8	number	number	NOUN
ajlsi-3268	30	9	of	of	ADP
ajlsi-3268	30	10	subsets	subset	NOUN
ajlsi-3268	30	11	,	,	PUNCT
ajlsi-3268	30	12	and	and	CCONJ
ajlsi-3268	30	13	one	one	NUM
ajlsi-3268	30	14	of	of	ADP
ajlsi-3268	30	15	these	these	DET
ajlsi-3268	30	16	cells	cell	NOUN
ajlsi-3268	30	17	is	be	AUX
ajlsi-3268	30	18	th17	th17	PROPN
ajlsi-3268	30	19	,	,	PUNCT
ajlsi-3268	30	20	which	which	PRON
ajlsi-3268	30	21	produces	produce	VERB
ajlsi-3268	30	22	the	the	DET
ajlsi-3268	30	23	cytokine	cytokine	NOUN
ajlsi-3268	30	24	il-17	il-17	ADP
ajlsi-3268	30	25	.	.	PUNCT
ajlsi-3268	31	1	the	the	DET
ajlsi-3268	31	2	research	research	NOUN
ajlsi-3268	31	3	findings	finding	VERB
ajlsi-3268	31	4	from	from	ADP
ajlsi-3268	31	5	animal	animal	NOUN
ajlsi-3268	31	6	1	1	NUM
ajlsi-3268	31	7	school	school	NOUN
ajlsi-3268	31	8	of	of	ADP
ajlsi-3268	31	9	life	life	NOUN
ajlsi-3268	31	10	sciences	sciences	PROPN
ajlsi-3268	31	11	,	,	PUNCT
ajlsi-3268	31	12	university	university	NOUN
ajlsi-3268	31	13	of	of	ADP
ajlsi-3268	31	14	bradford	bradford	PROPN
ajlsi-3268	31	15	,	,	PUNCT
ajlsi-3268	31	16	bradford	bradford	NOUN
ajlsi-3268	31	17	,	,	PUNCT
ajlsi-3268	31	18	bd7	bd7	NOUN
ajlsi-3268	31	19	1dp	1dp	NOUN
ajlsi-3268	31	20	,	,	PUNCT
ajlsi-3268	31	21	uk	uk	PROPN
ajlsi-3268	31	22	2	2	NUM
ajlsi-3268	31	23	school	school	NOUN
ajlsi-3268	31	24	of	of	ADP
ajlsi-3268	31	25	pharmacy	pharmacy	NOUN
ajlsi-3268	31	26	,	,	PUNCT
ajlsi-3268	31	27	university	university	NOUN
ajlsi-3268	31	28	of	of	ADP
ajlsi-3268	31	29	bradford	bradford	PROPN
ajlsi-3268	31	30	,	,	PUNCT
ajlsi-3268	31	31	richmond	richmond	PROPN
ajlsi-3268	31	32	road	road	NOUN
ajlsi-3268	31	33	,	,	PUNCT
ajlsi-3268	31	34	bradford	bradford	NOUN
ajlsi-3268	31	35	,	,	PUNCT
ajlsi-3268	31	36	bd7	bd7	NOUN
ajlsi-3268	31	37	1dp	1dp	NOUN
ajlsi-3268	31	38	,	,	PUNCT
ajlsi-3268	31	39	uk	uk	PROPN
ajlsi-3268	31	40	3	3	NUM
ajlsi-3268	31	41	bradford	bradford	NOUN
ajlsi-3268	31	42	teaching	teaching	NOUN
ajlsi-3268	31	43	hospitals	hospital	NOUN
ajlsi-3268	31	44	nhs	nhs	PROPN
ajlsi-3268	31	45	foundation	foundation	PROPN
ajlsi-3268	31	46	trust	trust	PROPN
ajlsi-3268	31	47	,	,	PUNCT
ajlsi-3268	31	48	st	st	PROPN
ajlsi-3268	31	49	luke	luke	PROPN
ajlsi-3268	31	50	’s	’s	PART
ajlsi-3268	31	51	hospital	hospital	NOUN
ajlsi-3268	31	52	,	,	PUNCT
ajlsi-3268	31	53	little	little	ADJ
ajlsi-3268	31	54	horton	horton	PROPN
ajlsi-3268	31	55	lane	lane	PROPN
ajlsi-3268	31	56	,	,	PUNCT
ajlsi-3268	31	57	bd5	bd5	NOUN
ajlsi-3268	31	58	0na	0na	NOUN
ajlsi-3268	31	59	,	,	PUNCT
ajlsi-3268	31	60	uk	uk	PROPN
ajlsi-3268	31	61	4	4	NUM
ajlsi-3268	31	62	institute	institute	PROPN
ajlsi-3268	31	63	of	of	ADP
ajlsi-3268	31	64	biomedical	biomedical	ADJ
ajlsi-3268	31	65	and	and	CCONJ
ajlsi-3268	31	66	clinical	clinical	ADJ
ajlsi-3268	31	67	science	science	NOUN
ajlsi-3268	31	68	,	,	PUNCT
ajlsi-3268	31	69	college	college	NOUN
ajlsi-3268	31	70	of	of	ADP
ajlsi-3268	31	71	medicine	medicine	NOUN
ajlsi-3268	31	72	and	and	CCONJ
ajlsi-3268	31	73	health	health	NOUN
ajlsi-3268	31	74	,	,	PUNCT
ajlsi-3268	31	75	university	university	NOUN
ajlsi-3268	31	76	of	of	ADP
ajlsi-3268	31	77	exeter	exeter	PROPN
ajlsi-3268	31	78	,	,	PUNCT
ajlsi-3268	31	79	ex2	ex2	PROPN
ajlsi-3268	31	80	5dw	5dw	PROPN
ajlsi-3268	31	81	,	,	PUNCT
ajlsi-3268	31	82	uk	uk	PROPN
ajlsi-3268	31	83	*	*	PUNCT
ajlsi-3268	31	84	corresponding	correspond	VERB
ajlsi-3268	31	85	author	author	NOUN
ajlsi-3268	31	86	’s	’s	PART
ajlsi-3268	31	87	e	e	NOUN
ajlsi-3268	31	88	-	-	NOUN
ajlsi-3268	31	89	mail	mail	NOUN
ajlsi-3268	31	90	:	:	PUNCT
ajlsi-3268	31	91	layas698@outlook.com	layas698@outlook.com	X
ajlsi-3268	31	92	pa	pa	PROPN
ajlsi-3268	31	93	ge	ge	PROPN
ajlsi-3268	31	94	28	28	NUM
ajlsi-3268	31	95	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-3268	31	96	am	am	NOUN
ajlsi-3268	31	97	.	.	PUNCT
ajlsi-3268	32	1	j.	j.	PROPN
ajlsi-3268	32	2	life	life	PROPN
ajlsi-3268	32	3	sci	sci	PROPN
ajlsi-3268	32	4	.	.	PUNCT
ajlsi-3268	32	5	innov	innov	PROPN
ajlsi-3268	32	6	.	.	PUNCT
ajlsi-3268	33	1	4(1	4(1	NOUN
ajlsi-3268	33	2	)	)	PUNCT
ajlsi-3268	34	1	27	27	NUM
ajlsi-3268	34	2	-	-	SYM
ajlsi-3268	34	3	35	35	NUM
ajlsi-3268	34	4	,	,	PUNCT
ajlsi-3268	34	5	2025	2025	NUM
ajlsi-3268	34	6	knockout	knockout	NOUN
ajlsi-3268	34	7	models	model	NOUN
ajlsi-3268	34	8	proposed	propose	VERB
ajlsi-3268	34	9	that	that	SCONJ
ajlsi-3268	34	10	il-17	il-17	ADV
ajlsi-3268	34	11	and	and	CCONJ
ajlsi-3268	34	12	th17	th17	NOUN
ajlsi-3268	34	13	play	play	VERB
ajlsi-3268	34	14	a	a	DET
ajlsi-3268	34	15	major	major	ADJ
ajlsi-3268	34	16	role	role	NOUN
ajlsi-3268	34	17	to	to	PART
ajlsi-3268	34	18	cause	cause	VERB
ajlsi-3268	34	19	the	the	DET
ajlsi-3268	34	20	pathogenesis	pathogenesis	NOUN
ajlsi-3268	34	21	of	of	ADP
ajlsi-3268	34	22	this	this	DET
ajlsi-3268	34	23	disease	disease	NOUN
ajlsi-3268	34	24	.	.	PUNCT
ajlsi-3268	35	1	by	by	ADP
ajlsi-3268	35	2	stimulating	stimulate	VERB
ajlsi-3268	35	3	keratinocyte	keratinocyte	NOUN
ajlsi-3268	35	4	multiplication	multiplication	NOUN
ajlsi-3268	35	5	in	in	ADP
ajlsi-3268	35	6	the	the	DET
ajlsi-3268	35	7	epidermis	epidermis	NOUN
ajlsi-3268	35	8	,	,	PUNCT
ajlsi-3268	35	9	th17	th17	PROPN
ajlsi-3268	35	10	cytokines	cytokine	NOUN
ajlsi-3268	35	11	il-17	il-17	ADV
ajlsi-3268	35	12	,	,	PUNCT
ajlsi-3268	35	13	il-21	il-21	PRON
ajlsi-3268	35	14	,	,	PUNCT
ajlsi-3268	35	15	and	and	CCONJ
ajlsi-3268	35	16	il-22	il-22	NOUN
ajlsi-3268	35	17	,	,	PUNCT
ajlsi-3268	35	18	which	which	PRON
ajlsi-3268	35	19	are	be	AUX
ajlsi-3268	35	20	released	release	VERB
ajlsi-3268	35	21	by	by	ADP
ajlsi-3268	35	22	activated	activate	VERB
ajlsi-3268	35	23	t	t	NOUN
ajlsi-3268	35	24	cells	cell	NOUN
ajlsi-3268	35	25	,	,	PUNCT
ajlsi-3268	35	26	the	the	DET
ajlsi-3268	35	27	adaptive	adaptive	ADJ
ajlsi-3268	35	28	immune	immune	ADJ
ajlsi-3268	35	29	system	system	NOUN
ajlsi-3268	35	30	is	be	AUX
ajlsi-3268	35	31	maintained	maintain	VERB
ajlsi-3268	35	32	and	and	CCONJ
ajlsi-3268	35	33	psoriatic	psoriatic	ADJ
ajlsi-3268	35	34	inflammation	inflammation	NOUN
ajlsi-3268	35	35	is	be	AUX
ajlsi-3268	35	36	sustained	sustain	VERB
ajlsi-3268	35	37	.	.	PUNCT
ajlsi-3268	36	1	il-17a	il-17a	PROPN
ajlsi-3268	36	2	has	have	AUX
ajlsi-3268	36	3	been	be	AUX
ajlsi-3268	36	4	found	find	VERB
ajlsi-3268	36	5	to	to	PART
ajlsi-3268	36	6	be	be	AUX
ajlsi-3268	36	7	used	use	VERB
ajlsi-3268	36	8	in	in	ADP
ajlsi-3268	36	9	the	the	DET
ajlsi-3268	36	10	treatment	treatment	NOUN
ajlsi-3268	36	11	of	of	ADP
ajlsi-3268	36	12	moderate	moderate	ADJ
ajlsi-3268	36	13	to	to	ADP
ajlsi-3268	36	14	severe	severe	ADJ
ajlsi-3268	36	15	psoriasis	psoriasis	NOUN
ajlsi-3268	36	16	plaque	plaque	NOUN
ajlsi-3268	36	17	with	with	ADP
ajlsi-3268	36	18	an	an	DET
ajlsi-3268	36	19	improved	improved	ADJ
ajlsi-3268	36	20	efficacy	efficacy	NOUN
ajlsi-3268	36	21	.	.	PUNCT
ajlsi-3268	37	1	the	the	DET
ajlsi-3268	37	2	inhibitory	inhibitory	ADJ
ajlsi-3268	37	3	mechanism	mechanism	NOUN
ajlsi-3268	37	4	of	of	ADP
ajlsi-3268	37	5	il-17a	il-17a	PROPN
ajlsi-3268	37	6	works	work	VERB
ajlsi-3268	37	7	swiftly	swiftly	ADV
ajlsi-3268	37	8	and	and	CCONJ
ajlsi-3268	37	9	induces	induce	VERB
ajlsi-3268	37	10	sustained	sustain	VERB
ajlsi-3268	37	11	responses	response	NOUN
ajlsi-3268	37	12	with	with	ADP
ajlsi-3268	37	13	a	a	DET
ajlsi-3268	37	14	significant	significant	ADJ
ajlsi-3268	37	15	safety	safety	NOUN
ajlsi-3268	37	16	assurance	assurance	NOUN
ajlsi-3268	37	17	profile	profile	NOUN
ajlsi-3268	37	18	.	.	PUNCT
ajlsi-3268	38	1	through	through	ADP
ajlsi-3268	38	2	the	the	DET
ajlsi-3268	38	3	clinical	clinical	ADJ
ajlsi-3268	38	4	severity	severity	NOUN
ajlsi-3268	38	5	of	of	ADP
ajlsi-3268	38	6	the	the	DET
ajlsi-3268	38	7	pathological	pathological	ADJ
ajlsi-3268	38	8	condition	condition	NOUN
ajlsi-3268	38	9	,	,	PUNCT
ajlsi-3268	38	10	treating	treat	VERB
ajlsi-3268	38	11	parameters	parameter	NOUN
ajlsi-3268	38	12	of	of	ADP
ajlsi-3268	38	13	psoriasis	psoriasis	NOUN
ajlsi-3268	38	14	are	be	AUX
ajlsi-3268	38	15	determined	determine	VERB
ajlsi-3268	38	16	,	,	PUNCT
ajlsi-3268	38	17	which	which	PRON
ajlsi-3268	38	18	are	be	AUX
ajlsi-3268	38	19	based	base	VERB
ajlsi-3268	38	20	on	on	ADP
ajlsi-3268	38	21	numerous	numerous	ADJ
ajlsi-3268	38	22	factors	factor	NOUN
ajlsi-3268	38	23	,	,	PUNCT
ajlsi-3268	38	24	for	for	ADP
ajlsi-3268	38	25	instance	instance	NOUN
ajlsi-3268	38	26	the	the	DET
ajlsi-3268	38	27	dimensions	dimension	NOUN
ajlsi-3268	38	28	of	of	ADP
ajlsi-3268	38	29	affected	affected	ADJ
ajlsi-3268	38	30	area	area	NOUN
ajlsi-3268	38	31	,	,	PUNCT
ajlsi-3268	38	32	the	the	DET
ajlsi-3268	38	33	pasi	pasi	NOUN
ajlsi-3268	38	34	grades	grade	NOUN
ajlsi-3268	38	35	,	,	PUNCT
ajlsi-3268	38	36	and	and	CCONJ
ajlsi-3268	38	37	the	the	DET
ajlsi-3268	38	38	life	life	NOUN
ajlsi-3268	38	39	quality	quality	NOUN
ajlsi-3268	38	40	index	index	NOUN
ajlsi-3268	38	41	of	of	ADP
ajlsi-3268	38	42	dermatology	dermatology	NOUN
ajlsi-3268	38	43	.	.	PUNCT
ajlsi-3268	39	1	mild	mild	ADJ
ajlsi-3268	39	2	conditions	condition	NOUN
ajlsi-3268	39	3	can	can	AUX
ajlsi-3268	39	4	be	be	AUX
ajlsi-3268	39	5	addressed	address	VERB
ajlsi-3268	39	6	with	with	ADP
ajlsi-3268	39	7	topical	topical	ADJ
ajlsi-3268	39	8	therapies	therapy	NOUN
ajlsi-3268	39	9	,	,	PUNCT
ajlsi-3268	39	10	whereas	whereas	SCONJ
ajlsi-3268	39	11	moderate	moderate	ADJ
ajlsi-3268	39	12	to	to	ADP
ajlsi-3268	39	13	severe	severe	ADJ
ajlsi-3268	39	14	cases	case	NOUN
ajlsi-3268	39	15	may	may	AUX
ajlsi-3268	39	16	necessitate	necessitate	VERB
ajlsi-3268	39	17	phototherapy	phototherapy	NOUN
ajlsi-3268	39	18	or	or	CCONJ
ajlsi-3268	39	19	systemic	systemic	ADJ
ajlsi-3268	39	20	therapy	therapy	NOUN
ajlsi-3268	39	21	,	,	PUNCT
ajlsi-3268	39	22	comprising	comprise	VERB
ajlsi-3268	39	23	biological	biological	ADJ
ajlsi-3268	39	24	or	or	CCONJ
ajlsi-3268	39	25	non	non	ADJ
ajlsi-3268	39	26	-	-	ADJ
ajlsi-3268	39	27	biological	biological	ADJ
ajlsi-3268	39	28	interventions	intervention	NOUN
ajlsi-3268	39	29	or	or	CCONJ
ajlsi-3268	39	30	a	a	DET
ajlsi-3268	39	31	combination	combination	NOUN
ajlsi-3268	39	32	of	of	ADP
ajlsi-3268	39	33	both	both	PRON
ajlsi-3268	39	34	.	.	PUNCT
ajlsi-3268	40	1	secukinumab	secukinumab	NOUN
ajlsi-3268	40	2	,	,	PUNCT
ajlsi-3268	40	3	also	also	ADV
ajlsi-3268	40	4	known	know	VERB
ajlsi-3268	40	5	as	as	ADP
ajlsi-3268	40	6	ain457	ain457	PROPN
ajlsi-3268	40	7	,	,	PUNCT
ajlsi-3268	40	8	is	be	AUX
ajlsi-3268	40	9	a	a	DET
ajlsi-3268	40	10	biological	biological	ADJ
ajlsi-3268	40	11	medication	medication	NOUN
ajlsi-3268	40	12	that	that	PRON
ajlsi-3268	40	13	functions	function	NOUN
ajlsi-3268	40	14	as	as	ADP
ajlsi-3268	40	15	an	an	DET
ajlsi-3268	40	16	antiil17a	antiil17a	X
ajlsi-3268	40	17	monoclonal	monoclonal	NOUN
ajlsi-3268	40	18	antibody	antibody	NOUN
ajlsi-3268	40	19	(	(	PUNCT
ajlsi-3268	40	20	mab	mab	NOUN
ajlsi-3268	40	21	)	)	PUNCT
ajlsi-3268	40	22	.	.	PUNCT
ajlsi-3268	41	1	it	it	PRON
ajlsi-3268	41	2	is	be	AUX
ajlsi-3268	41	3	employed	employ	VERB
ajlsi-3268	41	4	to	to	PART
ajlsi-3268	41	5	treat	treat	VERB
ajlsi-3268	41	6	moderate	moderate	ADJ
ajlsi-3268	41	7	and	and	CCONJ
ajlsi-3268	41	8	severe	severe	ADJ
ajlsi-3268	41	9	psoriasis	psoriasis	NOUN
ajlsi-3268	41	10	,	,	PUNCT
ajlsi-3268	41	11	as	as	ADV
ajlsi-3268	41	12	well	well	ADV
ajlsi-3268	41	13	as	as	ADP
ajlsi-3268	41	14	psoriatic	psoriatic	ADJ
ajlsi-3268	41	15	arthritis	arthritis	NOUN
ajlsi-3268	41	16	(	(	PUNCT
ajlsi-3268	41	17	wagener	wagener	NOUN
ajlsi-3268	41	18	et	et	PROPN
ajlsi-3268	41	19	al	al	PROPN
ajlsi-3268	41	20	.	.	PROPN
ajlsi-3268	41	21	,	,	PUNCT
ajlsi-3268	41	22	2013	2013	NUM
ajlsi-3268	41	23	)	)	PUNCT
ajlsi-3268	41	24	.	.	PUNCT
ajlsi-3268	42	1	chinese	chinese	ADJ
ajlsi-3268	42	2	hamster	hamster	PROPN
ajlsi-3268	42	3	ovary	ovary	NOUN
ajlsi-3268	42	4	(	(	PUNCT
ajlsi-3268	42	5	cho	cho	ADJ
ajlsi-3268	42	6	)	)	PUNCT
ajlsi-3268	42	7	cells	cell	NOUN
ajlsi-3268	42	8	were	be	AUX
ajlsi-3268	42	9	used	use	VERB
ajlsi-3268	42	10	to	to	PART
ajlsi-3268	42	11	manufacture	manufacture	VERB
ajlsi-3268	42	12	secukinumab	secukinumab	NOUN
ajlsi-3268	42	13	,	,	PUNCT
ajlsi-3268	42	14	an	an	DET
ajlsi-3268	42	15	igg1	igg1	NOUN
ajlsi-3268	42	16	/	/	SYM
ajlsi-3268	42	17	k	k	ADJ
ajlsi-3268	42	18	-	-	PUNCT
ajlsi-3268	42	19	class	class	NOUN
ajlsi-3268	42	20	property	property	NOUN
ajlsi-3268	42	21	(	(	PUNCT
ajlsi-3268	42	22	molden	molden	PROPN
ajlsi-3268	42	23	et	et	PROPN
ajlsi-3268	42	24	al	al	PROPN
ajlsi-3268	42	25	.	.	PROPN
ajlsi-3268	42	26	,	,	PUNCT
ajlsi-3268	42	27	2021	2021	NUM
ajlsi-3268	42	28	)	)	PUNCT
ajlsi-3268	42	29	.	.	PUNCT
ajlsi-3268	43	1	secukinumab	secukinumab	NOUN
ajlsi-3268	43	2	has	have	AUX
ajlsi-3268	43	3	been	be	AUX
ajlsi-3268	43	4	shown	show	VERB
ajlsi-3268	43	5	to	to	PART
ajlsi-3268	43	6	have	have	VERB
ajlsi-3268	43	7	a	a	DET
ajlsi-3268	43	8	superiority	superiority	NOUN
ajlsi-3268	43	9	over	over	ADP
ajlsi-3268	43	10	other	other	ADJ
ajlsi-3268	43	11	biological	biological	ADJ
ajlsi-3268	43	12	treatments	treatment	NOUN
ajlsi-3268	43	13	in	in	ADP
ajlsi-3268	43	14	terms	term	NOUN
ajlsi-3268	43	15	of	of	ADP
ajlsi-3268	43	16	achieving	achieve	VERB
ajlsi-3268	43	17	severity	severity	NOUN
ajlsi-3268	43	18	index	index	NOUN
ajlsi-3268	43	19	pasi	pasi	NOUN
ajlsi-3268	43	20	75	75	NUM
ajlsi-3268	43	21	(	(	PUNCT
ajlsi-3268	43	22	bagel	bagel	NOUN
ajlsi-3268	43	23	et	et	PROPN
ajlsi-3268	43	24	al	al	PROPN
ajlsi-3268	43	25	.	.	PROPN
ajlsi-3268	43	26	,	,	PUNCT
ajlsi-3268	43	27	2021	2021	NUM
ajlsi-3268	43	28	)	)	PUNCT
ajlsi-3268	43	29	.	.	PUNCT
ajlsi-3268	44	1	also	also	ADV
ajlsi-3268	44	2	,	,	PUNCT
ajlsi-3268	44	3	it	it	PRON
ajlsi-3268	44	4	has	have	VERB
ajlsi-3268	44	5	the	the	DET
ajlsi-3268	44	6	ability	ability	NOUN
ajlsi-3268	44	7	to	to	PART
ajlsi-3268	44	8	sustain	sustain	VERB
ajlsi-3268	44	9	its	its	PRON
ajlsi-3268	44	10	effectiveness	effectiveness	NOUN
ajlsi-3268	44	11	over	over	ADP
ajlsi-3268	44	12	time	time	NOUN
ajlsi-3268	44	13	contrasted	contrast	VERB
ajlsi-3268	44	14	to	to	ADP
ajlsi-3268	44	15	additional	additional	ADJ
ajlsi-3268	44	16	biological	biological	ADJ
ajlsi-3268	44	17	treatments	treatment	NOUN
ajlsi-3268	44	18	(	(	PUNCT
ajlsi-3268	44	19	bissonnette	bissonnette	NOUN
ajlsi-3268	44	20	et	et	PROPN
ajlsi-3268	44	21	al	al	PROPN
ajlsi-3268	44	22	.	.	PROPN
ajlsi-3268	44	23	,	,	PUNCT
ajlsi-3268	44	24	2018	2018	NUM
ajlsi-3268	44	25	)	)	PUNCT
ajlsi-3268	44	26	.	.	PUNCT
ajlsi-3268	45	1	neutralized	neutralize	VERB
ajlsi-3268	45	2	and	and	CCONJ
ajlsi-3268	45	3	binding	bind	VERB
ajlsi-3268	45	4	aspects	aspect	NOUN
ajlsi-3268	45	5	of	of	ADP
ajlsi-3268	45	6	the	the	DET
ajlsi-3268	45	7	cytokine	cytokine	NOUN
ajlsi-3268	45	8	interleukin-17a	interleukin-17a	PROPN
ajlsi-3268	45	9	(	(	PUNCT
ajlsi-3268	45	10	il17a	il17a	X
ajlsi-3268	45	11	)	)	PUNCT
ajlsi-3268	45	12	are	be	AUX
ajlsi-3268	45	13	responsible	responsible	ADJ
ajlsi-3268	45	14	to	to	PART
ajlsi-3268	45	15	improve	improve	VERB
ajlsi-3268	45	16	the	the	DET
ajlsi-3268	45	17	secukinumab	secukinumab	NOUN
ajlsi-3268	45	18	work	work	NOUN
ajlsi-3268	45	19	efficiency	efficiency	NOUN
ajlsi-3268	45	20	for	for	ADP
ajlsi-3268	45	21	the	the	DET
ajlsi-3268	45	22	treatment	treatment	NOUN
ajlsi-3268	45	23	of	of	ADP
ajlsi-3268	45	24	psoriasis	psoriasis	NOUN
ajlsi-3268	45	25	.	.	PUNCT
ajlsi-3268	46	1	secukinumab	secukinumab	NOUN
ajlsi-3268	46	2	is	be	AUX
ajlsi-3268	46	3	a	a	DET
ajlsi-3268	46	4	fully	fully	ADV
ajlsi-3268	46	5	human	human	ADJ
ajlsi-3268	46	6	mono	mono	NOUN
ajlsi-3268	46	7	-	-	PUNCT
ajlsi-3268	46	8	clonal	clonal	ADJ
ajlsi-3268	46	9	antibody	antibody	NOUN
ajlsi-3268	46	10	that	that	PRON
ajlsi-3268	46	11	selectively	selectively	ADV
ajlsi-3268	46	12	binds	bind	VERB
ajlsi-3268	46	13	and	and	CCONJ
ajlsi-3268	46	14	neutralizes	neutralize	VERB
ajlsi-3268	46	15	the	the	DET
ajlsi-3268	46	16	pro	pro	ADJ
ajlsi-3268	46	17	-	-	ADJ
ajlsi-3268	46	18	inflammatory	inflammatory	ADJ
ajlsi-3268	46	19	cytokine	cytokine	NOUN
ajlsi-3268	46	20	inter	inter	ADJ
ajlsi-3268	46	21	-	-	ADJ
ajlsi-3268	46	22	leukin-17a	leukin-17a	PROPN
ajlsi-3268	46	23	(	(	PUNCT
ajlsi-3268	46	24	il-17a31009130	il-17a31009130	PROPN
ajlsi-3268	46	25	)	)	PUNCT
ajlsi-3268	46	26	without	without	ADP
ajlsi-3268	46	27	producing	produce	VERB
ajlsi-3268	46	28	any	any	DET
ajlsi-3268	46	29	effect	effect	NOUN
ajlsi-3268	46	30	on	on	ADP
ajlsi-3268	46	31	il-17f	il-17f	ADJ
ajlsi-3268	46	32	and	and	CCONJ
ajlsi-3268	46	33	th17	th17	PROPN
ajlsi-3268	46	34	cells	cell	NOUN
ajlsi-3268	46	35	(	(	PUNCT
ajlsi-3268	46	36	berg	berg	PROPN
ajlsi-3268	46	37	et	et	PROPN
ajlsi-3268	46	38	al	al	PROPN
ajlsi-3268	46	39	.	.	PROPN
ajlsi-3268	46	40	,	,	PUNCT
ajlsi-3268	46	41	2021	2021	NUM
ajlsi-3268	46	42	)	)	PUNCT
ajlsi-3268	46	43	.	.	PUNCT
ajlsi-3268	47	1	additionally	additionally	ADV
ajlsi-3268	47	2	,	,	PUNCT
ajlsi-3268	47	3	it	it	PRON
ajlsi-3268	47	4	has	have	VERB
ajlsi-3268	47	5	no	no	DET
ajlsi-3268	47	6	direct	direct	ADJ
ajlsi-3268	47	7	impact	impact	NOUN
ajlsi-3268	47	8	on	on	ADP
ajlsi-3268	47	9	the	the	DET
ajlsi-3268	47	10	th1	th1	NOUN
ajlsi-3268	47	11	cascade	cascade	NOUN
ajlsi-3268	47	12	.	.	PUNCT
ajlsi-3268	48	1	current	current	ADJ
ajlsi-3268	48	2	studies	study	NOUN
ajlsi-3268	48	3	have	have	AUX
ajlsi-3268	48	4	revealed	reveal	VERB
ajlsi-3268	48	5	that	that	SCONJ
ajlsi-3268	48	6	increased	increase	VERB
ajlsi-3268	48	7	t	t	PROPN
ajlsi-3268	48	8	-	-	PUNCT
ajlsi-3268	48	9	cell	cell	NOUN
ajlsi-3268	48	10	abnormalities	abnormality	NOUN
ajlsi-3268	48	11	and	and	CCONJ
ajlsi-3268	48	12	oxidative	oxidative	ADJ
ajlsi-3268	48	13	stress	stress	NOUN
ajlsi-3268	48	14	(	(	PUNCT
ajlsi-3268	48	15	os	os	NOUN
ajlsi-3268	48	16	)	)	PUNCT
ajlsi-3268	48	17	are	be	AUX
ajlsi-3268	48	18	central	central	ADJ
ajlsi-3268	48	19	parameters	parameter	NOUN
ajlsi-3268	48	20	that	that	PRON
ajlsi-3268	48	21	lead	lead	VERB
ajlsi-3268	48	22	to	to	ADP
ajlsi-3268	48	23	the	the	DET
ajlsi-3268	48	24	pathogenesis	pathogenesis	NOUN
ajlsi-3268	48	25	of	of	ADP
ajlsi-3268	48	26	psoriasis	psoriasis	NOUN
ajlsi-3268	48	27	.	.	PUNCT
ajlsi-3268	49	1	reactive	reactive	ADJ
ajlsi-3268	49	2	oxygen	oxygen	NOUN
ajlsi-3268	49	3	species	specie	NOUN
ajlsi-3268	49	4	(	(	PUNCT
ajlsi-3268	49	5	ros	ros	PROPN
ajlsi-3268	49	6	)	)	PUNCT
ajlsi-3268	49	7	suppress	suppress	VERB
ajlsi-3268	49	8	regulatory	regulatory	ADJ
ajlsi-3268	49	9	t	t	NOUN
ajlsi-3268	49	10	lymphocytes	lymphocyte	VERB
ajlsi-3268	49	11	’	'	PUNCT
ajlsi-3268	49	12	(	(	PUNCT
ajlsi-3268	49	13	treg	treg	PROPN
ajlsi-3268	49	14	)	)	PUNCT
ajlsi-3268	49	15	ability	ability	NOUN
ajlsi-3268	49	16	to	to	PART
ajlsi-3268	49	17	reduce	reduce	VERB
ajlsi-3268	49	18	inflammation	inflammation	NOUN
ajlsi-3268	49	19	while	while	SCONJ
ajlsi-3268	49	20	promoting	promote	VERB
ajlsi-3268	49	21	the	the	DET
ajlsi-3268	49	22	growth	growth	NOUN
ajlsi-3268	49	23	and	and	CCONJ
ajlsi-3268	49	24	specialization	specialization	NOUN
ajlsi-3268	49	25	of	of	ADP
ajlsi-3268	49	26	th1/	th1/	PROPN
ajlsi-3268	49	27	th17	th17	PROPN
ajlsi-3268	49	28	/	/	SYM
ajlsi-3268	49	29	th22	th22	PROPN
ajlsi-3268	49	30	cells	cell	NOUN
ajlsi-3268	49	31	.	.	PUNCT
ajlsi-3268	50	1	successive	successive	ADJ
ajlsi-3268	50	2	secretions	secretion	NOUN
ajlsi-3268	50	3	of	of	ADP
ajlsi-3268	50	4	inflammatory	inflammatory	ADJ
ajlsi-3268	50	5	cytokines	cytokine	NOUN
ajlsi-3268	50	6	,	,	PUNCT
ajlsi-3268	50	7	such	such	ADJ
ajlsi-3268	50	8	as	as	ADP
ajlsi-3268	50	9	tumor	tumor	NOUN
ajlsi-3268	50	10	necrosis	necrosis	NOUN
ajlsi-3268	50	11	factor	factor	NOUN
ajlsi-3268	50	12	-	-	PUNCT
ajlsi-3268	50	13	alpha	alpha	NOUN
ajlsi-3268	50	14	(	(	PUNCT
ajlsi-3268	50	15	tnf	tnf	PROPN
ajlsi-3268	50	16	-	-	PUNCT
ajlsi-3268	50	17	α	α	NOUN
ajlsi-3268	50	18	)	)	PUNCT
ajlsi-3268	50	19	,	,	PUNCT
ajlsi-3268	50	20	vascular	vascular	ADJ
ajlsi-3268	50	21	endothelial	endothelial	ADJ
ajlsi-3268	50	22	growth	growth	NOUN
ajlsi-3268	50	23	factor	factor	NOUN
ajlsi-3268	50	24	(	(	PUNCT
ajlsi-3268	50	25	vegf	vegf	PROPN
ajlsi-3268	50	26	)	)	PUNCT
ajlsi-3268	50	27	,	,	PUNCT
ajlsi-3268	50	28	interleukin	interleukin	NOUN
ajlsi-3268	50	29	(	(	PUNCT
ajlsi-3268	50	30	il)-17	il)-17	PROPN
ajlsi-3268	50	31	,	,	PUNCT
ajlsi-3268	50	32	il-22	il-22	NOUN
ajlsi-3268	50	33	,	,	PUNCT
ajlsi-3268	50	34	and	and	CCONJ
ajlsi-3268	50	35	interferon	interferon	ADJ
ajlsi-3268	50	36	-	-	PUNCT
ajlsi-3268	50	37	gamma	gamma	NOUN
ajlsi-3268	50	38	(	(	PUNCT
ajlsi-3268	50	39	ifn	ifn	PROPN
ajlsi-3268	50	40	-	-	PUNCT
ajlsi-3268	50	41	γ	γ	NOUN
ajlsi-3268	50	42	)	)	PUNCT
ajlsi-3268	50	43	,	,	PUNCT
ajlsi-3268	50	44	stimulate	stimulate	VERB
ajlsi-3268	50	45	keratinocyte	keratinocyte	NOUN
ajlsi-3268	50	46	number	number	NOUN
ajlsi-3268	50	47	increasing	increase	VERB
ajlsi-3268	50	48	and	and	CCONJ
ajlsi-3268	50	49	angiogenesis	angiogenesis	NOUN
ajlsi-3268	50	50	(	(	PUNCT
ajlsi-3268	50	51	lai	lai	PROPN
ajlsi-3268	50	52	et	et	PROPN
ajlsi-3268	50	53	al	al	PROPN
ajlsi-3268	50	54	.	.	PROPN
ajlsi-3268	50	55	,	,	PUNCT
ajlsi-3268	50	56	2018	2018	NUM
ajlsi-3268	50	57	;	;	PUNCT
ajlsi-3268	50	58	ciążyńska	ciążyńska	PROPN
ajlsi-3268	50	59	et	et	PROPN
ajlsi-3268	50	60	al	al	PROPN
ajlsi-3268	50	61	.	.	PROPN
ajlsi-3268	50	62	,	,	PUNCT
ajlsi-3268	50	63	2021	2021	NUM
ajlsi-3268	50	64	)	)	PUNCT
ajlsi-3268	50	65	.	.	PUNCT
ajlsi-3268	51	1	liposomes	liposome	NOUN
ajlsi-3268	51	2	are	be	AUX
ajlsi-3268	51	3	vesicles	vesicle	NOUN
ajlsi-3268	51	4	that	that	PRON
ajlsi-3268	51	5	contain	contain	VERB
ajlsi-3268	51	6	several	several	ADJ
ajlsi-3268	51	7	thin	thin	ADJ
ajlsi-3268	51	8	layered	layered	ADJ
ajlsi-3268	51	9	membrane	membrane	NOUN
ajlsi-3268	51	10	or	or	CCONJ
ajlsi-3268	51	11	shells	shell	NOUN
ajlsi-3268	51	12	comprised	comprise	VERB
ajlsi-3268	51	13	of	of	ADP
ajlsi-3268	51	14	a	a	DET
ajlsi-3268	51	15	phospholipid	phospholipid	NOUN
ajlsi-3268	51	16	bilayer	bilayer	NOUN
ajlsi-3268	51	17	covering	cover	VERB
ajlsi-3268	51	18	an	an	DET
ajlsi-3268	51	19	insignificant	insignificant	ADJ
ajlsi-3268	51	20	amount	amount	NOUN
ajlsi-3268	51	21	of	of	ADP
ajlsi-3268	51	22	aqueous	aqueous	ADJ
ajlsi-3268	51	23	liquid	liquid	NOUN
ajlsi-3268	51	24	,	,	PUNCT
ajlsi-3268	51	25	used	use	VERB
ajlsi-3268	51	26	for	for	ADP
ajlsi-3268	51	27	biotechnological	biotechnological	ADJ
ajlsi-3268	51	28	and	and	CCONJ
ajlsi-3268	51	29	biomedical	biomedical	ADJ
ajlsi-3268	51	30	roles	role	NOUN
ajlsi-3268	51	31	.	.	PUNCT
ajlsi-3268	52	1	on	on	ADP
ajlsi-3268	52	2	the	the	DET
ajlsi-3268	52	3	basis	basis	NOUN
ajlsi-3268	52	4	of	of	ADP
ajlsi-3268	52	5	preparation	preparation	NOUN
ajlsi-3268	52	6	and	and	CCONJ
ajlsi-3268	52	7	its	its	PRON
ajlsi-3268	52	8	use	use	NOUN
ajlsi-3268	52	9	,	,	PUNCT
ajlsi-3268	52	10	they	they	PRON
ajlsi-3268	52	11	are	be	AUX
ajlsi-3268	52	12	different	different	ADJ
ajlsi-3268	52	13	in	in	ADP
ajlsi-3268	52	14	size	size	NOUN
ajlsi-3268	52	15	ranging	range	VERB
ajlsi-3268	52	16	from	from	ADP
ajlsi-3268	52	17	several	several	ADJ
ajlsi-3268	52	18	specific	specific	ADJ
ajlsi-3268	52	19	nanometers	nanometer	NOUN
ajlsi-3268	52	20	to	to	ADP
ajlsi-3268	52	21	hundred	hundred	NUM
ajlsi-3268	52	22	micrometers	micrometer	NOUN
ajlsi-3268	52	23	(	(	PUNCT
ajlsi-3268	52	24	lombardo	lombardo	PROPN
ajlsi-3268	52	25	&	&	CCONJ
ajlsi-3268	52	26	kiselev	kiselev	PROPN
ajlsi-3268	52	27	,	,	PUNCT
ajlsi-3268	52	28	2022	2022	NUM
ajlsi-3268	52	29	)	)	PUNCT
ajlsi-3268	52	30	.	.	PUNCT
ajlsi-3268	53	1	bio	bio	ADJ
ajlsi-3268	53	2	-	-	ADJ
ajlsi-3268	53	3	logically	logically	ADV
ajlsi-3268	53	4	active	active	ADJ
ajlsi-3268	53	5	compounds	compound	NOUN
ajlsi-3268	53	6	of	of	ADP
ajlsi-3268	53	7	liposomes	liposome	NOUN
ajlsi-3268	53	8	,	,	PUNCT
ajlsi-3268	53	9	such	such	ADJ
ajlsi-3268	53	10	as	as	ADP
ajlsi-3268	53	11	genetic	genetic	ADJ
ajlsi-3268	53	12	materials	material	NOUN
ajlsi-3268	53	13	,	,	PUNCT
ajlsi-3268	53	14	chelating	chelating	NOUN
ajlsi-3268	53	15	agents	agent	NOUN
ajlsi-3268	53	16	,	,	PUNCT
ajlsi-3268	53	17	proteins	protein	NOUN
ajlsi-3268	53	18	,	,	PUNCT
ajlsi-3268	53	19	enzymes	enzyme	NOUN
ajlsi-3268	53	20	,	,	PUNCT
ajlsi-3268	53	21	peptides	peptide	NOUN
ajlsi-3268	53	22	,	,	PUNCT
ajlsi-3268	53	23	vaccines	vaccine	NOUN
ajlsi-3268	53	24	,	,	PUNCT
ajlsi-3268	53	25	hormones	hormone	NOUN
ajlsi-3268	53	26	and	and	CCONJ
ajlsi-3268	53	27	antimicrobial	antimicrobial	ADJ
ajlsi-3268	53	28	agents	agent	NOUN
ajlsi-3268	53	29	have	have	AUX
ajlsi-3268	53	30	been	be	AUX
ajlsi-3268	53	31	evaluated	evaluate	VERB
ajlsi-3268	53	32	for	for	ADP
ajlsi-3268	53	33	patient	patient	ADJ
ajlsi-3268	53	34	use	use	NOUN
ajlsi-3268	53	35	.	.	PUNCT
ajlsi-3268	54	1	because	because	SCONJ
ajlsi-3268	54	2	of	of	ADP
ajlsi-3268	54	3	its	its	PRON
ajlsi-3268	54	4	superior	superior	ADJ
ajlsi-3268	54	5	mechanical	mechanical	ADJ
ajlsi-3268	54	6	,	,	PUNCT
ajlsi-3268	54	7	optical	optical	ADJ
ajlsi-3268	54	8	,	,	PUNCT
ajlsi-3268	54	9	and	and	CCONJ
ajlsi-3268	54	10	electrical	electrical	ADJ
ajlsi-3268	54	11	capabilities	capability	NOUN
ajlsi-3268	54	12	,	,	PUNCT
ajlsi-3268	54	13	quantum	quantum	NOUN
ajlsi-3268	54	14	mechanics	mechanic	NOUN
ajlsi-3268	54	15	,	,	PUNCT
ajlsi-3268	54	16	and	and	CCONJ
ajlsi-3268	54	17	nanoscale	nanoscale	NOUN
ajlsi-3268	54	18	volumesurface	volumesurface	NOUN
ajlsi-3268	54	19	area	area	NOUN
ajlsi-3268	54	20	ratio	ratio	NOUN
ajlsi-3268	54	21	,	,	PUNCT
ajlsi-3268	54	22	liposomes	liposome	NOUN
ajlsi-3268	54	23	are	be	AUX
ajlsi-3268	54	24	becoming	become	VERB
ajlsi-3268	54	25	more	more	ADV
ajlsi-3268	54	26	and	and	CCONJ
ajlsi-3268	54	27	more	more	ADV
ajlsi-3268	54	28	common	common	ADJ
ajlsi-3268	54	29	in	in	ADP
ajlsi-3268	54	30	sophisticated	sophisticated	ADJ
ajlsi-3268	54	31	technology	technology	NOUN
ajlsi-3268	54	32	(	(	PUNCT
ajlsi-3268	54	33	sercombe	sercombe	NOUN
ajlsi-3268	54	34	et	et	PROPN
ajlsi-3268	54	35	al	al	PROPN
ajlsi-3268	54	36	.	.	PROPN
ajlsi-3268	54	37	,	,	PUNCT
ajlsi-3268	54	38	2015	2015	NUM
ajlsi-3268	54	39	;	;	PUNCT
ajlsi-3268	54	40	nsairat	nsairat	NOUN
ajlsi-3268	54	41	et	et	PROPN
ajlsi-3268	54	42	al	al	PROPN
ajlsi-3268	54	43	.	.	PROPN
ajlsi-3268	54	44	,	,	PUNCT
ajlsi-3268	54	45	2022	2022	NUM
ajlsi-3268	54	46	)	)	PUNCT
ajlsi-3268	54	47	.	.	PUNCT
ajlsi-3268	55	1	because	because	SCONJ
ajlsi-3268	55	2	they	they	PRON
ajlsi-3268	55	3	increase	increase	VERB
ajlsi-3268	55	4	the	the	DET
ajlsi-3268	55	5	flow	flow	NOUN
ajlsi-3268	55	6	of	of	ADP
ajlsi-3268	55	7	drugs	drug	NOUN
ajlsi-3268	55	8	,	,	PUNCT
ajlsi-3268	55	9	they	they	PRON
ajlsi-3268	55	10	also	also	ADV
ajlsi-3268	55	11	aid	aid	VERB
ajlsi-3268	55	12	in	in	ADP
ajlsi-3268	55	13	reducing	reduce	VERB
ajlsi-3268	55	14	treatment	treatment	NOUN
ajlsi-3268	55	15	side	side	NOUN
ajlsi-3268	55	16	effects	effect	NOUN
ajlsi-3268	55	17	.	.	PUNCT
ajlsi-3268	56	1	this	this	DET
ajlsi-3268	56	2	study	study	NOUN
ajlsi-3268	56	3	aimed	aim	VERB
ajlsi-3268	56	4	to	to	PART
ajlsi-3268	56	5	determine	determine	VERB
ajlsi-3268	56	6	that	that	SCONJ
ajlsi-3268	56	7	how	how	SCONJ
ajlsi-3268	56	8	liposomes	liposome	NOUN
ajlsi-3268	56	9	and	and	CCONJ
ajlsi-3268	56	10	secukinumab	secukinumab	VERB
ajlsi-3268	56	11	bulk	bulk	ADJ
ajlsi-3268	56	12	form	form	NOUN
ajlsi-3268	56	13	affected	affect	VERB
ajlsi-3268	56	14	dna	dna	ADJ
ajlsi-3268	56	15	damage	damage	NOUN
ajlsi-3268	56	16	in	in	ADP
ajlsi-3268	56	17	peripheral	peripheral	ADJ
ajlsi-3268	56	18	blood	blood	NOUN
ajlsi-3268	56	19	cells	cell	NOUN
ajlsi-3268	56	20	from	from	ADP
ajlsi-3268	56	21	both	both	CCONJ
ajlsi-3268	56	22	healthy	healthy	ADJ
ajlsi-3268	56	23	people	people	NOUN
ajlsi-3268	56	24	and	and	CCONJ
ajlsi-3268	56	25	psoriasis	psoriasis	NOUN
ajlsi-3268	56	26	sufferers	sufferer	NOUN
ajlsi-3268	56	27	by	by	ADP
ajlsi-3268	56	28	using	use	VERB
ajlsi-3268	56	29	the	the	DET
ajlsi-3268	56	30	comet	comet	NOUN
ajlsi-3268	56	31	assay	assay	VERB
ajlsi-3268	56	32	and	and	CCONJ
ajlsi-3268	56	33	micronucleus	micronucleus	PROPN
ajlsi-3268	56	34	(	(	PUNCT
ajlsi-3268	56	35	cbmn	cbmn	PROPN
ajlsi-3268	56	36	)	)	PUNCT
ajlsi-3268	56	37	assay	assay	NOUN
ajlsi-3268	56	38	.	.	PUNCT
ajlsi-3268	57	1	additionally	additionally	ADV
ajlsi-3268	57	2	,	,	PUNCT
ajlsi-3268	57	3	the	the	DET
ajlsi-3268	57	4	study	study	NOUN
ajlsi-3268	57	5	aimed	aim	VERB
ajlsi-3268	57	6	to	to	PART
ajlsi-3268	57	7	determine	determine	VERB
ajlsi-3268	57	8	the	the	DET
ajlsi-3268	57	9	best	good	ADJ
ajlsi-3268	57	10	concentration	concentration	NOUN
ajlsi-3268	57	11	of	of	ADP
ajlsi-3268	57	12	figure	figure	NOUN
ajlsi-3268	57	13	1	1	NUM
ajlsi-3268	57	14	:	:	PUNCT
ajlsi-3268	57	15	pathogenesis	pathogenesis	NOUN
ajlsi-3268	57	16	of	of	ADP
ajlsi-3268	57	17	psoriasis	psoriasis	NOUN
ajlsi-3268	57	18	,	,	PUNCT
ajlsi-3268	57	19	the	the	DET
ajlsi-3268	57	20	cytokines	cytokine	NOUN
ajlsi-3268	57	21	were	be	AUX
ajlsi-3268	57	22	activated	activate	VERB
ajlsi-3268	57	23	in	in	ADP
ajlsi-3268	57	24	psoriasis	psoriasis	NOUN
ajlsi-3268	57	25	and	and	CCONJ
ajlsi-3268	57	26	their	their	PRON
ajlsi-3268	57	27	further	further	ADJ
ajlsi-3268	57	28	cascades	cascade	NOUN
ajlsi-3268	57	29	in	in	ADP
ajlsi-3268	57	30	the	the	DET
ajlsi-3268	57	31	skin	skin	NOUN
ajlsi-3268	57	32	.	.	PUNCT
ajlsi-3268	58	1	interleukin	interleukin	NOUN
ajlsi-3268	58	2	(	(	PUNCT
ajlsi-3268	58	3	il)-23	il)-23	AUX
ajlsi-3268	58	4	produced	produce	VERB
ajlsi-3268	58	5	by	by	ADP
ajlsi-3268	58	6	various	various	ADJ
ajlsi-3268	58	7	il-23producing	il-23produce	VERB
ajlsi-3268	58	8	cells	cell	NOUN
ajlsi-3268	58	9	induces	induce	VERB
ajlsi-3268	58	10	il-17	il-17	ADP
ajlsi-3268	58	11	production	production	NOUN
ajlsi-3268	58	12	from	from	ADP
ajlsi-3268	58	13	various	various	ADJ
ajlsi-3268	58	14	il-17	il-17	ADV
ajlsi-3268	58	15	-	-	PUNCT
ajlsi-3268	58	16	producing	produce	VERB
ajlsi-3268	58	17	cells	cell	NOUN
ajlsi-3268	58	18	such	such	ADJ
ajlsi-3268	58	19	as	as	ADP
ajlsi-3268	58	20	t	t	NOUN
ajlsi-3268	58	21	-	-	PUNCT
ajlsi-3268	58	22	helper	helper	NOUN
ajlsi-3268	58	23	(	(	PUNCT
ajlsi-3268	58	24	th)17	th)17	PROPN
ajlsi-3268	58	25	,	,	PUNCT
ajlsi-3268	58	26	il-17	il-17	ADV
ajlsi-3268	58	27	producing	produce	VERB
ajlsi-3268	58	28	cd8	cd8	PROPN
ajlsi-3268	58	29	+	+	PROPN
ajlsi-3268	58	30	t	t	PROPN
ajlsi-3268	58	31	cells	cell	NOUN
ajlsi-3268	58	32	(	(	PUNCT
ajlsi-3268	58	33	tc17	tc17	PROPN
ajlsi-3268	58	34	)	)	PUNCT
ajlsi-3268	58	35	,	,	PUNCT
ajlsi-3268	58	36	and	and	CCONJ
ajlsi-3268	58	37	innate	innate	ADJ
ajlsi-3268	58	38	lymphoid	lymphoid	NOUN
ajlsi-3268	58	39	cells	cell	NOUN
ajlsi-3268	58	40	type	type	VERB
ajlsi-3268	58	41	3	3	NUM
ajlsi-3268	58	42	(	(	PUNCT
ajlsi-3268	58	43	ilc3	ilc3	PROPN
ajlsi-3268	58	44	)	)	PUNCT
ajlsi-3268	58	45	.	.	PUNCT
ajlsi-3268	59	1	il-17	il-17	NUM
ajlsi-3268	59	2	stimulates	stimulate	VERB
ajlsi-3268	59	3	keratinocytes	keratinocyte	NOUN
ajlsi-3268	59	4	to	to	PART
ajlsi-3268	59	5	produce	produce	VERB
ajlsi-3268	59	6	inflammatory	inflammatory	ADJ
ajlsi-3268	59	7	cytokines	cytokine	NOUN
ajlsi-3268	59	8	/	/	SYM
ajlsi-3268	59	9	chemokines	chemokine	NOUN
ajlsi-3268	59	10	,	,	PUNCT
ajlsi-3268	59	11	which	which	PRON
ajlsi-3268	59	12	further	far	ADV
ajlsi-3268	59	13	activate	activate	VERB
ajlsi-3268	59	14	il-23	il-23	NOUN
ajlsi-3268	59	15	-	-	PUNCT
ajlsi-3268	59	16	producing	produce	VERB
ajlsi-3268	59	17	cells	cell	NOUN
ajlsi-3268	59	18	and	and	CCONJ
ajlsi-3268	59	19	recruit	recruit	NOUN
ajlsi-3268	59	20	il-17	il-17	ADV
ajlsi-3268	59	21	-	-	PUNCT
ajlsi-3268	59	22	producing	produce	VERB
ajlsi-3268	59	23	cells	cell	NOUN
ajlsi-3268	59	24	and	and	CCONJ
ajlsi-3268	59	25	neutrophils	neutrophil	NOUN
ajlsi-3268	59	26	pa	pa	PROPN
ajlsi-3268	59	27	ge	ge	PROPN
ajlsi-3268	59	28	29	29	NUM
ajlsi-3268	59	29	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-3268	59	30	am	am	NOUN
ajlsi-3268	59	31	.	.	PUNCT
ajlsi-3268	60	1	j.	j.	PROPN
ajlsi-3268	60	2	life	life	PROPN
ajlsi-3268	60	3	sci	sci	PROPN
ajlsi-3268	60	4	.	.	PUNCT
ajlsi-3268	60	5	innov	innov	PROPN
ajlsi-3268	60	6	.	.	PUNCT
ajlsi-3268	61	1	4(1	4(1	NOUN
ajlsi-3268	61	2	)	)	PUNCT
ajlsi-3268	62	1	27	27	NUM
ajlsi-3268	62	2	-	-	SYM
ajlsi-3268	62	3	35	35	NUM
ajlsi-3268	62	4	,	,	PUNCT
ajlsi-3268	62	5	2025	2025	NUM
ajlsi-3268	62	6	secukinumab	secukinumab	NOUN
ajlsi-3268	62	7	liposome	liposome	NOUN
ajlsi-3268	62	8	to	to	PART
ajlsi-3268	62	9	prepare	prepare	VERB
ajlsi-3268	62	10	topically	topically	ADV
ajlsi-3268	62	11	for	for	ADP
ajlsi-3268	62	12	treating	treat	VERB
ajlsi-3268	62	13	psoriasis	psoriasis	NOUN
ajlsi-3268	62	14	in	in	ADP
ajlsi-3268	62	15	the	the	DET
ajlsi-3268	62	16	future	future	NOUN
ajlsi-3268	62	17	.	.	PUNCT
ajlsi-3268	63	1	the	the	DET
ajlsi-3268	63	2	cellular	cellular	ADJ
ajlsi-3268	63	3	response	response	NOUN
ajlsi-3268	63	4	to	to	ADP
ajlsi-3268	63	5	the	the	DET
ajlsi-3268	63	6	bulk	bulk	NOUN
ajlsi-3268	63	7	and	and	CCONJ
ajlsi-3268	63	8	liposome	liposome	NOUN
ajlsi-3268	63	9	forms	form	NOUN
ajlsi-3268	63	10	was	be	AUX
ajlsi-3268	63	11	investigated	investigate	VERB
ajlsi-3268	63	12	and	and	CCONJ
ajlsi-3268	63	13	the	the	DET
ajlsi-3268	63	14	optimal	optimal	ADJ
ajlsi-3268	63	15	dose	dose	NOUN
ajlsi-3268	63	16	for	for	SCONJ
ajlsi-3268	63	17	bulk	bulk	NOUN
ajlsi-3268	63	18	and	and	CCONJ
ajlsi-3268	63	19	liposome	liposome	NOUN
ajlsi-3268	63	20	forms	form	NOUN
ajlsi-3268	63	21	was	be	AUX
ajlsi-3268	63	22	obtained	obtain	VERB
ajlsi-3268	63	23	.	.	PUNCT
ajlsi-3268	64	1	in	in	ADP
ajlsi-3268	64	2	the	the	DET
ajlsi-3268	64	3	presented	present	VERB
ajlsi-3268	64	4	study	study	NOUN
ajlsi-3268	64	5	,	,	PUNCT
ajlsi-3268	64	6	the	the	DET
ajlsi-3268	64	7	geno	geno	NOUN
ajlsi-3268	64	8	toxicity	toxicity	NOUN
ajlsi-3268	64	9	assays	assay	NOUN
ajlsi-3268	64	10	with	with	ADP
ajlsi-3268	64	11	different	different	ADJ
ajlsi-3268	64	12	end	end	NOUN
ajlsi-3268	64	13	-	-	PUNCT
ajlsi-3268	64	14	points	point	NOUN
ajlsi-3268	64	15	were	be	AUX
ajlsi-3268	64	16	used	use	VERB
ajlsi-3268	64	17	to	to	PART
ajlsi-3268	64	18	assess	assess	VERB
ajlsi-3268	64	19	the	the	DET
ajlsi-3268	64	20	impact	impact	NOUN
ajlsi-3268	64	21	of	of	ADP
ajlsi-3268	64	22	secukinumab	secukinumab	NOUN
ajlsi-3268	64	23	bulk	bulk	NOUN
ajlsi-3268	64	24	and	and	CCONJ
ajlsi-3268	64	25	liposome	liposome	VERB
ajlsi-3268	64	26	forms	form	NOUN
ajlsi-3268	64	27	on	on	ADP
ajlsi-3268	64	28	lymphocytes	lymphocyte	NOUN
ajlsi-3268	64	29	from	from	ADP
ajlsi-3268	64	30	psoriasis	psoriasis	NOUN
ajlsi-3268	64	31	patients	patient	NOUN
ajlsi-3268	64	32	contrasted	contrast	VERB
ajlsi-3268	64	33	to	to	ADP
ajlsi-3268	64	34	healthy	healthy	ADJ
ajlsi-3268	64	35	controls	control	NOUN
ajlsi-3268	64	36	(	(	PUNCT
ajlsi-3268	64	37	yamanaka	yamanaka	NOUN
ajlsi-3268	64	38	,	,	PUNCT
ajlsi-3268	64	39	2021	2021	NUM
ajlsi-3268	64	40	)	)	PUNCT
ajlsi-3268	64	41	.	.	PUNCT
ajlsi-3268	65	1	materials	material	NOUN
ajlsi-3268	65	2	and	and	CCONJ
ajlsi-3268	65	3	methods	method	NOUN
ajlsi-3268	65	4	materials	material	NOUN
ajlsi-3268	65	5	secukinumab	secukinumab	NOUN
ajlsi-3268	65	6	was	be	AUX
ajlsi-3268	65	7	obtained	obtain	VERB
ajlsi-3268	65	8	from	from	ADP
ajlsi-3268	65	9	novartis	novartis	NOUN
ajlsi-3268	65	10	pharmaceuticals	pharmaceutical	NOUN
ajlsi-3268	65	11	(	(	PUNCT
ajlsi-3268	65	12	cosentyx	cosentyx	NOUN
ajlsi-3268	65	13	)	)	PUNCT
ajlsi-3268	65	14	.	.	PUNCT
ajlsi-3268	66	1	1	1	NUM
ajlsi-3268	66	2	,	,	PUNCT
ajlsi-3268	66	3	2	2	NUM
ajlsi-3268	66	4	-	-	PUNCT
ajlsi-3268	66	5	dipalmitoyl	dipalmitoyl	NOUN
ajlsi-3268	66	6	-	-	PUNCT
ajlsi-3268	66	7	sn	sn	NOUN
ajlsi-3268	66	8	-	-	PUNCT
ajlsi-3268	66	9	glycero-3	glycero-3	NOUN
ajlsi-3268	66	10	-	-	PUNCT
ajlsi-3268	66	11	phosphorac-(1	phosphorac-(1	NOUN
ajlsi-3268	66	12	-	-	PUNCT
ajlsi-3268	66	13	glycerol	glycerol	NOUN
ajlsi-3268	66	14	)	)	PUNCT
ajlsi-3268	66	15	sodium	sodium	NOUN
ajlsi-3268	66	16	salt	salt	NOUN
ajlsi-3268	66	17	(	(	PUNCT
ajlsi-3268	66	18	dppg	dppg	PROPN
ajlsi-3268	66	19	)	)	PUNCT
ajlsi-3268	66	20	,	,	PUNCT
ajlsi-3268	66	21	1,2	1,2	NUM
ajlsi-3268	66	22	-	-	PUNCT
ajlsi-3268	66	23	dioleoyl	dioleoyl	ADJ
ajlsi-3268	66	24	-	-	PUNCT
ajlsi-3268	66	25	snglycero-3	snglycero-3	NOUN
ajlsi-3268	66	26	-	-	PUNCT
ajlsi-3268	66	27	phsphoethanolamine	phsphoethanolamine	ADJ
ajlsi-3268	66	28	(	(	PUNCT
ajlsi-3268	66	29	dope	dope	NOUN
ajlsi-3268	66	30	)	)	PUNCT
ajlsi-3268	66	31	,	,	PUNCT
ajlsi-3268	66	32	purity	purity	NOUN
ajlsi-3268	66	33	>	>	PROPN
ajlsi-3268	66	34	99	99	NUM
ajlsi-3268	66	35	%	%	NOUN
ajlsi-3268	66	36	,	,	PUNCT
ajlsi-3268	66	37	cholesterol	cholesterol	NOUN
ajlsi-3268	66	38	(	(	PUNCT
ajlsi-3268	66	39	chol	chol	NOUN
ajlsi-3268	66	40	)	)	PUNCT
ajlsi-3268	66	41	,	,	PUNCT
ajlsi-3268	66	42	methanol	methanol	NOUN
ajlsi-3268	66	43	,	,	PUNCT
ajlsi-3268	66	44	dichloromethane	dichloromethane	NOUN
ajlsi-3268	66	45	(	(	PUNCT
ajlsi-3268	66	46	dcm	dcm	PROPN
ajlsi-3268	66	47	)	)	PUNCT
ajlsi-3268	66	48	were	be	AUX
ajlsi-3268	66	49	obtained	obtain	VERB
ajlsi-3268	66	50	from	from	ADP
ajlsi-3268	66	51	sigma	sigma	PROPN
ajlsi-3268	66	52	-	-	PUNCT
ajlsi-3268	66	53	aldrich	aldrich	PROPN
ajlsi-3268	66	54	company	company	PROPN
ajlsi-3268	66	55	ltd	ltd	PROPN
ajlsi-3268	66	56	.	.	PROPN
ajlsi-3268	66	57	(	(	PUNCT
ajlsi-3268	66	58	uk	uk	PROPN
ajlsi-3268	66	59	)	)	PUNCT
ajlsi-3268	66	60	.	.	PUNCT
ajlsi-3268	67	1	all	all	DET
ajlsi-3268	67	2	other	other	ADJ
ajlsi-3268	67	3	reagents	reagent	NOUN
ajlsi-3268	67	4	used	use	VERB
ajlsi-3268	67	5	were	be	AUX
ajlsi-3268	67	6	derived	derive	VERB
ajlsi-3268	67	7	from	from	ADP
ajlsi-3268	67	8	sigma	sigma	PROPN
ajlsi-3268	67	9	aldrich	aldrich	PROPN
ajlsi-3268	67	10	u.k	u.k	PROPN
ajlsi-3268	67	11	.	.	PROPN
ajlsi-3268	67	12	unless	unless	SCONJ
ajlsi-3268	67	13	otherwise	otherwise	ADV
ajlsi-3268	67	14	stated	state	VERB
ajlsi-3268	67	15	.	.	PUNCT
ajlsi-3268	68	1	for	for	ADP
ajlsi-3268	68	2	the	the	DET
ajlsi-3268	68	3	preparation	preparation	NOUN
ajlsi-3268	68	4	of	of	ADP
ajlsi-3268	68	5	secukinumab	secukinumab	NOUN
ajlsi-3268	68	6	solutions	solution	NOUN
ajlsi-3268	68	7	,	,	PUNCT
ajlsi-3268	68	8	drugs	drug	NOUN
ajlsi-3268	68	9	were	be	AUX
ajlsi-3268	68	10	in	in	ADP
ajlsi-3268	68	11	distilled	distil	VERB
ajlsi-3268	68	12	water	water	NOUN
ajlsi-3268	68	13	(	(	PUNCT
ajlsi-3268	68	14	150mg	150mg	NOUN
ajlsi-3268	68	15	/	/	SYM
ajlsi-3268	68	16	ml	ml	NOUN
ajlsi-3268	68	17	)	)	PUNCT
ajlsi-3268	68	18	.	.	PUNCT
ajlsi-3268	69	1	a	a	DET
ajlsi-3268	69	2	75μg	75μg	ADJ
ajlsi-3268	69	3	/	/	SYM
ajlsi-3268	69	4	ml	ml	NOUN
ajlsi-3268	69	5	stock	stock	NOUN
ajlsi-3268	69	6	solution	solution	NOUN
ajlsi-3268	69	7	was	be	AUX
ajlsi-3268	69	8	prepared	prepare	VERB
ajlsi-3268	69	9	.	.	PUNCT
ajlsi-3268	70	1	the	the	DET
ajlsi-3268	70	2	prefilled	prefille	VERB
ajlsi-3268	70	3	secukinumab	secukinumab	NOUN
ajlsi-3268	70	4	syringes	syrinx	NOUN
ajlsi-3268	70	5	(	(	PUNCT
ajlsi-3268	70	6	150	150	NUM
ajlsi-3268	70	7	mg	mg	NOUN
ajlsi-3268	70	8	)	)	PUNCT
ajlsi-3268	70	9	were	be	AUX
ajlsi-3268	70	10	used	use	VERB
ajlsi-3268	70	11	in	in	ADP
ajlsi-3268	70	12	this	this	DET
ajlsi-3268	70	13	study	study	NOUN
ajlsi-3268	70	14	to	to	PART
ajlsi-3268	70	15	produce	produce	VERB
ajlsi-3268	70	16	the	the	DET
ajlsi-3268	70	17	liposome	liposome	NOUN
ajlsi-3268	70	18	format	format	NOUN
ajlsi-3268	70	19	of	of	ADP
ajlsi-3268	70	20	this	this	DET
ajlsi-3268	70	21	biological	biological	ADJ
ajlsi-3268	70	22	agent	agent	NOUN
ajlsi-3268	70	23	and	and	CCONJ
ajlsi-3268	70	24	investigate	investigate	VERB
ajlsi-3268	70	25	its	its	PRON
ajlsi-3268	70	26	comparison	comparison	NOUN
ajlsi-3268	70	27	with	with	ADP
ajlsi-3268	70	28	bulk	bulk	ADJ
ajlsi-3268	70	29	form	form	NOUN
ajlsi-3268	70	30	.	.	PUNCT
ajlsi-3268	71	1	the	the	DET
ajlsi-3268	71	2	compound	compound	NOUN
ajlsi-3268	71	3	was	be	AUX
ajlsi-3268	71	4	diluted	dilute	VERB
ajlsi-3268	71	5	to	to	ADP
ajlsi-3268	71	6	a	a	DET
ajlsi-3268	71	7	suitable	suitable	ADJ
ajlsi-3268	71	8	concentration	concentration	NOUN
ajlsi-3268	71	9	for	for	ADP
ajlsi-3268	71	10	treating	treat	VERB
ajlsi-3268	71	11	the	the	DET
ajlsi-3268	71	12	cells	cell	NOUN
ajlsi-3268	71	13	in	in	ADP
ajlsi-3268	71	14	vitro	vitro	X
ajlsi-3268	71	15	.	.	PUNCT
ajlsi-3268	72	1	characterization	characterization	NOUN
ajlsi-3268	72	2	and	and	CCONJ
ajlsi-3268	72	3	production	production	NOUN
ajlsi-3268	72	4	of	of	ADP
ajlsi-3268	72	5	peptide	peptide	NOUN
ajlsi-3268	72	6	-	-	PUNCT
ajlsi-3268	72	7	loaded	load	VERB
ajlsi-3268	72	8	liposome	liposome	NOUN
ajlsi-3268	72	9	liposomes	liposome	NOUN
ajlsi-3268	72	10	were	be	AUX
ajlsi-3268	72	11	prepared	prepare	VERB
ajlsi-3268	72	12	by	by	ADP
ajlsi-3268	72	13	using	use	VERB
ajlsi-3268	72	14	the	the	DET
ajlsi-3268	72	15	bangham	bangham	NOUN
ajlsi-3268	72	16	process	process	NOUN
ajlsi-3268	72	17	,	,	PUNCT
ajlsi-3268	72	18	which	which	PRON
ajlsi-3268	72	19	involved	involve	VERB
ajlsi-3268	72	20	dissolving	dissolve	VERB
ajlsi-3268	72	21	methanol	methanol	NOUN
ajlsi-3268	72	22	and	and	CCONJ
ajlsi-3268	72	23	dichloromethane	dichloromethane	NOUN
ajlsi-3268	72	24	(	(	PUNCT
ajlsi-3268	72	25	dcm	dcm	PROPN
ajlsi-3268	72	26	)	)	PUNCT
ajlsi-3268	72	27	and	and	CCONJ
ajlsi-3268	72	28	methanol	methanol	NOUN
ajlsi-3268	72	29	(	(	PUNCT
ajlsi-3268	72	30	3:1	3:1	NUM
ajlsi-3268	72	31	v	v	NOUN
ajlsi-3268	72	32	/	/	SYM
ajlsi-3268	72	33	v	v	NOUN
ajlsi-3268	72	34	)	)	PUNCT
ajlsi-3268	72	35	with1,2dipalmitoyl	with1,2dipalmitoyl	PROPN
ajlsi-3268	72	36	-	-	PUNCT
ajlsi-3268	72	37	sn	sn	PROPN
ajlsi-3268	72	38	-	-	PUNCT
ajlsi-3268	72	39	glycero-3	glycero-3	NOUN
ajlsi-3268	72	40	-	-	PUNCT
ajlsi-3268	72	41	phospho	phospho	ADJ
ajlsi-3268	72	42	-	-	PUNCT
ajlsi-3268	72	43	rac-(1	rac-(1	NOUN
ajlsi-3268	72	44	-	-	PUNCT
ajlsi-3268	72	45	glycerol	glycerol	NOUN
ajlsi-3268	72	46	)	)	PUNCT
ajlsi-3268	72	47	sodium	sodium	NOUN
ajlsi-3268	72	48	salt	salt	NOUN
ajlsi-3268	72	49	dppg	dppg	NOUN
ajlsi-3268	72	50	,	,	PUNCT
ajlsi-3268	72	51	and	and	CCONJ
ajlsi-3268	72	52	(	(	PUNCT
ajlsi-3268	72	53	2	2	NUM
ajlsi-3268	72	54	mg	mg	NUM
ajlsi-3268	72	55	)	)	PUNCT
ajlsi-3268	72	56	,	,	PUNCT
ajlsi-3268	72	57	1,2	1,2	NUM
ajlsi-3268	72	58	-	-	PUNCT
ajlsi-3268	72	59	dioleoyl	dioleoyl	ADJ
ajlsi-3268	72	60	-	-	PUNCT
ajlsi-3268	72	61	sn	sn	NOUN
ajlsi-3268	72	62	-	-	PUNCT
ajlsi-3268	72	63	glycero3	glycero3	NOUN
ajlsi-3268	72	64	-	-	PUNCT
ajlsi-3268	72	65	phsphoethanolamine	phsphoethanolamine	NOUN
ajlsi-3268	72	66	dope	dope	NOUN
ajlsi-3268	72	67	,	,	PUNCT
ajlsi-3268	72	68	and	and	CCONJ
ajlsi-3268	72	69	cholesterol	cholesterol	NOUN
ajlsi-3268	72	70	(	(	PUNCT
ajlsi-3268	72	71	2:2:1	2:2:1	NUM
ajlsi-3268	72	72	molar	molar	ADJ
ajlsi-3268	72	73	ratio	ratio	NOUN
ajlsi-3268	72	74	)	)	PUNCT
ajlsi-3268	72	75	.	.	PUNCT
ajlsi-3268	73	1	the	the	DET
ajlsi-3268	73	2	solution	solution	NOUN
ajlsi-3268	73	3	was	be	AUX
ajlsi-3268	73	4	transmitted	transmit	VERB
ajlsi-3268	73	5	to	to	ADP
ajlsi-3268	73	6	a	a	DET
ajlsi-3268	73	7	rotary	rotary	ADJ
ajlsi-3268	73	8	evaporator	evaporator	NOUN
ajlsi-3268	73	9	flask	flask	NOUN
ajlsi-3268	73	10	and	and	CCONJ
ajlsi-3268	73	11	at	at	ADP
ajlsi-3268	73	12	40	40	NUM
ajlsi-3268	73	13	°	°	NOUN
ajlsi-3268	73	14	c	c	NOUN
ajlsi-3268	73	15	the	the	DET
ajlsi-3268	73	16	respective	respective	ADJ
ajlsi-3268	73	17	organic	organic	ADJ
ajlsi-3268	73	18	solvent	solvent	NOUN
ajlsi-3268	73	19	mixture	mixture	NOUN
ajlsi-3268	73	20	and	and	CCONJ
ajlsi-3268	73	21	after	after	ADP
ajlsi-3268	73	22	six	six	NUM
ajlsi-3268	73	23	hours	hour	NOUN
ajlsi-3268	73	24	of	of	ADP
ajlsi-3268	73	25	evaporation	evaporation	NOUN
ajlsi-3268	73	26	,	,	PUNCT
ajlsi-3268	73	27	the	the	DET
ajlsi-3268	73	28	mixture	mixture	NOUN
ajlsi-3268	73	29	was	be	AUX
ajlsi-3268	73	30	rehydrated	rehydrate	VERB
ajlsi-3268	73	31	with	with	ADP
ajlsi-3268	73	32	10ml	10ml	ADJ
ajlsi-3268	73	33	distilled	distil	VERB
ajlsi-3268	73	34	water	water	NOUN
ajlsi-3268	73	35	.	.	PUNCT
ajlsi-3268	74	1	after	after	ADP
ajlsi-3268	74	2	that	that	PRON
ajlsi-3268	74	3	,	,	PUNCT
ajlsi-3268	74	4	the	the	DET
ajlsi-3268	74	5	films	film	NOUN
ajlsi-3268	74	6	were	be	AUX
ajlsi-3268	74	7	placed	place	VERB
ajlsi-3268	74	8	within	within	ADP
ajlsi-3268	74	9	1ml	1ml	NOUN
ajlsi-3268	74	10	of	of	ADP
ajlsi-3268	74	11	secukinumab	secukinumab	NOUN
ajlsi-3268	74	12	for	for	ADP
ajlsi-3268	74	13	1	1	NUM
ajlsi-3268	74	14	h	h	NOUN
ajlsi-3268	74	15	at	at	ADP
ajlsi-3268	74	16	60	60	NUM
ajlsi-3268	74	17	°	°	NOUN
ajlsi-3268	74	18	c	c	NOUN
ajlsi-3268	74	19	by	by	ADP
ajlsi-3268	74	20	employing	employ	VERB
ajlsi-3268	74	21	a	a	DET
ajlsi-3268	74	22	bath	bath	NOUN
ajlsi-3268	74	23	sonicator	sonicator	NOUN
ajlsi-3268	74	24	(	(	PUNCT
ajlsi-3268	74	25	150	150	NUM
ajlsi-3268	74	26	w	w	NOUN
ajlsi-3268	74	27	)	)	PUNCT
ajlsi-3268	74	28	,	,	PUNCT
ajlsi-3268	74	29	then	then	ADV
ajlsi-3268	74	30	the	the	DET
ajlsi-3268	74	31	sample	sample	NOUN
ajlsi-3268	74	32	exposed	expose	VERB
ajlsi-3268	74	33	through	through	ADP
ajlsi-3268	74	34	freeze	freeze	NOUN
ajlsi-3268	74	35	-	-	PUNCT
ajlsi-3268	74	36	thaw	thaw	NOUN
ajlsi-3268	74	37	cycles	cycle	NOUN
ajlsi-3268	74	38	at	at	ADP
ajlsi-3268	74	39	-20	-20	PROPN
ajlsi-3268	74	40	°	°	NOUN
ajlsi-3268	74	41	c	c	NOUN
ajlsi-3268	74	42	and	and	CCONJ
ajlsi-3268	74	43	thawing	thaw	VERB
ajlsi-3268	74	44	at	at	ADP
ajlsi-3268	74	45	60	60	NUM
ajlsi-3268	74	46	°	°	NOUN
ajlsi-3268	74	47	c	c	NOUN
ajlsi-3268	74	48	,	,	PUNCT
ajlsi-3268	74	49	and	and	CCONJ
ajlsi-3268	74	50	then	then	ADV
ajlsi-3268	74	51	diluted	dilute	VERB
ajlsi-3268	74	52	with	with	ADP
ajlsi-3268	74	53	75	75	NUM
ajlsi-3268	74	54	μg	μg	NOUN
ajlsi-3268	74	55	/	/	SYM
ajlsi-3268	74	56	ml	ml	PROPN
ajlsi-3268	74	57	of	of	ADP
ajlsi-3268	74	58	distilled	distil	VERB
ajlsi-3268	74	59	water	water	NOUN
ajlsi-3268	74	60	.	.	PUNCT
ajlsi-3268	75	1	centrifuging	centrifuge	VERB
ajlsi-3268	75	2	the	the	DET
ajlsi-3268	75	3	finished	finished	ADJ
ajlsi-3268	75	4	mixture	mixture	NOUN
ajlsi-3268	75	5	at	at	ADP
ajlsi-3268	75	6	22,000	22,000	NUM
ajlsi-3268	75	7	x	x	SYM
ajlsi-3268	75	8	g	g	NOUN
ajlsi-3268	75	9	for	for	ADP
ajlsi-3268	75	10	30	30	NUM
ajlsi-3268	75	11	minutes	minute	NOUN
ajlsi-3268	75	12	at	at	ADP
ajlsi-3268	75	13	4	4	NUM
ajlsi-3268	75	14	°	°	NOUN
ajlsi-3268	75	15	c	c	NOUN
ajlsi-3268	75	16	,	,	PUNCT
ajlsi-3268	75	17	helped	help	VERB
ajlsi-3268	75	18	to	to	PART
ajlsi-3268	75	19	guarantee	guarantee	VERB
ajlsi-3268	75	20	purification	purification	NOUN
ajlsi-3268	75	21	and	and	CCONJ
ajlsi-3268	75	22	eliminate	eliminate	VERB
ajlsi-3268	75	23	any	any	DET
ajlsi-3268	75	24	remaining	remain	VERB
ajlsi-3268	75	25	non	non	ADJ
ajlsi-3268	75	26	-	-	ADJ
ajlsi-3268	75	27	encapsulated	encapsulate	VERB
ajlsi-3268	75	28	medicines	medicine	NOUN
ajlsi-3268	75	29	.	.	PUNCT
ajlsi-3268	76	1	the	the	DET
ajlsi-3268	76	2	modest	modest	ADJ
ajlsi-3268	76	3	size	size	NOUN
ajlsi-3268	76	4	and	and	CCONJ
ajlsi-3268	76	5	poly	poly	ADJ
ajlsi-3268	76	6	disparity	disparity	NOUN
ajlsi-3268	76	7	index	index	NOUN
ajlsi-3268	76	8	of	of	ADP
ajlsi-3268	76	9	the	the	DET
ajlsi-3268	76	10	liposome	liposome	NOUN
ajlsi-3268	76	11	formulations	formulation	NOUN
ajlsi-3268	76	12	were	be	AUX
ajlsi-3268	76	13	evaluated	evaluate	VERB
ajlsi-3268	76	14	by	by	ADP
ajlsi-3268	76	15	means	mean	NOUN
ajlsi-3268	76	16	of	of	ADP
ajlsi-3268	76	17	dynamic	dynamic	ADJ
ajlsi-3268	76	18	light	light	NOUN
ajlsi-3268	76	19	scattering	scattering	NOUN
ajlsi-3268	76	20	(	(	PUNCT
ajlsi-3268	76	21	dls	dls	PROPN
ajlsi-3268	76	22	)	)	PUNCT
ajlsi-3268	76	23	with	with	ADP
ajlsi-3268	76	24	zetasizer	zetasizer	X
ajlsi-3268	76	25	zs-90	zs-90	NUM
ajlsi-3268	76	26	and	and	CCONJ
ajlsi-3268	76	27	model	model	VERB
ajlsi-3268	76	28	zen	zen	PROPN
ajlsi-3268	76	29	3600	3600	NUM
ajlsi-3268	76	30	.	.	PUNCT
ajlsi-3268	77	1	in	in	ADP
ajlsi-3268	77	2	triplicate	triplicate	NOUN
ajlsi-3268	77	3	form	form	NOUN
ajlsi-3268	77	4	,	,	PUNCT
ajlsi-3268	77	5	all	all	DET
ajlsi-3268	77	6	measurements	measurement	NOUN
ajlsi-3268	77	7	were	be	AUX
ajlsi-3268	77	8	performed	perform	VERB
ajlsi-3268	77	9	.	.	PUNCT
ajlsi-3268	78	1	measures	measure	NOUN
ajlsi-3268	78	2	were	be	AUX
ajlsi-3268	78	3	found	find	VERB
ajlsi-3268	78	4	to	to	PART
ajlsi-3268	78	5	be	be	AUX
ajlsi-3268	78	6	<	<	X
ajlsi-3268	78	7	150	150	NUM
ajlsi-3268	78	8	nanometers	nanometer	NOUN
ajlsi-3268	78	9	.	.	PUNCT
ajlsi-3268	79	1	ethical	ethical	ADJ
ajlsi-3268	79	2	approval	approval	NOUN
ajlsi-3268	79	3	the	the	DET
ajlsi-3268	79	4	study	study	NOUN
ajlsi-3268	79	5	on	on	ADP
ajlsi-3268	79	6	the	the	DET
ajlsi-3268	79	7	genetic	genetic	ADJ
ajlsi-3268	79	8	and	and	CCONJ
ajlsi-3268	79	9	environmental	environmental	ADJ
ajlsi-3268	79	10	effects	effect	NOUN
ajlsi-3268	79	11	on	on	ADP
ajlsi-3268	79	12	lymphocytes	lymphocyte	NOUN
ajlsi-3268	79	13	from	from	ADP
ajlsi-3268	79	14	different	different	ADJ
ajlsi-3268	79	15	illness	illness	NOUN
ajlsi-3268	79	16	situations	situation	NOUN
ajlsi-3268	79	17	,	,	PUNCT
ajlsi-3268	79	18	such	such	ADJ
ajlsi-3268	79	19	as	as	ADP
ajlsi-3268	79	20	inflammatory	inflammatory	ADJ
ajlsi-3268	79	21	,	,	PUNCT
ajlsi-3268	79	22	malignant	malignant	ADJ
ajlsi-3268	79	23	,	,	PUNCT
ajlsi-3268	79	24	and	and	CCONJ
ajlsi-3268	79	25	precancerous	precancerous	ADJ
ajlsi-3268	79	26	ones	one	NOUN
ajlsi-3268	79	27	,	,	PUNCT
ajlsi-3268	79	28	employing	employ	VERB
ajlsi-3268	79	29	different	different	ADJ
ajlsi-3268	79	30	genetic	genetic	ADJ
ajlsi-3268	79	31	endpoints	endpoint	NOUN
ajlsi-3268	79	32	,	,	PUNCT
ajlsi-3268	79	33	has	have	AUX
ajlsi-3268	79	34	been	be	AUX
ajlsi-3268	79	35	authorized	authorize	VERB
ajlsi-3268	79	36	by	by	ADP
ajlsi-3268	79	37	the	the	DET
ajlsi-3268	79	38	leeds	leeds	PROPN
ajlsi-3268	79	39	east	east	PROPN
ajlsi-3268	79	40	research	research	PROPN
ajlsi-3268	79	41	ethics	ethic	NOUN
ajlsi-3268	79	42	committee	committee	PROPN
ajlsi-3268	79	43	(	(	PUNCT
ajlsi-3268	79	44	rec	rec	PROPN
ajlsi-3268	79	45	)	)	PUNCT
ajlsi-3268	79	46	(	(	PUNCT
ajlsi-3268	79	47	rec	rec	X
ajlsi-3268	79	48	reference	reference	NOUN
ajlsi-3268	79	49	number	number	NOUN
ajlsi-3268	79	50	:	:	PUNCT
ajlsi-3268	79	51	12	12	NUM
ajlsi-3268	79	52	/	/	SYM
ajlsi-3268	79	53	yh/0464	yh/0464	PROPN
ajlsi-3268	79	54	)	)	PUNCT
ajlsi-3268	79	55	.	.	PUNCT
ajlsi-3268	80	1	ethical	ethical	ADJ
ajlsi-3268	80	2	approval	approval	NOUN
ajlsi-3268	80	3	has	have	AUX
ajlsi-3268	80	4	been	be	AUX
ajlsi-3268	80	5	given	give	VERB
ajlsi-3268	80	6	by	by	ADP
ajlsi-3268	80	7	the	the	DET
ajlsi-3268	80	8	subcommittee	subcommittee	NOUN
ajlsi-3268	80	9	for	for	ADP
ajlsi-3268	80	10	ethics	ethic	NOUN
ajlsi-3268	80	11	in	in	ADP
ajlsi-3268	80	12	research	research	NOUN
ajlsi-3268	80	13	with	with	ADP
ajlsi-3268	80	14	human	human	ADJ
ajlsi-3268	80	15	subjects	subject	NOUN
ajlsi-3268	80	16	at	at	ADP
ajlsi-3268	80	17	the	the	DET
ajlsi-3268	80	18	university	university	PROPN
ajlsi-3268	80	19	of	of	ADP
ajlsi-3268	80	20	bradford	bradford	NOUN
ajlsi-3268	80	21	(	(	PUNCT
ajlsi-3268	80	22	reference	reference	NOUN
ajlsi-3268	80	23	no	no	INTJ
ajlsi-3268	80	24	.	.	PUNCT
ajlsi-3268	80	25	:	:	PUNCT
ajlsi-3268	80	26	0405/8	0405/8	NUM
ajlsi-3268	80	27	)	)	PUNCT
ajlsi-3268	80	28	.	.	PUNCT
ajlsi-3268	81	1	the	the	DET
ajlsi-3268	81	2	research	research	NOUN
ajlsi-3268	81	3	support	support	NOUN
ajlsi-3268	81	4	and	and	CCONJ
ajlsi-3268	81	5	governance	governance	NOUN
ajlsi-3268	81	6	office	office	NOUN
ajlsi-3268	81	7	bradford	bradford	NOUN
ajlsi-3268	81	8	teaching	teach	VERB
ajlsi-3268	81	9	hospital	hospital	PROPN
ajlsi-3268	81	10	nhs	nhs	PROPN
ajlsi-3268	81	11	foundation	foundation	PROPN
ajlsi-3268	81	12	granted	grant	VERB
ajlsi-3268	81	13	the	the	DET
ajlsi-3268	81	14	re	re	ADJ
ajlsi-3268	81	15	da	da	PROPN
ajlsi-3268	81	16	number	number	NOUN
ajlsi-3268	81	17	:	:	PUNCT
ajlsi-3268	81	18	1202	1202	NUM
ajlsi-3268	81	19	.	.	PUNCT
ajlsi-3268	82	1	blood	blood	NOUN
ajlsi-3268	82	2	sample	sample	NOUN
ajlsi-3268	82	3	collection	collection	NOUN
ajlsi-3268	82	4	blood	blood	NOUN
ajlsi-3268	82	5	samples	sample	NOUN
ajlsi-3268	82	6	were	be	AUX
ajlsi-3268	82	7	collected	collect	VERB
ajlsi-3268	82	8	from	from	ADP
ajlsi-3268	82	9	40	40	NUM
ajlsi-3268	82	10	individuals	individual	NOUN
ajlsi-3268	82	11	(	(	PUNCT
ajlsi-3268	82	12	20	20	NUM
ajlsi-3268	82	13	healthy	healthy	ADJ
ajlsi-3268	82	14	and	and	CCONJ
ajlsi-3268	82	15	20	20	NUM
ajlsi-3268	82	16	patients	patient	NOUN
ajlsi-3268	82	17	)	)	PUNCT
ajlsi-3268	82	18	using	use	VERB
ajlsi-3268	82	19	the	the	DET
ajlsi-3268	82	20	vein	vein	ADJ
ajlsi-3268	82	21	-	-	PUNCT
ajlsi-3268	82	22	puncture	puncture	NOUN
ajlsi-3268	82	23	technique	technique	NOUN
ajlsi-3268	82	24	,	,	PUNCT
ajlsi-3268	82	25	after	after	ADP
ajlsi-3268	82	26	obtaining	obtain	VERB
ajlsi-3268	82	27	consent	consent	NOUN
ajlsi-3268	82	28	and	and	CCONJ
ajlsi-3268	82	29	following	follow	VERB
ajlsi-3268	82	30	safety	safety	NOUN
ajlsi-3268	82	31	measures	measure	NOUN
ajlsi-3268	82	32	.	.	PUNCT
ajlsi-3268	83	1	basic	basic	ADJ
ajlsi-3268	83	2	information	information	NOUN
ajlsi-3268	83	3	was	be	AUX
ajlsi-3268	83	4	gathered	gather	VERB
ajlsi-3268	83	5	from	from	ADP
ajlsi-3268	83	6	individuals	individual	NOUN
ajlsi-3268	83	7	about	about	ADP
ajlsi-3268	83	8	health	health	NOUN
ajlsi-3268	83	9	and	and	CCONJ
ajlsi-3268	83	10	lifestyle	lifestyle	NOUN
ajlsi-3268	83	11	factors	factor	NOUN
ajlsi-3268	83	12	using	use	VERB
ajlsi-3268	83	13	a	a	DET
ajlsi-3268	83	14	questionnaire	questionnaire	NOUN
ajlsi-3268	83	15	,	,	PUNCT
ajlsi-3268	83	16	as	as	SCONJ
ajlsi-3268	83	17	shown	show	VERB
ajlsi-3268	83	18	in	in	ADP
ajlsi-3268	83	19	table	table	NOUN
ajlsi-3268	83	20	.	.	PUNCT
ajlsi-3268	84	1	1	1	NUM
ajlsi-3268	84	2	,	,	PUNCT
ajlsi-3268	84	3	while	while	SCONJ
ajlsi-3268	84	4	healthy	healthy	ADJ
ajlsi-3268	84	5	individual	individual	NOUN
ajlsi-3268	84	6	’s	’s	PART
ajlsi-3268	84	7	data	datum	NOUN
ajlsi-3268	84	8	was	be	AUX
ajlsi-3268	84	9	presented	present	VERB
ajlsi-3268	84	10	in	in	ADP
ajlsi-3268	84	11	table	table	NOUN
ajlsi-3268	84	12	.	.	PUNCT
ajlsi-3268	85	1	2	2	X
ajlsi-3268	85	2	.	.	X
ajlsi-3268	85	3	blood	blood	NOUN
ajlsi-3268	85	4	was	be	AUX
ajlsi-3268	85	5	collected	collect	VERB
ajlsi-3268	85	6	from	from	ADP
ajlsi-3268	85	7	a	a	DET
ajlsi-3268	85	8	patient	patient	NOUN
ajlsi-3268	85	9	with	with	ADP
ajlsi-3268	85	10	moderate	moderate	ADJ
ajlsi-3268	85	11	psoriasis	psoriasis	NOUN
ajlsi-3268	85	12	under	under	ADP
ajlsi-3268	85	13	systemic	systemic	ADJ
ajlsi-3268	85	14	treatment	treatment	NOUN
ajlsi-3268	85	15	;	;	PUNCT
ajlsi-3268	85	16	non	non	NOUN
ajlsi-3268	85	17	were	be	AUX
ajlsi-3268	85	18	taking	take	VERB
ajlsi-3268	85	19	any	any	DET
ajlsi-3268	85	20	biological	biological	ADJ
ajlsi-3268	85	21	treatment	treatment	NOUN
ajlsi-3268	85	22	.	.	PUNCT
ajlsi-3268	86	1	table	table	NOUN
ajlsi-3268	86	2	1	1	NUM
ajlsi-3268	86	3	:	:	PUNCT
ajlsi-3268	86	4	list	list	NOUN
ajlsi-3268	86	5	of	of	ADP
ajlsi-3268	86	6	patients	patient	NOUN
ajlsi-3268	86	7	’	'	PUNCT
ajlsi-3268	86	8	confounding	confound	VERB
ajlsi-3268	86	9	factors	factor	NOUN
ajlsi-3268	86	10	c	c	NOUN
ajlsi-3268	86	11	on	on	ADP
ajlsi-3268	86	12	fo	fo	ADP
ajlsi-3268	86	13	un	un	PROPN
ajlsi-3268	86	14	di	di	PROPN
ajlsi-3268	86	15	ng	ng	PROPN
ajlsi-3268	86	16	fa	fa	INTJ
ajlsi-3268	86	17	ct	ct	INTJ
ajlsi-3268	86	18	or	or	CCONJ
ajlsi-3268	86	19	s	s	PRON
ajlsi-3268	86	20	c	c	NOUN
ajlsi-3268	86	21	at	at	ADP
ajlsi-3268	86	22	eg	eg	NOUN
ajlsi-3268	86	23	or	or	CCONJ
ajlsi-3268	86	24	ie	ie	X
ajlsi-3268	86	25	s	s	VERB
ajlsi-3268	87	1	fr	fr	PROPN
ajlsi-3268	87	2	eq	eq	PROPN
ajlsi-3268	87	3	ue	ue	PROPN
ajlsi-3268	87	4	nc	nc	PROPN
ajlsi-3268	87	5	ie	ie	X
ajlsi-3268	87	6	s	s	PROPN
ajlsi-3268	87	7	(	(	PUNCT
ajlsi-3268	87	8	n	n	NOUN
ajlsi-3268	87	9	=	=	SYM
ajlsi-3268	87	10	20	20	NUM
ajlsi-3268	87	11	)	)	PUNCT
ajlsi-3268	87	12	pe	pe	PROPN
ajlsi-3268	87	13	rc	rc	PROPN
ajlsi-3268	87	14	en	en	X
ajlsi-3268	87	15	ta	ta	PROPN
ajlsi-3268	87	16	ge	ge	PROPN
ajlsi-3268	87	17	(	(	PUNCT
ajlsi-3268	87	18	n	n	NOUN
ajlsi-3268	87	19	=	=	SYM
ajlsi-3268	87	20	20	20	NUM
ajlsi-3268	87	21	)	)	PUNCT
ajlsi-3268	87	22	age	age	NOUN
ajlsi-3268	87	23	21	21	NUM
ajlsi-3268	87	24	-	-	SYM
ajlsi-3268	87	25	40	40	NUM
ajlsi-3268	87	26	6	6	NUM
ajlsi-3268	87	27	30	30	NUM
ajlsi-3268	87	28	41	41	NUM
ajlsi-3268	87	29	-	-	SYM
ajlsi-3268	87	30	60	60	NUM
ajlsi-3268	87	31	7	7	NUM
ajlsi-3268	87	32	35	35	NUM
ajlsi-3268	87	33	60	60	NUM
ajlsi-3268	87	34	-	-	SYM
ajlsi-3268	87	35	80	80	NUM
ajlsi-3268	87	36	7	7	NUM
ajlsi-3268	87	37	35	35	NUM
ajlsi-3268	87	38	gender	gender	NOUN
ajlsi-3268	87	39	male	male	NOUN
ajlsi-3268	87	40	9	9	NUM
ajlsi-3268	87	41	45	45	NUM
ajlsi-3268	87	42	female	female	ADJ
ajlsi-3268	87	43	11	11	NUM
ajlsi-3268	87	44	55	55	NUM
ajlsi-3268	87	45	ethnicity	ethnicity	NOUN
ajlsi-3268	87	46	asian	asian	ADJ
ajlsi-3268	87	47	3	3	NUM
ajlsi-3268	87	48	15	15	NUM
ajlsi-3268	87	49	caucasian	caucasian	ADJ
ajlsi-3268	87	50	17	17	NUM
ajlsi-3268	87	51	85	85	NUM
ajlsi-3268	87	52	smoking	smoking	NOUN
ajlsi-3268	87	53	history	history	NOUN
ajlsi-3268	87	54	ex	ex	NOUN
ajlsi-3268	87	55	-	-	NOUN
ajlsi-3268	87	56	smoker	smoker	ADJ
ajlsi-3268	87	57	5	5	NUM
ajlsi-3268	87	58	25	25	NUM
ajlsi-3268	87	59	non	non	ADJ
ajlsi-3268	87	60	-	-	ADJ
ajlsi-3268	87	61	smoker	smoker	ADJ
ajlsi-3268	87	62	15	15	NUM
ajlsi-3268	87	63	75	75	NUM
ajlsi-3268	87	64	table	table	NOUN
ajlsi-3268	87	65	2	2	NUM
ajlsi-3268	87	66	:	:	PUNCT
ajlsi-3268	87	67	list	list	NOUN
ajlsi-3268	87	68	of	of	ADP
ajlsi-3268	87	69	healthy	healthy	ADJ
ajlsi-3268	87	70	controls	control	NOUN
ajlsi-3268	87	71	confounding	confound	VERB
ajlsi-3268	87	72	factors	factor	NOUN
ajlsi-3268	87	73	c	c	NOUN
ajlsi-3268	87	74	on	on	ADP
ajlsi-3268	87	75	fo	fo	ADP
ajlsi-3268	87	76	un	un	PROPN
ajlsi-3268	87	77	di	di	PROPN
ajlsi-3268	87	78	ng	ng	PROPN
ajlsi-3268	88	1	fa	fa	INTJ
ajlsi-3268	89	1	ct	ct	INTJ
ajlsi-3268	89	2	or	or	CCONJ
ajlsi-3268	89	3	s	s	PRON
ajlsi-3268	89	4	c	c	NOUN
ajlsi-3268	89	5	at	at	ADP
ajlsi-3268	89	6	eg	eg	NOUN
ajlsi-3268	89	7	or	or	CCONJ
ajlsi-3268	89	8	ie	ie	X
ajlsi-3268	89	9	s	s	VERB
ajlsi-3268	90	1	fr	fr	PROPN
ajlsi-3268	90	2	eq	eq	PROPN
ajlsi-3268	90	3	ue	ue	PROPN
ajlsi-3268	90	4	nc	nc	PROPN
ajlsi-3268	90	5	ie	ie	X
ajlsi-3268	90	6	s	s	PROPN
ajlsi-3268	90	7	(	(	PUNCT
ajlsi-3268	90	8	n	n	NOUN
ajlsi-3268	90	9	=	=	SYM
ajlsi-3268	90	10	20	20	NUM
ajlsi-3268	90	11	)	)	PUNCT
ajlsi-3268	90	12	pe	pe	PROPN
ajlsi-3268	90	13	rc	rc	PROPN
ajlsi-3268	90	14	en	en	X
ajlsi-3268	90	15	ta	ta	PROPN
ajlsi-3268	90	16	ge	ge	PROPN
ajlsi-3268	90	17	(	(	PUNCT
ajlsi-3268	90	18	n	n	NOUN
ajlsi-3268	90	19	=	=	SYM
ajlsi-3268	90	20	20	20	NUM
ajlsi-3268	90	21	age	age	NOUN
ajlsi-3268	90	22	20	20	NUM
ajlsi-3268	90	23	-	-	SYM
ajlsi-3268	90	24	35	35	NUM
ajlsi-3268	90	25	14	14	NUM
ajlsi-3268	90	26	70	70	NUM
ajlsi-3268	90	27	36	36	NUM
ajlsi-3268	90	28	-	-	SYM
ajlsi-3268	90	29	50	50	NUM
ajlsi-3268	90	30	6	6	NUM
ajlsi-3268	90	31	30	30	NUM
ajlsi-3268	90	32	gender	gender	NOUN
ajlsi-3268	90	33	male	male	NOUN
ajlsi-3268	90	34	10	10	NUM
ajlsi-3268	90	35	50	50	NUM
ajlsi-3268	90	36	female	female	ADJ
ajlsi-3268	90	37	10	10	NUM
ajlsi-3268	90	38	50	50	NUM
ajlsi-3268	90	39	ethnicity	ethnicity	NOUN
ajlsi-3268	90	40	asian	asian	ADJ
ajlsi-3268	90	41	10	10	NUM
ajlsi-3268	90	42	50	50	NUM
ajlsi-3268	90	43	caucasian	caucasian	NOUN
ajlsi-3268	90	44	7	7	NUM
ajlsi-3268	90	45	35	35	NUM
ajlsi-3268	90	46	african	african	ADJ
ajlsi-3268	90	47	1	1	NUM
ajlsi-3268	90	48	5	5	NUM
ajlsi-3268	90	49	arab	arab	ADJ
ajlsi-3268	90	50	2	2	NUM
ajlsi-3268	90	51	10	10	NUM
ajlsi-3268	90	52	smoking	smoking	NOUN
ajlsi-3268	90	53	history	history	NOUN
ajlsi-3268	90	54	non	non	NOUN
ajlsi-3268	90	55	smoker	smoker	VERB
ajlsi-3268	90	56	19	19	NUM
ajlsi-3268	90	57	95	95	NUM
ajlsi-3268	90	58	ex	ex	NOUN
ajlsi-3268	90	59	-	-	NOUN
ajlsi-3268	90	60	smoker	smoker	ADJ
ajlsi-3268	90	61	1	1	NUM
ajlsi-3268	90	62	5	5	NUM
ajlsi-3268	90	63	cell	cell	NOUN
ajlsi-3268	90	64	viability	viability	NOUN
ajlsi-3268	90	65	determination	determination	NOUN
ajlsi-3268	90	66	cell	cell	NOUN
ajlsi-3268	90	67	viability	viability	NOUN
ajlsi-3268	90	68	was	be	AUX
ajlsi-3268	90	69	determined	determine	VERB
ajlsi-3268	90	70	using	use	VERB
ajlsi-3268	90	71	the	the	DET
ajlsi-3268	90	72	cell	cell	NOUN
ajlsi-3268	90	73	counting	counting	NOUN
ajlsi-3268	90	74	kit	kit	NOUN
ajlsi-3268	90	75	8	8	NUM
ajlsi-3268	90	76	(	(	PUNCT
ajlsi-3268	90	77	cck8	cck8	PROPN
ajlsi-3268	90	78	)	)	PUNCT
ajlsi-3268	90	79	from	from	ADP
ajlsi-3268	90	80	vwr	vwr	PROPN
ajlsi-3268	90	81	,	,	PUNCT
ajlsi-3268	90	82	uk	uk	PROPN
ajlsi-3268	90	83	.	.	PROPN
ajlsi-3268	90	84	blood	blood	NOUN
ajlsi-3268	90	85	samples	sample	NOUN
ajlsi-3268	90	86	were	be	AUX
ajlsi-3268	90	87	added	add	VERB
ajlsi-3268	90	88	with	with	ADP
ajlsi-3268	90	89	the	the	DET
ajlsi-3268	90	90	chemicals	chemical	NOUN
ajlsi-3268	90	91	in	in	ADP
ajlsi-3268	90	92	eppendorf	eppendorf	PROPN
ajlsi-3268	90	93	tubes	tube	NOUN
ajlsi-3268	90	94	as	as	SCONJ
ajlsi-3268	90	95	described	describe	VERB
ajlsi-3268	90	96	earlier	early	ADV
ajlsi-3268	90	97	for	for	ADP
ajlsi-3268	90	98	pa	pa	PROPN
ajlsi-3268	90	99	ge	ge	PROPN
ajlsi-3268	90	100	30	30	NUM
ajlsi-3268	90	101	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-3268	90	102	am	am	NOUN
ajlsi-3268	90	103	.	.	PUNCT
ajlsi-3268	91	1	j.	j.	PROPN
ajlsi-3268	91	2	life	life	PROPN
ajlsi-3268	91	3	sci	sci	PROPN
ajlsi-3268	91	4	.	.	PUNCT
ajlsi-3268	91	5	innov	innov	PROPN
ajlsi-3268	91	6	.	.	PUNCT
ajlsi-3268	92	1	4(1	4(1	NOUN
ajlsi-3268	92	2	)	)	PUNCT
ajlsi-3268	93	1	27	27	NUM
ajlsi-3268	93	2	-	-	SYM
ajlsi-3268	93	3	35	35	NUM
ajlsi-3268	93	4	,	,	PUNCT
ajlsi-3268	93	5	2025	2025	NUM
ajlsi-3268	93	6	the	the	DET
ajlsi-3268	93	7	comet	comet	NOUN
ajlsi-3268	93	8	assay	assay	VERB
ajlsi-3268	93	9	treatment	treatment	NOUN
ajlsi-3268	93	10	step	step	NOUN
ajlsi-3268	93	11	and	and	CCONJ
ajlsi-3268	93	12	rpmi-1640	rpmi-1640	ADJ
ajlsi-3268	93	13	medium	medium	NOUN
ajlsi-3268	93	14	for	for	ADP
ajlsi-3268	93	15	the	the	DET
ajlsi-3268	93	16	preparation	preparation	NOUN
ajlsi-3268	93	17	of	of	ADP
ajlsi-3268	93	18	cell	cell	NOUN
ajlsi-3268	93	19	culture	culture	NOUN
ajlsi-3268	93	20	.	.	PUNCT
ajlsi-3268	94	1	after	after	SCONJ
ajlsi-3268	94	2	that	that	DET
ajlsi-3268	94	3	tubes	tube	NOUN
ajlsi-3268	94	4	were	be	AUX
ajlsi-3268	94	5	subjected	subject	VERB
ajlsi-3268	94	6	to	to	ADP
ajlsi-3268	94	7	centrifugation	centrifugation	NOUN
ajlsi-3268	94	8	at	at	ADP
ajlsi-3268	94	9	3000	3000	NUM
ajlsi-3268	94	10	rpm	rpm	NOUN
ajlsi-3268	94	11	(	(	PUNCT
ajlsi-3268	94	12	705	705	NUM
ajlsi-3268	94	13	g	g	NOUN
ajlsi-3268	94	14	)	)	PUNCT
ajlsi-3268	94	15	and	and	CCONJ
ajlsi-3268	94	16	the	the	DET
ajlsi-3268	94	17	remained	remain	VERB
ajlsi-3268	94	18	precipitates	precipitate	NOUN
ajlsi-3268	94	19	were	be	AUX
ajlsi-3268	94	20	discarded	discard	VERB
ajlsi-3268	94	21	,	,	PUNCT
ajlsi-3268	94	22	and	and	CCONJ
ajlsi-3268	94	23	the	the	DET
ajlsi-3268	94	24	mass	mass	NOUN
ajlsi-3268	94	25	of	of	ADP
ajlsi-3268	94	26	cells	cell	NOUN
ajlsi-3268	94	27	were	be	AUX
ajlsi-3268	94	28	suspended	suspend	VERB
ajlsi-3268	94	29	.	.	PUNCT
ajlsi-3268	95	1	following	follow	VERB
ajlsi-3268	95	2	the	the	DET
ajlsi-3268	95	3	manufacturer	manufacturer	NOUN
ajlsi-3268	95	4	’s	’s	PART
ajlsi-3268	95	5	procedure	procedure	NOUN
ajlsi-3268	95	6	,	,	PUNCT
ajlsi-3268	95	7	the	the	DET
ajlsi-3268	95	8	experimental	experimental	ADJ
ajlsi-3268	95	9	strategy	strategy	NOUN
ajlsi-3268	95	10	was	be	AUX
ajlsi-3268	95	11	carried	carry	VERB
ajlsi-3268	95	12	out	out	ADP
ajlsi-3268	95	13	and	and	CCONJ
ajlsi-3268	95	14	the	the	DET
ajlsi-3268	95	15	kit	kit	NOUN
ajlsi-3268	95	16	’s	’s	PART
ajlsi-3268	95	17	contents	content	NOUN
ajlsi-3268	95	18	were	be	AUX
ajlsi-3268	95	19	applied	apply	VERB
ajlsi-3268	95	20	to	to	ADP
ajlsi-3268	95	21	the	the	DET
ajlsi-3268	95	22	cell	cell	NOUN
ajlsi-3268	95	23	suspension	suspension	NOUN
ajlsi-3268	95	24	.	.	PUNCT
ajlsi-3268	96	1	cell	cell	NOUN
ajlsi-3268	96	2	viability	viability	NOUN
ajlsi-3268	96	3	of	of	ADP
ajlsi-3268	96	4	≥80	≥80	NUM
ajlsi-3268	96	5	%	%	NOUN
ajlsi-3268	96	6	was	be	AUX
ajlsi-3268	96	7	considered	consider	VERB
ajlsi-3268	96	8	for	for	ADP
ajlsi-3268	96	9	use	use	NOUN
ajlsi-3268	96	10	in	in	ADP
ajlsi-3268	96	11	all	all	DET
ajlsi-3268	96	12	experiments	experiment	NOUN
ajlsi-3268	96	13	.	.	PUNCT
ajlsi-3268	97	1	cell	cell	NOUN
ajlsi-3268	97	2	treatment	treatment	NOUN
ajlsi-3268	97	3	and	and	CCONJ
ajlsi-3268	97	4	the	the	DET
ajlsi-3268	97	5	comet	comet	NOUN
ajlsi-3268	97	6	assay	assay	VERB
ajlsi-3268	97	7	complete	complete	ADJ
ajlsi-3268	97	8	blood	blood	NOUN
ajlsi-3268	97	9	samples	sample	NOUN
ajlsi-3268	97	10	from	from	ADP
ajlsi-3268	97	11	20	20	NUM
ajlsi-3268	97	12	psoriasis	psoriasis	NOUN
ajlsi-3268	97	13	patients	patient	NOUN
ajlsi-3268	97	14	and	and	CCONJ
ajlsi-3268	97	15	20	20	NUM
ajlsi-3268	97	16	healthy	healthy	ADJ
ajlsi-3268	97	17	persons	person	NOUN
ajlsi-3268	97	18	were	be	AUX
ajlsi-3268	97	19	collected	collect	VERB
ajlsi-3268	97	20	and	and	CCONJ
ajlsi-3268	97	21	supplemented	supplement	VERB
ajlsi-3268	97	22	with	with	ADP
ajlsi-3268	97	23	10	10	NUM
ajlsi-3268	97	24	%	%	NOUN
ajlsi-3268	97	25	dmso	dmso	NOUN
ajlsi-3268	97	26	and	and	CCONJ
ajlsi-3268	97	27	rpmi	rpmi	NOUN
ajlsi-3268	97	28	medium	medium	ADJ
ajlsi-3268	97	29	and	and	CCONJ
ajlsi-3268	97	30	quickly	quickly	ADV
ajlsi-3268	97	31	stored	store	VERB
ajlsi-3268	97	32	at	at	ADP
ajlsi-3268	97	33	-80	-80	NOUN
ajlsi-3268	97	34	°	°	PROPN
ajlsi-3268	97	35	c	c	NOUN
ajlsi-3268	97	36	.	.	PUNCT
ajlsi-3268	98	1	five	five	NUM
ajlsi-3268	98	2	groups	group	NOUN
ajlsi-3268	98	3	were	be	AUX
ajlsi-3268	98	4	selected	select	VERB
ajlsi-3268	98	5	for	for	ADP
ajlsi-3268	98	6	treatment	treatment	NOUN
ajlsi-3268	98	7	,	,	PUNCT
ajlsi-3268	98	8	in	in	ADP
ajlsi-3268	98	9	order	order	NOUN
ajlsi-3268	98	10	to	to	PART
ajlsi-3268	98	11	conduct	conduct	VERB
ajlsi-3268	98	12	the	the	DET
ajlsi-3268	98	13	experiment	experiment	NOUN
ajlsi-3268	98	14	,	,	PUNCT
ajlsi-3268	98	15	including	include	VERB
ajlsi-3268	98	16	an	an	DET
ajlsi-3268	98	17	un	un	ADJ
ajlsi-3268	98	18	-	-	ADJ
ajlsi-3268	98	19	treated	treat	VERB
ajlsi-3268	98	20	group	group	NOUN
ajlsi-3268	98	21	(	(	PUNCT
ajlsi-3268	98	22	nc	nc	PROPN
ajlsi-3268	98	23	)	)	PUNCT
ajlsi-3268	98	24	containing	contain	VERB
ajlsi-3268	98	25	the	the	DET
ajlsi-3268	98	26	blood	blood	NOUN
ajlsi-3268	98	27	sample	sample	NOUN
ajlsi-3268	98	28	and	and	CCONJ
ajlsi-3268	98	29	rpmi	rpmi	NOUN
ajlsi-3268	98	30	1640	1640	NUM
ajlsi-3268	98	31	medium	medium	NOUN
ajlsi-3268	98	32	.	.	PUNCT
ajlsi-3268	99	1	a	a	DET
ajlsi-3268	99	2	positive	positive	ADJ
ajlsi-3268	99	3	control	control	NOUN
ajlsi-3268	99	4	containing	contain	VERB
ajlsi-3268	99	5	media	medium	NOUN
ajlsi-3268	99	6	,	,	PUNCT
ajlsi-3268	99	7	blood	blood	NOUN
ajlsi-3268	99	8	,	,	PUNCT
ajlsi-3268	99	9	and	and	CCONJ
ajlsi-3268	99	10	a	a	DET
ajlsi-3268	99	11	total	total	NOUN
ajlsi-3268	99	12	of	of	ADP
ajlsi-3268	99	13	10μl	10μl	ADV
ajlsi-3268	99	14	,	,	PUNCT
ajlsi-3268	99	15	75μm	75μm	ADJ
ajlsi-3268	99	16	/	/	SYM
ajlsi-3268	99	17	ml	ml	NOUN
ajlsi-3268	99	18	hydrogen	hydrogen	NOUN
ajlsi-3268	99	19	peroxide	peroxide	NOUN
ajlsi-3268	99	20	(	(	PUNCT
ajlsi-3268	99	21	h2o2	h2o2	NOUN
ajlsi-3268	99	22	)	)	PUNCT
ajlsi-3268	99	23	,	,	PUNCT
ajlsi-3268	99	24	and	and	CCONJ
ajlsi-3268	99	25	two	two	NUM
ajlsi-3268	99	26	treatment	treatment	NOUN
ajlsi-3268	99	27	groups	group	NOUN
ajlsi-3268	99	28	with	with	ADP
ajlsi-3268	99	29	different	different	ADJ
ajlsi-3268	99	30	doses	dose	NOUN
ajlsi-3268	99	31	of	of	ADP
ajlsi-3268	99	32	“	"	PUNCT
ajlsi-3268	99	33	secukinumab	secukinumab	NOUN
ajlsi-3268	99	34	(	(	PUNCT
ajlsi-3268	99	35	2.8	2.8	NUM
ajlsi-3268	99	36	µg	µg	ADV
ajlsi-3268	99	37	/ml	/ml	NOUN
ajlsi-3268	99	38	,	,	PUNCT
ajlsi-3268	99	39	2.1µg	2.1µg	NUM
ajlsi-3268	99	40	/	/	SYM
ajlsi-3268	99	41	ml	ml	NOUN
ajlsi-3268	99	42	)	)	PUNCT
ajlsi-3268	99	43	including	include	VERB
ajlsi-3268	99	44	or	or	CCONJ
ajlsi-3268	99	45	excluding	exclude	VERB
ajlsi-3268	99	46	h2o2	h2o2	NOUN
ajlsi-3268	99	47	”	"	PUNCT
ajlsi-3268	99	48	,	,	PUNCT
ajlsi-3268	99	49	and	and	CCONJ
ajlsi-3268	99	50	1000μl	1000μl	ADV
ajlsi-3268	99	51	of	of	ADP
ajlsi-3268	99	52	treatment	treatment	NOUN
ajlsi-3268	99	53	volume	volume	NOUN
ajlsi-3268	99	54	were	be	AUX
ajlsi-3268	99	55	used	use	VERB
ajlsi-3268	99	56	in	in	ADP
ajlsi-3268	99	57	the	the	DET
ajlsi-3268	99	58	experiment	experiment	NOUN
ajlsi-3268	99	59	.	.	PUNCT
ajlsi-3268	100	1	it	it	PRON
ajlsi-3268	100	2	was	be	AUX
ajlsi-3268	100	3	then	then	ADV
ajlsi-3268	100	4	“	"	PUNCT
ajlsi-3268	100	5	centrifuged	centrifuge	VERB
ajlsi-3268	100	6	at	at	ADP
ajlsi-3268	100	7	3000	3000	NUM
ajlsi-3268	100	8	rpm	rpm	NOUN
ajlsi-3268	100	9	”	"	PUNCT
ajlsi-3268	100	10	and	and	CCONJ
ajlsi-3268	100	11	incubated	incubate	VERB
ajlsi-3268	100	12	at	at	ADP
ajlsi-3268	100	13	37	37	NUM
ajlsi-3268	100	14	°	°	ADP
ajlsi-3268	100	15	c	c	NOUN
ajlsi-3268	100	16	(	(	PUNCT
ajlsi-3268	100	17	tice	tice	PROPN
ajlsi-3268	100	18	et	et	PROPN
ajlsi-3268	100	19	al	al	PROPN
ajlsi-3268	100	20	.	.	PROPN
ajlsi-3268	100	21	,	,	PUNCT
ajlsi-3268	100	22	2000	2000	NUM
ajlsi-3268	100	23	;	;	PUNCT
ajlsi-3268	100	24	najafzadeh	najafzadeh	PROPN
ajlsi-3268	100	25	&	&	CCONJ
ajlsi-3268	100	26	anderson	anderson	PROPN
ajlsi-3268	100	27	,	,	PUNCT
ajlsi-3268	100	28	2016	2016	NUM
ajlsi-3268	100	29	)	)	PUNCT
ajlsi-3268	100	30	.	.	PUNCT
ajlsi-3268	101	1	using	use	VERB
ajlsi-3268	101	2	a	a	DET
ajlsi-3268	101	3	computer	computer	NOUN
ajlsi-3268	101	4	terminal	terminal	NOUN
ajlsi-3268	101	5	komet	komet	PROPN
ajlsi-3268	101	6	6	6	NUM
ajlsi-3268	101	7	software	software	NOUN
ajlsi-3268	101	8	and	and	CCONJ
ajlsi-3268	101	9	kinetic	kinetic	ADJ
ajlsi-3268	101	10	imaging	imaging	NOUN
ajlsi-3268	101	11	(	(	PUNCT
ajlsi-3268	101	12	andor	andor	PROPN
ajlsi-3268	101	13	technology	technology	PROPN
ajlsi-3268	101	14	ltd	ltd	PROPN
ajlsi-3268	101	15	,	,	PUNCT
ajlsi-3268	101	16	belfast	belfast	PROPN
ajlsi-3268	101	17	)	)	PUNCT
ajlsi-3268	101	18	and	and	CCONJ
ajlsi-3268	101	19	fluorescence	fluorescence	NOUN
ajlsi-3268	101	20	microscope	microscope	NOUN
ajlsi-3268	101	21	(	(	PUNCT
ajlsi-3268	101	22	20x	20x	NOUN
ajlsi-3268	101	23	magnification	magnification	NOUN
ajlsi-3268	101	24	)	)	PUNCT
ajlsi-3268	101	25	equipped	equip	VERB
ajlsi-3268	101	26	with	with	ADP
ajlsi-3268	101	27	ccd	ccd	PROPN
ajlsi-3268	101	28	camera	camera	NOUN
ajlsi-3268	101	29	,	,	PUNCT
ajlsi-3268	101	30	100	100	NUM
ajlsi-3268	101	31	cells	cell	NOUN
ajlsi-3268	101	32	from	from	ADP
ajlsi-3268	101	33	each	each	DET
ajlsi-3268	101	34	treatment	treatment	NOUN
ajlsi-3268	101	35	group	group	NOUN
ajlsi-3268	101	36	were	be	AUX
ajlsi-3268	101	37	fixed	fix	VERB
ajlsi-3268	101	38	using	use	VERB
ajlsi-3268	101	39	comet	comet	NOUN
ajlsi-3268	101	40	assay	assay	NOUN
ajlsi-3268	101	41	parameters	parameter	NOUN
ajlsi-3268	101	42	such	such	ADJ
ajlsi-3268	101	43	as	as	ADP
ajlsi-3268	101	44	olive	olive	NOUN
ajlsi-3268	101	45	tail	tail	NOUN
ajlsi-3268	101	46	moment	moment	NOUN
ajlsi-3268	101	47	and	and	CCONJ
ajlsi-3268	101	48	percentage	percentage	NOUN
ajlsi-3268	101	49	tail	tail	NOUN
ajlsi-3268	101	50	dna	dna	NOUN
ajlsi-3268	101	51	.	.	PUNCT
ajlsi-3268	102	1	cytokinesis	cytokinesis	NOUN
ajlsi-3268	102	2	block	block	NOUN
ajlsi-3268	102	3	micronucleus	micronucleus	NOUN
ajlsi-3268	102	4	assay	assay	PROPN
ajlsi-3268	102	5	(	(	PUNCT
ajlsi-3268	102	6	cbmn	cbmn	NOUN
ajlsi-3268	102	7	)	)	PUNCT
ajlsi-3268	102	8	fresh	fresh	ADJ
ajlsi-3268	102	9	blood	blood	NOUN
ajlsi-3268	102	10	sample	sample	NOUN
ajlsi-3268	102	11	(	(	PUNCT
ajlsi-3268	102	12	350	350	NUM
ajlsi-3268	102	13	μl	μl	NUM
ajlsi-3268	102	14	)	)	PUNCT
ajlsi-3268	102	15	and	and	CCONJ
ajlsi-3268	102	16	130μl	130μl	NOUN
ajlsi-3268	102	17	of	of	ADP
ajlsi-3268	102	18	phytohaemagglutinin	phytohaemagglutinin	PROPN
ajlsi-3268	102	19	(	(	PUNCT
ajlsi-3268	102	20	pha	pha	PROPN
ajlsi-3268	102	21	)	)	PUNCT
ajlsi-3268	102	22	were	be	AUX
ajlsi-3268	102	23	added	add	VERB
ajlsi-3268	102	24	to	to	ADP
ajlsi-3268	102	25	25cm3	25cm3	NOUN
ajlsi-3268	102	26	vented	vent	VERB
ajlsi-3268	102	27	cap	cap	NOUN
ajlsi-3268	102	28	corning	corning	NOUN
ajlsi-3268	102	29	flasks	flask	NOUN
ajlsi-3268	102	30	containing	contain	VERB
ajlsi-3268	102	31	“	"	PUNCT
ajlsi-3268	102	32	4.5	4.5	NUM
ajlsi-3268	102	33	ml	ml	NOUN
ajlsi-3268	102	34	rpmi-1640	rpmi-1640	ADJ
ajlsi-3268	102	35	medium	medium	NOUN
ajlsi-3268	102	36	augmented	augment	VERB
ajlsi-3268	102	37	with	with	ADP
ajlsi-3268	102	38	1	1	NUM
ajlsi-3268	102	39	%	%	NOUN
ajlsi-3268	102	40	of	of	ADP
ajlsi-3268	102	41	penicillin	penicillin	NOUN
ajlsi-3268	102	42	-	-	PUNCT
ajlsi-3268	102	43	streptomycin	streptomycin	PROPN
ajlsi-3268	102	44	(	(	PUNCT
ajlsi-3268	102	45	aminoglycoside	aminoglycoside	ADV
ajlsi-3268	102	46	antibiotic	antibiotic	ADJ
ajlsi-3268	102	47	)	)	PUNCT
ajlsi-3268	102	48	and	and	CCONJ
ajlsi-3268	102	49	15	15	NUM
ajlsi-3268	102	50	%	%	NOUN
ajlsi-3268	102	51	fetal	fetal	ADJ
ajlsi-3268	102	52	bovine	bovine	NOUN
ajlsi-3268	102	53	serum	serum	NOUN
ajlsi-3268	102	54	(	(	PUNCT
ajlsi-3268	102	55	fbs	fbs	PROPN
ajlsi-3268	102	56	)	)	PUNCT
ajlsi-3268	102	57	”	"	PUNCT
ajlsi-3268	102	58	.	.	PUNCT
ajlsi-3268	102	59	followed	follow	VERB
ajlsi-3268	102	60	by	by	ADP
ajlsi-3268	102	61	incubation	incubation	NOUN
ajlsi-3268	102	62	for	for	ADP
ajlsi-3268	102	63	24h	24h	NOUN
ajlsi-3268	102	64	at	at	ADP
ajlsi-3268	102	65	room	room	NOUN
ajlsi-3268	102	66	temperature	temperature	NOUN
ajlsi-3268	102	67	i.e.	i.e.	X
ajlsi-3268	102	68	,	,	PUNCT
ajlsi-3268	102	69	37⁰c	37⁰c	NOUN
ajlsi-3268	102	70	in	in	ADP
ajlsi-3268	102	71	the	the	DET
ajlsi-3268	102	72	existence	existence	NOUN
ajlsi-3268	102	73	of	of	ADP
ajlsi-3268	102	74	5	5	NUM
ajlsi-3268	102	75	%	%	NOUN
ajlsi-3268	102	76	co2	co2	NOUN
ajlsi-3268	102	77	and	and	CCONJ
ajlsi-3268	102	78	then	then	ADV
ajlsi-3268	102	79	the	the	DET
ajlsi-3268	102	80	test	test	NOUN
ajlsi-3268	102	81	chemicals	chemical	NOUN
ajlsi-3268	102	82	secukinumab	secukinumab	VERB
ajlsi-3268	102	83	bulk	bulk	NOUN
ajlsi-3268	102	84	and	and	CCONJ
ajlsi-3268	102	85	liposome	liposome	NOUN
ajlsi-3268	102	86	,	,	PUNCT
ajlsi-3268	102	87	h2o2	h2o2	PROPN
ajlsi-3268	102	88	were	be	AUX
ajlsi-3268	102	89	added	add	VERB
ajlsi-3268	102	90	.	.	PUNCT
ajlsi-3268	103	1	for	for	SCONJ
ajlsi-3268	103	2	the	the	DET
ajlsi-3268	103	3	untreated	untreated	ADJ
ajlsi-3268	103	4	negative	negative	ADJ
ajlsi-3268	103	5	control	control	NOUN
ajlsi-3268	103	6	plain	plain	ADJ
ajlsi-3268	103	7	basic	basic	ADJ
ajlsi-3268	103	8	medium	medium	NOUN
ajlsi-3268	103	9	was	be	AUX
ajlsi-3268	103	10	used	use	VERB
ajlsi-3268	103	11	,	,	PUNCT
ajlsi-3268	103	12	and	and	CCONJ
ajlsi-3268	103	13	as	as	ADP
ajlsi-3268	103	14	positive	positive	ADJ
ajlsi-3268	103	15	controls	control	NOUN
ajlsi-3268	103	16	mitomycin	mitomycin	PROPN
ajlsi-3268	103	17	c	c	PROPN
ajlsi-3268	103	18	(	(	PUNCT
ajlsi-3268	103	19	mmc	mmc	PROPN
ajlsi-3268	103	20	)	)	PUNCT
ajlsi-3268	103	21	(	(	PUNCT
ajlsi-3268	103	22	0.4μm	0.4μm	NOUN
ajlsi-3268	103	23	)	)	PUNCT
ajlsi-3268	103	24	and	and	CCONJ
ajlsi-3268	103	25	h2o2	h2o2	NOUN
ajlsi-3268	103	26	,	,	PUNCT
ajlsi-3268	103	27	(	(	PUNCT
ajlsi-3268	103	28	75μm	75μm	NOUN
ajlsi-3268	103	29	)	)	PUNCT
ajlsi-3268	103	30	were	be	AUX
ajlsi-3268	103	31	used	use	VERB
ajlsi-3268	103	32	.	.	PUNCT
ajlsi-3268	104	1	in	in	ADP
ajlsi-3268	104	2	each	each	DET
ajlsi-3268	104	3	flask	flask	NOUN
ajlsi-3268	104	4	30μl	30μl	ADV
ajlsi-3268	104	5	of	of	ADP
ajlsi-3268	104	6	cytochalasin	cytochalasin	PROPN
ajlsi-3268	104	7	b	b	PROPN
ajlsi-3268	104	8	(	(	PUNCT
ajlsi-3268	104	9	cyt	cyt	PROPN
ajlsi-3268	104	10	b	b	PROPN
ajlsi-3268	104	11	)	)	PUNCT
ajlsi-3268	104	12	(	(	PUNCT
ajlsi-3268	104	13	1mg	1mg	NOUN
ajlsi-3268	104	14	/	/	SYM
ajlsi-3268	104	15	ml	ml	NOUN
ajlsi-3268	104	16	)	)	PUNCT
ajlsi-3268	104	17	was	be	AUX
ajlsi-3268	104	18	added	add	VERB
ajlsi-3268	104	19	at	at	ADP
ajlsi-3268	104	20	44h	44h	NOUN
ajlsi-3268	104	21	and	and	CCONJ
ajlsi-3268	104	22	cultured	cultured	ADJ
ajlsi-3268	104	23	under	under	ADP
ajlsi-3268	104	24	the	the	DET
ajlsi-3268	104	25	same	same	ADJ
ajlsi-3268	104	26	conditions	condition	NOUN
ajlsi-3268	104	27	for	for	ADP
ajlsi-3268	104	28	another	another	DET
ajlsi-3268	104	29	20h	20h	NOUN
ajlsi-3268	104	30	(	(	PUNCT
ajlsi-3268	104	31	fenech	fenech	PROPN
ajlsi-3268	104	32	et	et	PROPN
ajlsi-3268	104	33	al	al	PROPN
ajlsi-3268	104	34	.	.	PROPN
ajlsi-3268	104	35	,	,	PUNCT
ajlsi-3268	104	36	2016	2016	NUM
ajlsi-3268	104	37	)	)	PUNCT
ajlsi-3268	104	38	.	.	PUNCT
ajlsi-3268	105	1	using	use	VERB
ajlsi-3268	105	2	a	a	DET
ajlsi-3268	105	3	40x	40x	NOUN
ajlsi-3268	105	4	microscope	microscope	NOUN
ajlsi-3268	105	5	to	to	PART
ajlsi-3268	105	6	score	score	VERB
ajlsi-3268	105	7	1000	1000	NUM
ajlsi-3268	105	8	cells	cell	NOUN
ajlsi-3268	105	9	per	per	ADP
ajlsi-3268	105	10	treatment	treatment	NOUN
ajlsi-3268	105	11	group	group	NOUN
ajlsi-3268	105	12	,	,	PUNCT
ajlsi-3268	105	13	including	include	VERB
ajlsi-3268	105	14	the	the	DET
ajlsi-3268	105	15	nuclear	nuclear	ADJ
ajlsi-3268	105	16	division	division	NOUN
ajlsi-3268	105	17	index	index	NOUN
ajlsi-3268	105	18	and	and	CCONJ
ajlsi-3268	105	19	the	the	DET
ajlsi-3268	105	20	percentage	percentage	NOUN
ajlsi-3268	105	21	of	of	ADP
ajlsi-3268	105	22	binucleated	binucleate	VERB
ajlsi-3268	105	23	cells	cell	NOUN
ajlsi-3268	105	24	,	,	PUNCT
ajlsi-3268	105	25	the	the	DET
ajlsi-3268	105	26	frequency	frequency	NOUN
ajlsi-3268	105	27	of	of	ADP
ajlsi-3268	105	28	micro	micro	PROPN
ajlsi-3268	105	29	nuclei	nuclei	PROPN
ajlsi-3268	105	30	(	(	PUNCT
ajlsi-3268	105	31	mni	mni	X
ajlsi-3268	105	32	)	)	PUNCT
ajlsi-3268	105	33	was	be	AUX
ajlsi-3268	105	34	ascertained	ascertain	VERB
ajlsi-3268	105	35	(	(	PUNCT
ajlsi-3268	105	36	fenech	fenech	PROPN
ajlsi-3268	105	37	,	,	PUNCT
ajlsi-3268	105	38	2007	2007	NUM
ajlsi-3268	105	39	)	)	PUNCT
ajlsi-3268	105	40	.	.	PUNCT
ajlsi-3268	106	1	the	the	DET
ajlsi-3268	106	2	ndi	ndi	PROPN
ajlsi-3268	106	3	was	be	AUX
ajlsi-3268	106	4	calculated	calculate	VERB
ajlsi-3268	106	5	using	use	VERB
ajlsi-3268	106	6	the	the	DET
ajlsi-3268	106	7	equation	equation	NOUN
ajlsi-3268	106	8	eq	eq	ADJ
ajlsi-3268	106	9	.	.	PUNCT
ajlsi-3268	107	1	a.1	a.1	PROPN
ajlsi-3268	107	2	:	:	PUNCT
ajlsi-3268	107	3	ndi	ndi	PROPN
ajlsi-3268	107	4	=	=	PROPN
ajlsi-3268	107	5	m1	m1	PROPN
ajlsi-3268	107	6	+	+	CCONJ
ajlsi-3268	107	7	2(m2	2(m2	NUM
ajlsi-3268	107	8	)	)	PUNCT
ajlsi-3268	108	1	+	+	NUM
ajlsi-3268	108	2	3(m3	3(m3	X
ajlsi-3268	108	3	)	)	PUNCT
ajlsi-3268	108	4	/	/	SYM
ajlsi-3268	109	1	n	n	CCONJ
ajlsi-3268	109	2	where	where	SCONJ
ajlsi-3268	109	3	,	,	PUNCT
ajlsi-3268	109	4	m1	m1	PROPN
ajlsi-3268	109	5	=	=	SYM
ajlsi-3268	109	6	mononucleated	mononucleate	VERB
ajlsi-3268	109	7	cells	cell	NOUN
ajlsi-3268	109	8	,	,	PUNCT
ajlsi-3268	109	9	m2=	m2=	NUM
ajlsi-3268	109	10	binucleated	binucleate	VERB
ajlsi-3268	109	11	cells	cell	NOUN
ajlsi-3268	109	12	,	,	PUNCT
ajlsi-3268	109	13	m3	m3	PROPN
ajlsi-3268	109	14	=	=	PUNCT
ajlsi-3268	109	15	multinucleated	multinucleate	VERB
ajlsi-3268	109	16	cells	cell	NOUN
ajlsi-3268	109	17	,	,	PUNCT
ajlsi-3268	109	18	n	n	NOUN
ajlsi-3268	109	19	=	=	NUM
ajlsi-3268	109	20	total	total	ADJ
ajlsi-3268	109	21	number	number	NOUN
ajlsi-3268	109	22	of	of	ADP
ajlsi-3268	109	23	viable	viable	ADJ
ajlsi-3268	109	24	cells	cell	NOUN
ajlsi-3268	109	25	scored	score	VERB
ajlsi-3268	109	26	(	(	PUNCT
ajlsi-3268	109	27	fenech	fenech	X
ajlsi-3268	109	28	et	et	PROPN
ajlsi-3268	109	29	al	al	PROPN
ajlsi-3268	109	30	.	.	PROPN
ajlsi-3268	109	31	,	,	PUNCT
ajlsi-3268	109	32	2016	2016	NUM
ajlsi-3268	109	33	)	)	PUNCT
ajlsi-3268	109	34	.	.	PUNCT
ajlsi-3268	110	1	statistical	statistical	ADJ
ajlsi-3268	110	2	analysis	analysis	NOUN
ajlsi-3268	110	3	for	for	ADP
ajlsi-3268	110	4	the	the	DET
ajlsi-3268	110	5	determination	determination	NOUN
ajlsi-3268	110	6	of	of	ADP
ajlsi-3268	110	7	significant	significant	ADJ
ajlsi-3268	110	8	values	value	NOUN
ajlsi-3268	110	9	,	,	PUNCT
ajlsi-3268	110	10	data	datum	NOUN
ajlsi-3268	110	11	was	be	AUX
ajlsi-3268	110	12	analyzed	analyze	VERB
ajlsi-3268	110	13	through	through	ADP
ajlsi-3268	110	14	one	one	NUM
ajlsi-3268	110	15	-	-	PUNCT
ajlsi-3268	110	16	way	way	NOUN
ajlsi-3268	110	17	anova	anova	X
ajlsi-3268	110	18	(	(	PUNCT
ajlsi-3268	110	19	tofind	tofind	VERB
ajlsi-3268	110	20	the	the	DET
ajlsi-3268	110	21	difference	difference	NOUN
ajlsi-3268	110	22	between	between	ADP
ajlsi-3268	110	23	results	result	NOUN
ajlsi-3268	110	24	obtained	obtain	VERB
ajlsi-3268	110	25	from	from	ADP
ajlsi-3268	110	26	research	research	NOUN
ajlsi-3268	110	27	)	)	PUNCT
ajlsi-3268	110	28	and	and	CCONJ
ajlsi-3268	110	29	t	t	NOUN
ajlsi-3268	110	30	-	-	PUNCT
ajlsi-3268	110	31	tests	test	NOUN
ajlsi-3268	110	32	to	to	PART
ajlsi-3268	110	33	determine	determine	VERB
ajlsi-3268	110	34	the	the	DET
ajlsi-3268	110	35	significant	significant	ADJ
ajlsi-3268	110	36	values	value	NOUN
ajlsi-3268	110	37	.	.	PUNCT
ajlsi-3268	111	1	a	a	DET
ajlsi-3268	111	2	value	value	NOUN
ajlsi-3268	111	3	p=	p=	NOUN
ajlsi-3268	111	4	<	<	NOUN
ajlsi-3268	111	5	0.05	0.05	NUM
ajlsi-3268	111	6	was	be	AUX
ajlsi-3268	111	7	considered	consider	VERB
ajlsi-3268	111	8	statistically	statistically	ADV
ajlsi-3268	111	9	significant	significant	ADJ
ajlsi-3268	111	10	.	.	PUNCT
ajlsi-3268	112	1	graph	graph	NOUN
ajlsi-3268	112	2	pad	pad	NOUN
ajlsi-3268	112	3	prism	prism	NOUN
ajlsi-3268	112	4	8	8	NUM
ajlsi-3268	112	5	was	be	AUX
ajlsi-3268	112	6	used	use	VERB
ajlsi-3268	112	7	for	for	ADP
ajlsi-3268	112	8	statistical	statistical	ADJ
ajlsi-3268	112	9	data	datum	NOUN
ajlsi-3268	112	10	analysis	analysis	NOUN
ajlsi-3268	112	11	.	.	PUNCT
ajlsi-3268	113	1	results	result	NOUN
ajlsi-3268	113	2	and	and	CCONJ
ajlsi-3268	113	3	discussion	discussion	NOUN
ajlsi-3268	113	4	results	result	NOUN
ajlsi-3268	113	5	when	when	SCONJ
ajlsi-3268	113	6	secukinumab	secukinumab	NOUN
ajlsi-3268	113	7	liposomes	liposome	NOUN
ajlsi-3268	113	8	were	be	AUX
ajlsi-3268	113	9	tem	tem	NOUN
ajlsi-3268	113	10	-	-	PUNCT
ajlsi-3268	113	11	analyzed	analyze	VERB
ajlsi-3268	113	12	,	,	PUNCT
ajlsi-3268	113	13	homogeneous	homogeneous	ADJ
ajlsi-3268	113	14	,	,	PUNCT
ajlsi-3268	113	15	spherical	spherical	ADJ
ajlsi-3268	113	16	bio	bio	NOUN
ajlsi-3268	113	17	particles	particle	NOUN
ajlsi-3268	113	18	with	with	ADP
ajlsi-3268	113	19	sizes	size	NOUN
ajlsi-3268	113	20	between	between	ADP
ajlsi-3268	113	21	100	100	NUM
ajlsi-3268	113	22	and	and	CCONJ
ajlsi-3268	113	23	200	200	NUM
ajlsi-3268	113	24	nm	nm	NOUN
ajlsi-3268	113	25	were	be	AUX
ajlsi-3268	113	26	discovered	discover	VERB
ajlsi-3268	113	27	.	.	PUNCT
ajlsi-3268	114	1	figure	figure	VERB
ajlsi-3268	114	2	2	2	NUM
ajlsi-3268	114	3	:	:	PUNCT
ajlsi-3268	114	4	(	(	PUNCT
ajlsi-3268	114	5	a	a	X
ajlsi-3268	114	6	)	)	PUNCT
ajlsi-3268	114	7	tem	tem	NOUN
ajlsi-3268	114	8	analysis	analysis	NOUN
ajlsi-3268	114	9	of	of	ADP
ajlsi-3268	114	10	the	the	DET
ajlsi-3268	114	11	aqueous	aqueous	ADJ
ajlsi-3268	114	12	dispersion	dispersion	NOUN
ajlsi-3268	114	13	of	of	ADP
ajlsi-3268	114	14	secukinumab	secukinumab	NOUN
ajlsi-3268	114	15	,	,	PUNCT
ajlsi-3268	114	16	(	(	PUNCT
ajlsi-3268	114	17	b	b	X
ajlsi-3268	114	18	)	)	PUNCT
ajlsi-3268	114	19	tem	tem	PROPN
ajlsi-3268	114	20	imaging	image	VERB
ajlsi-3268	114	21	the	the	DET
ajlsi-3268	114	22	liposomal	liposomal	ADJ
ajlsi-3268	114	23	form	form	NOUN
ajlsi-3268	114	24	of	of	ADP
ajlsi-3268	114	25	secukinumab	secukinumab	NOUN
ajlsi-3268	114	26	figure	figure	NOUN
ajlsi-3268	114	27	3	3	NUM
ajlsi-3268	114	28	:	:	PUNCT
ajlsi-3268	114	29	cytotoxicity	cytotoxicity	NOUN
ajlsi-3268	114	30	of	of	ADP
ajlsi-3268	114	31	secukinumab	secukinumab	NOUN
ajlsi-3268	114	32	on	on	ADP
ajlsi-3268	114	33	human	human	ADJ
ajlsi-3268	114	34	peripheral	peripheral	ADJ
ajlsi-3268	114	35	lymphocytes	lymphocyte	NOUN
ajlsi-3268	114	36	after	after	ADP
ajlsi-3268	114	37	24	24	NUM
ajlsi-3268	114	38	hrs	hrs	NOUN
ajlsi-3268	114	39	exposure	exposure	NOUN
ajlsi-3268	114	40	to	to	ADP
ajlsi-3268	114	41	different	different	ADJ
ajlsi-3268	114	42	concentrations	concentration	NOUN
ajlsi-3268	114	43	(	(	PUNCT
ajlsi-3268	114	44	2.1	2.1	NUM
ajlsi-3268	114	45	,	,	PUNCT
ajlsi-3268	114	46	2.8	2.8	NUM
ajlsi-3268	114	47	,	,	PUNCT
ajlsi-3268	114	48	and	and	CCONJ
ajlsi-3268	114	49	3.751	3.751	NUM
ajlsi-3268	114	50	μg	μg	NOUN
ajlsi-3268	114	51	/	/	SYM
ajlsi-3268	114	52	ml	ml	NOUN
ajlsi-3268	114	53	)	)	PUNCT
ajlsi-3268	114	54	by	by	ADP
ajlsi-3268	114	55	using	use	VERB
ajlsi-3268	114	56	cck8	cck8	PROPN
ajlsi-3268	114	57	pa	pa	PROPN
ajlsi-3268	114	58	ge	ge	PROPN
ajlsi-3268	114	59	31	31	NUM
ajlsi-3268	114	60	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-3268	114	61	am	am	NOUN
ajlsi-3268	114	62	.	.	PUNCT
ajlsi-3268	115	1	j.	j.	PROPN
ajlsi-3268	115	2	life	life	PROPN
ajlsi-3268	115	3	sci	sci	PROPN
ajlsi-3268	115	4	.	.	PUNCT
ajlsi-3268	115	5	innov	innov	PROPN
ajlsi-3268	115	6	.	.	PUNCT
ajlsi-3268	116	1	4(1	4(1	NOUN
ajlsi-3268	116	2	)	)	PUNCT
ajlsi-3268	117	1	27	27	NUM
ajlsi-3268	117	2	-	-	SYM
ajlsi-3268	117	3	35	35	NUM
ajlsi-3268	117	4	,	,	PUNCT
ajlsi-3268	117	5	2025	2025	NUM
ajlsi-3268	117	6	the	the	DET
ajlsi-3268	117	7	proliferation	proliferation	NOUN
ajlsi-3268	117	8	rate	rate	NOUN
ajlsi-3268	117	9	was	be	AUX
ajlsi-3268	117	10	computed	compute	VERB
ajlsi-3268	117	11	by	by	ADP
ajlsi-3268	117	12	dividing	divide	VERB
ajlsi-3268	117	13	the	the	DET
ajlsi-3268	117	14	total	total	ADJ
ajlsi-3268	117	15	number	number	NOUN
ajlsi-3268	117	16	of	of	ADP
ajlsi-3268	117	17	counted	count	VERB
ajlsi-3268	117	18	cells	cell	NOUN
ajlsi-3268	117	19	by	by	ADP
ajlsi-3268	117	20	the	the	DET
ajlsi-3268	117	21	number	number	NOUN
ajlsi-3268	117	22	of	of	ADP
ajlsi-3268	117	23	living	live	VERB
ajlsi-3268	117	24	or	or	CCONJ
ajlsi-3268	117	25	viable	viable	ADJ
ajlsi-3268	117	26	cells	cell	NOUN
ajlsi-3268	117	27	.	.	PUNCT
ajlsi-3268	118	1	a	a	DET
ajlsi-3268	118	2	cell	cell	NOUN
ajlsi-3268	118	3	counting	counting	NOUN
ajlsi-3268	118	4	kit	kit	NOUN
ajlsi-3268	118	5	was	be	AUX
ajlsi-3268	118	6	used	use	VERB
ajlsi-3268	118	7	to	to	PART
ajlsi-3268	118	8	check	check	VERB
ajlsi-3268	118	9	the	the	DET
ajlsi-3268	118	10	integrity	integrity	NOUN
ajlsi-3268	118	11	and	and	CCONJ
ajlsi-3268	118	12	viability	viability	NOUN
ajlsi-3268	118	13	of	of	ADP
ajlsi-3268	118	14	the	the	DET
ajlsi-3268	118	15	lymphocytes	lymphocyte	NOUN
ajlsi-3268	118	16	,	,	PUNCT
ajlsi-3268	118	17	as	as	SCONJ
ajlsi-3268	118	18	shown	show	VERB
ajlsi-3268	118	19	in	in	ADP
ajlsi-3268	118	20	figure	figure	NOUN
ajlsi-3268	118	21	3	3	NUM
ajlsi-3268	118	22	.	.	PUNCT
ajlsi-3268	119	1	the	the	DET
ajlsi-3268	119	2	effects	effect	NOUN
ajlsi-3268	119	3	of	of	ADP
ajlsi-3268	119	4	secukinumab	secukinumab	NOUN
ajlsi-3268	119	5	and	and	CCONJ
ajlsi-3268	119	6	h2o2	h2o2	NOUN
ajlsi-3268	119	7	on	on	ADP
ajlsi-3268	119	8	the	the	DET
ajlsi-3268	119	9	lymphocytes	lymphocyte	NOUN
ajlsi-3268	119	10	from	from	ADP
ajlsi-3268	119	11	healthy	healthy	ADJ
ajlsi-3268	119	12	the	the	DET
ajlsi-3268	119	13	responses	response	NOUN
ajlsi-3268	119	14	of	of	ADP
ajlsi-3268	119	15	bulk	bulk	NOUN
ajlsi-3268	119	16	and	and	CCONJ
ajlsi-3268	119	17	liposome	liposome	VERB
ajlsi-3268	119	18	forms	form	NOUN
ajlsi-3268	119	19	of	of	ADP
ajlsi-3268	119	20	secukinumab	secukinumab	NOUN
ajlsi-3268	119	21	on	on	ADP
ajlsi-3268	119	22	lymphocytes	lymphocyte	NOUN
ajlsi-3268	119	23	of	of	ADP
ajlsi-3268	119	24	dna	dna	NOUN
ajlsi-3268	119	25	from	from	ADP
ajlsi-3268	119	26	healthy	healthy	ADJ
ajlsi-3268	119	27	and	and	CCONJ
ajlsi-3268	119	28	psoriatic	psoriatic	ADJ
ajlsi-3268	119	29	patients	patient	NOUN
ajlsi-3268	119	30	treated	treat	VERB
ajlsi-3268	119	31	with	with	ADP
ajlsi-3268	119	32	h2o2	h2o2	NOUN
ajlsi-3268	119	33	using	use	VERB
ajlsi-3268	119	34	“	"	PUNCT
ajlsi-3268	119	35	olive	olive	ADJ
ajlsi-3268	119	36	tail	tail	NOUN
ajlsi-3268	119	37	moment	moment	NOUN
ajlsi-3268	119	38	”	"	PUNCT
ajlsi-3268	119	39	(	(	PUNCT
ajlsi-3268	119	40	otm	otm	NOUN
ajlsi-3268	119	41	)	)	PUNCT
ajlsi-3268	119	42	,	,	PUNCT
ajlsi-3268	119	43	standard	standard	ADJ
ajlsi-3268	119	44	errors	error	NOUN
ajlsi-3268	119	45	and	and	CCONJ
ajlsi-3268	119	46	significance	significance	NOUN
ajlsi-3268	119	47	were	be	AUX
ajlsi-3268	119	48	displayed	display	VERB
ajlsi-3268	119	49	in	in	ADP
ajlsi-3268	119	50	the	the	DET
ajlsi-3268	119	51	figure	figure	NOUN
ajlsi-3268	119	52	4	4	NUM
ajlsi-3268	119	53	.	.	PUNCT
ajlsi-3268	119	54	using	use	VERB
ajlsi-3268	119	55	one	one	NUM
ajlsi-3268	119	56	-	-	PUNCT
ajlsi-3268	119	57	way	way	NOUN
ajlsi-3268	119	58	anova	anova	PROPN
ajlsi-3268	119	59	,	,	PUNCT
ajlsi-3268	119	60	the	the	DET
ajlsi-3268	119	61	study	study	NOUN
ajlsi-3268	119	62	showed	show	VERB
ajlsi-3268	119	63	that	that	SCONJ
ajlsi-3268	119	64	h2o2	h2o2	NOUN
ajlsi-3268	119	65	,	,	PUNCT
ajlsi-3268	119	66	treatments	treatment	NOUN
ajlsi-3268	119	67	significantly	significantly	ADV
ajlsi-3268	119	68	increased	increase	VERB
ajlsi-3268	119	69	dna	dna	ADJ
ajlsi-3268	119	70	damage	damage	NOUN
ajlsi-3268	119	71	in	in	ADP
ajlsi-3268	119	72	cells	cell	NOUN
ajlsi-3268	119	73	by	by	ADP
ajlsi-3268	119	74	increasing	increase	VERB
ajlsi-3268	119	75	otm	otm	NOUN
ajlsi-3268	119	76	*	*	PUNCT
ajlsi-3268	119	77	*	*	PUNCT
ajlsi-3268	119	78	p	p	X
ajlsi-3268	119	79	≤	≤	NOUN
ajlsi-3268	119	80	0.01	0.01	NUM
ajlsi-3268	119	81	in	in	ADP
ajlsi-3268	119	82	psoriatic	psoriatic	ADJ
ajlsi-3268	119	83	and	and	CCONJ
ajlsi-3268	119	84	*	*	NOUN
ajlsi-3268	119	85	*	*	PUNCT
ajlsi-3268	119	86	*	*	PUNCT
ajlsi-3268	119	87	p≤0.001	p≤0.001	VERB
ajlsi-3268	119	88	in	in	ADP
ajlsi-3268	119	89	healthy	healthy	ADJ
ajlsi-3268	119	90	individuals	individual	NOUN
ajlsi-3268	119	91	in	in	ADP
ajlsi-3268	119	92	comparison	comparison	NOUN
ajlsi-3268	119	93	to	to	ADP
ajlsi-3268	119	94	untreated	untreated	ADJ
ajlsi-3268	119	95	cells	cell	NOUN
ajlsi-3268	119	96	.	.	PUNCT
ajlsi-3268	120	1	however	however	ADV
ajlsi-3268	120	2	,	,	PUNCT
ajlsi-3268	120	3	secukinumab	secukinumab	NOUN
ajlsi-3268	120	4	treatments	treatment	NOUN
ajlsi-3268	120	5	in	in	ADP
ajlsi-3268	120	6	the	the	DET
ajlsi-3268	120	7	two	two	NUM
ajlsi-3268	120	8	different	different	ADJ
ajlsi-3268	120	9	forms	form	NOUN
ajlsi-3268	120	10	with	with	ADP
ajlsi-3268	120	11	or	or	CCONJ
ajlsi-3268	120	12	without	without	ADP
ajlsi-3268	120	13	h2o2	h2o2	NOUN
ajlsi-3268	120	14	were	be	AUX
ajlsi-3268	120	15	not	not	PART
ajlsi-3268	120	16	significant	significant	ADJ
ajlsi-3268	120	17	(	(	PUNCT
ajlsi-3268	120	18	ns	ns	NUM
ajlsi-3268	120	19	)	)	PUNCT
ajlsi-3268	120	20	.	.	PUNCT
ajlsi-3268	121	1	in	in	ADP
ajlsi-3268	121	2	comparison	comparison	NOUN
ajlsi-3268	121	3	with	with	ADP
ajlsi-3268	121	4	the	the	DET
ajlsi-3268	121	5	positive	positive	ADJ
ajlsi-3268	121	6	control	control	NOUN
ajlsi-3268	121	7	treatments	treatment	NOUN
ajlsi-3268	121	8	,	,	PUNCT
ajlsi-3268	121	9	a	a	DET
ajlsi-3268	121	10	remarkable	remarkable	ADJ
ajlsi-3268	121	11	reduction	reduction	NOUN
ajlsi-3268	121	12	in	in	ADP
ajlsi-3268	121	13	the	the	DET
ajlsi-3268	121	14	dna	dna	PROPN
ajlsi-3268	121	15	damage	damage	NOUN
ajlsi-3268	121	16	was	be	AUX
ajlsi-3268	121	17	observed	observe	VERB
ajlsi-3268	121	18	after	after	ADP
ajlsi-3268	121	19	the	the	DET
ajlsi-3268	121	20	addition	addition	NOUN
ajlsi-3268	121	21	of	of	ADP
ajlsi-3268	121	22	secukinumab	secukinumab	NOUN
ajlsi-3268	121	23	*	*	PUNCT
ajlsi-3268	121	24	*	*	PUNCT
ajlsi-3268	121	25	*	*	VERB
ajlsi-3268	121	26	p≤0.001	p≤0.001	PROPN
ajlsi-3268	121	27	for	for	ADP
ajlsi-3268	121	28	the	the	DET
ajlsi-3268	121	29	bulk	bulk	NOUN
ajlsi-3268	121	30	in	in	ADP
ajlsi-3268	121	31	patients	patient	NOUN
ajlsi-3268	121	32	without	without	ADP
ajlsi-3268	121	33	the	the	DET
ajlsi-3268	121	34	h2o2	h2o2	NOUN
ajlsi-3268	121	35	,	,	PUNCT
ajlsi-3268	121	36	and	and	CCONJ
ajlsi-3268	121	37	*	*	PUNCT
ajlsi-3268	121	38	*	*	PUNCT
ajlsi-3268	121	39	p	p	X
ajlsi-3268	121	40	≤	≤	NOUN
ajlsi-3268	121	41	0.01	0.01	NUM
ajlsi-3268	121	42	for	for	ADP
ajlsi-3268	121	43	all	all	DET
ajlsi-3268	121	44	the	the	DET
ajlsi-3268	121	45	other	other	ADJ
ajlsi-3268	121	46	treatments	treatment	NOUN
ajlsi-3268	121	47	,	,	PUNCT
ajlsi-3268	121	48	as	as	SCONJ
ajlsi-3268	121	49	shown	show	VERB
ajlsi-3268	121	50	in	in	ADP
ajlsi-3268	121	51	figure	figure	NOUN
ajlsi-3268	121	52	4	4	NUM
ajlsi-3268	121	53	.	.	PUNCT
ajlsi-3268	121	54	figure	figure	VERB
ajlsi-3268	121	55	4	4	NUM
ajlsi-3268	121	56	:	:	PUNCT
ajlsi-3268	121	57	the	the	DET
ajlsi-3268	121	58	effects	effect	NOUN
ajlsi-3268	121	59	of	of	ADP
ajlsi-3268	121	60	secukinumab	secukinumab	NOUN
ajlsi-3268	121	61	and	and	CCONJ
ajlsi-3268	121	62	h2o2	h2o2	NOUN
ajlsi-3268	121	63	,	,	PUNCT
ajlsi-3268	121	64	on	on	ADP
ajlsi-3268	121	65	the	the	DET
ajlsi-3268	121	66	lymphocytes	lymphocyte	NOUN
ajlsi-3268	121	67	from	from	ADP
ajlsi-3268	121	68	healthy	healthy	ADJ
ajlsi-3268	121	69	and	and	CCONJ
ajlsi-3268	121	70	patient	patient	ADJ
ajlsi-3268	121	71	groups	group	NOUN
ajlsi-3268	121	72	measuring	measure	VERB
ajlsi-3268	121	73	otm	otm	NOUN
ajlsi-3268	121	74	(	(	PUNCT
ajlsi-3268	121	75	*	*	PUNCT
ajlsi-3268	121	76	com	com	NOUN
ajlsi-3268	121	77	-	-	PUNCT
ajlsi-3268	121	78	paring	paring	NOUN
ajlsi-3268	121	79	the	the	DET
ajlsi-3268	121	80	treatments	treatment	NOUN
ajlsi-3268	121	81	to	to	ADP
ajlsi-3268	121	82	the	the	PRON
ajlsi-3268	121	83	without	without	ADP
ajlsi-3268	121	84	treatments	treatment	NOUN
ajlsi-3268	121	85	or	or	CCONJ
ajlsi-3268	121	86	negative	negative	ADJ
ajlsi-3268	121	87	control	control	NOUN
ajlsi-3268	121	88	or	or	CCONJ
ajlsi-3268	121	89	nc	nc	PROPN
ajlsi-3268	121	90	,	,	PUNCT
ajlsi-3268	121	91	ns	ns	NUM
ajlsi-3268	121	92	(	(	PUNCT
ajlsi-3268	121	93	non	non	ADJ
ajlsi-3268	121	94	-	-	ADJ
ajlsi-3268	121	95	significant	significant	ADJ
ajlsi-3268	121	96	)	)	PUNCT
ajlsi-3268	121	97	comparing	compare	VERB
ajlsi-3268	121	98	the	the	DET
ajlsi-3268	121	99	groups	group	NOUN
ajlsi-3268	121	100	with	with	ADP
ajlsi-3268	121	101	different	different	ADJ
ajlsi-3268	121	102	treatments	treatment	NOUN
ajlsi-3268	121	103	to	to	ADP
ajlsi-3268	121	104	the	the	DET
ajlsi-3268	121	105	nc	nc	PROPN
ajlsi-3268	121	106	group	group	PROPN
ajlsi-3268	121	107	,	,	PUNCT
ajlsi-3268	121	108	+	+	PUNCT
ajlsi-3268	121	109	comparing	compare	VERB
ajlsi-3268	121	110	the	the	DET
ajlsi-3268	121	111	groups	group	NOUN
ajlsi-3268	121	112	with	with	ADP
ajlsi-3268	121	113	different	different	ADJ
ajlsi-3268	121	114	treatments	treatment	NOUN
ajlsi-3268	121	115	to	to	ADP
ajlsi-3268	121	116	the	the	DET
ajlsi-3268	121	117	positive	positive	ADJ
ajlsi-3268	121	118	control	control	NOUN
ajlsi-3268	121	119	or	or	CCONJ
ajlsi-3268	121	120	pc	pc	NOUN
ajlsi-3268	121	121	)	)	PUNCT
ajlsi-3268	121	122	(	(	PUNCT
ajlsi-3268	121	123	n=20	n=20	NOUN
ajlsi-3268	121	124	in	in	ADP
ajlsi-3268	121	125	the	the	DET
ajlsi-3268	121	126	healthy	healthy	ADJ
ajlsi-3268	121	127	control	control	NOUN
ajlsi-3268	121	128	group	group	NOUN
ajlsi-3268	121	129	and	and	CCONJ
ajlsi-3268	121	130	20	20	NUM
ajlsi-3268	121	131	in	in	ADP
ajlsi-3268	121	132	the	the	DET
ajlsi-3268	121	133	patient	patient	NOUN
ajlsi-3268	121	134	group	group	NOUN
ajlsi-3268	121	135	)	)	PUNCT
ajlsi-3268	121	136	,	,	PUNCT
ajlsi-3268	121	137	)	)	PUNCT
ajlsi-3268	121	138	,	,	PUNCT
ajlsi-3268	121	139	n	n	CCONJ
ajlsi-3268	121	140	/	/	SYM
ajlsi-3268	121	141	c	c	PROPN
ajlsi-3268	121	142	stands	stand	VERB
ajlsi-3268	121	143	for	for	ADP
ajlsi-3268	121	144	the	the	DET
ajlsi-3268	121	145	negative	negative	ADJ
ajlsi-3268	121	146	control	control	NOUN
ajlsi-3268	121	147	,	,	PUNCT
ajlsi-3268	121	148	p	p	X
ajlsi-3268	121	149	/	/	SYM
ajlsi-3268	121	150	c	c	NOUN
ajlsi-3268	121	151	;	;	PUNCT
ajlsi-3268	121	152	positive	positive	ADJ
ajlsi-3268	121	153	control	control	NOUN
ajlsi-3268	121	154	,	,	PUNCT
ajlsi-3268	121	155	bulk	bulk	NOUN
ajlsi-3268	121	156	;	;	PUNCT
ajlsi-3268	121	157	secukinumab	secukinumab	NOUN
ajlsi-3268	121	158	bulk	bulk	NOUN
ajlsi-3268	121	159	,	,	PUNCT
ajlsi-3268	121	160	liposome	liposome	NOUN
ajlsi-3268	121	161	(	(	PUNCT
ajlsi-3268	121	162	liposome	liposome	NOUN
ajlsi-3268	121	163	form	form	NOUN
ajlsi-3268	121	164	of	of	ADP
ajlsi-3268	121	165	secukinumab	secukinumab	NOUN
ajlsi-3268	121	166	)	)	PUNCT
ajlsi-3268	121	167	,	,	PUNCT
ajlsi-3268	121	168	empty	empty	ADJ
ajlsi-3268	121	169	;	;	PUNCT
ajlsi-3268	121	170	liposomes	liposome	NOUN
ajlsi-3268	121	171	with	with	ADP
ajlsi-3268	121	172	no	no	DET
ajlsi-3268	121	173	drug	drug	NOUN
ajlsi-3268	121	174	,	,	PUNCT
ajlsi-3268	121	175	hydrogen	hydrogen	NOUN
ajlsi-3268	121	176	peroxide	peroxide	NOUN
ajlsi-3268	121	177	(	(	PUNCT
ajlsi-3268	121	178	h2o2	h2o2	NOUN
ajlsi-3268	121	179	)	)	PUNCT
ajlsi-3268	121	180	results	result	NOUN
ajlsi-3268	121	181	presented	present	VERB
ajlsi-3268	121	182	in	in	ADP
ajlsi-3268	121	183	figure	figure	NOUN
ajlsi-3268	121	184	4	4	NUM
ajlsi-3268	121	185	illustrate	illustrate	VERB
ajlsi-3268	121	186	the	the	DET
ajlsi-3268	121	187	responses	response	NOUN
ajlsi-3268	121	188	of	of	ADP
ajlsi-3268	121	189	bulk	bulk	NOUN
ajlsi-3268	121	190	and	and	CCONJ
ajlsi-3268	121	191	liposome	liposome	VERB
ajlsi-3268	121	192	forms	form	NOUN
ajlsi-3268	121	193	of	of	ADP
ajlsi-3268	121	194	secukinumab	secukinumab	NOUN
ajlsi-3268	121	195	on	on	ADP
ajlsi-3268	121	196	lymphocyte	lymphocyte	ADJ
ajlsi-3268	121	197	dna	dna	NOUN
ajlsi-3268	121	198	from	from	ADP
ajlsi-3268	121	199	healthy	healthy	ADJ
ajlsi-3268	121	200	and	and	CCONJ
ajlsi-3268	121	201	psoriatic	psoriatic	ADJ
ajlsi-3268	121	202	individuals	individual	NOUN
ajlsi-3268	121	203	treated	treat	VERB
ajlsi-3268	121	204	with	with	ADP
ajlsi-3268	121	205	h2o2	h2o2	NOUN
ajlsi-3268	121	206	using	use	VERB
ajlsi-3268	121	207	tail	tail	NOUN
ajlsi-3268	121	208	dna	dna	PROPN
ajlsi-3268	121	209	%	%	NOUN
ajlsi-3268	121	210	,	,	PUNCT
ajlsi-3268	121	211	standard	standard	ADJ
ajlsi-3268	121	212	errors	error	NOUN
ajlsi-3268	121	213	se	se	ADV
ajlsi-3268	121	214	and	and	CCONJ
ajlsi-3268	121	215	significance	significance	NOUN
ajlsi-3268	121	216	.	.	PUNCT
ajlsi-3268	122	1	dna	dna	PROPN
ajlsi-3268	122	2	damage	damage	NOUN
ajlsi-3268	122	3	observed	observe	VERB
ajlsi-3268	122	4	in	in	ADP
ajlsi-3268	122	5	the	the	DET
ajlsi-3268	122	6	patient	patient	NOUN
ajlsi-3268	122	7	group	group	NOUN
ajlsi-3268	122	8	was	be	AUX
ajlsi-3268	122	9	higher	high	ADJ
ajlsi-3268	122	10	compared	compare	VERB
ajlsi-3268	122	11	to	to	ADP
ajlsi-3268	122	12	the	the	DET
ajlsi-3268	122	13	healthy	healthy	ADJ
ajlsi-3268	122	14	as	as	SCONJ
ajlsi-3268	122	15	predicted	predict	VERB
ajlsi-3268	122	16	.	.	PUNCT
ajlsi-3268	123	1	the	the	DET
ajlsi-3268	123	2	pc	pc	NOUN
ajlsi-3268	123	3	revealed	reveal	VERB
ajlsi-3268	123	4	a	a	DET
ajlsi-3268	123	5	significant	significant	ADJ
ajlsi-3268	123	6	rise	rise	NOUN
ajlsi-3268	123	7	in	in	ADP
ajlsi-3268	123	8	the	the	DET
ajlsi-3268	123	9	tail	tail	NOUN
ajlsi-3268	123	10	dna	dna	PROPN
ajlsi-3268	123	11	control	control	NOUN
ajlsi-3268	123	12	cells	cell	NOUN
ajlsi-3268	123	13	,	,	PUNCT
ajlsi-3268	123	14	*	*	PUNCT
ajlsi-3268	123	15	*	*	PUNCT
ajlsi-3268	123	16	*	*	PUNCT
ajlsi-3268	123	17	*	*	PUNCT
ajlsi-3268	123	18	p	p	X
ajlsi-3268	123	19	≤	≤	NUM
ajlsi-3268	123	20	0.0001	0.0001	NUM
ajlsi-3268	123	21	.	.	PUNCT
ajlsi-3268	124	1	in	in	ADP
ajlsi-3268	124	2	comparison	comparison	NOUN
ajlsi-3268	124	3	to	to	ADP
ajlsi-3268	124	4	the	the	DET
ajlsi-3268	124	5	nc	nc	PROPN
ajlsi-3268	124	6	,	,	PUNCT
ajlsi-3268	124	7	secukinumab	secukinumab	NOUN
ajlsi-3268	124	8	treatments	treatment	NOUN
ajlsi-3268	124	9	—	—	PUNCT
ajlsi-3268	124	10	liposomal	liposomal	ADJ
ajlsi-3268	124	11	and	and	CCONJ
ajlsi-3268	124	12	bulk	bulk	NOUN
ajlsi-3268	124	13	,	,	PUNCT
ajlsi-3268	124	14	with	with	ADP
ajlsi-3268	124	15	or	or	CCONJ
ajlsi-3268	124	16	without	without	ADP
ajlsi-3268	124	17	h2o2	h2o2	NOUN
ajlsi-3268	124	18	,	,	PUNCT
ajlsi-3268	124	19	were	be	AUX
ajlsi-3268	124	20	not	not	PART
ajlsi-3268	124	21	very	very	ADV
ajlsi-3268	124	22	important	important	ADJ
ajlsi-3268	124	23	.	.	PUNCT
ajlsi-3268	125	1	when	when	SCONJ
ajlsi-3268	125	2	compared	compare	VERB
ajlsi-3268	125	3	to	to	ADP
ajlsi-3268	125	4	pc	pc	NOUN
ajlsi-3268	125	5	therapies	therapy	NOUN
ajlsi-3268	125	6	,	,	PUNCT
ajlsi-3268	125	7	the	the	DET
ajlsi-3268	125	8	inclusion	inclusion	NOUN
ajlsi-3268	125	9	of	of	ADP
ajlsi-3268	125	10	secukinumab	secukinumab	NOUN
ajlsi-3268	125	11	+	+	PROPN
ajlsi-3268	125	12	+	+	PROPN
ajlsi-3268	125	13	+	+	ADJ
ajlsi-3268	125	14	+	+	NOUN
ajlsi-3268	125	15	p	p	ADJ
ajlsi-3268	125	16	≤	≤	NOUN
ajlsi-3268	125	17	0.000	0.000	NUM
ajlsi-3268	125	18	,	,	PUNCT
ajlsi-3268	125	19	considerably	considerably	ADV
ajlsi-3268	125	20	reduced	reduce	VERB
ajlsi-3268	125	21	the	the	DET
ajlsi-3268	125	22	damage	damage	NOUN
ajlsi-3268	125	23	,	,	PUNCT
ajlsi-3268	125	24	as	as	SCONJ
ajlsi-3268	125	25	shown	show	VERB
ajlsi-3268	125	26	in	in	ADP
ajlsi-3268	125	27	figure	figure	NOUN
ajlsi-3268	125	28	5	5	NUM
ajlsi-3268	125	29	.	.	PUNCT
ajlsi-3268	125	30	figure	figure	VERB
ajlsi-3268	125	31	5	5	NUM
ajlsi-3268	125	32	:	:	PUNCT
ajlsi-3268	125	33	the	the	DET
ajlsi-3268	125	34	effects	effect	NOUN
ajlsi-3268	125	35	of	of	ADP
ajlsi-3268	125	36	secukinumab	secukinumab	NOUN
ajlsi-3268	125	37	and	and	CCONJ
ajlsi-3268	125	38	h2o2	h2o2	NOUN
ajlsi-3268	125	39	on	on	ADP
ajlsi-3268	125	40	the	the	DET
ajlsi-3268	125	41	lymphocytes	lymphocyte	NOUN
ajlsi-3268	125	42	from	from	ADP
ajlsi-3268	125	43	20	20	NUM
ajlsi-3268	125	44	healthy	healthy	ADJ
ajlsi-3268	125	45	and	and	CCONJ
ajlsi-3268	125	46	20	20	NUM
ajlsi-3268	125	47	patient	patient	ADJ
ajlsi-3268	125	48	groups	group	NOUN
ajlsi-3268	125	49	measuring	measure	VERB
ajlsi-3268	125	50	tail	tail	NOUN
ajlsi-3268	125	51	dna%	dna%	VERB
ajlsi-3268	125	52	(	(	PUNCT
ajlsi-3268	125	53	*	*	VERB
ajlsi-3268	125	54	comparing	compare	VERB
ajlsi-3268	125	55	the	the	DET
ajlsi-3268	125	56	treatments	treatment	NOUN
ajlsi-3268	125	57	to	to	ADP
ajlsi-3268	125	58	the	the	DET
ajlsi-3268	125	59	nc	nc	PROPN
ajlsi-3268	125	60	,	,	PUNCT
ajlsi-3268	125	61	ns	ns	NUM
ajlsi-3268	125	62	(	(	PUNCT
ajlsi-3268	125	63	non	non	ADJ
ajlsi-3268	125	64	-	-	ADJ
ajlsi-3268	125	65	significant	significant	ADJ
ajlsi-3268	125	66	)	)	PUNCT
ajlsi-3268	125	67	comparing	compare	VERB
ajlsi-3268	125	68	the	the	DET
ajlsi-3268	125	69	treatments	treatment	NOUN
ajlsi-3268	125	70	to	to	ADP
ajlsi-3268	125	71	the	the	DET
ajlsi-3268	125	72	nc	nc	PROPN
ajlsi-3268	125	73	,	,	PUNCT
ajlsi-3268	125	74	+	+	PUNCT
ajlsi-3268	125	75	comparing	compare	VERB
ajlsi-3268	125	76	the	the	DET
ajlsi-3268	125	77	treat	treat	NOUN
ajlsi-3268	125	78	-	-	PUNCT
ajlsi-3268	125	79	ments	ment	NOUN
ajlsi-3268	125	80	to	to	ADP
ajlsi-3268	125	81	the	the	DET
ajlsi-3268	125	82	pc	pc	NOUN
ajlsi-3268	125	83	)	)	PUNCT
ajlsi-3268	125	84	(	(	PUNCT
ajlsi-3268	125	85	n=20	n=20	NOUN
ajlsi-3268	125	86	in	in	ADP
ajlsi-3268	125	87	the	the	DET
ajlsi-3268	125	88	healthy	healthy	ADJ
ajlsi-3268	125	89	control	control	NOUN
ajlsi-3268	125	90	group	group	NOUN
ajlsi-3268	125	91	and	and	CCONJ
ajlsi-3268	125	92	20	20	NUM
ajlsi-3268	125	93	in	in	ADP
ajlsi-3268	125	94	the	the	DET
ajlsi-3268	125	95	patient	patient	NOUN
ajlsi-3268	125	96	group	group	NOUN
ajlsi-3268	125	97	)	)	PUNCT
ajlsi-3268	125	98	,	,	PUNCT
ajlsi-3268	125	99	)	)	PUNCT
ajlsi-3268	125	100	,	,	PUNCT
ajlsi-3268	125	101	n	n	CCONJ
ajlsi-3268	125	102	/	/	SYM
ajlsi-3268	125	103	c	c	PROPN
ajlsi-3268	125	104	stands	stand	VERB
ajlsi-3268	125	105	for	for	ADP
ajlsi-3268	125	106	the	the	DET
ajlsi-3268	125	107	negative	negative	ADJ
ajlsi-3268	125	108	control	control	NOUN
ajlsi-3268	125	109	,	,	PUNCT
ajlsi-3268	125	110	p	p	X
ajlsi-3268	125	111	/	/	SYM
ajlsi-3268	125	112	c	c	NOUN
ajlsi-3268	125	113	;	;	PUNCT
ajlsi-3268	125	114	positive	positive	ADJ
ajlsi-3268	125	115	control	control	NOUN
ajlsi-3268	125	116	,	,	PUNCT
ajlsi-3268	125	117	bulk	bulk	NOUN
ajlsi-3268	125	118	;	;	PUNCT
ajlsi-3268	125	119	secukinumab	secukinumab	NOUN
ajlsi-3268	125	120	bulk	bulk	NOUN
ajlsi-3268	125	121	,	,	PUNCT
ajlsi-3268	125	122	liposome	liposome	NOUN
ajlsi-3268	125	123	(	(	PUNCT
ajlsi-3268	125	124	liposome	liposome	NOUN
ajlsi-3268	125	125	form	form	NOUN
ajlsi-3268	125	126	of	of	ADP
ajlsi-3268	125	127	secukinumab	secukinumab	NOUN
ajlsi-3268	125	128	)	)	PUNCT
ajlsi-3268	125	129	,	,	PUNCT
ajlsi-3268	125	130	empty	empty	ADJ
ajlsi-3268	125	131	;	;	PUNCT
ajlsi-3268	125	132	liposomes	liposome	NOUN
ajlsi-3268	125	133	with	with	ADP
ajlsi-3268	125	134	no	no	DET
ajlsi-3268	125	135	drug	drug	NOUN
ajlsi-3268	125	136	,	,	PUNCT
ajlsi-3268	125	137	hydrogen	hydrogen	NOUN
ajlsi-3268	125	138	peroxide	peroxide	NOUN
ajlsi-3268	125	139	(	(	PUNCT
ajlsi-3268	125	140	h2o2	h2o2	NOUN
ajlsi-3268	125	141	)	)	PUNCT
ajlsi-3268	125	142	.	.	PUNCT
ajlsi-3268	126	1	pa	pa	PROPN
ajlsi-3268	126	2	ge	ge	PROPN
ajlsi-3268	126	3	32	32	NUM
ajlsi-3268	126	4	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-3268	126	5	am	am	NOUN
ajlsi-3268	126	6	.	.	PUNCT
ajlsi-3268	127	1	j.	j.	PROPN
ajlsi-3268	127	2	life	life	PROPN
ajlsi-3268	127	3	sci	sci	PROPN
ajlsi-3268	127	4	.	.	PUNCT
ajlsi-3268	127	5	innov	innov	PROPN
ajlsi-3268	127	6	.	.	PUNCT
ajlsi-3268	128	1	4(1	4(1	NOUN
ajlsi-3268	128	2	)	)	PUNCT
ajlsi-3268	129	1	27	27	NUM
ajlsi-3268	129	2	-	-	SYM
ajlsi-3268	129	3	35	35	NUM
ajlsi-3268	129	4	,	,	PUNCT
ajlsi-3268	129	5	2025	2025	NUM
ajlsi-3268	129	6	cytokinesis	cytokinesis	NOUN
ajlsi-3268	129	7	block	block	NOUN
ajlsi-3268	129	8	micronucleus	micronucleus	NOUN
ajlsi-3268	129	9	assay	assay	NOUN
ajlsi-3268	129	10	(	(	PUNCT
ajlsi-3268	129	11	cbmn	cbmn	PROPN
ajlsi-3268	129	12	)	)	PUNCT
ajlsi-3268	129	13	the	the	DET
ajlsi-3268	129	14	micronucleus	micronucleus	PROPN
ajlsi-3268	129	15	assay	assay	PROPN
ajlsi-3268	129	16	reveals	reveal	VERB
ajlsi-3268	129	17	higher	high	ADJ
ajlsi-3268	129	18	levels	level	NOUN
ajlsi-3268	129	19	of	of	ADP
ajlsi-3268	129	20	mnis	mnis	PROPN
ajlsi-3268	129	21	in	in	ADP
ajlsi-3268	129	22	patients	patient	NOUN
ajlsi-3268	129	23	who	who	PRON
ajlsi-3268	129	24	are	be	AUX
ajlsi-3268	129	25	not	not	PART
ajlsi-3268	129	26	receiving	receive	VERB
ajlsi-3268	129	27	therapy	therapy	NOUN
ajlsi-3268	129	28	,	,	PUNCT
ajlsi-3268	129	29	making	make	VERB
ajlsi-3268	129	30	it	it	PRON
ajlsi-3268	129	31	a	a	DET
ajlsi-3268	129	32	dependable	dependable	ADJ
ajlsi-3268	129	33	and	and	CCONJ
ajlsi-3268	129	34	appropriate	appropriate	ADJ
ajlsi-3268	129	35	approach	approach	NOUN
ajlsi-3268	129	36	for	for	ADP
ajlsi-3268	129	37	examining	examine	VERB
ajlsi-3268	129	38	dna	dna	PROPN
ajlsi-3268	129	39	damage	damage	NOUN
ajlsi-3268	129	40	at	at	ADP
ajlsi-3268	129	41	chromosomal	chromosomal	ADJ
ajlsi-3268	129	42	levels	level	NOUN
ajlsi-3268	129	43	.	.	PUNCT
ajlsi-3268	130	1	secukinumab	secukinumab	PROPN
ajlsi-3268	130	2	2.1µg	2.1µg	NUM
ajlsi-3268	130	3	/	/	SYM
ajlsi-3268	130	4	ml	ml	X
ajlsi-3268	130	5	in	in	ADP
ajlsi-3268	130	6	bulk	bulk	NOUN
ajlsi-3268	130	7	and	and	CCONJ
ajlsi-3268	130	8	liposome	liposome	NOUN
ajlsi-3268	130	9	forms	form	NOUN
ajlsi-3268	130	10	has	have	AUX
ajlsi-3268	130	11	shown	show	VERB
ajlsi-3268	130	12	some	some	DET
ajlsi-3268	130	13	attenuation	attenuation	NOUN
ajlsi-3268	130	14	of	of	ADP
ajlsi-3268	130	15	the	the	DET
ajlsi-3268	130	16	consequences	consequence	NOUN
ajlsi-3268	130	17	caused	cause	VERB
ajlsi-3268	130	18	by	by	ADP
ajlsi-3268	130	19	h2o2	h2o2	NOUN
ajlsi-3268	130	20	,	,	PUNCT
ajlsi-3268	130	21	as	as	SCONJ
ajlsi-3268	130	22	illustrated	illustrate	VERB
ajlsi-3268	130	23	in	in	ADP
ajlsi-3268	130	24	figure	figure	NOUN
ajlsi-3268	130	25	6	6	NUM
ajlsi-3268	130	26	.	.	PUNCT
ajlsi-3268	130	27	figure	figure	VERB
ajlsi-3268	130	28	6	6	NUM
ajlsi-3268	130	29	:	:	PUNCT
ajlsi-3268	130	30	the	the	DET
ajlsi-3268	130	31	average	average	NOUN
ajlsi-3268	130	32	of	of	ADP
ajlsi-3268	130	33	mni	mni	PROPN
ajlsi-3268	130	34	in	in	ADP
ajlsi-3268	130	35	binc	binc	NOUN
ajlsi-3268	130	36	scored	score	VERB
ajlsi-3268	130	37	per	per	ADP
ajlsi-3268	130	38	1000	1000	NUM
ajlsi-3268	130	39	cells	cell	NOUN
ajlsi-3268	130	40	from	from	ADP
ajlsi-3268	130	41	5	5	NUM
ajlsi-3268	130	42	healthy	healthy	ADJ
ajlsi-3268	130	43	individuals	individual	NOUN
ajlsi-3268	130	44	and	and	CCONJ
ajlsi-3268	130	45	5	5	NUM
ajlsi-3268	130	46	psoriasis	psoriasis	NOUN
ajlsi-3268	130	47	patients	patient	NOUN
ajlsi-3268	130	48	,	,	PUNCT
ajlsi-3268	130	49	n=1000	n=1000	PROPN
ajlsi-3268	130	50	.	.	PROPN
ajlsi-3268	130	51	data	datum	NOUN
ajlsi-3268	130	52	are	be	AUX
ajlsi-3268	130	53	expressed	express	VERB
ajlsi-3268	130	54	as	as	SCONJ
ajlsi-3268	130	55	means	mean	VERB
ajlsi-3268	130	56	±	±	NUM
ajlsi-3268	130	57	standard	standard	ADJ
ajlsi-3268	130	58	error	error	NOUN
ajlsi-3268	130	59	(	(	PUNCT
ajlsi-3268	130	60	se).seven	se).seven	ADJ
ajlsi-3268	130	61	treatment	treatment	NOUN
ajlsi-3268	130	62	groups	group	NOUN
ajlsi-3268	130	63	included	include	VERB
ajlsi-3268	130	64	the	the	DET
ajlsi-3268	130	65	negative	negative	ADJ
ajlsi-3268	130	66	control	control	NOUN
ajlsi-3268	130	67	,	,	PUNCT
ajlsi-3268	130	68	two	two	NUM
ajlsi-3268	130	69	positive	positive	ADJ
ajlsi-3268	130	70	control	control	NOUN
ajlsi-3268	130	71	groups	group	NOUN
ajlsi-3268	130	72	(	(	PUNCT
ajlsi-3268	130	73	0.4	0.4	NUM
ajlsi-3268	130	74	µm	µm	ADP
ajlsi-3268	130	75	mmc	mmc	PROPN
ajlsi-3268	130	76	)	)	PUNCT
ajlsi-3268	130	77	(	(	PUNCT
ajlsi-3268	130	78	75µм	75µм	NOUN
ajlsi-3268	130	79	of	of	ADP
ajlsi-3268	130	80	h2o2	h2o2	NOUN
ajlsi-3268	130	81	)	)	PUNCT
ajlsi-3268	130	82	,	,	PUNCT
ajlsi-3268	130	83	2.1µg	2.1µg	NUM
ajlsi-3268	130	84	/	/	SYM
ajlsi-3268	130	85	ml	ml	PROPN
ajlsi-3268	130	86	of	of	ADP
ajlsi-3268	130	87	secukinumab	secukinumab	NOUN
ajlsi-3268	130	88	,	,	PUNCT
ajlsi-3268	130	89	2.1µg	2.1µg	NUM
ajlsi-3268	130	90	/	/	SYM
ajlsi-3268	130	91	ml	ml	PROPN
ajlsi-3268	130	92	of	of	ADP
ajlsi-3268	130	93	secukinumab	secukinumab	NOUN
ajlsi-3268	130	94	with	with	ADP
ajlsi-3268	130	95	h2o2	h2o2	NOUN
ajlsi-3268	130	96	and	and	CCONJ
ajlsi-3268	130	97	the	the	DET
ajlsi-3268	130	98	liposome	liposome	NOUN
ajlsi-3268	130	99	form	form	NOUN
ajlsi-3268	130	100	of	of	ADP
ajlsi-3268	130	101	both	both	PRON
ajlsi-3268	130	102	(	(	PUNCT
ajlsi-3268	130	103	*	*	PUNCT
ajlsi-3268	130	104	*	*	PUNCT
ajlsi-3268	130	105	*	*	PUNCT
ajlsi-3268	130	106	represents	represent	VERB
ajlsi-3268	130	107	p	p	PRON
ajlsi-3268	130	108	<	<	X
ajlsi-3268	130	109	0.0001	0.0001	NUM
ajlsi-3268	130	110	,	,	PUNCT
ajlsi-3268	130	111	*	*	PUNCT
ajlsi-3268	130	112	*	*	PUNCT
ajlsi-3268	130	113	p<0.001	p<0.001	ADJ
ajlsi-3268	130	114	,	,	PUNCT
ajlsi-3268	130	115	*	*	PUNCT
ajlsi-3268	130	116	p<0.02	p<0.02	PROPN
ajlsi-3268	130	117	,	,	PUNCT
ajlsi-3268	130	118	*	*	ADJ
ajlsi-3268	130	119	p<0.018	p<0.018	NOUN
ajlsi-3268	130	120	,	,	PUNCT
ajlsi-3268	130	121	ns	ns	ADJ
ajlsi-3268	130	122	=	=	NOUN
ajlsi-3268	130	123	not	not	PART
ajlsi-3268	130	124	significant	significant	ADJ
ajlsi-3268	130	125	)	)	PUNCT
ajlsi-3268	130	126	.	.	PUNCT
ajlsi-3268	131	1	(	(	PUNCT
ajlsi-3268	131	2	n=5	n=5	PROPN
ajlsi-3268	131	3	in	in	ADP
ajlsi-3268	131	4	the	the	DET
ajlsi-3268	131	5	healthy	healthy	ADJ
ajlsi-3268	131	6	control	control	NOUN
ajlsi-3268	131	7	group	group	NOUN
ajlsi-3268	131	8	and	and	CCONJ
ajlsi-3268	131	9	5	5	NUM
ajlsi-3268	131	10	in	in	ADP
ajlsi-3268	131	11	the	the	DET
ajlsi-3268	131	12	patient	patient	NOUN
ajlsi-3268	131	13	group	group	NOUN
ajlsi-3268	131	14	)	)	PUNCT
ajlsi-3268	131	15	,	,	PUNCT
ajlsi-3268	131	16	)	)	PUNCT
ajlsi-3268	131	17	,	,	PUNCT
ajlsi-3268	131	18	n	n	CCONJ
ajlsi-3268	131	19	/	/	SYM
ajlsi-3268	131	20	c	c	PROPN
ajlsi-3268	131	21	stands	stand	VERB
ajlsi-3268	131	22	for	for	ADP
ajlsi-3268	131	23	the	the	DET
ajlsi-3268	131	24	negative	negative	ADJ
ajlsi-3268	131	25	control	control	NOUN
ajlsi-3268	131	26	,	,	PUNCT
ajlsi-3268	131	27	p	p	X
ajlsi-3268	131	28	/	/	SYM
ajlsi-3268	131	29	c	c	NOUN
ajlsi-3268	131	30	;	;	PUNCT
ajlsi-3268	131	31	positive	positive	ADJ
ajlsi-3268	131	32	control	control	NOUN
ajlsi-3268	131	33	,	,	PUNCT
ajlsi-3268	131	34	bulk	bulk	NOUN
ajlsi-3268	131	35	;	;	PUNCT
ajlsi-3268	131	36	secukinumab	secukinumab	NOUN
ajlsi-3268	131	37	bulk	bulk	NOUN
ajlsi-3268	131	38	,	,	PUNCT
ajlsi-3268	131	39	liposome	liposome	NOUN
ajlsi-3268	131	40	(	(	PUNCT
ajlsi-3268	131	41	liposome	liposome	NOUN
ajlsi-3268	131	42	form	form	NOUN
ajlsi-3268	131	43	of	of	ADP
ajlsi-3268	131	44	secukinumab	secukinumab	NOUN
ajlsi-3268	131	45	)	)	PUNCT
ajlsi-3268	131	46	,	,	PUNCT
ajlsi-3268	131	47	empty	empty	ADJ
ajlsi-3268	131	48	;	;	PUNCT
ajlsi-3268	131	49	liposomes	liposome	NOUN
ajlsi-3268	131	50	with	with	ADP
ajlsi-3268	131	51	no	no	DET
ajlsi-3268	131	52	drug	drug	NOUN
ajlsi-3268	131	53	,	,	PUNCT
ajlsi-3268	131	54	hydrogen	hydrogen	NOUN
ajlsi-3268	131	55	peroxide	peroxide	NOUN
ajlsi-3268	131	56	(	(	PUNCT
ajlsi-3268	131	57	h2o2	h2o2	NOUN
ajlsi-3268	131	58	)	)	PUNCT
ajlsi-3268	131	59	discussion	discussion	NOUN
ajlsi-3268	131	60	secukinumab	secukinumab	NOUN
ajlsi-3268	131	61	currently	currently	ADV
ajlsi-3268	131	62	is	be	AUX
ajlsi-3268	131	63	one	one	NUM
ajlsi-3268	131	64	of	of	ADP
ajlsi-3268	131	65	the	the	DET
ajlsi-3268	131	66	best	good	ADJ
ajlsi-3268	131	67	choices	choice	NOUN
ajlsi-3268	131	68	with	with	ADP
ajlsi-3268	131	69	proper	proper	ADJ
ajlsi-3268	131	70	efficacy	efficacy	NOUN
ajlsi-3268	131	71	on	on	ADP
ajlsi-3268	131	72	psoriasis	psoriasis	NOUN
ajlsi-3268	131	73	conditions	condition	NOUN
ajlsi-3268	131	74	,	,	PUNCT
ajlsi-3268	131	75	even	even	ADV
ajlsi-3268	131	76	on	on	ADP
ajlsi-3268	131	77	the	the	DET
ajlsi-3268	131	78	increased	increase	VERB
ajlsi-3268	131	79	level	level	NOUN
ajlsi-3268	131	80	of	of	ADP
ajlsi-3268	131	81	il-23	il-23	NOUN
ajlsi-3268	131	82	and	and	CCONJ
ajlsi-3268	131	83	jak	jak	PROPN
ajlsi-3268	131	84	inhibitors	inhibitor	NOUN
ajlsi-3268	131	85	.	.	PUNCT
ajlsi-3268	132	1	however	however	ADV
ajlsi-3268	132	2	,	,	PUNCT
ajlsi-3268	132	3	in	in	ADP
ajlsi-3268	132	4	the	the	DET
ajlsi-3268	132	5	case	case	NOUN
ajlsi-3268	132	6	of	of	ADP
ajlsi-3268	132	7	secukinumab	secukinumab	NOUN
ajlsi-3268	132	8	failure	failure	NOUN
ajlsi-3268	132	9	,	,	PUNCT
ajlsi-3268	132	10	combined	combined	ADJ
ajlsi-3268	132	11	therapy	therapy	NOUN
ajlsi-3268	132	12	would	would	AUX
ajlsi-3268	132	13	be	be	AUX
ajlsi-3268	132	14	ideal	ideal	ADJ
ajlsi-3268	132	15	(	(	PUNCT
ajlsi-3268	132	16	damiani	damiani	PROPN
ajlsi-3268	132	17	et	et	PROPN
ajlsi-3268	132	18	al	al	PROPN
ajlsi-3268	132	19	.	.	PROPN
ajlsi-3268	132	20	,	,	PUNCT
ajlsi-3268	132	21	2022	2022	NUM
ajlsi-3268	132	22	)	)	PUNCT
ajlsi-3268	132	23	.	.	PUNCT
ajlsi-3268	133	1	also	also	ADV
ajlsi-3268	133	2	,	,	PUNCT
ajlsi-3268	133	3	secukinumab	secukinumab	NOUN
ajlsi-3268	133	4	is	be	AUX
ajlsi-3268	133	5	a	a	DET
ajlsi-3268	133	6	well	well	ADV
ajlsi-3268	133	7	-	-	PUNCT
ajlsi-3268	133	8	known	know	VERB
ajlsi-3268	133	9	biological	biological	ADJ
ajlsi-3268	133	10	therapy	therapy	NOUN
ajlsi-3268	133	11	considered	consider	VERB
ajlsi-3268	133	12	the	the	DET
ajlsi-3268	133	13	most	most	ADV
ajlsi-3268	133	14	cost	cost	NOUN
ajlsi-3268	133	15	-	-	PUNCT
ajlsi-3268	133	16	effective	effective	ADJ
ajlsi-3268	133	17	bio	bio	ADJ
ajlsi-3268	133	18	-	-	ADJ
ajlsi-3268	133	19	logical	logical	ADJ
ajlsi-3268	133	20	agent	agent	NOUN
ajlsi-3268	133	21	(	(	PUNCT
ajlsi-3268	133	22	schweikert	schweikert	NOUN
ajlsi-3268	133	23	et	et	PROPN
ajlsi-3268	133	24	al	al	PROPN
ajlsi-3268	133	25	.	.	PROPN
ajlsi-3268	133	26	,	,	PUNCT
ajlsi-3268	133	27	2020	2020	NUM
ajlsi-3268	133	28	)	)	PUNCT
ajlsi-3268	133	29	.	.	PUNCT
ajlsi-3268	134	1	moreover	moreover	ADV
ajlsi-3268	134	2	,	,	PUNCT
ajlsi-3268	134	3	a	a	DET
ajlsi-3268	134	4	range	range	NOUN
ajlsi-3268	134	5	of	of	ADP
ajlsi-3268	134	6	side	side	NOUN
ajlsi-3268	134	7	effects	effect	NOUN
ajlsi-3268	134	8	linked	link	VERB
ajlsi-3268	134	9	with	with	ADP
ajlsi-3268	134	10	these	these	DET
ajlsi-3268	134	11	biological	biological	ADJ
ajlsi-3268	134	12	compounds	compound	NOUN
ajlsi-3268	134	13	,	,	PUNCT
ajlsi-3268	134	14	such	such	ADJ
ajlsi-3268	134	15	as	as	ADP
ajlsi-3268	134	16	paradoxical	paradoxical	ADJ
ajlsi-3268	134	17	reactions	reaction	NOUN
ajlsi-3268	134	18	(	(	PUNCT
ajlsi-3268	134	19	prs	prs	NOUN
ajlsi-3268	134	20	)	)	PUNCT
ajlsi-3268	134	21	,	,	PUNCT
ajlsi-3268	134	22	which	which	PRON
ajlsi-3268	134	23	are	be	AUX
ajlsi-3268	134	24	the	the	DET
ajlsi-3268	134	25	result	result	NOUN
ajlsi-3268	134	26	of	of	ADP
ajlsi-3268	134	27	worsening	worsen	VERB
ajlsi-3268	134	28	of	of	ADP
ajlsi-3268	134	29	immunemediated	immunemediate	VERB
ajlsi-3268	134	30	inflammatory	inflammatory	ADJ
ajlsi-3268	134	31	disease	disease	NOUN
ajlsi-3268	134	32	(	(	PUNCT
ajlsi-3268	134	33	miyagawa	miyagawa	PROPN
ajlsi-3268	134	34	,	,	PUNCT
ajlsi-3268	134	35	2022	2022	NUM
ajlsi-3268	134	36	)	)	PUNCT
ajlsi-3268	134	37	and	and	CCONJ
ajlsi-3268	134	38	increased	increase	VERB
ajlsi-3268	134	39	eosinophilic	eosinophilic	ADJ
ajlsi-3268	134	40	disorders	disorder	NOUN
ajlsi-3268	134	41	(	(	PUNCT
ajlsi-3268	134	42	bridgewood	bridgewood	PROPN
ajlsi-3268	134	43	et	et	PROPN
ajlsi-3268	134	44	al	al	PROPN
ajlsi-3268	134	45	.	.	PROPN
ajlsi-3268	134	46	,	,	PUNCT
ajlsi-3268	134	47	,	,	PUNCT
ajlsi-3268	134	48	2022	2022	NUM
ajlsi-3268	134	49	)	)	PUNCT
ajlsi-3268	134	50	.	.	PUNCT
ajlsi-3268	135	1	it	it	PRON
ajlsi-3268	135	2	is	be	AUX
ajlsi-3268	135	3	therefore	therefore	ADV
ajlsi-3268	135	4	desirable	desirable	ADJ
ajlsi-3268	135	5	to	to	PART
ajlsi-3268	135	6	reduce	reduce	VERB
ajlsi-3268	135	7	the	the	DET
ajlsi-3268	135	8	con	con	NOUN
ajlsi-3268	135	9	-	-	PUNCT
ajlsi-3268	135	10	centration	centration	NOUN
ajlsi-3268	135	11	of	of	ADP
ajlsi-3268	135	12	the	the	DET
ajlsi-3268	135	13	antibody	antibody	NOUN
ajlsi-3268	135	14	in	in	ADP
ajlsi-3268	135	15	the	the	DET
ajlsi-3268	135	16	blood	blood	NOUN
ajlsi-3268	135	17	and	and	CCONJ
ajlsi-3268	135	18	increase	increase	VERB
ajlsi-3268	135	19	its	its	PRON
ajlsi-3268	135	20	residency	residency	NOUN
ajlsi-3268	135	21	in	in	ADP
ajlsi-3268	135	22	the	the	DET
ajlsi-3268	135	23	psoriatic	psoriatic	ADJ
ajlsi-3268	135	24	dermal	dermal	NOUN
ajlsi-3268	135	25	layer	layer	NOUN
ajlsi-3268	135	26	by	by	ADP
ajlsi-3268	135	27	encapsulation	encapsulation	NOUN
ajlsi-3268	135	28	in	in	ADP
ajlsi-3268	135	29	liposomes	liposome	NOUN
ajlsi-3268	135	30	.	.	PUNCT
ajlsi-3268	136	1	using	use	VERB
ajlsi-3268	136	2	the	the	DET
ajlsi-3268	136	3	comet	comet	NOUN
ajlsi-3268	136	4	and	and	CCONJ
ajlsi-3268	136	5	cbmn	cbmn	ADJ
ajlsi-3268	136	6	assays	assay	NOUN
ajlsi-3268	136	7	,	,	PUNCT
ajlsi-3268	136	8	the	the	DET
ajlsi-3268	136	9	study	study	NOUN
ajlsi-3268	136	10	examined	examine	VERB
ajlsi-3268	136	11	the	the	DET
ajlsi-3268	136	12	effects	effect	NOUN
ajlsi-3268	136	13	of	of	ADP
ajlsi-3268	136	14	“	"	PUNCT
ajlsi-3268	136	15	secukinumab	secukinumab	VERB
ajlsi-3268	136	16	bulk	bulk	NOUN
ajlsi-3268	136	17	and	and	CCONJ
ajlsi-3268	136	18	liposome	liposome	NOUN
ajlsi-3268	136	19	forms	form	NOUN
ajlsi-3268	136	20	”	"	PUNCT
ajlsi-3268	136	21	on	on	ADP
ajlsi-3268	136	22	human	human	ADJ
ajlsi-3268	136	23	peripheral	peripheral	ADJ
ajlsi-3268	136	24	lymphocytes	lymphocyte	NOUN
ajlsi-3268	136	25	from	from	ADP
ajlsi-3268	136	26	20	20	NUM
ajlsi-3268	136	27	psoriasis	psoriasis	NOUN
ajlsi-3268	136	28	patients	patient	NOUN
ajlsi-3268	136	29	and	and	CCONJ
ajlsi-3268	136	30	20	20	NUM
ajlsi-3268	136	31	healthy	healthy	ADJ
ajlsi-3268	136	32	persons	person	NOUN
ajlsi-3268	136	33	.	.	PUNCT
ajlsi-3268	137	1	the	the	DET
ajlsi-3268	137	2	research	research	NOUN
ajlsi-3268	137	3	examined	examine	VERB
ajlsi-3268	137	4	secukinumab	secukinumab	NOUN
ajlsi-3268	137	5	’s	’s	PART
ajlsi-3268	137	6	possible	possible	ADJ
ajlsi-3268	137	7	protective	protective	ADJ
ajlsi-3268	137	8	effects	effect	NOUN
ajlsi-3268	137	9	on	on	ADP
ajlsi-3268	137	10	h2o2	h2o2	ADV
ajlsi-3268	137	11	-	-	ADJ
ajlsi-3268	137	12	induced	induced	ADJ
ajlsi-3268	137	13	dna	dna	NOUN
ajlsi-3268	137	14	damage	damage	NOUN
ajlsi-3268	137	15	in	in	ADP
ajlsi-3268	137	16	lymphocytes	lymphocyte	NOUN
ajlsi-3268	137	17	,	,	PUNCT
ajlsi-3268	137	18	demonstrating	demonstrate	VERB
ajlsi-3268	137	19	the	the	DET
ajlsi-3268	137	20	anti	anti	ADJ
ajlsi-3268	137	21	-	-	ADJ
ajlsi-3268	137	22	oxidant	oxidant	ADJ
ajlsi-3268	137	23	properties	property	NOUN
ajlsi-3268	137	24	of	of	ADP
ajlsi-3268	137	25	both	both	DET
ajlsi-3268	137	26	forms	form	NOUN
ajlsi-3268	137	27	and	and	CCONJ
ajlsi-3268	137	28	damage	damage	NOUN
ajlsi-3268	137	29	that	that	PRON
ajlsi-3268	137	30	was	be	AUX
ajlsi-3268	137	31	similar	similar	ADJ
ajlsi-3268	137	32	to	to	ADP
ajlsi-3268	137	33	that	that	PRON
ajlsi-3268	137	34	of	of	ADP
ajlsi-3268	137	35	patients	patient	NOUN
ajlsi-3268	137	36	who	who	PRON
ajlsi-3268	137	37	were	be	AUX
ajlsi-3268	137	38	not	not	PART
ajlsi-3268	137	39	treated	treat	VERB
ajlsi-3268	137	40	.	.	PUNCT
ajlsi-3268	138	1	our	our	PRON
ajlsi-3268	138	2	results	result	NOUN
ajlsi-3268	138	3	showed	show	VERB
ajlsi-3268	138	4	that	that	DET
ajlsi-3268	138	5	secukinumab	secukinumab	NOUN
ajlsi-3268	138	6	significantly	significantly	ADV
ajlsi-3268	138	7	de	de	PROPN
ajlsi-3268	138	8	-	-	VERB
ajlsi-3268	138	9	creased	crease	VERB
ajlsi-3268	138	10	the	the	DET
ajlsi-3268	138	11	percentage	percentage	NOUN
ajlsi-3268	138	12	of	of	ADP
ajlsi-3268	138	13	dna	dna	PROPN
ajlsi-3268	138	14	damage	damage	NOUN
ajlsi-3268	138	15	in	in	ADP
ajlsi-3268	138	16	lymphocytes	lymphocyte	NOUN
ajlsi-3268	138	17	in	in	ADP
ajlsi-3268	138	18	the	the	DET
ajlsi-3268	138	19	comet	comet	NOUN
ajlsi-3268	138	20	assay	assay	VERB
ajlsi-3268	138	21	(	(	PUNCT
ajlsi-3268	139	1	+	+	NOUN
ajlsi-3268	139	2	+	+	NOUN
ajlsi-3268	139	3	+	+	X
ajlsi-3268	139	4	p	p	X
ajlsi-3268	139	5	<	<	X
ajlsi-3268	139	6	0.001	0.001	NUM
ajlsi-3268	139	7	)	)	PUNCT
ajlsi-3268	139	8	.	.	PUNCT
ajlsi-3268	140	1	both	both	DET
ajlsi-3268	140	2	groups	group	NOUN
ajlsi-3268	140	3	had	have	VERB
ajlsi-3268	140	4	considerable	considerable	ADJ
ajlsi-3268	140	5	levels	level	NOUN
ajlsi-3268	140	6	of	of	ADP
ajlsi-3268	140	7	dna	dna	PROPN
ajlsi-3268	140	8	damage	damage	NOUN
ajlsi-3268	140	9	,	,	PUNCT
ajlsi-3268	140	10	according	accord	VERB
ajlsi-3268	140	11	to	to	ADP
ajlsi-3268	140	12	the	the	DET
ajlsi-3268	140	13	comet	comet	NOUN
ajlsi-3268	140	14	assay	assay	VERB
ajlsi-3268	140	15	,	,	PUNCT
ajlsi-3268	140	16	but	but	CCONJ
ajlsi-3268	140	17	secukinumab	secukinumab	NOUN
ajlsi-3268	140	18	dramatically	dramatically	ADV
ajlsi-3268	140	19	reduced	reduce	VERB
ajlsi-3268	140	20	the	the	DET
ajlsi-3268	140	21	effects	effect	NOUN
ajlsi-3268	140	22	of	of	ADP
ajlsi-3268	140	23	h2o2	h2o2	NOUN
ajlsi-3268	140	24	in	in	ADP
ajlsi-3268	140	25	both	both	CCONJ
ajlsi-3268	140	26	liposomal	liposomal	ADJ
ajlsi-3268	140	27	and	and	CCONJ
ajlsi-3268	140	28	bulk	bulk	ADJ
ajlsi-3268	140	29	forms	form	NOUN
ajlsi-3268	140	30	.	.	PUNCT
ajlsi-3268	141	1	the	the	DET
ajlsi-3268	141	2	investigation	investigation	NOUN
ajlsi-3268	141	3	,	,	PUNCT
ajlsi-3268	141	4	which	which	PRON
ajlsi-3268	141	5	used	use	VERB
ajlsi-3268	141	6	both	both	DET
ajlsi-3268	141	7	versions	version	NOUN
ajlsi-3268	141	8	of	of	ADP
ajlsi-3268	141	9	secukinumab	secukinumab	NOUN
ajlsi-3268	141	10	,	,	PUNCT
ajlsi-3268	141	11	supplemented	supplement	VERB
ajlsi-3268	141	12	with	with	ADP
ajlsi-3268	141	13	or	or	CCONJ
ajlsi-3268	141	14	without	without	ADP
ajlsi-3268	141	15	h2o2	h2o2	NOUN
ajlsi-3268	141	16	,	,	PUNCT
ajlsi-3268	141	17	to	to	PART
ajlsi-3268	141	18	treat	treat	VERB
ajlsi-3268	141	19	patient	patient	ADJ
ajlsi-3268	141	20	groups	group	NOUN
ajlsi-3268	141	21	and	and	CCONJ
ajlsi-3268	141	22	healthy	healthy	ADJ
ajlsi-3268	141	23	individuals	individual	NOUN
ajlsi-3268	141	24	,	,	PUNCT
ajlsi-3268	141	25	did	do	AUX
ajlsi-3268	141	26	not	not	PART
ajlsi-3268	141	27	find	find	VERB
ajlsi-3268	141	28	any	any	DET
ajlsi-3268	141	29	statistically	statistically	ADV
ajlsi-3268	141	30	significant	significant	ADJ
ajlsi-3268	141	31	differences	difference	NOUN
ajlsi-3268	141	32	in	in	ADP
ajlsi-3268	141	33	dna	dna	PROPN
ajlsi-3268	141	34	damage	damage	NOUN
ajlsi-3268	141	35	.	.	PUNCT
ajlsi-3268	142	1	empty	empty	ADJ
ajlsi-3268	142	2	liposomes	liposome	NOUN
ajlsi-3268	142	3	had	have	VERB
ajlsi-3268	142	4	no	no	DET
ajlsi-3268	142	5	significant	significant	ADJ
ajlsi-3268	142	6	damage	damage	NOUN
ajlsi-3268	142	7	on	on	ADP
ajlsi-3268	142	8	the	the	DET
ajlsi-3268	142	9	cell	cell	NOUN
ajlsi-3268	142	10	,	,	PUNCT
ajlsi-3268	142	11	which	which	PRON
ajlsi-3268	142	12	shows	show	VERB
ajlsi-3268	142	13	that	that	SCONJ
ajlsi-3268	142	14	it	it	PRON
ajlsi-3268	142	15	in	in	ADP
ajlsi-3268	142	16	itself	itself	PRON
ajlsi-3268	142	17	is	be	AUX
ajlsi-3268	142	18	safe	safe	ADJ
ajlsi-3268	142	19	on	on	ADP
ajlsi-3268	142	20	cells	cell	NOUN
ajlsi-3268	142	21	.	.	PUNCT
ajlsi-3268	143	1	according	accord	VERB
ajlsi-3268	143	2	to	to	ADP
ajlsi-3268	143	3	the	the	DET
ajlsi-3268	143	4	study	study	NOUN
ajlsi-3268	143	5	,	,	PUNCT
ajlsi-3268	143	6	secukinumab	secukinumab	NOUN
ajlsi-3268	143	7	may	may	AUX
ajlsi-3268	143	8	be	be	AUX
ajlsi-3268	143	9	able	able	ADJ
ajlsi-3268	143	10	to	to	PART
ajlsi-3268	143	11	both	both	CCONJ
ajlsi-3268	143	12	protect	protect	VERB
ajlsi-3268	143	13	and	and	CCONJ
ajlsi-3268	143	14	lessen	lessen	VERB
ajlsi-3268	143	15	the	the	DET
ajlsi-3268	143	16	damage	damage	NOUN
ajlsi-3268	143	17	that	that	PRON
ajlsi-3268	143	18	h2o2	h2o2	NOUN
ajlsi-3268	143	19	causes	cause	VERB
ajlsi-3268	143	20	to	to	PART
ajlsi-3268	143	21	dna	dna	VERB
ajlsi-3268	143	22	in	in	ADP
ajlsi-3268	143	23	both	both	CCONJ
ajlsi-3268	143	24	healthy	healthy	ADJ
ajlsi-3268	143	25	people	people	NOUN
ajlsi-3268	143	26	and	and	CCONJ
ajlsi-3268	143	27	psoriasis	psoriasis	NOUN
ajlsi-3268	143	28	patients	patient	NOUN
ajlsi-3268	143	29	.	.	PUNCT
ajlsi-3268	144	1	oxidative	oxidative	ADJ
ajlsi-3268	144	2	stress	stress	NOUN
ajlsi-3268	144	3	-	-	PUNCT
ajlsi-3268	144	4	induced	induce	VERB
ajlsi-3268	144	5	synthesis	synthesis	NOUN
ajlsi-3268	144	6	and	and	CCONJ
ajlsi-3268	144	7	amplification	amplification	NOUN
ajlsi-3268	144	8	of	of	ADP
ajlsi-3268	144	9	pro	pro	ADJ
ajlsi-3268	144	10	-	-	ADJ
ajlsi-3268	144	11	inflammatory	inflammatory	ADJ
ajlsi-3268	144	12	cytokines	cytokine	NOUN
ajlsi-3268	144	13	can	can	AUX
ajlsi-3268	144	14	be	be	AUX
ajlsi-3268	144	15	inhibited	inhibit	VERB
ajlsi-3268	144	16	by	by	ADP
ajlsi-3268	144	17	the	the	DET
ajlsi-3268	144	18	anti	anti	ADJ
ajlsi-3268	144	19	-	-	ADJ
ajlsi-3268	144	20	il-17	il-17	ADV
ajlsi-3268	144	21	drug	drug	NOUN
ajlsi-3268	144	22	secukinumab	secukinumab	NOUN
ajlsi-3268	144	23	(	(	PUNCT
ajlsi-3268	144	24	zou	zou	PROPN
ajlsi-3268	144	25	&	&	CCONJ
ajlsi-3268	144	26	meng	meng	PROPN
ajlsi-3268	144	27	,	,	PUNCT
ajlsi-3268	144	28	2021	2021	NUM
ajlsi-3268	144	29	)	)	PUNCT
ajlsi-3268	144	30	.	.	PUNCT
ajlsi-3268	145	1	increased	increase	VERB
ajlsi-3268	145	2	reactive	reactive	ADJ
ajlsi-3268	145	3	oxygen	oxygen	NOUN
ajlsi-3268	145	4	species	specie	NOUN
ajlsi-3268	145	5	(	(	PUNCT
ajlsi-3268	145	6	ros	ros	PROPN
ajlsi-3268	145	7	)	)	PUNCT
ajlsi-3268	145	8	damage	damage	NOUN
ajlsi-3268	145	9	dna	dna	PROPN
ajlsi-3268	145	10	,	,	PUNCT
ajlsi-3268	145	11	lipids	lipid	NOUN
ajlsi-3268	145	12	,	,	PUNCT
ajlsi-3268	145	13	and	and	CCONJ
ajlsi-3268	145	14	proteins	protein	NOUN
ajlsi-3268	145	15	,	,	PUNCT
ajlsi-3268	145	16	as	as	ADV
ajlsi-3268	145	17	well	well	ADV
ajlsi-3268	145	18	as	as	ADP
ajlsi-3268	145	19	signaling	signal	VERB
ajlsi-3268	145	20	molecules	molecule	NOUN
ajlsi-3268	145	21	and	and	CCONJ
ajlsi-3268	145	22	other	other	ADJ
ajlsi-3268	145	23	physiological	physiological	ADJ
ajlsi-3268	145	24	activities	activity	NOUN
ajlsi-3268	145	25	,	,	PUNCT
ajlsi-3268	145	26	leading	lead	VERB
ajlsi-3268	145	27	to	to	ADP
ajlsi-3268	145	28	diseases	disease	NOUN
ajlsi-3268	145	29	through	through	ADP
ajlsi-3268	145	30	oxidative	oxidative	ADJ
ajlsi-3268	145	31	stress	stress	NOUN
ajlsi-3268	145	32	.	.	PUNCT
ajlsi-3268	146	1	when	when	SCONJ
ajlsi-3268	146	2	compared	compare	VERB
ajlsi-3268	146	3	to	to	ADP
ajlsi-3268	146	4	the	the	DET
ajlsi-3268	146	5	negative	negative	ADJ
ajlsi-3268	146	6	control	control	NOUN
ajlsi-3268	146	7	,	,	PUNCT
ajlsi-3268	146	8	the	the	DET
ajlsi-3268	146	9	oxidative	oxidative	ADJ
ajlsi-3268	146	10	stress	stress	NOUN
ajlsi-3268	146	11	therapy	therapy	NOUN
ajlsi-3268	146	12	secukinumab	secukinumab	NOUN
ajlsi-3268	146	13	did	do	AUX
ajlsi-3268	146	14	not	not	PART
ajlsi-3268	146	15	significantly	significantly	ADV
ajlsi-3268	146	16	damage	damage	VERB
ajlsi-3268	146	17	dna	dna	NOUN
ajlsi-3268	146	18	in	in	ADP
ajlsi-3268	146	19	lymphocytes	lymphocyte	NOUN
ajlsi-3268	146	20	from	from	ADP
ajlsi-3268	146	21	either	either	CCONJ
ajlsi-3268	146	22	patient	patient	ADJ
ajlsi-3268	146	23	group	group	NOUN
ajlsi-3268	146	24	or	or	CCONJ
ajlsi-3268	146	25	from	from	ADP
ajlsi-3268	146	26	healthy	healthy	ADJ
ajlsi-3268	146	27	individuals	individual	NOUN
ajlsi-3268	146	28	.	.	PUNCT
ajlsi-3268	147	1	the	the	DET
ajlsi-3268	147	2	outcomes	outcome	NOUN
ajlsi-3268	147	3	were	be	AUX
ajlsi-3268	147	4	very	very	ADV
ajlsi-3268	147	5	similar	similar	ADJ
ajlsi-3268	147	6	to	to	ADP
ajlsi-3268	147	7	those	those	PRON
ajlsi-3268	147	8	of	of	ADP
ajlsi-3268	147	9	the	the	DET
ajlsi-3268	147	10	negative	negative	ADJ
ajlsi-3268	147	11	control	control	NOUN
ajlsi-3268	147	12	.	.	PUNCT
ajlsi-3268	148	1	this	this	PRON
ajlsi-3268	148	2	suggests	suggest	VERB
ajlsi-3268	148	3	that	that	SCONJ
ajlsi-3268	148	4	the	the	DET
ajlsi-3268	148	5	concentration	concentration	NOUN
ajlsi-3268	148	6	of	of	ADP
ajlsi-3268	148	7	2.1μg	2.1μg	NUM
ajlsi-3268	148	8	/	/	SYM
ajlsi-3268	148	9	ml	ml	PROPN
ajlsi-3268	148	10	of	of	ADP
ajlsi-3268	148	11	secukinumab	secukinumab	NOUN
ajlsi-3268	148	12	is	be	AUX
ajlsi-3268	148	13	nongenotoxic	nongenotoxic	ADJ
ajlsi-3268	148	14	to	to	ADP
ajlsi-3268	148	15	the	the	DET
ajlsi-3268	148	16	cells	cell	NOUN
ajlsi-3268	148	17	in	in	ADP
ajlsi-3268	148	18	both	both	DET
ajlsi-3268	148	19	groups	group	NOUN
ajlsi-3268	148	20	.	.	PUNCT
ajlsi-3268	149	1	hydrogen	hydrogen	NOUN
ajlsi-3268	149	2	peroxide	peroxide	NOUN
ajlsi-3268	149	3	is	be	AUX
ajlsi-3268	149	4	an	an	DET
ajlsi-3268	149	5	oxidative	oxidative	ADJ
ajlsi-3268	149	6	stress	stress	NOUN
ajlsi-3268	149	7	inducer	inducer	NOUN
ajlsi-3268	149	8	compound	compound	NOUN
ajlsi-3268	149	9	which	which	PRON
ajlsi-3268	149	10	causes	cause	VERB
ajlsi-3268	149	11	significant	significant	ADJ
ajlsi-3268	149	12	amounts	amount	NOUN
ajlsi-3268	149	13	of	of	ADP
ajlsi-3268	149	14	oxidative	oxidative	ADJ
ajlsi-3268	149	15	stress	stress	NOUN
ajlsi-3268	149	16	-	-	PUNCT
ajlsi-3268	149	17	related	relate	VERB
ajlsi-3268	149	18	dna	dna	NOUN
ajlsi-3268	149	19	damage	damage	NOUN
ajlsi-3268	149	20	in	in	ADP
ajlsi-3268	149	21	peripheral	peripheral	ADJ
ajlsi-3268	149	22	lymphocyte	lymphocyte	ADJ
ajlsi-3268	149	23	cells	cell	NOUN
ajlsi-3268	149	24	(	(	PUNCT
ajlsi-3268	149	25	najafzadeh	najafzadeh	ADV
ajlsi-3268	149	26	et	et	PROPN
ajlsi-3268	149	27	al	al	PROPN
ajlsi-3268	149	28	.	.	PROPN
ajlsi-3268	149	29	,	,	PUNCT
ajlsi-3268	149	30	2009	2009	NUM
ajlsi-3268	149	31	;	;	PUNCT
ajlsi-3268	149	32	stanić	stanić	PROPN
ajlsi-3268	149	33	et	et	PROPN
ajlsi-3268	149	34	al	al	PROPN
ajlsi-3268	149	35	.	.	PROPN
ajlsi-3268	149	36	,	,	PUNCT
ajlsi-3268	149	37	2016	2016	NUM
ajlsi-3268	149	38	)	)	PUNCT
ajlsi-3268	149	39	.	.	PUNCT
ajlsi-3268	150	1	our	our	PRON
ajlsi-3268	150	2	results	result	NOUN
ajlsi-3268	150	3	are	be	AUX
ajlsi-3268	150	4	in	in	ADP
ajlsi-3268	150	5	accordance	accordance	NOUN
ajlsi-3268	150	6	with	with	ADP
ajlsi-3268	150	7	these	these	DET
ajlsi-3268	150	8	studies	study	NOUN
ajlsi-3268	150	9	as	as	SCONJ
ajlsi-3268	150	10	h2o2	h2o2	NOUN
ajlsi-3268	150	11	significantly	significantly	ADV
ajlsi-3268	150	12	induced	induce	VERB
ajlsi-3268	150	13	dna	dna	ADJ
ajlsi-3268	150	14	damage	damage	NOUN
ajlsi-3268	150	15	in	in	ADP
ajlsi-3268	150	16	both	both	DET
ajlsi-3268	150	17	subjective	subjective	ADJ
ajlsi-3268	150	18	groups	group	NOUN
ajlsi-3268	150	19	;	;	PUNCT
ajlsi-3268	150	20	healthy	healthy	ADJ
ajlsi-3268	150	21	individuals	individual	NOUN
ajlsi-3268	150	22	and	and	CCONJ
ajlsi-3268	150	23	psoriasis	psoriasis	NOUN
ajlsi-3268	150	24	patients	patient	NOUN
ajlsi-3268	150	25	.	.	PUNCT
ajlsi-3268	151	1	when	when	SCONJ
ajlsi-3268	151	2	compared	compare	VERB
ajlsi-3268	151	3	to	to	ADP
ajlsi-3268	151	4	the	the	DET
ajlsi-3268	151	5	positive	positive	ADJ
ajlsi-3268	151	6	control	control	NOUN
ajlsi-3268	151	7	alone	alone	ADV
ajlsi-3268	151	8	,	,	PUNCT
ajlsi-3268	151	9	the	the	DET
ajlsi-3268	151	10	administration	administration	NOUN
ajlsi-3268	151	11	of	of	ADP
ajlsi-3268	151	12	various	various	ADJ
ajlsi-3268	151	13	pa	pa	PROPN
ajlsi-3268	151	14	ge	ge	PROPN
ajlsi-3268	151	15	33	33	NUM
ajlsi-3268	151	16	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-3268	151	17	am	am	NOUN
ajlsi-3268	151	18	.	.	PUNCT
ajlsi-3268	152	1	j.	j.	PROPN
ajlsi-3268	152	2	life	life	PROPN
ajlsi-3268	152	3	sci	sci	PROPN
ajlsi-3268	152	4	.	.	PUNCT
ajlsi-3268	152	5	innov	innov	PROPN
ajlsi-3268	152	6	.	.	PUNCT
ajlsi-3268	153	1	4(1	4(1	NOUN
ajlsi-3268	153	2	)	)	PUNCT
ajlsi-3268	154	1	27	27	NUM
ajlsi-3268	154	2	-	-	SYM
ajlsi-3268	154	3	35	35	NUM
ajlsi-3268	154	4	,	,	PUNCT
ajlsi-3268	154	5	2025	2025	NUM
ajlsi-3268	154	6	forms	form	NOUN
ajlsi-3268	154	7	of	of	ADP
ajlsi-3268	154	8	secukinumab	secukinumab	NOUN
ajlsi-3268	154	9	,	,	PUNCT
ajlsi-3268	154	10	such	such	ADJ
ajlsi-3268	154	11	as	as	ADP
ajlsi-3268	154	12	liposome	liposome	NOUN
ajlsi-3268	154	13	and	and	CCONJ
ajlsi-3268	154	14	bulk	bulk	ADJ
ajlsi-3268	154	15	form	form	NOUN
ajlsi-3268	154	16	,	,	PUNCT
ajlsi-3268	154	17	dramatically	dramatically	ADV
ajlsi-3268	154	18	decreased	decrease	VERB
ajlsi-3268	154	19	dna	dna	PROPN
ajlsi-3268	154	20	damage	damage	NOUN
ajlsi-3268	154	21	caused	cause	VERB
ajlsi-3268	154	22	by	by	ADP
ajlsi-3268	154	23	h2o2	h2o2	PROPN
ajlsi-3268	154	24	.	.	PROPN
ajlsi-3268	154	25	secukinumab	secukinumab	NOUN
ajlsi-3268	154	26	,	,	PUNCT
ajlsi-3268	154	27	with	with	ADP
ajlsi-3268	154	28	antioxidant	antioxidant	ADJ
ajlsi-3268	154	29	defense	defense	NOUN
ajlsi-3268	154	30	playing	play	VERB
ajlsi-3268	154	31	a	a	DET
ajlsi-3268	154	32	part	part	NOUN
ajlsi-3268	154	33	,	,	PUNCT
ajlsi-3268	154	34	reduced	reduce	VERB
ajlsi-3268	154	35	damage	damage	NOUN
ajlsi-3268	154	36	to	to	ADP
ajlsi-3268	154	37	a	a	DET
ajlsi-3268	154	38	level	level	NOUN
ajlsi-3268	154	39	comparable	comparable	ADJ
ajlsi-3268	154	40	to	to	ADP
ajlsi-3268	154	41	the	the	DET
ajlsi-3268	154	42	untreated	untreated	ADJ
ajlsi-3268	154	43	control	control	PROPN
ajlsi-3268	154	44	group	group	NOUN
ajlsi-3268	154	45	.	.	PUNCT
ajlsi-3268	155	1	the	the	DET
ajlsi-3268	155	2	psoriasis	psoriasis	NOUN
ajlsi-3268	155	3	area	area	NOUN
ajlsi-3268	155	4	and	and	CCONJ
ajlsi-3268	155	5	severity	severity	NOUN
ajlsi-3268	155	6	index	index	NOUN
ajlsi-3268	155	7	and	and	CCONJ
ajlsi-3268	155	8	oxidative	oxidative	ADJ
ajlsi-3268	155	9	stress	stress	NOUN
ajlsi-3268	155	10	indicators	indicator	NOUN
ajlsi-3268	155	11	were	be	AUX
ajlsi-3268	155	12	found	find	VERB
ajlsi-3268	155	13	to	to	PART
ajlsi-3268	155	14	be	be	AUX
ajlsi-3268	155	15	positively	positively	ADV
ajlsi-3268	155	16	correlated	correlate	VERB
ajlsi-3268	155	17	.	.	PUNCT
ajlsi-3268	156	1	using	use	VERB
ajlsi-3268	156	2	cck8	cck8	PROPN
ajlsi-3268	156	3	,	,	PUNCT
ajlsi-3268	156	4	the	the	DET
ajlsi-3268	156	5	study	study	NOUN
ajlsi-3268	156	6	examined	examine	VERB
ajlsi-3268	156	7	the	the	DET
ajlsi-3268	156	8	cytotoxic	cytotoxic	ADJ
ajlsi-3268	156	9	effects	effect	NOUN
ajlsi-3268	156	10	of	of	ADP
ajlsi-3268	156	11	secukinumab	secukinumab	NOUN
ajlsi-3268	156	12	on	on	ADP
ajlsi-3268	156	13	healthy	healthy	ADJ
ajlsi-3268	156	14	peripheral	peripheral	ADJ
ajlsi-3268	156	15	lymphocytes	lymphocyte	NOUN
ajlsi-3268	156	16	,	,	PUNCT
ajlsi-3268	156	17	and	and	CCONJ
ajlsi-3268	156	18	the	the	DET
ajlsi-3268	156	19	results	result	NOUN
ajlsi-3268	156	20	showed	show	VERB
ajlsi-3268	156	21	that	that	SCONJ
ajlsi-3268	156	22	these	these	DET
ajlsi-3268	156	23	cells	cell	NOUN
ajlsi-3268	156	24	were	be	AUX
ajlsi-3268	156	25	cytotoxic	cytotoxic	ADJ
ajlsi-3268	156	26	in	in	ADP
ajlsi-3268	156	27	a	a	DET
ajlsi-3268	156	28	concentration	concentration	NOUN
ajlsi-3268	156	29	-	-	PUNCT
ajlsi-3268	156	30	dependent	dependent	ADJ
ajlsi-3268	156	31	manner	manner	NOUN
ajlsi-3268	156	32	(	(	PUNCT
ajlsi-3268	156	33	lin	lin	PROPN
ajlsi-3268	156	34	&	&	CCONJ
ajlsi-3268	156	35	huang	huang	PROPN
ajlsi-3268	156	36	,	,	PUNCT
ajlsi-3268	156	37	2016	2016	NUM
ajlsi-3268	156	38	)	)	PUNCT
ajlsi-3268	156	39	.	.	PUNCT
ajlsi-3268	157	1	it	it	PRON
ajlsi-3268	157	2	was	be	AUX
ajlsi-3268	157	3	observed	observe	VERB
ajlsi-3268	157	4	that	that	SCONJ
ajlsi-3268	157	5	,	,	PUNCT
ajlsi-3268	157	6	increased	increase	VERB
ajlsi-3268	157	7	concentration	concentration	NOUN
ajlsi-3268	157	8	of	of	ADP
ajlsi-3268	157	9	secukinumab	secukinumab	NOUN
ajlsi-3268	157	10	(	(	PUNCT
ajlsi-3268	157	11	3.75µg	3.75µg	NOUN
ajlsi-3268	157	12	/	/	SYM
ajlsi-3268	157	13	ml	ml	NOUN
ajlsi-3268	157	14	)	)	PUNCT
ajlsi-3268	157	15	was	be	AUX
ajlsi-3268	157	16	found	find	VERB
ajlsi-3268	157	17	to	to	PART
ajlsi-3268	157	18	be	be	AUX
ajlsi-3268	157	19	cytotoxic	cytotoxic	ADJ
ajlsi-3268	157	20	,	,	PUNCT
ajlsi-3268	157	21	while	while	SCONJ
ajlsi-3268	157	22	the	the	DET
ajlsi-3268	157	23	two	two	NUM
ajlsi-3268	157	24	lower	low	ADJ
ajlsi-3268	157	25	concentrations	concentration	NOUN
ajlsi-3268	157	26	of	of	ADP
ajlsi-3268	157	27	the	the	DET
ajlsi-3268	157	28	drugs	drug	NOUN
ajlsi-3268	157	29	were	be	AUX
ajlsi-3268	157	30	tested	test	VERB
ajlsi-3268	157	31	2.1µg	2.1µg	NUM
ajlsi-3268	157	32	/	/	SYM
ajlsi-3268	157	33	ml	ml	NOUN
ajlsi-3268	157	34	and	and	CCONJ
ajlsi-3268	157	35	2.8µg	2.8µg	NUM
ajlsi-3268	157	36	/	/	SYM
ajlsi-3268	157	37	ml	ml	NOUN
ajlsi-3268	157	38	,	,	PUNCT
ajlsi-3268	157	39	had	have	VERB
ajlsi-3268	157	40	increased	increase	VERB
ajlsi-3268	157	41	cell	cell	NOUN
ajlsi-3268	157	42	survival	survival	NOUN
ajlsi-3268	157	43	rates	rate	NOUN
ajlsi-3268	157	44	of	of	ADP
ajlsi-3268	157	45	over	over	ADP
ajlsi-3268	157	46	75	75	NUM
ajlsi-3268	157	47	%	%	NOUN
ajlsi-3268	157	48	.	.	PUNCT
ajlsi-3268	158	1	the	the	DET
ajlsi-3268	158	2	cbmn	cbmn	NOUN
ajlsi-3268	158	3	assay	assay	NOUN
ajlsi-3268	158	4	is	be	AUX
ajlsi-3268	158	5	an	an	DET
ajlsi-3268	158	6	effective	effective	ADJ
ajlsi-3268	158	7	test	test	NOUN
ajlsi-3268	158	8	to	to	PART
ajlsi-3268	158	9	study	study	VERB
ajlsi-3268	158	10	the	the	DET
ajlsi-3268	158	11	capability	capability	NOUN
ajlsi-3268	158	12	of	of	ADP
ajlsi-3268	158	13	genotoxic	genotoxic	ADJ
ajlsi-3268	158	14	agents	agent	NOUN
ajlsi-3268	158	15	to	to	PART
ajlsi-3268	158	16	cause	cause	VERB
ajlsi-3268	158	17	various	various	ADJ
ajlsi-3268	158	18	clastogenic	clastogenic	NOUN
ajlsi-3268	158	19	(	(	PUNCT
ajlsi-3268	158	20	chromosome	chromosome	NOUN
ajlsi-3268	158	21	breakage	breakage	NOUN
ajlsi-3268	158	22	)	)	PUNCT
ajlsi-3268	158	23	and	and	CCONJ
ajlsi-3268	158	24	an	an	DET
ajlsi-3268	158	25	eugenic	eugenic	ADJ
ajlsi-3268	158	26	effects	effect	NOUN
ajlsi-3268	158	27	(	(	PUNCT
ajlsi-3268	158	28	causing	cause	VERB
ajlsi-3268	158	29	daughter	daughter	NOUN
ajlsi-3268	158	30	cells	cell	NOUN
ajlsi-3268	158	31	to	to	PART
ajlsi-3268	158	32	have	have	VERB
ajlsi-3268	158	33	an	an	DET
ajlsi-3268	158	34	abnormal	abnormal	ADJ
ajlsi-3268	158	35	number	number	NOUN
ajlsi-3268	158	36	of	of	ADP
ajlsi-3268	158	37	chromosomes	chromosome	NOUN
ajlsi-3268	158	38	during	during	ADP
ajlsi-3268	158	39	cell	cell	NOUN
ajlsi-3268	158	40	division	division	NOUN
ajlsi-3268	158	41	)	)	PUNCT
ajlsi-3268	158	42	(	(	PUNCT
ajlsi-3268	158	43	fenech	fenech	PROPN
ajlsi-3268	158	44	,	,	PUNCT
ajlsi-3268	158	45	2009	2009	NUM
ajlsi-3268	158	46	)	)	PUNCT
ajlsi-3268	158	47	.	.	PUNCT
ajlsi-3268	159	1	it	it	PRON
ajlsi-3268	159	2	was	be	AUX
ajlsi-3268	159	3	utilized	utilize	VERB
ajlsi-3268	159	4	in	in	ADP
ajlsi-3268	159	5	the	the	DET
ajlsi-3268	159	6	current	current	ADJ
ajlsi-3268	159	7	study	study	NOUN
ajlsi-3268	159	8	to	to	PART
ajlsi-3268	159	9	describe	describe	VERB
ajlsi-3268	159	10	the	the	DET
ajlsi-3268	159	11	effects	effect	NOUN
ajlsi-3268	159	12	of	of	ADP
ajlsi-3268	159	13	secukinumab	secukinumab	NOUN
ajlsi-3268	159	14	on	on	ADP
ajlsi-3268	159	15	healthy	healthy	ADJ
ajlsi-3268	159	16	individuals	individual	NOUN
ajlsi-3268	159	17	versus	versus	ADP
ajlsi-3268	159	18	psoriasis	psoriasis	NOUN
ajlsi-3268	159	19	patients	patient	NOUN
ajlsi-3268	159	20	.	.	PUNCT
ajlsi-3268	160	1	also	also	ADV
ajlsi-3268	160	2	,	,	PUNCT
ajlsi-3268	160	3	to	to	PART
ajlsi-3268	160	4	determine	determine	VERB
ajlsi-3268	160	5	the	the	DET
ajlsi-3268	160	6	protective	protective	ADJ
ajlsi-3268	160	7	potential	potential	NOUN
ajlsi-3268	160	8	of	of	ADP
ajlsi-3268	160	9	the	the	DET
ajlsi-3268	160	10	drug	drug	NOUN
ajlsi-3268	160	11	against	against	ADP
ajlsi-3268	160	12	h2o2	h2o2	ADV
ajlsi-3268	160	13	-	-	ADJ
ajlsi-3268	160	14	induced	induced	ADJ
ajlsi-3268	160	15	geno	geno	NOUN
ajlsi-3268	160	16	toxicity	toxicity	NOUN
ajlsi-3268	160	17	.	.	PUNCT
ajlsi-3268	161	1	this	this	DET
ajlsi-3268	161	2	assay	assay	PROPN
ajlsi-3268	161	3	assesses	assess	VERB
ajlsi-3268	161	4	several	several	ADJ
ajlsi-3268	161	5	parameters	parameter	NOUN
ajlsi-3268	161	6	,	,	PUNCT
ajlsi-3268	161	7	including	include	VERB
ajlsi-3268	161	8	micronuclei	micronucleus	NOUN
ajlsi-3268	161	9	(	(	PUNCT
ajlsi-3268	161	10	mni	mni	PROPN
ajlsi-3268	161	11	)	)	PUNCT
ajlsi-3268	161	12	,	,	PUNCT
ajlsi-3268	161	13	which	which	PRON
ajlsi-3268	161	14	form	form	VERB
ajlsi-3268	161	15	during	during	ADP
ajlsi-3268	161	16	anaphase	anaphase	NOUN
ajlsi-3268	161	17	and	and	CCONJ
ajlsi-3268	161	18	indicate	indicate	VERB
ajlsi-3268	161	19	chromosomal	chromosomal	ADJ
ajlsi-3268	161	20	remains	remain	NOUN
ajlsi-3268	161	21	or	or	CCONJ
ajlsi-3268	161	22	lost	lose	VERB
ajlsi-3268	161	23	chromosomes	chromosome	NOUN
ajlsi-3268	161	24	generated	generate	VERB
ajlsi-3268	161	25	during	during	ADP
ajlsi-3268	161	26	nuclear	nuclear	ADJ
ajlsi-3268	161	27	division	division	NOUN
ajlsi-3268	161	28	.	.	PUNCT
ajlsi-3268	162	1	to	to	PART
ajlsi-3268	162	2	enhance	enhance	VERB
ajlsi-3268	162	3	the	the	DET
ajlsi-3268	162	4	sensitivity	sensitivity	NOUN
ajlsi-3268	162	5	and	and	CCONJ
ajlsi-3268	162	6	reliability	reliability	NOUN
ajlsi-3268	162	7	of	of	ADP
ajlsi-3268	162	8	the	the	DET
ajlsi-3268	162	9	assay	assay	NOUN
ajlsi-3268	162	10	,	,	PUNCT
ajlsi-3268	162	11	cytokinesis	cytokinesis	NOUN
ajlsi-3268	162	12	is	be	AUX
ajlsi-3268	162	13	blocked	block	VERB
ajlsi-3268	162	14	using	use	VERB
ajlsi-3268	162	15	cytochalasin	cytochalasin	PROPN
ajlsi-3268	162	16	b	b	PROPN
ajlsi-3268	162	17	,	,	PUNCT
ajlsi-3268	162	18	which	which	PRON
ajlsi-3268	162	19	facilitates	facilitate	VERB
ajlsi-3268	162	20	the	the	DET
ajlsi-3268	162	21	accumulation	accumulation	NOUN
ajlsi-3268	162	22	of	of	ADP
ajlsi-3268	162	23	binc	binc	PROPN
ajlsi-3268	162	24	.	.	PUNCT
ajlsi-3268	163	1	the	the	DET
ajlsi-3268	163	2	presence	presence	NOUN
ajlsi-3268	163	3	of	of	ADP
ajlsi-3268	163	4	mni	mni	PROPN
ajlsi-3268	163	5	in	in	ADP
ajlsi-3268	163	6	binc	binc	NOUN
ajlsi-3268	163	7	only	only	ADV
ajlsi-3268	163	8	reflects	reflect	VERB
ajlsi-3268	163	9	damage	damage	NOUN
ajlsi-3268	163	10	induced	induce	VERB
ajlsi-3268	163	11	after	after	ADP
ajlsi-3268	163	12	treatment	treatment	NOUN
ajlsi-3268	163	13	,	,	PUNCT
ajlsi-3268	163	14	reducing	reduce	VERB
ajlsi-3268	163	15	the	the	DET
ajlsi-3268	163	16	possibility	possibility	NOUN
ajlsi-3268	163	17	of	of	ADP
ajlsi-3268	163	18	scoring	score	VERB
ajlsi-3268	163	19	pre	pre	ADJ
ajlsi-3268	163	20	-	-	ADJ
ajlsi-3268	163	21	existing	exist	VERB
ajlsi-3268	163	22	damage	damage	NOUN
ajlsi-3268	163	23	.	.	PUNCT
ajlsi-3268	164	1	this	this	DET
ajlsi-3268	164	2	approach	approach	NOUN
ajlsi-3268	164	3	effectively	effectively	ADV
ajlsi-3268	164	4	determines	determine	VERB
ajlsi-3268	164	5	the	the	DET
ajlsi-3268	164	6	effects	effect	NOUN
ajlsi-3268	164	7	of	of	ADP
ajlsi-3268	164	8	the	the	DET
ajlsi-3268	164	9	test	test	NOUN
ajlsi-3268	164	10	chemicals	chemical	NOUN
ajlsi-3268	164	11	.	.	PUNCT
ajlsi-3268	165	1	by	by	ADP
ajlsi-3268	165	2	implementing	implement	VERB
ajlsi-3268	165	3	this	this	DET
ajlsi-3268	165	4	methodology	methodology	NOUN
ajlsi-3268	165	5	,	,	PUNCT
ajlsi-3268	165	6	the	the	DET
ajlsi-3268	165	7	sensitivity	sensitivity	NOUN
ajlsi-3268	165	8	and	and	CCONJ
ajlsi-3268	165	9	reliability	reliability	NOUN
ajlsi-3268	165	10	of	of	ADP
ajlsi-3268	165	11	the	the	DET
ajlsi-3268	165	12	assay	assay	NOUN
ajlsi-3268	165	13	are	be	AUX
ajlsi-3268	165	14	increased	increase	VERB
ajlsi-3268	165	15	,	,	PUNCT
ajlsi-3268	165	16	and	and	CCONJ
ajlsi-3268	165	17	the	the	DET
ajlsi-3268	165	18	effects	effect	NOUN
ajlsi-3268	165	19	of	of	ADP
ajlsi-3268	165	20	the	the	DET
ajlsi-3268	165	21	test	test	NOUN
ajlsi-3268	165	22	chemicals	chemical	NOUN
ajlsi-3268	165	23	are	be	AUX
ajlsi-3268	165	24	accurately	accurately	ADV
ajlsi-3268	165	25	determined	determine	VERB
ajlsi-3268	165	26	(	(	PUNCT
ajlsi-3268	165	27	magdolenova	magdolenova	X
ajlsi-3268	165	28	et	et	PROPN
ajlsi-3268	165	29	al	al	PROPN
ajlsi-3268	165	30	.	.	PROPN
ajlsi-3268	165	31	,	,	PUNCT
ajlsi-3268	165	32	2012	2012	NUM
ajlsi-3268	165	33	;	;	PUNCT
ajlsi-3268	165	34	co	co	NOUN
ajlsi-3268	165	35	-	-	NOUN
ajlsi-3268	165	36	operation	operation	NOUN
ajlsi-3268	165	37	ofe	ofe	NOUN
ajlsi-3268	165	38	,	,	PUNCT
ajlsi-3268	165	39	2010	2010	NUM
ajlsi-3268	165	40	)	)	PUNCT
ajlsi-3268	165	41	.	.	PUNCT
ajlsi-3268	166	1	in	in	ADP
ajlsi-3268	166	2	comparison	comparison	NOUN
ajlsi-3268	166	3	with	with	ADP
ajlsi-3268	166	4	the	the	DET
ajlsi-3268	166	5	untreated	untreated	ADJ
ajlsi-3268	166	6	cells	cell	NOUN
ajlsi-3268	166	7	,	,	PUNCT
ajlsi-3268	166	8	no	no	DET
ajlsi-3268	166	9	effects	effect	NOUN
ajlsi-3268	166	10	on	on	ADP
ajlsi-3268	166	11	mni	mni	ADJ
ajlsi-3268	166	12	frequency	frequency	NOUN
ajlsi-3268	166	13	were	be	AUX
ajlsi-3268	166	14	reported	report	VERB
ajlsi-3268	166	15	when	when	SCONJ
ajlsi-3268	166	16	the	the	DET
ajlsi-3268	166	17	lymphocytes	lymphocyte	NOUN
ajlsi-3268	166	18	of	of	ADP
ajlsi-3268	166	19	healthy	healthy	ADJ
ajlsi-3268	166	20	patients	patient	NOUN
ajlsi-3268	166	21	receiving	receive	VERB
ajlsi-3268	166	22	both	both	DET
ajlsi-3268	166	23	kinds	kind	NOUN
ajlsi-3268	166	24	of	of	ADP
ajlsi-3268	166	25	secukinumab	secukinumab	NOUN
ajlsi-3268	166	26	treatment	treatment	NOUN
ajlsi-3268	166	27	.	.	PUNCT
ajlsi-3268	167	1	“	"	PUNCT
ajlsi-3268	167	2	the	the	DET
ajlsi-3268	167	3	mni	mni	ADJ
ajlsi-3268	167	4	frequency	frequency	NOUN
ajlsi-3268	167	5	in	in	ADP
ajlsi-3268	167	6	lymphocytes(***p<0.001	lymphocytes(***p<0.001	PROPN
ajlsi-3268	167	7	)	)	PUNCT
ajlsi-3268	167	8	was	be	AUX
ajlsi-3268	167	9	considerably	considerably	ADV
ajlsi-3268	167	10	elevated	elevate	VERB
ajlsi-3268	167	11	by	by	ADP
ajlsi-3268	167	12	the	the	DET
ajlsi-3268	167	13	mmc	mmc	NOUN
ajlsi-3268	167	14	and	and	CCONJ
ajlsi-3268	167	15	75	75	NUM
ajlsi-3268	167	16	μm	μm	NUM
ajlsi-3268	167	17	h2o2	h2o2	NOUN
ajlsi-3268	167	18	,	,	PUNCT
ajlsi-3268	167	19	yet	yet	ADV
ajlsi-3268	167	20	secukinumab	secukinumab	NOUN
ajlsi-3268	167	21	(	(	PUNCT
ajlsi-3268	167	22	bulk	bulk	NOUN
ajlsi-3268	167	23	or	or	CCONJ
ajlsi-3268	167	24	liposome	liposome	VERB
ajlsi-3268	167	25	co	co	VERB
ajlsi-3268	167	26	-	-	VERB
ajlsi-3268	167	27	supplemented	supplement	VERB
ajlsi-3268	167	28	with	with	ADP
ajlsi-3268	167	29	h2o2	h2o2	NOUN
ajlsi-3268	167	30	)	)	PUNCT
ajlsi-3268	167	31	exhibited	exhibit	VERB
ajlsi-3268	167	32	significant	significant	ADJ
ajlsi-3268	167	33	reduction	reduction	NOUN
ajlsi-3268	167	34	in	in	ADP
ajlsi-3268	167	35	the	the	DET
ajlsi-3268	167	36	number	number	NOUN
ajlsi-3268	167	37	of	of	ADP
ajlsi-3268	167	38	mni	mni	PROPN
ajlsi-3268	167	39	in	in	ADP
ajlsi-3268	167	40	lymphocytes	lymphocyte	NOUN
ajlsi-3268	167	41	(	(	PUNCT
ajlsi-3268	167	42	*	*	NOUN
ajlsi-3268	167	43	p<0.05	p<0.05	NOUN
ajlsi-3268	167	44	)	)	PUNCT
ajlsi-3268	167	45	”	"	PUNCT
ajlsi-3268	167	46	.	.	PUNCT
ajlsi-3268	168	1	“	"	PUNCT
ajlsi-3268	168	2	it	it	PRON
ajlsi-3268	168	3	was	be	AUX
ajlsi-3268	168	4	manifested	manifest	VERB
ajlsi-3268	168	5	that	that	SCONJ
ajlsi-3268	168	6	liposomal	liposomal	PROPN
ajlsi-3268	168	7	secukinumab	secukinumab	NOUN
ajlsi-3268	168	8	caused	cause	VERB
ajlsi-3268	168	9	a	a	DET
ajlsi-3268	168	10	significant	significant	ADJ
ajlsi-3268	168	11	reduction	reduction	NOUN
ajlsi-3268	168	12	in	in	ADP
ajlsi-3268	168	13	the	the	DET
ajlsi-3268	168	14	number	number	NOUN
ajlsi-3268	168	15	of	of	ADP
ajlsi-3268	168	16	mnis	mnis	PROPN
ajlsi-3268	168	17	in	in	ADP
ajlsi-3268	168	18	patients	patient	NOUN
ajlsi-3268	168	19	(	(	PUNCT
ajlsi-3268	168	20	*	*	PUNCT
ajlsi-3268	168	21	*	*	PUNCT
ajlsi-3268	168	22	*	*	PUNCT
ajlsi-3268	168	23	p<0.001	p<0.001	VERB
ajlsi-3268	168	24	as	as	SCONJ
ajlsi-3268	168	25	compared	compare	VERB
ajlsi-3268	168	26	to	to	ADP
ajlsi-3268	168	27	un	un	ADJ
ajlsi-3268	168	28	-	-	ADJ
ajlsi-3268	168	29	treated	treat	VERB
ajlsi-3268	168	30	cells	cell	NOUN
ajlsi-3268	168	31	)	)	PUNCT
ajlsi-3268	168	32	.	.	PUNCT
ajlsi-3268	169	1	moreover	moreover	ADV
ajlsi-3268	169	2	,	,	PUNCT
ajlsi-3268	169	3	the	the	DET
ajlsi-3268	169	4	inclusion	inclusion	NOUN
ajlsi-3268	169	5	of	of	ADP
ajlsi-3268	169	6	mmc	mmc	NOUN
ajlsi-3268	169	7	and	and	CCONJ
ajlsi-3268	169	8	75	75	NUM
ajlsi-3268	169	9	μm	μm	NOUN
ajlsi-3268	169	10	h2o2	h2o2	NOUN
ajlsi-3268	169	11	revealed	reveal	VERB
ajlsi-3268	169	12	a	a	DET
ajlsi-3268	169	13	significant	significant	ADJ
ajlsi-3268	169	14	increase	increase	NOUN
ajlsi-3268	169	15	(	(	PUNCT
ajlsi-3268	169	16	*	*	PUNCT
ajlsi-3268	169	17	*	*	PUNCT
ajlsi-3268	169	18	*	*	PUNCT
ajlsi-3268	169	19	p<0.001	p<0.001	X
ajlsi-3268	169	20	)	)	PUNCT
ajlsi-3268	169	21	in	in	ADP
ajlsi-3268	169	22	the	the	DET
ajlsi-3268	169	23	mni	mni	ADJ
ajlsi-3268	169	24	number	number	NOUN
ajlsi-3268	169	25	in	in	ADP
ajlsi-3268	169	26	lymphocyte	lymphocyte	ADJ
ajlsi-3268	169	27	count	count	NOUN
ajlsi-3268	169	28	in	in	ADP
ajlsi-3268	169	29	comparison	comparison	NOUN
ajlsi-3268	169	30	to	to	ADP
ajlsi-3268	169	31	untreated	untreated	ADJ
ajlsi-3268	169	32	cells	cell	NOUN
ajlsi-3268	169	33	”	"	PUNCT
ajlsi-3268	169	34	.	.	PUNCT
ajlsi-3268	170	1	this	this	PRON
ajlsi-3268	170	2	all	all	PRON
ajlsi-3268	170	3	confirms	confirm	VERB
ajlsi-3268	170	4	the	the	DET
ajlsi-3268	170	5	safety	safety	NOUN
ajlsi-3268	170	6	of	of	ADP
ajlsi-3268	170	7	secukinumab	secukinumab	NOUN
ajlsi-3268	170	8	in	in	ADP
ajlsi-3268	170	9	both	both	DET
ajlsi-3268	170	10	forms	form	NOUN
ajlsi-3268	170	11	,	,	PUNCT
ajlsi-3268	170	12	bulk	bulk	NOUN
ajlsi-3268	170	13	and	and	CCONJ
ajlsi-3268	170	14	liposome	liposome	NOUN
ajlsi-3268	170	15	,	,	PUNCT
ajlsi-3268	170	16	on	on	ADP
ajlsi-3268	170	17	lymphocytes	lymphocyte	NOUN
ajlsi-3268	170	18	.	.	PUNCT
ajlsi-3268	171	1	this	this	PRON
ajlsi-3268	171	2	could	could	AUX
ajlsi-3268	171	3	be	be	AUX
ajlsi-3268	171	4	the	the	DET
ajlsi-3268	171	5	first	first	ADJ
ajlsi-3268	171	6	step	step	NOUN
ajlsi-3268	171	7	in	in	ADP
ajlsi-3268	171	8	using	use	VERB
ajlsi-3268	171	9	the	the	DET
ajlsi-3268	171	10	liposome	liposome	NOUN
ajlsi-3268	171	11	form	form	NOUN
ajlsi-3268	171	12	as	as	ADP
ajlsi-3268	171	13	a	a	DET
ajlsi-3268	171	14	topical	topical	ADJ
ajlsi-3268	171	15	treatment	treatment	NOUN
ajlsi-3268	171	16	.	.	PUNCT
ajlsi-3268	172	1	therefore	therefore	ADV
ajlsi-3268	172	2	,	,	PUNCT
ajlsi-3268	172	3	the	the	DET
ajlsi-3268	172	4	results	result	NOUN
ajlsi-3268	172	5	demonstrate	demonstrate	VERB
ajlsi-3268	172	6	that	that	SCONJ
ajlsi-3268	172	7	all	all	DET
ajlsi-3268	172	8	the	the	DET
ajlsi-3268	172	9	treatment	treatment	NOUN
ajlsi-3268	172	10	sets	set	NOUN
ajlsi-3268	172	11	from	from	ADP
ajlsi-3268	172	12	both	both	DET
ajlsi-3268	172	13	investigative	investigative	ADJ
ajlsi-3268	172	14	groups	group	NOUN
ajlsi-3268	172	15	have	have	AUX
ajlsi-3268	172	16	shown	show	VERB
ajlsi-3268	172	17	the	the	DET
ajlsi-3268	172	18	binc	binc	NOUN
ajlsi-3268	172	19	%	%	NOUN
ajlsi-3268	172	20	and	and	CCONJ
ajlsi-3268	172	21	the	the	DET
ajlsi-3268	172	22	ndi	ndi	PROPN
ajlsi-3268	172	23	within	within	ADP
ajlsi-3268	172	24	the	the	DET
ajlsi-3268	172	25	normal	normal	ADJ
ajlsi-3268	172	26	ranges	range	NOUN
ajlsi-3268	172	27	:	:	PUNCT
ajlsi-3268	172	28	a	a	DET
ajlsi-3268	172	29	typical	typical	ADJ
ajlsi-3268	172	30	ndi	ndi	PROPN
ajlsi-3268	172	31	value	value	NOUN
ajlsi-3268	172	32	represents	represent	VERB
ajlsi-3268	172	33	a	a	DET
ajlsi-3268	172	34	successful	successful	ADJ
ajlsi-3268	172	35	division	division	NOUN
ajlsi-3268	172	36	.	.	PUNCT
ajlsi-3268	173	1	evaluation	evaluation	NOUN
ajlsi-3268	173	2	of	of	ADP
ajlsi-3268	173	3	the	the	DET
ajlsi-3268	173	4	assays	assay	NOUN
ajlsi-3268	173	5	shows	show	VERB
ajlsi-3268	173	6	that	that	SCONJ
ajlsi-3268	173	7	treatment	treatment	NOUN
ajlsi-3268	173	8	of	of	ADP
ajlsi-3268	173	9	healthy	healthy	ADJ
ajlsi-3268	173	10	and	and	CCONJ
ajlsi-3268	173	11	patient	patient	ADJ
ajlsi-3268	173	12	groups	group	NOUN
ajlsi-3268	173	13	with	with	ADP
ajlsi-3268	173	14	secukinumab	secukinumab	NOUN
ajlsi-3268	173	15	in	in	ADP
ajlsi-3268	173	16	both	both	DET
ajlsi-3268	173	17	forms	form	NOUN
ajlsi-3268	173	18	did	do	AUX
ajlsi-3268	173	19	not	not	PART
ajlsi-3268	173	20	induce	induce	VERB
ajlsi-3268	173	21	a	a	DET
ajlsi-3268	173	22	significant	significant	ADJ
ajlsi-3268	173	23	number	number	NOUN
ajlsi-3268	173	24	of	of	ADP
ajlsi-3268	173	25	mni	mni	PROPN
ajlsi-3268	173	26	in	in	ADP
ajlsi-3268	173	27	binc	binc	NOUN
ajlsi-3268	173	28	at	at	ADP
ajlsi-3268	173	29	basal	basal	ADJ
ajlsi-3268	173	30	levels	level	NOUN
ajlsi-3268	173	31	.	.	PUNCT
ajlsi-3268	174	1	however	however	ADV
ajlsi-3268	174	2	,	,	PUNCT
ajlsi-3268	174	3	when	when	SCONJ
ajlsi-3268	174	4	2.1μg	2.1μg	NUM
ajlsi-3268	174	5	/	/	SYM
ajlsi-3268	174	6	ml	ml	NOUN
ajlsi-3268	174	7	of	of	ADP
ajlsi-3268	174	8	the	the	DET
ajlsi-3268	174	9	drug	drug	NOUN
ajlsi-3268	174	10	was	be	AUX
ajlsi-3268	174	11	co	co	VERB
ajlsi-3268	174	12	-	-	VERB
ajlsi-3268	174	13	treated	treat	VERB
ajlsi-3268	174	14	with	with	ADP
ajlsi-3268	174	15	h2o2	h2o2	NOUN
ajlsi-3268	174	16	,	,	PUNCT
ajlsi-3268	174	17	secukinumab	secukinumab	NOUN
ajlsi-3268	174	18	provided	provide	VERB
ajlsi-3268	174	19	substantial	substantial	ADJ
ajlsi-3268	174	20	protection	protection	NOUN
ajlsi-3268	174	21	against	against	ADP
ajlsi-3268	174	22	h2o2	h2o2	ADV
ajlsi-3268	174	23	-	-	ADJ
ajlsi-3268	174	24	induced	induced	ADJ
ajlsi-3268	174	25	damage	damage	NOUN
ajlsi-3268	174	26	and	and	CCONJ
ajlsi-3268	174	27	reduced	reduce	VERB
ajlsi-3268	174	28	the	the	DET
ajlsi-3268	174	29	frequency	frequency	NOUN
ajlsi-3268	174	30	of	of	ADP
ajlsi-3268	174	31	mni	mni	PROPN
ajlsi-3268	174	32	in	in	ADP
ajlsi-3268	174	33	healthy	healthy	ADJ
ajlsi-3268	174	34	binc	binc	PROPN
ajlsi-3268	174	35	.	.	PUNCT
ajlsi-3268	175	1	a	a	DET
ajlsi-3268	175	2	significantly	significantly	ADV
ajlsi-3268	175	3	raised	raise	VERB
ajlsi-3268	175	4	number	number	NOUN
ajlsi-3268	175	5	of	of	ADP
ajlsi-3268	175	6	mni	mni	PROPN
ajlsi-3268	175	7	were	be	AUX
ajlsi-3268	175	8	observed	observe	VERB
ajlsi-3268	175	9	in	in	ADP
ajlsi-3268	175	10	mono	mono	PROPN
ajlsi-3268	175	11	nc	nc	PROPN
ajlsi-3268	175	12	of	of	ADP
ajlsi-3268	175	13	the	the	DET
ajlsi-3268	175	14	patient	patient	NOUN
ajlsi-3268	175	15	group	group	NOUN
ajlsi-3268	175	16	compared	compare	VERB
ajlsi-3268	175	17	to	to	ADP
ajlsi-3268	175	18	healthy	healthy	ADJ
ajlsi-3268	175	19	individuals	individual	NOUN
ajlsi-3268	175	20	,	,	PUNCT
ajlsi-3268	175	21	which	which	PRON
ajlsi-3268	175	22	indicates	indicate	VERB
ajlsi-3268	175	23	pre	pre	NOUN
ajlsi-3268	175	24	-	-	NOUN
ajlsi-3268	175	25	existence	existence	NOUN
ajlsi-3268	175	26	of	of	ADP
ajlsi-3268	175	27	dna	dna	NOUN
ajlsi-3268	175	28	and	and	CCONJ
ajlsi-3268	175	29	chromosomal	chromosomal	ADJ
ajlsi-3268	175	30	damage	damage	NOUN
ajlsi-3268	175	31	due	due	ADP
ajlsi-3268	175	32	to	to	ADP
ajlsi-3268	175	33	the	the	DET
ajlsi-3268	175	34	disease	disease	NOUN
ajlsi-3268	175	35	state	state	NOUN
ajlsi-3268	175	36	,	,	PUNCT
ajlsi-3268	175	37	medications	medication	NOUN
ajlsi-3268	175	38	or	or	CCONJ
ajlsi-3268	175	39	other	other	ADJ
ajlsi-3268	175	40	confounding	confound	VERB
ajlsi-3268	175	41	factors	factor	NOUN
ajlsi-3268	175	42	.	.	PUNCT
ajlsi-3268	176	1	secukinumab	secukinumab	NOUN
ajlsi-3268	176	2	2.1μg	2.1μg	NUM
ajlsi-3268	176	3	/	/	SYM
ajlsi-3268	176	4	ml	ml	NOUN
ajlsi-3268	176	5	re	re	VERB
ajlsi-3268	176	6	-	-	VERB
ajlsi-3268	176	7	duced	duce	VERB
ajlsi-3268	176	8	the	the	DET
ajlsi-3268	176	9	frequency	frequency	NOUN
ajlsi-3268	176	10	of	of	ADP
ajlsi-3268	176	11	mni	mni	PROPN
ajlsi-3268	176	12	in	in	ADP
ajlsi-3268	176	13	mononc	mononc	ADV
ajlsi-3268	176	14	of	of	ADP
ajlsi-3268	176	15	the	the	DET
ajlsi-3268	176	16	patient	patient	ADJ
ajlsi-3268	176	17	group	group	NOUN
ajlsi-3268	176	18	at	at	ADP
ajlsi-3268	176	19	a	a	DET
ajlsi-3268	176	20	basal	basal	ADJ
ajlsi-3268	176	21	level	level	NOUN
ajlsi-3268	176	22	.	.	PUNCT
ajlsi-3268	177	1	however	however	ADV
ajlsi-3268	177	2	,	,	PUNCT
ajlsi-3268	177	3	the	the	DET
ajlsi-3268	177	4	results	result	NOUN
ajlsi-3268	177	5	were	be	AUX
ajlsi-3268	177	6	not	not	PART
ajlsi-3268	177	7	statistically	statistically	ADV
ajlsi-3268	177	8	significant	significant	ADJ
ajlsi-3268	177	9	.	.	PUNCT
ajlsi-3268	178	1	the	the	DET
ajlsi-3268	178	2	consistency	consistency	NOUN
ajlsi-3268	178	3	of	of	ADP
ajlsi-3268	178	4	the	the	DET
ajlsi-3268	178	5	data	data	NOUN
ajlsi-3268	178	6	suggests	suggest	VERB
ajlsi-3268	178	7	that	that	SCONJ
ajlsi-3268	178	8	con	con	NOUN
ajlsi-3268	178	9	-	-	PUNCT
ajlsi-3268	178	10	founding	found	VERB
ajlsi-3268	178	11	factors	factor	NOUN
ajlsi-3268	178	12	were	be	AUX
ajlsi-3268	178	13	not	not	PART
ajlsi-3268	178	14	an	an	DET
ajlsi-3268	178	15	issue	issue	NOUN
ajlsi-3268	178	16	.	.	PUNCT
ajlsi-3268	179	1	limitations	limitation	NOUN
ajlsi-3268	179	2	➢	➢	VERB
ajlsi-3268	179	3	due	due	ADP
ajlsi-3268	179	4	to	to	ADP
ajlsi-3268	179	5	differing	differing	ADJ
ajlsi-3268	179	6	degrees	degree	NOUN
ajlsi-3268	179	7	of	of	ADP
ajlsi-3268	179	8	safety	safety	NOUN
ajlsi-3268	179	9	and	and	CCONJ
ajlsi-3268	179	10	efficacy	efficacy	NOUN
ajlsi-3268	179	11	,	,	PUNCT
ajlsi-3268	179	12	standardizing	standardize	VERB
ajlsi-3268	179	13	liposomal	liposomal	ADJ
ajlsi-3268	179	14	and	and	CCONJ
ajlsi-3268	179	15	bulk	bulk	NOUN
ajlsi-3268	179	16	secukinumab	secukinumab	NOUN
ajlsi-3268	179	17	formulations	formulation	NOUN
ajlsi-3268	179	18	and	and	CCONJ
ajlsi-3268	179	19	dosages	dosage	NOUN
ajlsi-3268	179	20	is	be	AUX
ajlsi-3268	179	21	essential	essential	ADJ
ajlsi-3268	179	22	to	to	ADP
ajlsi-3268	179	23	maintaining	maintain	VERB
ajlsi-3268	179	24	similar	similar	ADJ
ajlsi-3268	179	25	results	result	NOUN
ajlsi-3268	179	26	throughout	throughout	ADP
ajlsi-3268	179	27	investigations	investigation	NOUN
ajlsi-3268	179	28	.	.	PUNCT
ajlsi-3268	180	1	➢	➢	VERB
ajlsi-3268	180	2	the	the	DET
ajlsi-3268	180	3	liposomal	liposomal	NOUN
ajlsi-3268	180	4	and	and	CCONJ
ajlsi-3268	180	5	bulk	bulk	ADJ
ajlsi-3268	180	6	medication	medication	NOUN
ajlsi-3268	180	7	secukinumab	secukinumab	NOUN
ajlsi-3268	180	8	may	may	AUX
ajlsi-3268	180	9	protect	protect	VERB
ajlsi-3268	180	10	against	against	ADP
ajlsi-3268	180	11	oxidative	oxidative	ADJ
ajlsi-3268	180	12	stress	stress	NOUN
ajlsi-3268	180	13	,	,	PUNCT
ajlsi-3268	180	14	but	but	CCONJ
ajlsi-3268	180	15	more	more	ADJ
ajlsi-3268	180	16	research	research	NOUN
ajlsi-3268	180	17	is	be	AUX
ajlsi-3268	180	18	necessary	necessary	ADJ
ajlsi-3268	180	19	to	to	PART
ajlsi-3268	180	20	assess	assess	VERB
ajlsi-3268	180	21	any	any	DET
ajlsi-3268	180	22	possible	possible	ADJ
ajlsi-3268	180	23	off	off	ADP
ajlsi-3268	180	24	-	-	PUNCT
ajlsi-3268	180	25	target	target	NOUN
ajlsi-3268	180	26	effects	effect	NOUN
ajlsi-3268	180	27	and	and	CCONJ
ajlsi-3268	180	28	determine	determine	VERB
ajlsi-3268	180	29	the	the	DET
ajlsi-3268	180	30	treatment	treatment	NOUN
ajlsi-3268	180	31	’s	’s	PART
ajlsi-3268	180	32	overall	overall	ADJ
ajlsi-3268	180	33	risk	risk	NOUN
ajlsi-3268	180	34	-	-	PUNCT
ajlsi-3268	180	35	benefit	benefit	NOUN
ajlsi-3268	180	36	profile	profile	NOUN
ajlsi-3268	180	37	.	.	PUNCT
ajlsi-3268	181	1	conclusion	conclusion	NOUN
ajlsi-3268	181	2	the	the	DET
ajlsi-3268	181	3	aim	aim	NOUN
ajlsi-3268	181	4	of	of	ADP
ajlsi-3268	181	5	this	this	DET
ajlsi-3268	181	6	study	study	NOUN
ajlsi-3268	181	7	was	be	AUX
ajlsi-3268	181	8	to	to	PART
ajlsi-3268	181	9	investigate	investigate	VERB
ajlsi-3268	181	10	the	the	DET
ajlsi-3268	181	11	effect	effect	NOUN
ajlsi-3268	181	12	of	of	ADP
ajlsi-3268	181	13	secukinumab	secukinumab	NOUN
ajlsi-3268	181	14	,	,	PUNCT
ajlsi-3268	181	15	in	in	ADP
ajlsi-3268	181	16	both	both	CCONJ
ajlsi-3268	181	17	liposomal	liposomal	ADJ
ajlsi-3268	181	18	and	and	CCONJ
ajlsi-3268	181	19	non	non	ADJ
ajlsi-3268	181	20	-	-	ADJ
ajlsi-3268	181	21	liposomal	liposomal	ADJ
ajlsi-3268	181	22	forms	form	NOUN
ajlsi-3268	181	23	,	,	PUNCT
ajlsi-3268	181	24	on	on	ADP
ajlsi-3268	181	25	dna	dna	PROPN
ajlsi-3268	181	26	damage	damage	NOUN
ajlsi-3268	181	27	in	in	ADP
ajlsi-3268	181	28	healthy	healthy	ADJ
ajlsi-3268	181	29	individuals	individual	NOUN
ajlsi-3268	181	30	and	and	CCONJ
ajlsi-3268	181	31	psoriasis	psoriasis	NOUN
ajlsi-3268	181	32	patients	patient	NOUN
ajlsi-3268	181	33	.	.	PUNCT
ajlsi-3268	182	1	despite	despite	SCONJ
ajlsi-3268	182	2	higher	high	ADJ
ajlsi-3268	182	3	levels	level	NOUN
ajlsi-3268	182	4	of	of	ADP
ajlsi-3268	182	5	damage	damage	NOUN
ajlsi-3268	182	6	in	in	ADP
ajlsi-3268	182	7	the	the	DET
ajlsi-3268	182	8	sick	sick	ADJ
ajlsi-3268	182	9	group	group	NOUN
ajlsi-3268	182	10	compared	compare	VERB
ajlsi-3268	182	11	to	to	ADP
ajlsi-3268	182	12	the	the	DET
ajlsi-3268	182	13	healthy	healthy	ADJ
ajlsi-3268	182	14	group	group	NOUN
ajlsi-3268	182	15	,	,	PUNCT
ajlsi-3268	182	16	secukinumab	secukinumab	NOUN
ajlsi-3268	182	17	significantly	significantly	ADV
ajlsi-3268	182	18	reduced	reduce	VERB
ajlsi-3268	182	19	h2o2	h2o2	ADV
ajlsi-3268	182	20	-	-	ADJ
ajlsi-3268	182	21	induced	induced	ADJ
ajlsi-3268	182	22	dna	dna	NOUN
ajlsi-3268	182	23	damage	damage	NOUN
ajlsi-3268	182	24	in	in	ADP
ajlsi-3268	182	25	the	the	DET
ajlsi-3268	182	26	presence	presence	NOUN
ajlsi-3268	182	27	of	of	ADP
ajlsi-3268	182	28	h2o2	h2o2	NOUN
ajlsi-3268	182	29	,	,	PUNCT
ajlsi-3268	182	30	attenuating	attenuate	VERB
ajlsi-3268	182	31	its	its	PRON
ajlsi-3268	182	32	harmful	harmful	ADJ
ajlsi-3268	182	33	effects	effect	NOUN
ajlsi-3268	182	34	.	.	PUNCT
ajlsi-3268	183	1	the	the	DET
ajlsi-3268	183	2	results	result	NOUN
ajlsi-3268	183	3	were	be	AUX
ajlsi-3268	183	4	consistent	consistent	ADJ
ajlsi-3268	183	5	across	across	ADP
ajlsi-3268	183	6	the	the	DET
ajlsi-3268	183	7	comet	comet	NOUN
ajlsi-3268	183	8	and	and	CCONJ
ajlsi-3268	183	9	micronucleus	micronucleus	ADJ
ajlsi-3268	183	10	assays	assay	NOUN
ajlsi-3268	183	11	,	,	PUNCT
ajlsi-3268	183	12	with	with	ADP
ajlsi-3268	183	13	secukinumab	secukinumab	NOUN
ajlsi-3268	183	14	2.1μg	2.1μg	NUM
ajlsi-3268	183	15	/	/	SYM
ajlsi-3268	183	16	ml	ml	ADV
ajlsi-3268	183	17	demonstrating	demonstrate	VERB
ajlsi-3268	183	18	enhanced	enhanced	ADJ
ajlsi-3268	183	19	efficacy	efficacy	NOUN
ajlsi-3268	183	20	against	against	ADP
ajlsi-3268	183	21	h2o2	h2o2	NOUN
ajlsi-3268	183	22	-	-	PUNCT
ajlsi-3268	183	23	mediated	mediate	VERB
ajlsi-3268	183	24	dna	dna	NOUN
ajlsi-3268	183	25	damage	damage	NOUN
ajlsi-3268	183	26	.	.	PUNCT
ajlsi-3268	184	1	according	accord	VERB
ajlsi-3268	184	2	to	to	ADP
ajlsi-3268	184	3	the	the	DET
ajlsi-3268	184	4	study	study	NOUN
ajlsi-3268	184	5	,	,	PUNCT
ajlsi-3268	184	6	both	both	DET
ajlsi-3268	184	7	types	type	NOUN
ajlsi-3268	184	8	of	of	ADP
ajlsi-3268	184	9	secukinumab	secukinumab	NOUN
ajlsi-3268	184	10	have	have	VERB
ajlsi-3268	184	11	the	the	DET
ajlsi-3268	184	12	ability	ability	NOUN
ajlsi-3268	184	13	to	to	PART
ajlsi-3268	184	14	protect	protect	VERB
ajlsi-3268	184	15	against	against	ADP
ajlsi-3268	184	16	oxidative	oxidative	ADJ
ajlsi-3268	184	17	stress	stress	NOUN
ajlsi-3268	184	18	caused	cause	VERB
ajlsi-3268	184	19	by	by	ADP
ajlsi-3268	184	20	h2o2	h2o2	PROPN
ajlsi-3268	184	21	,	,	PUNCT
ajlsi-3268	184	22	which	which	PRON
ajlsi-3268	184	23	may	may	AUX
ajlsi-3268	184	24	help	help	VERB
ajlsi-3268	184	25	with	with	ADP
ajlsi-3268	184	26	repair	repair	NOUN
ajlsi-3268	184	27	without	without	ADP
ajlsi-3268	184	28	having	have	VERB
ajlsi-3268	184	29	a	a	DET
ajlsi-3268	184	30	major	major	ADJ
ajlsi-3268	184	31	negative	negative	ADJ
ajlsi-3268	184	32	impact	impact	NOUN
ajlsi-3268	184	33	on	on	ADP
ajlsi-3268	184	34	geno	geno	NOUN
ajlsi-3268	184	35	toxicity	toxicity	NOUN
ajlsi-3268	184	36	.	.	PUNCT
ajlsi-3268	185	1	furthermore	furthermore	ADV
ajlsi-3268	185	2	,	,	PUNCT
ajlsi-3268	185	3	the	the	DET
ajlsi-3268	185	4	liposomal	liposomal	ADJ
ajlsi-3268	185	5	form	form	NOUN
ajlsi-3268	185	6	of	of	ADP
ajlsi-3268	185	7	the	the	DET
ajlsi-3268	185	8	drug	drug	NOUN
ajlsi-3268	185	9	was	be	AUX
ajlsi-3268	185	10	found	find	VERB
ajlsi-3268	185	11	to	to	PART
ajlsi-3268	185	12	be	be	AUX
ajlsi-3268	185	13	safe	safe	ADJ
ajlsi-3268	185	14	for	for	ADP
ajlsi-3268	185	15	localized	localized	ADJ
ajlsi-3268	185	16	treatment	treatment	NOUN
ajlsi-3268	185	17	via	via	ADP
ajlsi-3268	185	18	subcutaneous	subcutaneous	ADJ
ajlsi-3268	185	19	injection	injection	NOUN
ajlsi-3268	185	20	or	or	CCONJ
ajlsi-3268	185	21	transdermal	transdermal	ADJ
ajlsi-3268	185	22	drug	drug	NOUN
ajlsi-3268	185	23	delivery	delivery	NOUN
ajlsi-3268	185	24	preparation	preparation	NOUN
ajlsi-3268	185	25	.	.	PUNCT
ajlsi-3268	186	1	however	however	ADV
ajlsi-3268	186	2	,	,	PUNCT
ajlsi-3268	186	3	additional	additional	ADJ
ajlsi-3268	186	4	investigations	investigation	NOUN
ajlsi-3268	186	5	are	be	AUX
ajlsi-3268	186	6	required	require	VERB
ajlsi-3268	186	7	to	to	PART
ajlsi-3268	186	8	elucidate	elucidate	VERB
ajlsi-3268	186	9	other	other	ADJ
ajlsi-3268	186	10	possible	possible	ADJ
ajlsi-3268	186	11	molecular	molecular	ADJ
ajlsi-3268	186	12	mechanisms	mechanism	NOUN
ajlsi-3268	186	13	involved	involve	VERB
ajlsi-3268	186	14	.	.	PUNCT
ajlsi-3268	187	1	in	in	ADP
ajlsi-3268	187	2	conclusion	conclusion	NOUN
ajlsi-3268	187	3	,	,	PUNCT
ajlsi-3268	187	4	this	this	DET
ajlsi-3268	187	5	study	study	NOUN
ajlsi-3268	187	6	demonstrated	demonstrate	VERB
ajlsi-3268	187	7	the	the	DET
ajlsi-3268	187	8	ability	ability	NOUN
ajlsi-3268	187	9	to	to	PART
ajlsi-3268	187	10	effectively	effectively	ADV
ajlsi-3268	187	11	deliver	deliver	VERB
ajlsi-3268	187	12	secukinumab	secukinumab	NOUN
ajlsi-3268	187	13	via	via	ADP
ajlsi-3268	187	14	liposomes	liposome	NOUN
ajlsi-3268	187	15	,	,	PUNCT
ajlsi-3268	187	16	which	which	PRON
ajlsi-3268	187	17	may	may	AUX
ajlsi-3268	187	18	have	have	VERB
ajlsi-3268	187	19	clinical	clinical	ADJ
ajlsi-3268	187	20	applications	application	NOUN
ajlsi-3268	187	21	.	.	PUNCT
ajlsi-3268	188	1	these	these	DET
ajlsi-3268	188	2	results	result	NOUN
ajlsi-3268	188	3	highlight	highlight	VERB
ajlsi-3268	188	4	the	the	DET
ajlsi-3268	188	5	potential	potential	NOUN
ajlsi-3268	188	6	of	of	ADP
ajlsi-3268	188	7	secukinumab	secukinumab	NOUN
ajlsi-3268	188	8	to	to	PART
ajlsi-3268	188	9	serve	serve	VERB
ajlsi-3268	188	10	as	as	ADP
ajlsi-3268	188	11	a	a	DET
ajlsi-3268	188	12	protective	protective	ADJ
ajlsi-3268	188	13	agent	agent	NOUN
ajlsi-3268	188	14	against	against	ADP
ajlsi-3268	188	15	oxidative	oxidative	ADJ
ajlsi-3268	188	16	stress	stress	NOUN
ajlsi-3268	188	17	-	-	PUNCT
ajlsi-3268	188	18	induced	induce	VERB
ajlsi-3268	188	19	dna	dna	PROPN
ajlsi-3268	188	20	dam	dam	NOUN
ajlsi-3268	188	21	-	-	NOUN
ajlsi-3268	188	22	age	age	NOUN
ajlsi-3268	188	23	.	.	PUNCT
ajlsi-3268	189	1	overall	overall	ADV
ajlsi-3268	189	2	,	,	PUNCT
ajlsi-3268	189	3	this	this	DET
ajlsi-3268	189	4	study	study	NOUN
ajlsi-3268	189	5	provides	provide	VERB
ajlsi-3268	189	6	valuable	valuable	ADJ
ajlsi-3268	189	7	insight	insight	NOUN
ajlsi-3268	189	8	into	into	ADP
ajlsi-3268	189	9	the	the	DET
ajlsi-3268	189	10	effects	effect	NOUN
ajlsi-3268	189	11	of	of	ADP
ajlsi-3268	189	12	secukinumab	secukinumab	NOUN
ajlsi-3268	189	13	on	on	ADP
ajlsi-3268	189	14	dna	dna	PROPN
ajlsi-3268	189	15	damage	damage	NOUN
ajlsi-3268	189	16	and	and	CCONJ
ajlsi-3268	189	17	its	its	PRON
ajlsi-3268	189	18	potential	potential	ADJ
ajlsi-3268	189	19	clinical	clinical	ADJ
ajlsi-3268	189	20	applications	application	NOUN
ajlsi-3268	189	21	.	.	PUNCT
ajlsi-3268	190	1	pa	pa	PROPN
ajlsi-3268	190	2	ge	ge	PROPN
ajlsi-3268	190	3	34	34	NUM
ajlsi-3268	190	4	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-3268	190	5	am	am	NOUN
ajlsi-3268	190	6	.	.	PUNCT
ajlsi-3268	191	1	j.	j.	PROPN
ajlsi-3268	191	2	life	life	PROPN
ajlsi-3268	191	3	sci	sci	PROPN
ajlsi-3268	191	4	.	.	PUNCT
ajlsi-3268	191	5	innov	innov	PROPN
ajlsi-3268	191	6	.	.	PUNCT
ajlsi-3268	192	1	4(1	4(1	NOUN
ajlsi-3268	192	2	)	)	PUNCT
ajlsi-3268	193	1	27	27	NUM
ajlsi-3268	193	2	-	-	SYM
ajlsi-3268	193	3	35	35	NUM
ajlsi-3268	193	4	,	,	PUNCT
ajlsi-3268	193	5	2025	2025	NUM
ajlsi-3268	193	6	recommendations	recommendation	NOUN
ajlsi-3268	193	7	➢	➢	VERB
ajlsi-3268	193	8	extensive	extensive	ADJ
ajlsi-3268	193	9	research	research	NOUN
ajlsi-3268	193	10	ought	ought	AUX
ajlsi-3268	193	11	to	to	PART
ajlsi-3268	193	12	appraise	appraise	VERB
ajlsi-3268	193	13	secukinumab	secukinumab	NOUN
ajlsi-3268	193	14	’s	’s	PART
ajlsi-3268	193	15	enduring	endure	VERB
ajlsi-3268	193	16	impacts	impact	NOUN
ajlsi-3268	193	17	on	on	ADP
ajlsi-3268	193	18	oxidative	oxidative	ADJ
ajlsi-3268	193	19	stress	stress	NOUN
ajlsi-3268	193	20	and	and	CCONJ
ajlsi-3268	193	21	geno	geno	NOUN
ajlsi-3268	193	22	toxicity	toxicity	NOUN
ajlsi-3268	193	23	in	in	ADP
ajlsi-3268	193	24	order	order	NOUN
ajlsi-3268	193	25	to	to	PART
ajlsi-3268	193	26	appraise	appraise	VERB
ajlsi-3268	193	27	its	its	PRON
ajlsi-3268	193	28	resilience	resilience	NOUN
ajlsi-3268	193	29	and	and	CCONJ
ajlsi-3268	193	30	possible	possible	ADJ
ajlsi-3268	193	31	unfavorable	unfavorable	ADJ
ajlsi-3268	193	32	consequences	consequence	NOUN
ajlsi-3268	193	33	in	in	ADP
ajlsi-3268	193	34	the	the	DET
ajlsi-3268	193	35	long	long	ADJ
ajlsi-3268	193	36	run	run	NOUN
ajlsi-3268	193	37	.	.	PUNCT
ajlsi-3268	194	1	➢	➢	VERB
ajlsi-3268	194	2	large	large	ADJ
ajlsi-3268	194	3	-	-	PUNCT
ajlsi-3268	194	4	scale	scale	NOUN
ajlsi-3268	194	5	clinical	clinical	ADJ
ajlsi-3268	194	6	trials	trial	NOUN
ajlsi-3268	194	7	involving	involve	VERB
ajlsi-3268	194	8	human	human	ADJ
ajlsi-3268	194	9	participants	participant	NOUN
ajlsi-3268	194	10	are	be	AUX
ajlsi-3268	194	11	required	require	VERB
ajlsi-3268	194	12	for	for	ADP
ajlsi-3268	194	13	further	further	ADJ
ajlsi-3268	194	14	research	research	NOUN
ajlsi-3268	194	15	studies	study	NOUN
ajlsi-3268	194	16	to	to	PART
ajlsi-3268	194	17	evaluate	evaluate	VERB
ajlsi-3268	194	18	secukinumab	secukinumab	NOUN
ajlsi-3268	194	19	’s	’s	PART
ajlsi-3268	194	20	efficacy	efficacy	NOUN
ajlsi-3268	194	21	,	,	PUNCT
ajlsi-3268	194	22	safety	safety	NOUN
ajlsi-3268	194	23	,	,	PUNCT
ajlsi-3268	194	24	and	and	CCONJ
ajlsi-3268	194	25	tolerability	tolerability	NOUN
ajlsi-3268	194	26	in	in	ADP
ajlsi-3268	194	27	a	a	DET
ajlsi-3268	194	28	range	range	NOUN
ajlsi-3268	194	29	of	of	ADP
ajlsi-3268	194	30	patient	patient	ADJ
ajlsi-3268	194	31	populations	population	NOUN
ajlsi-3268	194	32	.	.	PUNCT
ajlsi-3268	195	1	acknowledgement	acknowledgement	NOUN
ajlsi-3268	195	2	authors	author	NOUN
ajlsi-3268	195	3	are	be	AUX
ajlsi-3268	195	4	thankful	thankful	ADJ
ajlsi-3268	195	5	to	to	ADP
ajlsi-3268	195	6	university	university	PROPN
ajlsi-3268	195	7	of	of	ADP
ajlsi-3268	195	8	bradford	bradford	PROPN
ajlsi-3268	195	9	,	,	PUNCT
ajlsi-3268	195	10	for	for	ADP
ajlsi-3268	195	11	their	their	PRON
ajlsi-3268	195	12	continued	continue	VERB
ajlsi-3268	195	13	support	support	NOUN
ajlsi-3268	195	14	in	in	ADP
ajlsi-3268	195	15	this	this	DET
ajlsi-3268	195	16	research	research	NOUN
ajlsi-3268	195	17	work	work	NOUN
ajlsi-3268	195	18	.	.	PUNCT
ajlsi-3268	196	1	authors	author	NOUN
ajlsi-3268	196	2	contribution	contribution	VERB
ajlsi-3268	196	3	all	all	DET
ajlsi-3268	196	4	authors	author	NOUN
ajlsi-3268	196	5	contributed	contribute	VERB
ajlsi-3268	196	6	to	to	ADP
ajlsi-3268	196	7	the	the	DET
ajlsi-3268	196	8	study	study	NOUN
ajlsi-3268	196	9	conception	conception	NOUN
ajlsi-3268	196	10	and	and	CCONJ
ajlsi-3268	196	11	design	design	NOUN
ajlsi-3268	196	12	.	.	PUNCT
ajlsi-3268	197	1	g.	g.	PROPN
ajlsi-3268	197	2	layas	layas	PROPN
ajlsi-3268	197	3	&	&	CCONJ
ajlsi-3268	197	4	m.	m.	PROPN
ajlsi-3268	197	5	isreb	isreb	PROPN
ajlsi-3268	197	6	n.	n.	PROPN
ajlsi-3268	197	7	ghaderi	ghaderi	PROPN
ajlsi-3268	197	8	&	&	CCONJ
ajlsi-3268	197	9	fanila	fanila	PROPN
ajlsi-3268	197	10	:	:	PUNCT
ajlsi-3268	197	11	conceptualization	conceptualization	NOUN
ajlsi-3268	197	12	,	,	PUNCT
ajlsi-3268	197	13	methodology	methodology	NOUN
ajlsi-3268	197	14	including	include	VERB
ajlsi-3268	197	15	ethica	ethica	PROPN
ajlsi-3268	197	16	approval	approval	NOUN
ajlsi-3268	197	17	,	,	PUNCT
ajlsi-3268	197	18	samples	sample	VERB
ajlsi-3268	197	19	collections	collection	NOUN
ajlsi-3268	197	20	and	and	CCONJ
ajlsi-3268	197	21	statistical	statistical	ADJ
ajlsi-3268	197	22	analysis	analysis	NOUN
ajlsi-3268	197	23	;	;	PUNCT
ajlsi-3268	197	24	p.	p.	NOUN
ajlsi-3268	197	25	akhbari	akhbari	NOUN
ajlsi-3268	197	26	,	,	PUNCT
ajlsi-3268	197	27	d.	d.	PROPN
ajlsi-3268	197	28	andreson	andreson	PROPN
ajlsi-3268	197	29	:	:	PUNCT
ajlsi-3268	197	30	analytical	analytical	ADJ
ajlsi-3268	197	31	interpretation	interpretation	NOUN
ajlsi-3268	197	32	;	;	PUNCT
ajlsi-3268	197	33	a.	a.	PROPN
ajlsi-3268	197	34	wright	wright	PROPN
ajlsi-3268	197	35	&	&	CCONJ
ajlsi-3268	197	36	m.	m.	PROPN
ajlsi-3268	197	37	najafzadeh	najafzadeh	PROPN
ajlsi-3268	197	38	:	:	PUNCT
ajlsi-3268	197	39	research	research	NOUN
ajlsi-3268	197	40	discussion	discussion	NOUN
ajlsi-3268	197	41	and	and	CCONJ
ajlsi-3268	197	42	review	review	NOUN
ajlsi-3268	197	43	.	.	PUNCT
ajlsi-3268	198	1	abbreviations	abbreviation	NOUN
ajlsi-3268	198	2	cho	cho	PROPN
ajlsi-3268	198	3	chinese	chinese	ADJ
ajlsi-3268	198	4	hamster	hamster	PROPN
ajlsi-3268	198	5	ovary	ovary	ADJ
ajlsi-3268	198	6	cells	cell	NOUN
ajlsi-3268	198	7	chol	chol	VERB
ajlsi-3268	198	8	cholesterol	cholesterol	NOUN
ajlsi-3268	198	9	cbmn	cbmn	NOUN
ajlsi-3268	198	10	cytokinesis	cytokinesis	NOUN
ajlsi-3268	198	11	-	-	PUNCT
ajlsi-3268	198	12	block	block	NOUN
ajlsi-3268	198	13	micronucleus	micronucleus	PROPN
ajlsi-3268	198	14	dcm	dcm	PROPN
ajlsi-3268	198	15	methanol	methanol	NOUN
ajlsi-3268	198	16	dichloromethane	dichloromethane	NOUN
ajlsi-3268	198	17	dope	dope	NOUN
ajlsi-3268	198	18	dioleoyl	dioleoyl	PROPN
ajlsi-3268	198	19	phsphoethanolamine	phsphoethanolamine	PROPN
ajlsi-3268	198	20	dppg	dppg	PROPN
ajlsi-3268	198	21	1,2	1,2	NUM
ajlsi-3268	198	22	-	-	PUNCT
ajlsi-3268	198	23	dipalmitoyl	dipalmitoyl	ADJ
ajlsi-3268	198	24	-	-	PUNCT
ajlsi-3268	198	25	sn	sn	NOUN
ajlsi-3268	198	26	-	-	PUNCT
ajlsi-3268	198	27	glycerol	glycerol	NOUN
ajlsi-3268	198	28	sodium	sodium	NOUN
ajlsi-3268	198	29	salt	salt	NOUN
ajlsi-3268	198	30	il-17	il-17	ADP
ajlsi-3268	198	31	interleukin	interleukin	PROPN
ajlsi-3268	198	32	17	17	NUM
ajlsi-3268	198	33	mab	mab	NOUN
ajlsi-3268	198	34	monoclonal	monoclonal	NOUN
ajlsi-3268	198	35	antibody	antibody	NOUN
ajlsi-3268	198	36	psai	psai	NOUN
ajlsi-3268	198	37	psoriasis	psoriasis	NOUN
ajlsi-3268	198	38	area	area	NOUN
ajlsi-3268	198	39	and	and	CCONJ
ajlsi-3268	198	40	severity	severity	NOUN
ajlsi-3268	198	41	index	index	NOUN
ajlsi-3268	198	42	th	th	PROPN
ajlsi-3268	198	43	t	t	PROPN
ajlsi-3268	198	44	-	-	PUNCT
ajlsi-3268	198	45	helper	helper	NOUN
ajlsi-3268	198	46	cells	cell	NOUN
ajlsi-3268	198	47	tnfa	tnfa	VERB
ajlsi-3268	198	48	tumor	tumor	NOUN
ajlsi-3268	198	49	necrosis	necrosis	NOUN
ajlsi-3268	198	50	factor	factor	NOUN
ajlsi-3268	198	51	-	-	PUNCT
ajlsi-3268	198	52	alpha	alpha	NOUN
ajlsi-3268	198	53	rpmi	rpmi	NOUN
ajlsi-3268	198	54	mammalian	mammalian	ADJ
ajlsi-3268	198	55	cell	cell	NOUN
ajlsi-3268	198	56	culture	culture	NOUN
ajlsi-3268	198	57	media/	media/	PROPN
ajlsi-3268	198	58	roswell	roswell	PROPN
ajlsi-3268	198	59	park	park	PROPN
ajlsi-3268	198	60	memorial	memorial	PROPN
ajlsi-3268	198	61	institute	institute	PROPN
ajlsi-3268	198	62	references	reference	NOUN
ajlsi-3268	198	63	bagel	bagel	NOUN
ajlsi-3268	198	64	,	,	PUNCT
ajlsi-3268	198	65	j.	j.	PROPN
ajlsi-3268	198	66	,	,	PUNCT
ajlsi-3268	198	67	blauvelt	blauvelt	PROPN
ajlsi-3268	198	68	,	,	PUNCT
ajlsi-3268	198	69	a.	a.	NOUN
ajlsi-3268	198	70	,	,	PUNCT
ajlsi-3268	198	71	nia	nia	PROPN
ajlsi-3268	198	72	,	,	PUNCT
ajlsi-3268	198	73	j.	j.	PROPN
ajlsi-3268	198	74	,	,	PUNCT
ajlsi-3268	198	75	hashim	hashim	PROPN
ajlsi-3268	198	76	,	,	PUNCT
ajlsi-3268	198	77	p.	p.	NOUN
ajlsi-3268	198	78	,	,	PUNCT
ajlsi-3268	198	79	patekar	patekar	NOUN
ajlsi-3268	198	80	,	,	PUNCT
ajlsi-3268	198	81	m.	m.	NOUN
ajlsi-3268	198	82	,	,	PUNCT
ajlsi-3268	198	83	de	de	PROPN
ajlsi-3268	198	84	vera	vera	NOUN
ajlsi-3268	198	85	,	,	PUNCT
ajlsi-3268	198	86	a.	a.	NOUN
ajlsi-3268	198	87	(	(	PUNCT
ajlsi-3268	198	88	2021	2021	NUM
ajlsi-3268	198	89	)	)	PUNCT
ajlsi-3268	198	90	.	.	PUNCT
ajlsi-3268	199	1	secukinumab	secukinumab	PROPN
ajlsi-3268	199	2	maintains	maintain	VERB
ajlsi-3268	199	3	superiority	superiority	NOUN
ajlsi-3268	199	4	over	over	ADP
ajlsi-3268	199	5	ustekinumab	ustekinumab	NOUN
ajlsi-3268	199	6	in	in	ADP
ajlsi-3268	199	7	clearing	clear	VERB
ajlsi-3268	199	8	skin	skin	NOUN
ajlsi-3268	199	9	and	and	CCONJ
ajlsi-3268	199	10	improving	improve	VERB
ajlsi-3268	199	11	quality	quality	NOUN
ajlsi-3268	199	12	of	of	ADP
ajlsi-3268	199	13	life	life	NOUN
ajlsi-3268	199	14	in	in	ADP
ajlsi-3268	199	15	patients	patient	NOUN
ajlsi-3268	199	16	with	with	ADP
ajlsi-3268	199	17	moderate	moderate	ADJ
ajlsi-3268	199	18	to	to	ADP
ajlsi-3268	199	19	severe	severe	ADJ
ajlsi-3268	199	20	plaque	plaque	NOUN
ajlsi-3268	199	21	psoriasis	psoriasis	NOUN
ajlsi-3268	199	22	:	:	PUNCT
ajlsi-3268	199	23	52	52	NUM
ajlsi-3268	199	24	-	-	PUNCT
ajlsi-3268	199	25	week	week	NOUN
ajlsi-3268	199	26	results	result	NOUN
ajlsi-3268	199	27	from	from	ADP
ajlsi-3268	199	28	a	a	DET
ajlsi-3268	199	29	double	double	ADJ
ajlsi-3268	199	30	-	-	PUNCT
ajlsi-3268	199	31	blind	blind	ADJ
ajlsi-3268	199	32	phase	phase	NOUN
ajlsi-3268	199	33	3b	3b	NOUN
ajlsi-3268	199	34	trial	trial	NOUN
ajlsi-3268	199	35	(	(	PUNCT
ajlsi-3268	199	36	clarity	clarity	NOUN
ajlsi-3268	199	37	)	)	PUNCT
ajlsi-3268	199	38	.	.	PUNCT
ajlsi-3268	200	1	journal	journal	NOUN
ajlsi-3268	200	2	of	of	ADP
ajlsi-3268	200	3	the	the	DET
ajlsi-3268	200	4	european	european	PROPN
ajlsi-3268	200	5	academy	academy	PROPN
ajlsi-3268	200	6	of	of	ADP
ajlsi-3268	200	7	dermatology	dermatology	NOUN
ajlsi-3268	200	8	and	and	CCONJ
ajlsi-3268	200	9	venereology	venereology	NOUN
ajlsi-3268	200	10	,	,	PUNCT
ajlsi-3268	200	11	35(1	35(1	NUM
ajlsi-3268	200	12	)	)	PUNCT
ajlsi-3268	200	13	,	,	PUNCT
ajlsi-3268	200	14	135–142	135–142	NUM
ajlsi-3268	200	15	.	.	PUNCT
ajlsi-3268	201	1	berg	berg	PROPN
ajlsi-3268	201	2	,	,	PUNCT
ajlsi-3268	201	3	s.	s.	PROPN
ajlsi-3268	201	4	h.	h.	PROPN
ajlsi-3268	201	5	,	,	PUNCT
ajlsi-3268	201	6	balogh	balogh	PROPN
ajlsi-3268	201	7	,	,	PUNCT
ajlsi-3268	201	8	e.	e.	PROPN
ajlsi-3268	201	9	a.	a.	PROPN
ajlsi-3268	201	10	,	,	PUNCT
ajlsi-3268	201	11	ghamrawi	ghamrawi	PROPN
ajlsi-3268	201	12	,	,	PUNCT
ajlsi-3268	201	13	r.	r.	PROPN
ajlsi-3268	201	14	i.	i.	PROPN
ajlsi-3268	201	15	,	,	PUNCT
ajlsi-3268	201	16	&	&	CCONJ
ajlsi-3268	201	17	feldman	feldman	PROPN
ajlsi-3268	201	18	,	,	PUNCT
ajlsi-3268	201	19	s.	s.	PROPN
ajlsi-3268	201	20	r.	r.	PROPN
ajlsi-3268	201	21	(	(	PUNCT
ajlsi-3268	201	22	2021	2021	NUM
ajlsi-3268	201	23	)	)	PUNCT
ajlsi-3268	201	24	.	.	PUNCT
ajlsi-3268	202	1	a	a	DET
ajlsi-3268	202	2	review	review	NOUN
ajlsi-3268	202	3	of	of	ADP
ajlsi-3268	202	4	secukinumab	secukinumab	NOUN
ajlsi-3268	202	5	in	in	ADP
ajlsi-3268	202	6	psoriasis	psoriasis	NOUN
ajlsi-3268	202	7	treatment	treatment	NOUN
ajlsi-3268	202	8	.	.	PUNCT
ajlsi-3268	203	1	immunotherapy	immunotherapy	NOUN
ajlsi-3268	203	2	,	,	PUNCT
ajlsi-3268	203	3	13(3	13(3	NUM
ajlsi-3268	203	4	)	)	PUNCT
ajlsi-3268	203	5	,	,	PUNCT
ajlsi-3268	203	6	201–216	201–216	NUM
ajlsi-3268	203	7	.	.	PUNCT
ajlsi-3268	204	1	bissonnette	bissonnette	NOUN
ajlsi-3268	204	2	,	,	PUNCT
ajlsi-3268	204	3	r.	r.	PROPN
ajlsi-3268	204	4	,	,	PUNCT
ajlsi-3268	204	5	luger	luger	PROPN
ajlsi-3268	204	6	,	,	PUNCT
ajlsi-3268	204	7	t.	t.	PROPN
ajlsi-3268	204	8	,	,	PUNCT
ajlsi-3268	204	9	thaçi	thaçi	NOUN
ajlsi-3268	204	10	,	,	PUNCT
ajlsi-3268	204	11	d.	d.	PROPN
ajlsi-3268	204	12	,	,	PUNCT
ajlsi-3268	204	13	toth	toth	PROPN
ajlsi-3268	204	14	,	,	PUNCT
ajlsi-3268	204	15	d.	d.	PROPN
ajlsi-3268	204	16	,	,	PUNCT
ajlsi-3268	204	17	lacombe	lacombe	PROPN
ajlsi-3268	204	18	,	,	PUNCT
ajlsi-3268	204	19	a.	a.	PROPN
ajlsi-3268	204	20	,	,	PUNCT
ajlsi-3268	204	21	xia	xia	PROPN
ajlsi-3268	204	22	,	,	PUNCT
ajlsi-3268	204	23	s.	s.	PROPN
ajlsi-3268	204	24	(	(	PUNCT
ajlsi-3268	204	25	2018	2018	NUM
ajlsi-3268	204	26	)	)	PUNCT
ajlsi-3268	204	27	.	.	PUNCT
ajlsi-3268	205	1	secukinumab	secukinumab	NOUN
ajlsi-3268	205	2	demonstrates	demonstrate	VERB
ajlsi-3268	205	3	high	high	ADJ
ajlsi-3268	205	4	sustained	sustain	VERB
ajlsi-3268	205	5	efficacy	efficacy	NOUN
ajlsi-3268	205	6	and	and	CCONJ
ajlsi-3268	205	7	a	a	DET
ajlsi-3268	205	8	favourable	favourable	ADJ
ajlsi-3268	205	9	safety	safety	NOUN
ajlsi-3268	205	10	profile	profile	NOUN
ajlsi-3268	205	11	in	in	ADP
ajlsi-3268	205	12	patients	patient	NOUN
ajlsi-3268	205	13	with	with	ADP
ajlsi-3268	205	14	moderate‐to‐severe	moderate‐to‐severe	PROPN
ajlsi-3268	205	15	psoriasis	psoriasis	NOUN
ajlsi-3268	205	16	through	through	ADP
ajlsi-3268	205	17	5	5	NUM
ajlsi-3268	205	18	years	year	NOUN
ajlsi-3268	205	19	of	of	ADP
ajlsi-3268	205	20	treatment	treatment	NOUN
ajlsi-3268	205	21	(	(	PUNCT
ajlsi-3268	205	22	sculpture	sculpture	NOUN
ajlsi-3268	205	23	extension	extension	NOUN
ajlsi-3268	205	24	study	study	NOUN
ajlsi-3268	205	25	)	)	PUNCT
ajlsi-3268	205	26	.	.	PUNCT
ajlsi-3268	206	1	journal	journal	NOUN
ajlsi-3268	206	2	of	of	ADP
ajlsi-3268	206	3	the	the	DET
ajlsi-3268	206	4	european	european	PROPN
ajlsi-3268	206	5	academy	academy	PROPN
ajlsi-3268	206	6	of	of	ADP
ajlsi-3268	206	7	dermatology	dermatology	NOUN
ajlsi-3268	206	8	and	and	CCONJ
ajlsi-3268	206	9	venereology	venereology	NOUN
ajlsi-3268	206	10	,	,	PUNCT
ajlsi-3268	206	11	32(9	32(9	NUM
ajlsi-3268	206	12	)	)	PUNCT
ajlsi-3268	206	13	,	,	PUNCT
ajlsi-3268	206	14	1507–1514	1507–1514	NUM
ajlsi-3268	206	15	.	.	PUNCT
ajlsi-3268	207	1	bridgewood	bridgewood	PROPN
ajlsi-3268	207	2	,	,	PUNCT
ajlsi-3268	207	3	c.	c.	PROPN
ajlsi-3268	207	4	,	,	PUNCT
ajlsi-3268	207	5	wittmann	wittmann	PROPN
ajlsi-3268	207	6	,	,	PUNCT
ajlsi-3268	207	7	m.	m.	NOUN
ajlsi-3268	207	8	,	,	PUNCT
ajlsi-3268	207	9	macleod	macleod	PROPN
ajlsi-3268	207	10	,	,	PUNCT
ajlsi-3268	207	11	t.	t.	PROPN
ajlsi-3268	207	12	,	,	PUNCT
ajlsi-3268	207	13	watad	watad	PROPN
ajlsi-3268	207	14	,	,	PUNCT
ajlsi-3268	207	15	a.	a.	PROPN
ajlsi-3268	207	16	,	,	PUNCT
ajlsi-3268	207	17	newton	newton	PROPN
ajlsi-3268	207	18	,	,	PUNCT
ajlsi-3268	207	19	d.	d.	PROPN
ajlsi-3268	207	20	,	,	PUNCT
ajlsi-3268	207	21	bhan	bhan	PROPN
ajlsi-3268	207	22	,	,	PUNCT
ajlsi-3268	207	23	k.	k.	PROPN
ajlsi-3268	207	24	(	(	PUNCT
ajlsi-3268	207	25	2022	2022	NUM
ajlsi-3268	207	26	)	)	PUNCT
ajlsi-3268	207	27	.	.	PUNCT
ajlsi-3268	208	1	t	t	PROPN
ajlsi-3268	208	2	helper	helper	NOUN
ajlsi-3268	208	3	2	2	NUM
ajlsi-3268	208	4	il-4/	il-4/	NOUN
ajlsi-3268	208	5	il-13	il-13	ADP
ajlsi-3268	208	6	dual	dual	ADJ
ajlsi-3268	208	7	blockade	blockade	NOUN
ajlsi-3268	208	8	with	with	ADP
ajlsi-3268	208	9	dupilumab	dupilumab	NOUN
ajlsi-3268	208	10	is	be	AUX
ajlsi-3268	208	11	linked	link	VERB
ajlsi-3268	208	12	to	to	ADP
ajlsi-3268	208	13	some	some	DET
ajlsi-3268	208	14	emergent	emergent	NOUN
ajlsi-3268	208	15	t	t	NOUN
ajlsi-3268	208	16	helper	helper	NOUN
ajlsi-3268	208	17	17	17	NUM
ajlsi-3268	208	18	–	–	PUNCT
ajlsi-3268	208	19	type	type	NOUN
ajlsi-3268	208	20	diseases	disease	NOUN
ajlsi-3268	208	21	,	,	PUNCT
ajlsi-3268	208	22	including	include	VERB
ajlsi-3268	208	23	seronegative	seronegative	ADJ
ajlsi-3268	208	24	arthritis	arthritis	NOUN
ajlsi-3268	208	25	and	and	CCONJ
ajlsi-3268	208	26	enthesitis	enthesitis	NOUN
ajlsi-3268	208	27	/	/	SYM
ajlsi-3268	208	28	enthesopathy	enthesopathy	ADJ
ajlsi-3268	208	29	,	,	PUNCT
ajlsi-3268	208	30	but	but	CCONJ
ajlsi-3268	208	31	not	not	PART
ajlsi-3268	208	32	to	to	ADP
ajlsi-3268	208	33	humoral	humoral	ADJ
ajlsi-3268	208	34	autoimmune	autoimmune	ADJ
ajlsi-3268	208	35	diseases	disease	NOUN
ajlsi-3268	208	36	.	.	PUNCT
ajlsi-3268	209	1	journal	journal	NOUN
ajlsi-3268	209	2	of	of	ADP
ajlsi-3268	209	3	investigative	investigative	ADJ
ajlsi-3268	209	4	dermatology	dermatology	NOUN
ajlsi-3268	209	5	,	,	PUNCT
ajlsi-3268	209	6	142(10	142(10	NUM
ajlsi-3268	209	7	)	)	PUNCT
ajlsi-3268	209	8	,	,	PUNCT
ajlsi-3268	209	9	2660–2667	2660–2667	NOUN
ajlsi-3268	209	10	.	.	PUNCT
ajlsi-3268	210	1	chen	chen	PROPN
ajlsi-3268	210	2	,	,	PUNCT
ajlsi-3268	210	3	l.	l.	PROPN
ajlsi-3268	210	4	,	,	PUNCT
ajlsi-3268	210	5	deng	deng	PROPN
ajlsi-3268	210	6	,	,	PUNCT
ajlsi-3268	210	7	h.	h.	PROPN
ajlsi-3268	210	8	,	,	PUNCT
ajlsi-3268	210	9	cui	cui	PROPN
ajlsi-3268	210	10	,	,	PUNCT
ajlsi-3268	210	11	h.	h.	PROPN
ajlsi-3268	210	12	,	,	PUNCT
ajlsi-3268	210	13	fang	fang	PROPN
ajlsi-3268	210	14	,	,	PUNCT
ajlsi-3268	210	15	j.	j.	PROPN
ajlsi-3268	210	16	,	,	PUNCT
ajlsi-3268	210	17	zuo	zuo	PROPN
ajlsi-3268	210	18	,	,	PUNCT
ajlsi-3268	210	19	z.	z.	PROPN
ajlsi-3268	210	20	,	,	PUNCT
ajlsi-3268	210	21	deng	deng	PROPN
ajlsi-3268	210	22	,	,	PUNCT
ajlsi-3268	210	23	j.	j.	PROPN
ajlsi-3268	210	24	,	,	PUNCT
ajlsi-3268	210	25	...	...	PUNCT
ajlsi-3268	210	26	&	&	CCONJ
ajlsi-3268	210	27	zhao	zhao	PROPN
ajlsi-3268	210	28	,	,	PUNCT
ajlsi-3268	210	29	l.	l.	PROPN
ajlsi-3268	210	30	(	(	PUNCT
ajlsi-3268	210	31	2018	2018	NUM
ajlsi-3268	210	32	)	)	PUNCT
ajlsi-3268	210	33	.	.	PUNCT
ajlsi-3268	211	1	inflammatory	inflammatory	ADJ
ajlsi-3268	211	2	responses	response	NOUN
ajlsi-3268	211	3	and	and	CCONJ
ajlsi-3268	211	4	inflammation	inflammation	NOUN
ajlsi-3268	211	5	-	-	PUNCT
ajlsi-3268	211	6	associated	associate	VERB
ajlsi-3268	211	7	diseases	disease	NOUN
ajlsi-3268	211	8	in	in	ADP
ajlsi-3268	211	9	organs	organ	NOUN
ajlsi-3268	211	10	.	.	PUNCT
ajlsi-3268	212	1	oncotarget	oncotarget	NOUN
ajlsi-3268	212	2	,	,	PUNCT
ajlsi-3268	212	3	9(6	9(6	NUM
ajlsi-3268	212	4	)	)	PUNCT
ajlsi-3268	212	5	,	,	PUNCT
ajlsi-3268	212	6	7204–7218	7204–7218	NUM
ajlsi-3268	212	7	.	.	PUNCT
ajlsi-3268	213	1	ciążyńska	ciążyńska	PROPN
ajlsi-3268	213	2	,	,	PUNCT
ajlsi-3268	213	3	m.	m.	NOUN
ajlsi-3268	213	4	,	,	PUNCT
ajlsi-3268	213	5	olejniczak	olejniczak	NOUN
ajlsi-3268	213	6	-	-	PUNCT
ajlsi-3268	213	7	staruch	staruch	ADJ
ajlsi-3268	213	8	,	,	PUNCT
ajlsi-3268	213	9	i.	i.	NOUN
ajlsi-3268	213	10	,	,	PUNCT
ajlsi-3268	213	11	sobolewska	sobolewska	PROPN
ajlsi-3268	213	12	-	-	PUNCT
ajlsi-3268	213	13	sztychny	sztychny	PROPN
ajlsi-3268	213	14	,	,	PUNCT
ajlsi-3268	213	15	d.	d.	PROPN
ajlsi-3268	213	16	,	,	PUNCT
ajlsi-3268	213	17	narbutt	narbutt	PROPN
ajlsi-3268	213	18	,	,	PUNCT
ajlsi-3268	213	19	j.	j.	PROPN
ajlsi-3268	213	20	,	,	PUNCT
ajlsi-3268	213	21	skibińska	skibińska	NOUN
ajlsi-3268	213	22	,	,	PUNCT
ajlsi-3268	213	23	m.	m.	NOUN
ajlsi-3268	213	24	,	,	PUNCT
ajlsi-3268	213	25	&	&	CCONJ
ajlsi-3268	213	26	lesiak	lesiak	PROPN
ajlsi-3268	213	27	,	,	PUNCT
ajlsi-3268	213	28	a.	a.	NOUN
ajlsi-3268	213	29	(	(	PUNCT
ajlsi-3268	213	30	2021	2021	NUM
ajlsi-3268	213	31	)	)	PUNCT
ajlsi-3268	213	32	.	.	PUNCT
ajlsi-3268	214	1	ultraviolet	ultraviolet	ADJ
ajlsi-3268	214	2	radiation	radiation	NOUN
ajlsi-3268	214	3	and	and	CCONJ
ajlsi-3268	214	4	chronic	chronic	ADJ
ajlsi-3268	214	5	inflammation	inflammation	NOUN
ajlsi-3268	214	6	—	—	PUNCT
ajlsi-3268	214	7	molecules	molecule	NOUN
ajlsi-3268	214	8	and	and	CCONJ
ajlsi-3268	214	9	mechanisms	mechanism	NOUN
ajlsi-3268	214	10	involved	involve	VERB
ajlsi-3268	214	11	in	in	ADP
ajlsi-3268	214	12	skin	skin	NOUN
ajlsi-3268	214	13	carcinogenesis	carcinogenesis	NOUN
ajlsi-3268	214	14	:	:	PUNCT
ajlsi-3268	214	15	a	a	DET
ajlsi-3268	214	16	narrative	narrative	NOUN
ajlsi-3268	214	17	review	review	NOUN
ajlsi-3268	214	18	.	.	PUNCT
ajlsi-3268	215	1	life	life	NOUN
ajlsi-3268	215	2	,	,	PUNCT
ajlsi-3268	215	3	11(4	11(4	NUM
ajlsi-3268	215	4	)	)	PUNCT
ajlsi-3268	215	5	,	,	PUNCT
ajlsi-3268	215	6	326	326	NUM
ajlsi-3268	215	7	.	.	X
ajlsi-3268	216	1	damiani	damiani	PROPN
ajlsi-3268	216	2	,	,	PUNCT
ajlsi-3268	216	3	g.	g.	PROPN
ajlsi-3268	216	4	,	,	PUNCT
ajlsi-3268	216	5	odorici	odorici	NOUN
ajlsi-3268	216	6	,	,	PUNCT
ajlsi-3268	216	7	g.	g.	PROPN
ajlsi-3268	216	8	,	,	PUNCT
ajlsi-3268	216	9	pacifico	pacifico	PROPN
ajlsi-3268	216	10	,	,	PUNCT
ajlsi-3268	216	11	a.	a.	NOUN
ajlsi-3268	216	12	,	,	PUNCT
ajlsi-3268	216	13	morrone	morrone	NOUN
ajlsi-3268	216	14	,	,	PUNCT
ajlsi-3268	216	15	a.	a.	NOUN
ajlsi-3268	216	16	,	,	PUNCT
ajlsi-3268	216	17	conic	conic	NOUN
ajlsi-3268	216	18	,	,	PUNCT
ajlsi-3268	216	19	r.	r.	PROPN
ajlsi-3268	216	20	r.	r.	PROPN
ajlsi-3268	216	21	,	,	PUNCT
ajlsi-3268	216	22	davidson	davidson	NOUN
ajlsi-3268	216	23	,	,	PUNCT
ajlsi-3268	216	24	t.	t.	PROPN
ajlsi-3268	216	25	,	,	PUNCT
ajlsi-3268	216	26	et	et	PROPN
ajlsi-3268	216	27	al	al	PROPN
ajlsi-3268	216	28	.	.	PROPN
ajlsi-3268	216	29	(	(	PUNCT
ajlsi-3268	216	30	2022	2022	NUM
ajlsi-3268	216	31	)	)	PUNCT
ajlsi-3268	216	32	.	.	PUNCT
ajlsi-3268	217	1	secukinumab	secukinumab	PROPN
ajlsi-3268	217	2	loss	loss	PROPN
ajlsi-3268	217	3	of	of	ADP
ajlsi-3268	217	4	efficacy	efficacy	NOUN
ajlsi-3268	217	5	is	be	AUX
ajlsi-3268	217	6	perfectly	perfectly	ADV
ajlsi-3268	217	7	counteracted	counteract	VERB
ajlsi-3268	217	8	by	by	ADP
ajlsi-3268	217	9	the	the	DET
ajlsi-3268	217	10	introduction	introduction	NOUN
ajlsi-3268	217	11	of	of	ADP
ajlsi-3268	217	12	combination	combination	NOUN
ajlsi-3268	217	13	therapy	therapy	NOUN
ajlsi-3268	217	14	(	(	PUNCT
ajlsi-3268	217	15	rescue	rescue	NOUN
ajlsi-3268	217	16	therapy	therapy	NOUN
ajlsi-3268	217	17	):	):	PUNCT
ajlsi-3268	217	18	data	datum	NOUN
ajlsi-3268	217	19	from	from	ADP
ajlsi-3268	217	20	a	a	DET
ajlsi-3268	217	21	multicenter	multicenter	ADJ
ajlsi-3268	217	22	real	real	ADJ
ajlsi-3268	217	23	-	-	PUNCT
ajlsi-3268	217	24	life	life	NOUN
ajlsi-3268	217	25	study	study	NOUN
ajlsi-3268	217	26	in	in	ADP
ajlsi-3268	217	27	a	a	DET
ajlsi-3268	217	28	cohort	cohort	NOUN
ajlsi-3268	217	29	of	of	ADP
ajlsi-3268	217	30	italian	italian	ADJ
ajlsi-3268	217	31	psoriatic	psoriatic	ADJ
ajlsi-3268	217	32	patients	patient	NOUN
ajlsi-3268	217	33	that	that	PRON
ajlsi-3268	217	34	avoided	avoid	VERB
ajlsi-3268	217	35	secukinumab	secukinumab	NOUN
ajlsi-3268	217	36	switching	switching	NOUN
ajlsi-3268	217	37	.	.	PUNCT
ajlsi-3268	218	1	pharmaceuticals	pharmaceutical	NOUN
ajlsi-3268	218	2	,	,	PUNCT
ajlsi-3268	218	3	15(1	15(1	NUM
ajlsi-3268	218	4	)	)	PUNCT
ajlsi-3268	218	5	,	,	PUNCT
ajlsi-3268	218	6	95	95	NUM
ajlsi-3268	218	7	elder	elder	NOUN
ajlsi-3268	218	8	,	,	PUNCT
ajlsi-3268	218	9	j.	j.	PROPN
ajlsi-3268	218	10	t.	t.	PROPN
ajlsi-3268	218	11	(	(	PUNCT
ajlsi-3268	218	12	ed	ed	NOUN
ajlsi-3268	218	13	.	.	PUNCT
ajlsi-3268	218	14	)	)	PUNCT
ajlsi-3268	218	15	.	.	PUNCT
ajlsi-3268	219	1	(	(	PUNCT
ajlsi-3268	219	2	2018	2018	NUM
ajlsi-3268	219	3	)	)	PUNCT
ajlsi-3268	219	4	.	.	PUNCT
ajlsi-3268	220	1	expanded	expand	VERB
ajlsi-3268	220	2	genome	genome	NOUN
ajlsi-3268	220	3	-	-	PUNCT
ajlsi-3268	220	4	wide	wide	ADJ
ajlsi-3268	220	5	association	association	NOUN
ajlsi-3268	220	6	study	study	NOUN
ajlsi-3268	220	7	meta	meta	ADJ
ajlsi-3268	220	8	-	-	PUNCT
ajlsi-3268	220	9	analysis	analysis	NOUN
ajlsi-3268	220	10	of	of	ADP
ajlsi-3268	220	11	psoriasis	psoriasis	NOUN
ajlsi-3268	220	12	expands	expand	VERB
ajlsi-3268	220	13	the	the	DET
ajlsi-3268	220	14	catalog	catalog	NOUN
ajlsi-3268	220	15	of	of	ADP
ajlsi-3268	220	16	common	common	ADJ
ajlsi-3268	220	17	psoriasis	psoriasis	NOUN
ajlsi-3268	220	18	-	-	PUNCT
ajlsi-3268	220	19	associated	associate	VERB
ajlsi-3268	220	20	variants	variant	NOUN
ajlsi-3268	220	21	.	.	PUNCT
ajlsi-3268	221	1	journal	journal	NOUN
ajlsi-3268	221	2	of	of	ADP
ajlsi-3268	221	3	investigative	investigative	ADJ
ajlsi-3268	221	4	dermatology	dermatology	NOUN
ajlsi-3268	221	5	symposium	symposium	NOUN
ajlsi-3268	221	6	proceedings	proceeding	NOUN
ajlsi-3268	221	7	.	.	PUNCT
ajlsi-3268	222	1	elsevier	elsevier	NOUN
ajlsi-3268	222	2	.	.	PUNCT
ajlsi-3268	223	1	fenech	fenech	PROPN
ajlsi-3268	223	2	,	,	PUNCT
ajlsi-3268	223	3	m.	m.	NOUN
ajlsi-3268	223	4	,	,	PUNCT
ajlsi-3268	223	5	knasmueller	knasmueller	NOUN
ajlsi-3268	223	6	,	,	PUNCT
ajlsi-3268	223	7	s.	s.	PROPN
ajlsi-3268	223	8	,	,	PUNCT
ajlsi-3268	223	9	bolognesi	bolognesi	NOUN
ajlsi-3268	223	10	,	,	PUNCT
ajlsi-3268	223	11	c.	c.	NOUN
ajlsi-3268	223	12	,	,	PUNCT
ajlsi-3268	223	13	bonassi	bonassi	PROPN
ajlsi-3268	223	14	,	,	PUNCT
ajlsi-3268	223	15	s.	s.	PROPN
ajlsi-3268	223	16	,	,	PUNCT
ajlsi-3268	223	17	holland	holland	PROPN
ajlsi-3268	223	18	,	,	PUNCT
ajlsi-3268	223	19	n.	n.	PROPN
ajlsi-3268	223	20	,	,	PUNCT
ajlsi-3268	223	21	migliore	migliore	PROPN
ajlsi-3268	223	22	,	,	PUNCT
ajlsi-3268	223	23	l.	l.	PROPN
ajlsi-3268	223	24	,	,	PUNCT
ajlsi-3268	223	25	et	et	PROPN
ajlsi-3268	223	26	al	al	PROPN
ajlsi-3268	223	27	.	.	PUNCT
ajlsi-3268	224	1	(	(	PUNCT
ajlsi-3268	224	2	2016	2016	NUM
ajlsi-3268	224	3	)	)	PUNCT
ajlsi-3268	224	4	.	.	PUNCT
ajlsi-3268	225	1	molecular	molecular	ADJ
ajlsi-3268	225	2	mechanisms	mechanism	NOUN
ajlsi-3268	225	3	by	by	ADP
ajlsi-3268	225	4	which	which	PRON
ajlsi-3268	225	5	in	in	ADP
ajlsi-3268	225	6	vivo	vivo	ADJ
ajlsi-3268	225	7	exposure	exposure	NOUN
ajlsi-3268	225	8	to	to	ADP
ajlsi-3268	225	9	exogenous	exogenous	ADJ
ajlsi-3268	225	10	chemical	chemical	ADJ
ajlsi-3268	225	11	genotoxic	genotoxic	ADJ
ajlsi-3268	225	12	agents	agent	NOUN
ajlsi-3268	225	13	can	can	AUX
ajlsi-3268	225	14	lead	lead	VERB
ajlsi-3268	225	15	to	to	ADP
ajlsi-3268	225	16	micronucleus	micronucleus	NOUN
ajlsi-3268	225	17	formation	formation	NOUN
ajlsi-3268	225	18	in	in	ADP
ajlsi-3268	225	19	lymphocytes	lymphocyte	NOUN
ajlsi-3268	225	20	in	in	ADP
ajlsi-3268	225	21	vivo	vivo	NOUN
ajlsi-3268	225	22	and	and	CCONJ
ajlsi-3268	225	23	ex	ex	ADJ
ajlsi-3268	225	24	vivo	vivo	NOUN
ajlsi-3268	225	25	in	in	ADP
ajlsi-3268	225	26	humans	human	NOUN
ajlsi-3268	225	27	.	.	PUNCT
ajlsi-3268	226	1	mutation	mutation	NOUN
ajlsi-3268	226	2	research	research	NOUN
ajlsi-3268	226	3	/	/	SYM
ajlsi-3268	226	4	reviews	review	NOUN
ajlsi-3268	226	5	in	in	ADP
ajlsi-3268	226	6	mutation	mutation	NOUN
ajlsi-3268	226	7	research	research	NOUN
ajlsi-3268	226	8	,	,	PUNCT
ajlsi-3268	226	9	770	770	NUM
ajlsi-3268	226	10	,	,	PUNCT
ajlsi-3268	226	11	12–25	12–25	NUM
ajlsi-3268	226	12	.	.	PUNCT
ajlsi-3268	227	1	fenech	fenech	PROPN
ajlsi-3268	227	2	,	,	PUNCT
ajlsi-3268	227	3	m.	m.	NOUN
ajlsi-3268	227	4	(	(	PUNCT
ajlsi-3268	227	5	2007	2007	NUM
ajlsi-3268	227	6	)	)	PUNCT
ajlsi-3268	227	7	.	.	PUNCT
ajlsi-3268	228	1	cytokinesis	cytokinesis	NOUN
ajlsi-3268	228	2	-	-	PUNCT
ajlsi-3268	228	3	block	block	NOUN
ajlsi-3268	228	4	micronucleus	micronucleus	NOUN
ajlsi-3268	228	5	cytome	cytome	NOUN
ajlsi-3268	228	6	assay	assay	PROPN
ajlsi-3268	228	7	.	.	PUNCT
ajlsi-3268	229	1	nature	nature	NOUN
ajlsi-3268	229	2	protocols	protocol	NOUN
ajlsi-3268	229	3	,	,	PUNCT
ajlsi-3268	229	4	2(5	2(5	NUM
ajlsi-3268	229	5	)	)	PUNCT
ajlsi-3268	229	6	,	,	PUNCT
ajlsi-3268	229	7	1084–1104	1084–1104	NOUN
ajlsi-3268	229	8	.	.	PUNCT
ajlsi-3268	230	1	fenech	fenech	PROPN
ajlsi-3268	230	2	,	,	PUNCT
ajlsi-3268	230	3	m.	m.	NOUN
ajlsi-3268	230	4	(	(	PUNCT
ajlsi-3268	230	5	2009	2009	NUM
ajlsi-3268	230	6	)	)	PUNCT
ajlsi-3268	230	7	.	.	PUNCT
ajlsi-3268	231	1	a	a	DET
ajlsi-3268	231	2	lifetime	lifetime	NOUN
ajlsi-3268	231	3	passion	passion	NOUN
ajlsi-3268	231	4	for	for	ADP
ajlsi-3268	231	5	micronucleus	micronucleus	ADJ
ajlsi-3268	231	6	cytome	cytome	ADJ
ajlsi-3268	231	7	assays	assay	NOUN
ajlsi-3268	231	8	—	—	PUNCT
ajlsi-3268	231	9	reflections	reflection	NOUN
ajlsi-3268	231	10	from	from	ADP
ajlsi-3268	231	11	down	down	ADP
ajlsi-3268	231	12	under	under	ADP
ajlsi-3268	231	13	.	.	PUNCT
ajlsi-3268	232	1	mutation	mutation	NOUN
ajlsi-3268	232	2	research	research	NOUN
ajlsi-3268	232	3	/	/	SYM
ajlsi-3268	232	4	reviews	review	NOUN
ajlsi-3268	232	5	in	in	ADP
ajlsi-3268	232	6	mutation	mutation	NOUN
ajlsi-3268	232	7	research	research	NOUN
ajlsi-3268	232	8	,	,	PUNCT
ajlsi-3268	232	9	681(23	681(23	NOUN
ajlsi-3268	232	10	)	)	PUNCT
ajlsi-3268	232	11	,	,	PUNCT
ajlsi-3268	232	12	111–117	111–117	NUM
ajlsi-3268	232	13	.	.	PUNCT
ajlsi-3268	233	1	griffiths	griffiths	PROPN
ajlsi-3268	233	2	,	,	PUNCT
ajlsi-3268	233	3	c.	c.	PROPN
ajlsi-3268	233	4	e.	e.	PROPN
ajlsi-3268	233	5	,	,	PUNCT
ajlsi-3268	233	6	&	&	CCONJ
ajlsi-3268	233	7	barker	barker	PROPN
ajlsi-3268	233	8	,	,	PUNCT
ajlsi-3268	233	9	j.	j.	PROPN
ajlsi-3268	233	10	n.	n.	PROPN
ajlsi-3268	233	11	(	(	PUNCT
ajlsi-3268	233	12	2007	2007	NUM
ajlsi-3268	233	13	)	)	PUNCT
ajlsi-3268	233	14	.	.	PUNCT
ajlsi-3268	234	1	pathogenesis	pathogenesis	NOUN
ajlsi-3268	234	2	and	and	CCONJ
ajlsi-3268	234	3	clinical	clinical	ADJ
ajlsi-3268	234	4	features	feature	NOUN
ajlsi-3268	234	5	of	of	ADP
ajlsi-3268	234	6	psoriasis	psoriasis	NOUN
ajlsi-3268	234	7	.	.	PUNCT
ajlsi-3268	235	1	the	the	DET
ajlsi-3268	235	2	lancet	lancet	NOUN
ajlsi-3268	235	3	,	,	PUNCT
ajlsi-3268	235	4	370(9583	370(9583	NUM
ajlsi-3268	235	5	)	)	PUNCT
ajlsi-3268	235	6	,	,	PUNCT
ajlsi-3268	235	7	263–271	263–271	NUM
ajlsi-3268	235	8	.	.	PUNCT
ajlsi-3268	236	1	kadam	kadam	PROPN
ajlsi-3268	236	2	,	,	PUNCT
ajlsi-3268	236	3	d.	d.	PROPN
ajlsi-3268	236	4	p.	p.	PROPN
ajlsi-3268	236	5	,	,	PUNCT
ajlsi-3268	236	6	suryakar	suryakar	NOUN
ajlsi-3268	236	7	,	,	PUNCT
ajlsi-3268	236	8	a.	a.	NOUN
ajlsi-3268	236	9	n.	n.	PROPN
ajlsi-3268	236	10	,	,	PUNCT
ajlsi-3268	236	11	ankush	ankush	PROPN
ajlsi-3268	236	12	,	,	PUNCT
ajlsi-3268	236	13	r.	r.	PROPN
ajlsi-3268	236	14	d.	d.	PROPN
ajlsi-3268	236	15	,	,	PUNCT
ajlsi-3268	236	16	kadam	kadam	PROPN
ajlsi-3268	236	17	,	,	PUNCT
ajlsi-3268	236	18	c.	c.	PROPN
ajlsi-3268	236	19	y.	y.	PROPN
ajlsi-3268	236	20	,	,	PUNCT
ajlsi-3268	236	21	&	&	CCONJ
ajlsi-3268	236	22	deshpande	deshpande	PROPN
ajlsi-3268	236	23	,	,	PUNCT
ajlsi-3268	236	24	k.	k.	PROPN
ajlsi-3268	236	25	h.	h.	PROPN
ajlsi-3268	236	26	(	(	PUNCT
ajlsi-3268	236	27	2010	2010	NUM
ajlsi-3268	236	28	)	)	PUNCT
ajlsi-3268	236	29	.	.	PUNCT
ajlsi-3268	237	1	role	role	NOUN
ajlsi-3268	237	2	of	of	ADP
ajlsi-3268	237	3	oxidative	oxidative	ADJ
ajlsi-3268	237	4	stress	stress	NOUN
ajlsi-3268	237	5	in	in	ADP
ajlsi-3268	237	6	various	various	ADJ
ajlsi-3268	237	7	stages	stage	NOUN
ajlsi-3268	237	8	of	of	ADP
ajlsi-3268	237	9	psoriasis	psoriasis	NOUN
ajlsi-3268	237	10	.	.	PUNCT
ajlsi-3268	238	1	indian	indian	ADJ
ajlsi-3268	238	2	journal	journal	PROPN
ajlsi-3268	238	3	of	of	ADP
ajlsi-3268	238	4	clinical	clinical	ADJ
ajlsi-3268	238	5	biochemistry	biochemistry	NOUN
ajlsi-3268	238	6	,	,	PUNCT
ajlsi-3268	238	7	25	25	NUM
ajlsi-3268	238	8	,	,	PUNCT
ajlsi-3268	238	9	388–392	388–392	NUM
ajlsi-3268	238	10	.	.	PUNCT
ajlsi-3268	238	11	lai	lai	PROPN
ajlsi-3268	238	12	,	,	PUNCT
ajlsi-3268	238	13	r.	r.	PROPN
ajlsi-3268	238	14	,	,	PUNCT
ajlsi-3268	238	15	xian	xian	PROPN
ajlsi-3268	238	16	,	,	PUNCT
ajlsi-3268	238	17	d.	d.	PROPN
ajlsi-3268	238	18	,	,	PUNCT
ajlsi-3268	238	19	xiong	xiong	PROPN
ajlsi-3268	238	20	,	,	PUNCT
ajlsi-3268	238	21	x.	x.	PROPN
ajlsi-3268	238	22	,	,	PUNCT
ajlsi-3268	238	23	yang	yang	PROPN
ajlsi-3268	238	24	,	,	PUNCT
ajlsi-3268	238	25	l.	l.	PROPN
ajlsi-3268	238	26	,	,	PUNCT
ajlsi-3268	238	27	song	song	NOUN
ajlsi-3268	238	28	,	,	PUNCT
ajlsi-3268	238	29	j.	j.	PROPN
ajlsi-3268	238	30	,	,	PUNCT
ajlsi-3268	238	31	&	&	CCONJ
ajlsi-3268	238	32	zhong	zhong	PROPN
ajlsi-3268	238	33	,	,	PUNCT
ajlsi-3268	238	34	j.	j.	PROPN
ajlsi-3268	238	35	(	(	PUNCT
ajlsi-3268	238	36	2018	2018	NUM
ajlsi-3268	238	37	)	)	PUNCT
ajlsi-3268	238	38	.	.	PUNCT
ajlsi-3268	239	1	proanthocyanidins	proanthocyanidin	NOUN
ajlsi-3268	239	2	:	:	PUNCT
ajlsi-3268	239	3	novel	novel	ADJ
ajlsi-3268	239	4	treatment	treatment	NOUN
ajlsi-3268	239	5	for	for	ADP
ajlsi-3268	239	6	psoriasis	psoriasis	NOUN
ajlsi-3268	239	7	that	that	PRON
ajlsi-3268	239	8	reduces	reduce	VERB
ajlsi-3268	239	9	oxidative	oxidative	ADJ
ajlsi-3268	239	10	stress	stress	NOUN
ajlsi-3268	239	11	and	and	CCONJ
ajlsi-3268	239	12	modulates	modulate	NOUN
ajlsi-3268	239	13	th17	th17	PROPN
ajlsi-3268	239	14	and	and	CCONJ
ajlsi-3268	239	15	treg	treg	PROPN
ajlsi-3268	239	16	cells	cell	NOUN
ajlsi-3268	239	17	.	.	PUNCT
ajlsi-3268	240	1	redox	redox	ADJ
ajlsi-3268	240	2	report	report	NOUN
ajlsi-3268	240	3	,	,	PUNCT
ajlsi-3268	240	4	23(1	23(1	NUM
ajlsi-3268	240	5	)	)	PUNCT
ajlsi-3268	240	6	,	,	PUNCT
ajlsi-3268	240	7	130–135	130–135	NUM
ajlsi-3268	240	8	.	.	PUNCT
ajlsi-3268	241	1	lin	lin	PROPN
ajlsi-3268	241	2	,	,	PUNCT
ajlsi-3268	241	3	x.	x.	PROPN
ajlsi-3268	241	4	,	,	PUNCT
ajlsi-3268	241	5	&	&	CCONJ
ajlsi-3268	241	6	huang	huang	PROPN
ajlsi-3268	241	7	,	,	PUNCT
ajlsi-3268	241	8	t.	t.	PROPN
ajlsi-3268	241	9	(	(	PUNCT
ajlsi-3268	241	10	2016	2016	NUM
ajlsi-3268	241	11	)	)	PUNCT
ajlsi-3268	241	12	.	.	PUNCT
ajlsi-3268	242	1	oxidative	oxidative	ADJ
ajlsi-3268	242	2	stress	stress	NOUN
ajlsi-3268	242	3	in	in	ADP
ajlsi-3268	242	4	psoriasis	psoriasis	NOUN
ajlsi-3268	242	5	and	and	CCONJ
ajlsi-3268	242	6	potential	potential	ADJ
ajlsi-3268	242	7	therapeutic	therapeutic	ADJ
ajlsi-3268	242	8	use	use	NOUN
ajlsi-3268	242	9	of	of	ADP
ajlsi-3268	242	10	antioxidants	antioxidant	NOUN
ajlsi-3268	242	11	.	.	PUNCT
ajlsi-3268	243	1	free	free	ADJ
ajlsi-3268	243	2	radical	radical	ADJ
ajlsi-3268	243	3	research	research	NOUN
ajlsi-3268	243	4	,	,	PUNCT
ajlsi-3268	243	5	50(6	50(6	NUM
ajlsi-3268	243	6	)	)	PUNCT
ajlsi-3268	243	7	,	,	PUNCT
ajlsi-3268	243	8	585–595	585–595	NUM
ajlsi-3268	243	9	.	.	PUNCT
ajlsi-3268	244	1	lombardo	lombardo	PROPN
ajlsi-3268	244	2	,	,	PUNCT
ajlsi-3268	244	3	d.	d.	PROPN
ajlsi-3268	244	4	,	,	PUNCT
ajlsi-3268	244	5	&	&	CCONJ
ajlsi-3268	244	6	kiselev	kiselev	PROPN
ajlsi-3268	244	7	,	,	PUNCT
ajlsi-3268	244	8	m.	m.	NOUN
ajlsi-3268	244	9	a.	a.	NOUN
ajlsi-3268	244	10	(	(	PUNCT
ajlsi-3268	244	11	2022	2022	NUM
ajlsi-3268	244	12	)	)	PUNCT
ajlsi-3268	244	13	.	.	PUNCT
ajlsi-3268	245	1	methods	method	NOUN
ajlsi-3268	245	2	of	of	ADP
ajlsi-3268	245	3	liposomes	liposome	NOUN
ajlsi-3268	245	4	preparation	preparation	NOUN
ajlsi-3268	245	5	:	:	PUNCT
ajlsi-3268	245	6	formation	formation	NOUN
ajlsi-3268	245	7	and	and	CCONJ
ajlsi-3268	245	8	control	control	NOUN
ajlsi-3268	245	9	factors	factor	NOUN
ajlsi-3268	245	10	of	of	ADP
ajlsi-3268	245	11	versatile	versatile	ADJ
ajlsi-3268	245	12	nanocarriers	nanocarrier	NOUN
ajlsi-3268	245	13	for	for	ADP
ajlsi-3268	245	14	biomedical	biomedical	ADJ
ajlsi-3268	245	15	and	and	CCONJ
ajlsi-3268	245	16	nanomedicine	nanomedicine	ADJ
ajlsi-3268	245	17	application	application	NOUN
ajlsi-3268	245	18	.	.	PUNCT
ajlsi-3268	246	1	pharmaceutics	pharmaceutic	NOUN
ajlsi-3268	246	2	,	,	PUNCT
ajlsi-3268	246	3	14(3	14(3	NUM
ajlsi-3268	246	4	)	)	PUNCT
ajlsi-3268	246	5	,	,	PUNCT
ajlsi-3268	246	6	543	543	NUM
ajlsi-3268	246	7	.	.	PUNCT
ajlsi-3268	246	8	matsuzaki	matsuzaki	PROPN
ajlsi-3268	246	9	,	,	PUNCT
ajlsi-3268	246	10	g.	g.	PROPN
ajlsi-3268	246	11	,	,	PUNCT
ajlsi-3268	246	12	&	&	CCONJ
ajlsi-3268	246	13	umemura	umemura	PROPN
ajlsi-3268	246	14	,	,	PUNCT
ajlsi-3268	246	15	m.	m.	NOUN
ajlsi-3268	246	16	(	(	PUNCT
ajlsi-3268	246	17	2018	2018	NUM
ajlsi-3268	246	18	)	)	PUNCT
ajlsi-3268	246	19	.	.	PUNCT
ajlsi-3268	247	1	interleukin‐17	interleukin‐17	ADJ
ajlsi-3268	247	2	family	family	NOUN
ajlsi-3268	247	3	cytokines	cytokine	VERB
ajlsi-3268	247	4	in	in	ADP
ajlsi-3268	247	5	protective	protective	ADJ
ajlsi-3268	247	6	immunity	immunity	NOUN
ajlsi-3268	247	7	against	against	ADP
ajlsi-3268	247	8	pa	pa	PROPN
ajlsi-3268	247	9	ge	ge	PROPN
ajlsi-3268	247	10	35	35	NUM
ajlsi-3268	247	11	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-3268	247	12	am	am	NOUN
ajlsi-3268	247	13	.	.	PUNCT
ajlsi-3268	248	1	j.	j.	PROPN
ajlsi-3268	248	2	life	life	PROPN
ajlsi-3268	248	3	sci	sci	PROPN
ajlsi-3268	248	4	.	.	PUNCT
ajlsi-3268	248	5	innov	innov	PROPN
ajlsi-3268	248	6	.	.	PUNCT
ajlsi-3268	249	1	4(1	4(1	NOUN
ajlsi-3268	249	2	)	)	PUNCT
ajlsi-3268	250	1	27	27	NUM
ajlsi-3268	250	2	-	-	SYM
ajlsi-3268	250	3	35	35	NUM
ajlsi-3268	250	4	,	,	PUNCT
ajlsi-3268	250	5	2025	2025	NUM
ajlsi-3268	250	6	infections	infection	NOUN
ajlsi-3268	250	7	:	:	PUNCT
ajlsi-3268	250	8	role	role	NOUN
ajlsi-3268	250	9	of	of	ADP
ajlsi-3268	250	10	hematopoietic	hematopoietic	ADJ
ajlsi-3268	250	11	cell‐derived	cell‐derived	ADJ
ajlsi-3268	250	12	and	and	CCONJ
ajlsi-3268	250	13	non‐hematopoietic	non‐hematopoietic	ADJ
ajlsi-3268	250	14	cell‐derived	cell‐derive	VERB
ajlsi-3268	250	15	interleukin‐17s	interleukin‐17s	PROPN
ajlsi-3268	250	16	.	.	PUNCT
ajlsi-3268	251	1	microbiology	microbiology	NOUN
ajlsi-3268	251	2	and	and	CCONJ
ajlsi-3268	251	3	immunology	immunology	NOUN
ajlsi-3268	251	4	,	,	PUNCT
ajlsi-3268	251	5	62(1	62(1	NOUN
ajlsi-3268	251	6	)	)	PUNCT
ajlsi-3268	251	7	,	,	PUNCT
ajlsi-3268	251	8	1–13	1–13	NOUN
ajlsi-3268	251	9	.	.	PUNCT
ajlsi-3268	252	1	magdolenova	magdolenova	PROPN
ajlsi-3268	252	2	,	,	PUNCT
ajlsi-3268	252	3	z.	z.	PROPN
ajlsi-3268	252	4	,	,	PUNCT
ajlsi-3268	252	5	lorenzo	lorenzo	PROPN
ajlsi-3268	252	6	,	,	PUNCT
ajlsi-3268	252	7	y.	y.	PROPN
ajlsi-3268	252	8	,	,	PUNCT
ajlsi-3268	252	9	collins	collins	PROPN
ajlsi-3268	252	10	,	,	PUNCT
ajlsi-3268	252	11	a.	a.	PROPN
ajlsi-3268	252	12	,	,	PUNCT
ajlsi-3268	252	13	&	&	CCONJ
ajlsi-3268	252	14	dusinska	dusinska	PROPN
ajlsi-3268	252	15	,	,	PUNCT
ajlsi-3268	252	16	m.	m.	NOUN
ajlsi-3268	252	17	(	(	PUNCT
ajlsi-3268	252	18	2012	2012	NUM
ajlsi-3268	252	19	)	)	PUNCT
ajlsi-3268	252	20	.	.	PUNCT
ajlsi-3268	253	1	can	can	AUX
ajlsi-3268	253	2	standard	standard	VERB
ajlsi-3268	253	3	genotoxicity	genotoxicity	NOUN
ajlsi-3268	253	4	tests	test	NOUN
ajlsi-3268	253	5	be	be	AUX
ajlsi-3268	253	6	applied	apply	VERB
ajlsi-3268	253	7	to	to	ADP
ajlsi-3268	253	8	nanoparticles	nanoparticle	NOUN
ajlsi-3268	253	9	?	?	PUNCT
ajlsi-3268	254	1	journal	journal	NOUN
ajlsi-3268	254	2	of	of	ADP
ajlsi-3268	254	3	toxicology	toxicology	NOUN
ajlsi-3268	254	4	and	and	CCONJ
ajlsi-3268	254	5	environmental	environmental	ADJ
ajlsi-3268	254	6	health	health	NOUN
ajlsi-3268	254	7	,	,	PUNCT
ajlsi-3268	254	8	part	part	NOUN
ajlsi-3268	254	9	a	a	PRON
ajlsi-3268	254	10	,	,	PUNCT
ajlsi-3268	254	11	75(13	75(13	NUM
ajlsi-3268	254	12	-	-	SYM
ajlsi-3268	254	13	15	15	NUM
ajlsi-3268	254	14	)	)	PUNCT
ajlsi-3268	254	15	,	,	PUNCT
ajlsi-3268	254	16	800–806	800–806	NUM
ajlsi-3268	254	17	.	.	PUNCT
ajlsi-3268	255	1	miyagawa	miyagawa	PROPN
ajlsi-3268	255	2	,	,	PUNCT
ajlsi-3268	255	3	f.	f.	PROPN
ajlsi-3268	255	4	(	(	PUNCT
ajlsi-3268	255	5	2022	2022	NUM
ajlsi-3268	255	6	)	)	PUNCT
ajlsi-3268	255	7	.	.	PUNCT
ajlsi-3268	256	1	pathogenesis	pathogenesis	NOUN
ajlsi-3268	256	2	of	of	ADP
ajlsi-3268	256	3	paradoxical	paradoxical	ADJ
ajlsi-3268	256	4	reactions	reaction	NOUN
ajlsi-3268	256	5	associated	associate	VERB
ajlsi-3268	256	6	with	with	ADP
ajlsi-3268	256	7	targeted	target	VERB
ajlsi-3268	256	8	biologic	biologic	NOUN
ajlsi-3268	256	9	agents	agent	NOUN
ajlsi-3268	256	10	for	for	ADP
ajlsi-3268	256	11	inflammatory	inflammatory	ADJ
ajlsi-3268	256	12	skin	skin	NOUN
ajlsi-3268	256	13	diseases	disease	NOUN
ajlsi-3268	256	14	.	.	PUNCT
ajlsi-3268	257	1	biomedicines	biomedicine	NOUN
ajlsi-3268	257	2	,	,	PUNCT
ajlsi-3268	257	3	10(7	10(7	NUM
ajlsi-3268	257	4	)	)	PUNCT
ajlsi-3268	257	5	,	,	PUNCT
ajlsi-3268	257	6	1485	1485	NUM
ajlsi-3268	257	7	.	.	PUNCT
ajlsi-3268	258	1	molden	molden	PROPN
ajlsi-3268	258	2	,	,	PUNCT
ajlsi-3268	258	3	r.	r.	PROPN
ajlsi-3268	258	4	,	,	PUNCT
ajlsi-3268	258	5	hu	hu	PROPN
ajlsi-3268	258	6	,	,	PUNCT
ajlsi-3268	258	7	m.	m.	NOUN
ajlsi-3268	258	8	,	,	PUNCT
ajlsi-3268	258	9	yen	yen	NOUN
ajlsi-3268	258	10	,	,	PUNCT
ajlsi-3268	258	11	e.	e.	PROPN
ajlsi-3268	258	12	s.	s.	PROPN
ajlsi-3268	258	13	,	,	PUNCT
ajlsi-3268	258	14	saggese	saggese	PROPN
ajlsi-3268	258	15	,	,	PUNCT
ajlsi-3268	258	16	d.	d.	PROPN
ajlsi-3268	258	17	,	,	PUNCT
ajlsi-3268	258	18	reilly	reilly	PROPN
ajlsi-3268	258	19	,	,	PUNCT
ajlsi-3268	258	20	j.	j.	PROPN
ajlsi-3268	258	21	,	,	PUNCT
ajlsi-3268	258	22	mattila	mattila	PROPN
ajlsi-3268	258	23	,	,	PUNCT
ajlsi-3268	258	24	j.	j.	PROPN
ajlsi-3268	258	25	(	(	PUNCT
ajlsi-3268	258	26	eds	eds	PROPN
ajlsi-3268	258	27	.	.	PUNCT
ajlsi-3268	258	28	)	)	PUNCT
ajlsi-3268	258	29	.	.	PUNCT
ajlsi-3268	259	1	(	(	PUNCT
ajlsi-3268	259	2	2021	2021	NUM
ajlsi-3268	259	3	)	)	PUNCT
ajlsi-3268	259	4	.	.	PUNCT
ajlsi-3268	260	1	host	host	NOUN
ajlsi-3268	260	2	cell	cell	NOUN
ajlsi-3268	260	3	protein	protein	NOUN
ajlsi-3268	260	4	profiling	profiling	NOUN
ajlsi-3268	260	5	of	of	ADP
ajlsi-3268	260	6	commercial	commercial	ADJ
ajlsi-3268	260	7	therapeutic	therapeutic	ADJ
ajlsi-3268	260	8	protein	protein	NOUN
ajlsi-3268	260	9	drugs	drug	NOUN
ajlsi-3268	260	10	as	as	ADP
ajlsi-3268	260	11	a	a	DET
ajlsi-3268	260	12	benchmark	benchmark	NOUN
ajlsi-3268	260	13	for	for	ADP
ajlsi-3268	260	14	monoclonal	monoclonal	NOUN
ajlsi-3268	260	15	antibody	antibody	NOUN
ajlsi-3268	260	16	-	-	PUNCT
ajlsi-3268	260	17	based	base	VERB
ajlsi-3268	260	18	therapeutic	therapeutic	ADJ
ajlsi-3268	260	19	protein	protein	NOUN
ajlsi-3268	260	20	development	development	NOUN
ajlsi-3268	260	21	.	.	PUNCT
ajlsi-3268	261	1	mabs	mab	NOUN
ajlsi-3268	261	2	,	,	PUNCT
ajlsi-3268	261	3	13(1	13(1	NUM
ajlsi-3268	261	4	)	)	PUNCT
ajlsi-3268	261	5	,	,	PUNCT
ajlsi-3268	261	6	1901684	1901684	NUM
ajlsi-3268	261	7	.	.	PUNCT
ajlsi-3268	262	1	najafzadeh	najafzadeh	PROPN
ajlsi-3268	262	2	,	,	PUNCT
ajlsi-3268	262	3	m.	m.	NOUN
ajlsi-3268	262	4	,	,	PUNCT
ajlsi-3268	262	5	&	&	CCONJ
ajlsi-3268	262	6	anderson	anderson	PROPN
ajlsi-3268	262	7	,	,	PUNCT
ajlsi-3268	262	8	d.	d.	PROPN
ajlsi-3268	262	9	(	(	PUNCT
ajlsi-3268	262	10	2016	2016	NUM
ajlsi-3268	262	11	)	)	PUNCT
ajlsi-3268	262	12	.	.	PUNCT
ajlsi-3268	263	1	the	the	DET
ajlsi-3268	263	2	use	use	NOUN
ajlsi-3268	263	3	of	of	ADP
ajlsi-3268	263	4	isolated	isolated	ADJ
ajlsi-3268	263	5	peripheral	peripheral	ADJ
ajlsi-3268	263	6	lymphocytes	lymphocyte	NOUN
ajlsi-3268	263	7	and	and	CCONJ
ajlsi-3268	263	8	human	human	ADJ
ajlsi-3268	263	9	whole	whole	ADJ
ajlsi-3268	263	10	blood	blood	NOUN
ajlsi-3268	263	11	in	in	ADP
ajlsi-3268	263	12	the	the	DET
ajlsi-3268	263	13	comet	comet	NOUN
ajlsi-3268	263	14	assay	assay	VERB
ajlsi-3268	263	15	.	.	PUNCT
ajlsi-3268	264	1	comet	comet	PROPN
ajlsi-3268	264	2	assay	assay	VERB
ajlsi-3268	264	3	in	in	ADP
ajlsi-3268	264	4	toxicology	toxicology	NOUN
ajlsi-3268	264	5	,	,	PUNCT
ajlsi-3268	264	6	177–191	177–191	NUM
ajlsi-3268	264	7	.	.	PUNCT
ajlsi-3268	265	1	najafzadeh	najafzadeh	PROPN
ajlsi-3268	265	2	,	,	PUNCT
ajlsi-3268	265	3	m.	m.	NOUN
ajlsi-3268	265	4	,	,	PUNCT
ajlsi-3268	265	5	gueidan	gueidan	PROPN
ajlsi-3268	265	6	,	,	PUNCT
ajlsi-3268	265	7	c.	c.	PROPN
ajlsi-3268	265	8	,	,	PUNCT
ajlsi-3268	265	9	badali	badali	PROPN
ajlsi-3268	265	10	,	,	PUNCT
ajlsi-3268	265	11	h.	h.	PROPN
ajlsi-3268	265	12	,	,	PUNCT
ajlsi-3268	265	13	van	van	PROPN
ajlsi-3268	265	14	den	den	PROPN
ajlsi-3268	265	15	ende	ende	NOUN
ajlsi-3268	265	16	,	,	PUNCT
ajlsi-3268	265	17	a.	a.	NOUN
ajlsi-3268	265	18	g.	g.	PROPN
ajlsi-3268	265	19	,	,	PUNCT
ajlsi-3268	265	20	xi	xi	PROPN
ajlsi-3268	265	21	,	,	PUNCT
ajlsi-3268	265	22	l.	l.	PROPN
ajlsi-3268	265	23	,	,	PUNCT
ajlsi-3268	265	24	&	&	CCONJ
ajlsi-3268	265	25	de	de	PROPN
ajlsi-3268	265	26	hoog	hoog	PROPN
ajlsi-3268	265	27	,	,	PUNCT
ajlsi-3268	265	28	g.	g.	PROPN
ajlsi-3268	265	29	(	(	PUNCT
ajlsi-3268	265	30	2009	2009	NUM
ajlsi-3268	265	31	)	)	PUNCT
ajlsi-3268	265	32	.	.	PUNCT
ajlsi-3268	266	1	genetic	genetic	ADJ
ajlsi-3268	266	2	diversity	diversity	NOUN
ajlsi-3268	266	3	and	and	CCONJ
ajlsi-3268	266	4	species	species	NOUN
ajlsi-3268	266	5	delimitation	delimitation	NOUN
ajlsi-3268	266	6	in	in	ADP
ajlsi-3268	266	7	the	the	DET
ajlsi-3268	266	8	opportunistic	opportunistic	ADJ
ajlsi-3268	266	9	genus	genus	NOUN
ajlsi-3268	266	10	fonsecaea	fonsecaea	NOUN
ajlsi-3268	266	11	.	.	PUNCT
ajlsi-3268	267	1	medical	medical	ADJ
ajlsi-3268	267	2	mycology	mycology	NOUN
ajlsi-3268	267	3	,	,	PUNCT
ajlsi-3268	267	4	47(1	47(1	NUM
ajlsi-3268	267	5	)	)	PUNCT
ajlsi-3268	267	6	,	,	PUNCT
ajlsi-3268	267	7	17–25	17–25	NUM
ajlsi-3268	267	8	.	.	PUNCT
ajlsi-3268	268	1	nestle	nestle	PROPN
ajlsi-3268	268	2	,	,	PUNCT
ajlsi-3268	268	3	f.	f.	PROPN
ajlsi-3268	268	4	,	,	PUNCT
ajlsi-3268	268	5	turka	turka	PROPN
ajlsi-3268	268	6	,	,	PUNCT
ajlsi-3268	268	7	l.	l.	PROPN
ajlsi-3268	268	8	,	,	PUNCT
ajlsi-3268	268	9	&	&	CCONJ
ajlsi-3268	268	10	nickoloff	nickoloff	PROPN
ajlsi-3268	268	11	,	,	PUNCT
ajlsi-3268	268	12	b.	b.	PROPN
ajlsi-3268	268	13	(	(	PUNCT
ajlsi-3268	268	14	1994	1994	NUM
ajlsi-3268	268	15	)	)	PUNCT
ajlsi-3268	268	16	.	.	PUNCT
ajlsi-3268	269	1	characterization	characterization	NOUN
ajlsi-3268	269	2	of	of	ADP
ajlsi-3268	269	3	dermal	dermal	ADJ
ajlsi-3268	269	4	dendritic	dendritic	ADJ
ajlsi-3268	269	5	cells	cell	NOUN
ajlsi-3268	269	6	in	in	ADP
ajlsi-3268	269	7	psoriasis	psoriasis	NOUN
ajlsi-3268	269	8	:	:	PUNCT
ajlsi-3268	269	9	autostimulation	autostimulation	NOUN
ajlsi-3268	269	10	of	of	ADP
ajlsi-3268	269	11	t	t	PROPN
ajlsi-3268	269	12	lymphocytes	lymphocyte	NOUN
ajlsi-3268	269	13	and	and	CCONJ
ajlsi-3268	269	14	induction	induction	NOUN
ajlsi-3268	269	15	of	of	ADP
ajlsi-3268	269	16	th1	th1	NOUN
ajlsi-3268	269	17	type	type	NOUN
ajlsi-3268	269	18	cytokines	cytokine	NOUN
ajlsi-3268	269	19	.	.	PUNCT
ajlsi-3268	270	1	the	the	DET
ajlsi-3268	270	2	journal	journal	NOUN
ajlsi-3268	270	3	of	of	ADP
ajlsi-3268	270	4	clinical	clinical	ADJ
ajlsi-3268	270	5	investigation	investigation	NOUN
ajlsi-3268	270	6	,	,	PUNCT
ajlsi-3268	270	7	94(1	94(1	NUM
ajlsi-3268	270	8	)	)	PUNCT
ajlsi-3268	270	9	,	,	PUNCT
ajlsi-3268	270	10	202–209	202–209	NUM
ajlsi-3268	270	11	.	.	PUNCT
ajlsi-3268	271	1	nsairat	nsairat	PROPN
ajlsi-3268	271	2	,	,	PUNCT
ajlsi-3268	271	3	h.	h.	PROPN
ajlsi-3268	271	4	,	,	PUNCT
ajlsi-3268	271	5	khater	khater	PROPN
ajlsi-3268	271	6	,	,	PUNCT
ajlsi-3268	271	7	d.	d.	PROPN
ajlsi-3268	271	8	,	,	PUNCT
ajlsi-3268	271	9	sayed	say	VERB
ajlsi-3268	271	10	,	,	PUNCT
ajlsi-3268	271	11	u.	u.	PROPN
ajlsi-3268	271	12	,	,	PUNCT
ajlsi-3268	271	13	odeh	odeh	PROPN
ajlsi-3268	271	14	,	,	PUNCT
ajlsi-3268	271	15	f.	f.	PROPN
ajlsi-3268	271	16	,	,	PUNCT
ajlsi-3268	271	17	al	al	PROPN
ajlsi-3268	271	18	bawab	bawab	PROPN
ajlsi-3268	271	19	,	,	PUNCT
ajlsi-3268	271	20	a.	a.	PROPN
ajlsi-3268	271	21	,	,	PUNCT
ajlsi-3268	271	22	&	&	CCONJ
ajlsi-3268	271	23	alshaer	alshaer	PROPN
ajlsi-3268	271	24	,	,	PUNCT
ajlsi-3268	271	25	w.	w.	PROPN
ajlsi-3268	271	26	(	(	PUNCT
ajlsi-3268	271	27	2022	2022	NUM
ajlsi-3268	271	28	)	)	PUNCT
ajlsi-3268	271	29	.	.	PUNCT
ajlsi-3268	272	1	liposomes	liposome	NOUN
ajlsi-3268	272	2	:	:	PUNCT
ajlsi-3268	272	3	structure	structure	NOUN
ajlsi-3268	272	4	,	,	PUNCT
ajlsi-3268	272	5	composition	composition	NOUN
ajlsi-3268	272	6	,	,	PUNCT
ajlsi-3268	272	7	types	type	NOUN
ajlsi-3268	272	8	,	,	PUNCT
ajlsi-3268	272	9	and	and	CCONJ
ajlsi-3268	272	10	clinical	clinical	ADJ
ajlsi-3268	272	11	applications	application	NOUN
ajlsi-3268	272	12	.	.	PUNCT
ajlsi-3268	273	1	heliyon	heliyon	NOUN
ajlsi-3268	273	2	,	,	PUNCT
ajlsi-3268	273	3	8(2	8(2	NUM
ajlsi-3268	273	4	)	)	PUNCT
ajlsi-3268	273	5	,	,	PUNCT
ajlsi-3268	273	6	e08829	e08829	PROPN
ajlsi-3268	273	7	.	.	PROPN
ajlsi-3268	273	8	organisation	organisation	NOUN
ajlsi-3268	273	9	for	for	ADP
ajlsi-3268	273	10	economic	economic	ADJ
ajlsi-3268	273	11	co	co	NOUN
ajlsi-3268	273	12	-	-	NOUN
ajlsi-3268	273	13	operation	operation	NOUN
ajlsi-3268	273	14	and	and	CCONJ
ajlsi-3268	273	15	development	development	NOUN
ajlsi-3268	273	16	(	(	PUNCT
ajlsi-3268	273	17	oecd	oecd	PROPN
ajlsi-3268	273	18	)	)	PUNCT
ajlsi-3268	273	19	.	.	PUNCT
ajlsi-3268	274	1	(	(	PUNCT
ajlsi-3268	274	2	2010	2010	NUM
ajlsi-3268	274	3	)	)	PUNCT
ajlsi-3268	274	4	.	.	PUNCT
ajlsi-3268	275	1	test	test	NOUN
ajlsi-3268	275	2	no	no	INTJ
ajlsi-3268	275	3	.	.	NOUN
ajlsi-3268	276	1	487	487	NUM
ajlsi-3268	276	2	:	:	PUNCT
ajlsi-3268	276	3	in	in	ADP
ajlsi-3268	276	4	vitro	vitro	X
ajlsi-3268	276	5	mammalian	mammalian	ADJ
ajlsi-3268	276	6	cell	cell	NOUN
ajlsi-3268	276	7	micronucleus	micronucleus	PROPN
ajlsi-3268	276	8	test	test	NOUN
ajlsi-3268	276	9	.	.	PUNCT
ajlsi-3268	277	1	oecd	oecd	PROPN
ajlsi-3268	277	2	publishing	publishing	PROPN
ajlsi-3268	277	3	.	.	PUNCT
ajlsi-3268	278	1	rendon	rendon	PROPN
ajlsi-3268	278	2	,	,	PUNCT
ajlsi-3268	278	3	a.	a.	PROPN
ajlsi-3268	278	4	,	,	PUNCT
ajlsi-3268	278	5	&	&	CCONJ
ajlsi-3268	278	6	schäkel	schäkel	PROPN
ajlsi-3268	278	7	,	,	PUNCT
ajlsi-3268	278	8	k.	k.	PROPN
ajlsi-3268	278	9	(	(	PUNCT
ajlsi-3268	278	10	2019	2019	NUM
ajlsi-3268	278	11	)	)	PUNCT
ajlsi-3268	278	12	.	.	PUNCT
ajlsi-3268	279	1	psoriasis	psoriasis	NOUN
ajlsi-3268	279	2	pathogenesis	pathogenesis	NOUN
ajlsi-3268	279	3	and	and	CCONJ
ajlsi-3268	279	4	treatment	treatment	NOUN
ajlsi-3268	279	5	.	.	PUNCT
ajlsi-3268	280	1	international	international	ADJ
ajlsi-3268	280	2	journal	journal	NOUN
ajlsi-3268	280	3	of	of	ADP
ajlsi-3268	280	4	molecular	molecular	ADJ
ajlsi-3268	280	5	sciences	science	NOUN
ajlsi-3268	280	6	,	,	PUNCT
ajlsi-3268	280	7	20(6	20(6	NOUN
ajlsi-3268	280	8	)	)	PUNCT
ajlsi-3268	280	9	,	,	PUNCT
ajlsi-3268	280	10	1475	1475	NUM
ajlsi-3268	280	11	.	.	PUNCT
ajlsi-3268	281	1	sercombe	sercombe	NOUN
ajlsi-3268	281	2	,	,	PUNCT
ajlsi-3268	281	3	l.	l.	PROPN
ajlsi-3268	281	4	,	,	PUNCT
ajlsi-3268	281	5	veerati	veerati	PROPN
ajlsi-3268	281	6	,	,	PUNCT
ajlsi-3268	281	7	t.	t.	PROPN
ajlsi-3268	281	8	,	,	PUNCT
ajlsi-3268	281	9	moheimani	moheimani	PROPN
ajlsi-3268	281	10	,	,	PUNCT
ajlsi-3268	281	11	f.	f.	PROPN
ajlsi-3268	281	12	,	,	PUNCT
ajlsi-3268	281	13	wu	wu	PROPN
ajlsi-3268	281	14	,	,	PUNCT
ajlsi-3268	281	15	s.	s.	PROPN
ajlsi-3268	281	16	y.	y.	PROPN
ajlsi-3268	281	17	,	,	PUNCT
ajlsi-3268	281	18	sood	sood	PROPN
ajlsi-3268	281	19	,	,	PUNCT
ajlsi-3268	281	20	a.	a.	PROPN
ajlsi-3268	281	21	k.	k.	PROPN
ajlsi-3268	281	22	,	,	PUNCT
ajlsi-3268	281	23	&	&	CCONJ
ajlsi-3268	281	24	hua	hua	PROPN
ajlsi-3268	281	25	,	,	PUNCT
ajlsi-3268	281	26	s.	s.	PROPN
ajlsi-3268	281	27	(	(	PUNCT
ajlsi-3268	281	28	2015	2015	NUM
ajlsi-3268	281	29	)	)	PUNCT
ajlsi-3268	281	30	.	.	PUNCT
ajlsi-3268	282	1	advances	advance	NOUN
ajlsi-3268	282	2	and	and	CCONJ
ajlsi-3268	282	3	challenges	challenge	NOUN
ajlsi-3268	282	4	of	of	ADP
ajlsi-3268	282	5	liposome	liposome	NOUN
ajlsi-3268	282	6	assisted	assist	VERB
ajlsi-3268	282	7	drug	drug	NOUN
ajlsi-3268	282	8	delivery	delivery	NOUN
ajlsi-3268	282	9	.	.	PUNCT
ajlsi-3268	283	1	frontiers	frontier	NOUN
ajlsi-3268	283	2	in	in	ADP
ajlsi-3268	283	3	pharmacology	pharmacology	NOUN
ajlsi-3268	283	4	,	,	PUNCT
ajlsi-3268	283	5	6	6	NUM
ajlsi-3268	283	6	,	,	PUNCT
ajlsi-3268	283	7	286	286	NUM
ajlsi-3268	283	8	.	.	PUNCT
ajlsi-3268	283	9	schweikert	schweikert	PROPN
ajlsi-3268	283	10	,	,	PUNCT
ajlsi-3268	283	11	b.	b.	PROPN
ajlsi-3268	283	12	,	,	PUNCT
ajlsi-3268	283	13	malmberg	malmberg	PROPN
ajlsi-3268	283	14	,	,	PUNCT
ajlsi-3268	283	15	c.	c.	PROPN
ajlsi-3268	283	16	,	,	PUNCT
ajlsi-3268	283	17	åkerborg	åkerborg	ADJ
ajlsi-3268	283	18	,	,	PUNCT
ajlsi-3268	283	19	ö.	ö.	PROPN
ajlsi-3268	283	20	,	,	PUNCT
ajlsi-3268	283	21	kumar	kumar	PROPN
ajlsi-3268	283	22	,	,	PUNCT
ajlsi-3268	283	23	g.	g.	PROPN
ajlsi-3268	283	24	,	,	PUNCT
ajlsi-3268	283	25	nott	nott	ADJ
ajlsi-3268	283	26	,	,	PUNCT
ajlsi-3268	283	27	d.	d.	PROPN
ajlsi-3268	283	28	,	,	PUNCT
ajlsi-3268	283	29	kiri	kiri	PROPN
ajlsi-3268	283	30	,	,	PUNCT
ajlsi-3268	283	31	s.	s.	PROPN
ajlsi-3268	283	32	(	(	PUNCT
ajlsi-3268	283	33	2020	2020	NUM
ajlsi-3268	283	34	)	)	PUNCT
ajlsi-3268	283	35	.	.	PUNCT
ajlsi-3268	284	1	cost	cost	NOUN
ajlsi-3268	284	2	-	-	PUNCT
ajlsi-3268	284	3	effectiveness	effectiveness	NOUN
ajlsi-3268	284	4	analysis	analysis	NOUN
ajlsi-3268	284	5	of	of	ADP
ajlsi-3268	284	6	sequential	sequential	ADJ
ajlsi-3268	284	7	biologic	biologic	NOUN
ajlsi-3268	284	8	therapy	therapy	NOUN
ajlsi-3268	284	9	with	with	ADP
ajlsi-3268	284	10	ixekizumab	ixekizumab	NOUN
ajlsi-3268	284	11	versus	versus	ADP
ajlsi-3268	284	12	secukinumab	secukinumab	NOUN
ajlsi-3268	284	13	in	in	ADP
ajlsi-3268	284	14	the	the	DET
ajlsi-3268	284	15	treatment	treatment	NOUN
ajlsi-3268	284	16	of	of	ADP
ajlsi-3268	284	17	active	active	ADJ
ajlsi-3268	284	18	psoriatic	psoriatic	ADJ
ajlsi-3268	284	19	arthritis	arthritis	NOUN
ajlsi-3268	284	20	with	with	ADP
ajlsi-3268	284	21	concomitant	concomitant	ADJ
ajlsi-3268	284	22	moderate	moderate	ADJ
ajlsi-3268	284	23	-	-	PUNCT
ajlsi-3268	284	24	to	to	ADP
ajlsi-3268	284	25	-	-	PUNCT
ajlsi-3268	284	26	severe	severe	ADJ
ajlsi-3268	284	27	psoriasis	psoriasis	NOUN
ajlsi-3268	284	28	in	in	ADP
ajlsi-3268	284	29	the	the	DET
ajlsi-3268	284	30	uk	uk	PROPN
ajlsi-3268	284	31	.	.	PROPN
ajlsi-3268	284	32	pharmacoeconomics	pharmacoeconomic	NOUN
ajlsi-3268	284	33	open	open	VERB
ajlsi-3268	284	34	,	,	PUNCT
ajlsi-3268	284	35	4(4	4(4	NUM
ajlsi-3268	284	36	)	)	PUNCT
ajlsi-3268	284	37	,	,	PUNCT
ajlsi-3268	284	38	635–648	635–648	NUM
ajlsi-3268	284	39	.	.	PUNCT
ajlsi-3268	285	1	stanić	stanić	PROPN
ajlsi-3268	285	2	,	,	PUNCT
ajlsi-3268	285	3	d.	d.	PROPN
ajlsi-3268	285	4	,	,	PUNCT
ajlsi-3268	285	5	plećaš	plećaš	NOUN
ajlsi-3268	285	6	-	-	PUNCT
ajlsi-3268	285	7	solarović	solarović	NOUN
ajlsi-3268	285	8	,	,	PUNCT
ajlsi-3268	285	9	b.	b.	PROPN
ajlsi-3268	285	10	,	,	PUNCT
ajlsi-3268	285	11	petrović	petrović	PROPN
ajlsi-3268	285	12	,	,	PUNCT
ajlsi-3268	285	13	j.	j.	PROPN
ajlsi-3268	285	14	,	,	PUNCT
ajlsi-3268	285	15	bogavacstanojević	bogavacstanojević	NOUN
ajlsi-3268	285	16	,	,	PUNCT
ajlsi-3268	285	17	n.	n.	NOUN
ajlsi-3268	285	18	,	,	PUNCT
ajlsi-3268	285	19	sopić	sopić	NOUN
ajlsi-3268	285	20	,	,	PUNCT
ajlsi-3268	285	21	m.	m.	NOUN
ajlsi-3268	285	22	,	,	PUNCT
ajlsi-3268	285	23	kotur	kotur	PROPN
ajlsi-3268	285	24	-	-	PUNCT
ajlsi-3268	285	25	stevuljević	stevuljević	NOUN
ajlsi-3268	285	26	,	,	PUNCT
ajlsi-3268	285	27	j.	j.	PROPN
ajlsi-3268	285	28	,	,	PUNCT
ajlsi-3268	285	29	et	et	PROPN
ajlsi-3268	285	30	al	al	PROPN
ajlsi-3268	285	31	.	.	PUNCT
ajlsi-3268	286	1	(	(	PUNCT
ajlsi-3268	286	2	2016	2016	NUM
ajlsi-3268	286	3	)	)	PUNCT
ajlsi-3268	286	4	.	.	PUNCT
ajlsi-3268	287	1	hydrogen	hydrogen	NOUN
ajlsi-3268	287	2	peroxide	peroxide	NOUN
ajlsi-3268	287	3	-	-	PUNCT
ajlsi-3268	287	4	induced	induce	VERB
ajlsi-3268	287	5	oxidative	oxidative	ADJ
ajlsi-3268	287	6	damage	damage	NOUN
ajlsi-3268	287	7	in	in	ADP
ajlsi-3268	287	8	peripheral	peripheral	ADJ
ajlsi-3268	287	9	blood	blood	NOUN
ajlsi-3268	287	10	lymphocytes	lymphocyte	VERB
ajlsi-3268	287	11	from	from	ADP
ajlsi-3268	287	12	rats	rat	NOUN
ajlsi-3268	287	13	chronically	chronically	ADV
ajlsi-3268	287	14	treated	treat	VERB
ajlsi-3268	287	15	with	with	ADP
ajlsi-3268	287	16	corticosterone	corticosterone	NOUN
ajlsi-3268	287	17	:	:	PUNCT
ajlsi-3268	287	18	the	the	DET
ajlsi-3268	287	19	protective	protective	ADJ
ajlsi-3268	287	20	effect	effect	NOUN
ajlsi-3268	287	21	of	of	ADP
ajlsi-3268	287	22	oxytocin	oxytocin	PROPN
ajlsi-3268	287	23	treatment	treatment	NOUN
ajlsi-3268	287	24	.	.	PUNCT
ajlsi-3268	288	1	chemico	chemico	ADJ
ajlsi-3268	288	2	-	-	ADJ
ajlsi-3268	288	3	biological	biological	ADJ
ajlsi-3268	288	4	interactions	interaction	NOUN
ajlsi-3268	288	5	,	,	PUNCT
ajlsi-3268	288	6	256	256	NUM
ajlsi-3268	288	7	,	,	PUNCT
ajlsi-3268	288	8	134–141	134–141	NUM
ajlsi-3268	288	9	.	.	PUNCT
ajlsi-3268	289	1	tice	tice	PROPN
ajlsi-3268	289	2	,	,	PUNCT
ajlsi-3268	289	3	r.	r.	PROPN
ajlsi-3268	289	4	r.	r.	PROPN
ajlsi-3268	289	5	,	,	PUNCT
ajlsi-3268	289	6	agurell	agurell	PROPN
ajlsi-3268	289	7	,	,	PUNCT
ajlsi-3268	289	8	e.	e.	PROPN
ajlsi-3268	289	9	,	,	PUNCT
ajlsi-3268	289	10	anderson	anderson	PROPN
ajlsi-3268	289	11	,	,	PUNCT
ajlsi-3268	289	12	d.	d.	PROPN
ajlsi-3268	289	13	,	,	PUNCT
ajlsi-3268	289	14	burlinson	burlinson	PROPN
ajlsi-3268	289	15	,	,	PUNCT
ajlsi-3268	289	16	b.	b.	PROPN
ajlsi-3268	289	17	,	,	PUNCT
ajlsi-3268	289	18	hartmann	hartmann	PROPN
ajlsi-3268	289	19	,	,	PUNCT
ajlsi-3268	289	20	a.	a.	PROPN
ajlsi-3268	289	21	,	,	PUNCT
ajlsi-3268	289	22	kobayashi	kobayashi	PROPN
ajlsi-3268	289	23	,	,	PUNCT
ajlsi-3268	289	24	h.	h.	PROPN
ajlsi-3268	289	25	,	,	PUNCT
ajlsi-3268	289	26	...	...	PUNCT
ajlsi-3268	289	27	&	&	CCONJ
ajlsi-3268	289	28	sasaki	sasaki	PROPN
ajlsi-3268	289	29	,	,	PUNCT
ajlsi-3268	289	30	y.	y.	PROPN
ajlsi-3268	289	31	f.	f.	PROPN
ajlsi-3268	289	32	(	(	PUNCT
ajlsi-3268	289	33	2000	2000	NUM
ajlsi-3268	289	34	)	)	PUNCT
ajlsi-3268	289	35	.	.	PUNCT
ajlsi-3268	290	1	single	single	ADJ
ajlsi-3268	290	2	cell	cell	NOUN
ajlsi-3268	290	3	gel	gel	NOUN
ajlsi-3268	290	4	/	/	SYM
ajlsi-3268	290	5	comet	comet	NOUN
ajlsi-3268	290	6	assay	assay	VERB
ajlsi-3268	290	7	:	:	PUNCT
ajlsi-3268	290	8	guidelines	guideline	NOUN
ajlsi-3268	290	9	for	for	ADP
ajlsi-3268	290	10	in	in	ADP
ajlsi-3268	290	11	vitro	vitro	X
ajlsi-3268	290	12	and	and	CCONJ
ajlsi-3268	290	13	in	in	ADP
ajlsi-3268	290	14	vivo	vivo	ADJ
ajlsi-3268	290	15	genetic	genetic	ADJ
ajlsi-3268	290	16	toxicology	toxicology	NOUN
ajlsi-3268	290	17	testing	testing	NOUN
ajlsi-3268	290	18	.	.	PUNCT
ajlsi-3268	291	1	environmental	environmental	ADJ
ajlsi-3268	291	2	and	and	CCONJ
ajlsi-3268	291	3	molecular	molecular	ADJ
ajlsi-3268	291	4	mutagenesis	mutagenesis	NOUN
ajlsi-3268	291	5	,	,	PUNCT
ajlsi-3268	291	6	35(3	35(3	NUM
ajlsi-3268	291	7	)	)	PUNCT
ajlsi-3268	291	8	,	,	PUNCT
ajlsi-3268	291	9	206–221	206–221	NUM
ajlsi-3268	291	10	.	.	PUNCT
ajlsi-3268	291	11	wagener	wagener	NOUN
ajlsi-3268	291	12	,	,	PUNCT
ajlsi-3268	291	13	f.	f.	PROPN
ajlsi-3268	291	14	a.	a.	PROPN
ajlsi-3268	291	15	,	,	PUNCT
ajlsi-3268	291	16	carels	carel	NOUN
ajlsi-3268	291	17	,	,	PUNCT
ajlsi-3268	291	18	c.	c.	PROPN
ajlsi-3268	291	19	e.	e.	PROPN
ajlsi-3268	291	20	,	,	PUNCT
ajlsi-3268	291	21	&	&	CCONJ
ajlsi-3268	291	22	lundvig	lundvig	PROPN
ajlsi-3268	291	23	,	,	PUNCT
ajlsi-3268	291	24	d.	d.	PROPN
ajlsi-3268	291	25	m.	m.	PROPN
ajlsi-3268	291	26	(	(	PUNCT
ajlsi-3268	291	27	2013	2013	NUM
ajlsi-3268	291	28	)	)	PUNCT
ajlsi-3268	291	29	.	.	PUNCT
ajlsi-3268	292	1	targeting	target	VERB
ajlsi-3268	292	2	the	the	DET
ajlsi-3268	292	3	redox	redox	ADJ
ajlsi-3268	292	4	balance	balance	NOUN
ajlsi-3268	292	5	in	in	ADP
ajlsi-3268	292	6	inflammatory	inflammatory	ADJ
ajlsi-3268	292	7	skin	skin	NOUN
ajlsi-3268	292	8	conditions	condition	NOUN
ajlsi-3268	292	9	.	.	PUNCT
ajlsi-3268	293	1	international	international	ADJ
ajlsi-3268	293	2	journal	journal	NOUN
ajlsi-3268	293	3	of	of	ADP
ajlsi-3268	293	4	molecular	molecular	ADJ
ajlsi-3268	293	5	sciences	science	NOUN
ajlsi-3268	293	6	,	,	PUNCT
ajlsi-3268	293	7	14(5	14(5	NUM
ajlsi-3268	293	8	)	)	PUNCT
ajlsi-3268	293	9	,	,	PUNCT
ajlsi-3268	293	10	9126–9167	9126–9167	NUM
ajlsi-3268	293	11	.	.	PUNCT
ajlsi-3268	294	1	yamanaka	yamanaka	PROPN
ajlsi-3268	294	2	,	,	PUNCT
ajlsi-3268	294	3	k.	k.	PROPN
ajlsi-3268	294	4	(	(	PUNCT
ajlsi-3268	294	5	2021	2021	NUM
ajlsi-3268	294	6	)	)	PUNCT
ajlsi-3268	294	7	.	.	PUNCT
ajlsi-3268	295	1	skin	skin	NOUN
ajlsi-3268	295	2	disease	disease	NOUN
ajlsi-3268	295	3	and	and	CCONJ
ajlsi-3268	295	4	comorbidities	comorbiditie	NOUN
ajlsi-3268	295	5	.	.	PUNCT
ajlsi-3268	296	1	mdpi	mdpi	PROPN
ajlsi-3268	296	2	,	,	PUNCT
ajlsi-3268	296	3	11(8	11(8	NUM
ajlsi-3268	296	4	)	)	PUNCT
ajlsi-3268	296	5	,	,	PUNCT
ajlsi-3268	296	6	5754	5754	NUM
ajlsi-3268	296	7	.	.	PUNCT
ajlsi-3268	297	1	zou	zou	PROPN
ajlsi-3268	297	2	,	,	PUNCT
ajlsi-3268	297	3	y.	y.	PROPN
ajlsi-3268	297	4	,	,	PUNCT
ajlsi-3268	297	5	&	&	CCONJ
ajlsi-3268	297	6	meng	meng	PROPN
ajlsi-3268	297	7	,	,	PUNCT
ajlsi-3268	297	8	z.	z.	PROPN
ajlsi-3268	297	9	(	(	PUNCT
ajlsi-3268	297	10	2021	2021	NUM
ajlsi-3268	297	11	)	)	PUNCT
ajlsi-3268	297	12	.	.	PUNCT
ajlsi-3268	298	1	literature	literature	NOUN
ajlsi-3268	298	2	overview	overview	NOUN
ajlsi-3268	298	3	of	of	ADP
ajlsi-3268	298	4	the	the	DET
ajlsi-3268	298	5	il-17	il-17	NUM
ajlsi-3268	298	6	inhibition	inhibition	NOUN
ajlsi-3268	298	7	from	from	ADP
ajlsi-3268	298	8	psoriasis	psoriasis	NOUN
ajlsi-3268	298	9	to	to	ADP
ajlsi-3268	298	10	covid-19	covid-19	PROPN
ajlsi-3268	298	11	.	.	PROPN
ajlsi-3268	298	12	journal	journal	PROPN
ajlsi-3268	298	13	of	of	ADP
ajlsi-3268	298	14	inflammation	inflammation	PROPN
ajlsi-3268	298	15	research	research	NOUN
ajlsi-3268	298	16	,	,	PUNCT
ajlsi-3268	298	17	14	14	NUM
ajlsi-3268	298	18	,	,	PUNCT
ajlsi-3268	298	19	5611–5621	5611–5621	NUM
ajlsi-3268	298	20	.	.	PUNCT